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I declare that this thesis is my own composition, and that none of the work herein has 
been submitted in support of an application for any other degree or professional 
qualification. The idea of investigating the risk of intracranial haemorrhage or focal 
neurological deficit and performing an individual patient data meta-analysis (IPDMA) 
was conceived by Professor Rustam Al-Shahi Salman (RA-SS), and that of comparing 
outcome after treatment by RA-SS and Dr Fiona Moultrie. The Scottish Intracranial 
Vascular Malformation Study (SIVMS) was designed and set up by RA-SS, and the 
SIVMS database was created by David Perry and further developed by Aidan 
Hutchison. RA-SS designed the literature search strategy for the systematic review, 
and I adapted it for the literature review chapter. I assisted RA-SS and Susanne 
Maxwell in collecting data for the later cohort of SIVMS adults who had been 
diagnosed with cerebral cavernous malformation. Professor Gordon Murray (GDM) 
and I wrote the protocol for the IPDMA, and I drafted the two statistical analysis plans 
(for the treatment-comparison and IPDMA). I extracted, checked, cleaned, analysed 
and interpreted the data for the two Scottish cohorts. Under guidance from RA-SS and 
GDM, I acted as the IPDMA co-ordinator: I invited fifteen research groups to 
participate in the IPDMA, designed data questionnaires for those groups that agreed 
to collaborate, and liaised with them throughout the duration of the project. I checked 
and cleaned all the data, pooled the data from the five cohorts into a single dataset, and 
analysed and interpreted the pooled data, according to the above-mentioned protocol 
and statistical analysis plan, both of which had been approved by all the contributors. 
 






   




A cerebral cavernous malformation (CCM) is a small cluster of thin-walled, dilated 
blood vessels within the brain which is prone to bleed. Although the quantity of blood 
leaking tends to be small, even a small intracranial haemorrhage (ICH) can result in a 
clinically significant neurological deficit. Because some focal neurological deficits 
(FND) may in fact be haemorrhages that were undetected by imaging, FND were also 
included in the analysis wherever possible. In Scotland, between 2006 and 2010, the 
annual CCM detection rate was 0.8 per 100,000 people. Since estimates of prognosis 
inform decisions about whether to treat CCM, it is crucial that the untreated clinical 
course of the disease is fully understood. 
Aim  
The aims of this thesis are (i) to quantify the risk of ICH (or ICH or FND, referred to 
as ‘clinical event’) for an untreated adult within five years of CCM diagnosis, (ii) to 
identify prognostic factors for ICH (clinical event), and (iii) to create a model to 
predict, at the time of diagnosis, an individual’s risk of a subsequent ICH (clinical 
event).  
Methods  
Initially, a literature review was undertaken. Then data from adults diagnosed with 
CCM in the Scottish Intracranial Vascular Malformation Study (SIVMS) were 
analysed. SIVMS is a prospective, population-based cohort study: it includes all adults 
resident in Scotland at the time of diagnosis of a first-ever intracranial vascular 
malformation during the two five-year periods 1999–2003 and 2006–2010. Time-to-
event methods were employed to compare the estimated risk of ICH (clinical event) 
for those who experienced a first ICH (clinical event) during untreated five-year 
follow-up with those who experienced a second ICH (clinical event). A statistical 
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challenge when analysing clinical outcomes from patients with CCM is that the 
outcome event of ICH or FND is comparatively rare; therefore a larger cohort of CCM 
patients was required to identify more robustly potential predictors of ICH (clinical 
event) and to create a prognostic model to predict, at the time of diagnosis, an 
individual’s risk of a subsequent ICH (clinical event).  Three research groups agreed 
to contribute their data to enable an individual patient data meta-analysis (IPDMA) to 
be undertaken.  
Results  
In the two SIVMS cohorts, 136 (1999–2003) and 165 adults (2006–2010) were 
diagnosed with CCM. In the earlier cohort, the estimated risk of a first ICH within five 
years of presentation (2.4%, 95% CI 0.0% to 5.7%) was significantly lower (p < 
0.0001) than the risk of a recurrent ICH (31.9%, 95% CI 4.5% to 59.3%), but the 
annual risk of a recurrence declined over the five-year period. In the same cohort, 
women had an increased risk of a second clinical event (log-rank χ2(1) = 6.2, p = 0.01). 
The IPDMA was based on 988 adults, 62 of whom suffered a first ICH within five 
years of CCM diagnosis. When the data were pooled, the estimated adjusted hazard 
ratio for first ICH for clinical presentation (ICH/FND vs other presentation) was 4.5 
(95% CI 1.5 to 13.4) and for brainstem location (brainstem vs other location) the 
adjusted hazard ratio was 3.3 (95% CI 1.5 to 7.2); age, sex and CCM multiplicity did 
not add any additional prognostic information.  
Conclusion  
In this thesis two risk factors have been identified that are independently associated 
with increased likelihood of experiencing an ICH (or clinical event) within five years 
of diagnosis. A prognostic model has been built and evaluated, based on these factors. 
Other areas to be explored in the future include external validation of the model and 
investigating the effects of (i) antithrombotic therapy and (ii) pregnancy on the 
progression of the disease. 
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Chapter 1: Introduction and outline of thesis 
 
Cerebral cavernous malformations (CCM) are the second most common form of 
intracranial vascular malformation, and their diagnosis has increased exponentially in 
the past twenty years, due to the widespread usage of magnetic resonance imaging 
(MRI). Before the availability of MRI, cavernous malformations could only be 
diagnosed conclusively after surgery or at autopsy; since brain imaging has become 
standard practice, however, many more asymptomatic cavernous malformations have 
been diagnosed. From the early 1990s onwards there have been a number of research 
papers published, but many of these have concentrated on interventional treatment or 
have produced conflicting evidence; consequently the untreated clinical course of the 
condition and the long-term patient outcome are not fully understood at present.  
Intracranial haemorrhage (ICH) is one of the more potentially disabling outcomes for 
people who have been diagnosed with cerebral cavernous malformation. Not all 
haemorrhages that occur can be detected, however, since ICH identification is reliant 
upon timely neuro-imaging of an appropriate modality being undertaken. Therefore, 
whenever possible in this thesis, a composite outcome of ICH or focal neurological 
deficit (FND) was analysed, since the effects of FND can be of equal severity for 
patients, and in certain instances an FND may in fact be an unidentified ICH, if neuro-
imaging either has not been performed or has been unable to detect the ICH (for 
example, because it has been obscured by the CCM).  
The aims of this thesis are to investigate the risk of ICH or FND in adults who have 
received a first-ever CCM diagnosis, to identify any baseline characteristics that might 
be associated with that risk, and to build a prognostic model that can be used at the 
time of CCM diagnosis, to predict the risk of an ICH (or either ICH or FND) within 
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five years of diagnosis. The rationale for restricting the length of follow-up to five 
years is discussed at several points throughout the thesis (e.g., subsections 4.2.4, 6.6.2 
and 9.2.1 below).The following questions are explored in detail: 
1. What are the estimated five-year risks of first and recurrent ICH, definitely due 
to CCM: 
a. in two cohorts of adults newly diagnosed with CCM, drawn from the 
Scottish population?  
b. in five cohorts of newly diagnosed adults, from western Europe and 
North America? These five cohorts comprise the individual patient data 
meta-analysis (IPDMA). 
2. What are the estimated five-year risks of first and second ICH or FND, 
definitely or possibly due to CCM: 
a. in the two Scottish cohorts?  
b. in the five cohorts forming the IPDMA? 
3. Which baseline characteristics are associated with the risk of ICH or FND 
occurring within five years of CCM diagnosis: 
a. in the two Scottish cohorts?  
b. in the five cohorts forming the IPDMA? 
4. Over the course of five years, from the time of first clinical event, how does 
the level of dependence compare for adults who have experienced a single 
clinical event (ICH or FND) and those who have suffered a recurrence? 
5. How does the functional outcome of adults diagnosed with CCM who have 
undergone interventional treatment compare with those who have been 
managed conservatively? 
6. Is it possible to predict, at the time of diagnosis, an individual’s risk of a 
subsequent ICH or FND, assuming no interventional treatment is performed in 
the intervening period? 
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The thesis is arranged in the following order. First, a brief description of CCM is given 
in Chapter 2, and the level of knowledge pertaining to haemorrhage or focal 
neurological deficit in CCM at the beginning of this research project is outlined in a 
short literature review (Chapter 3).  
In Chapter 4, data from adults diagnosed with cerebral cavernous malformation in the 
Scottish Intracranial Vascular Malformation Study (SIVMS) will be analysed; the 
risks of a first and recurrent ICH (and the composite outcome of ICH or FND) over 
five years of untreated follow-up will be estimated, and the functional outcome of 
adults who have suffered at least one ICH or FND will be examined. In Chapter 5, 
there is a slight change of focus: using the data from the first cohort of SIVMS, the 
functional and clinical outcomes of those who received interventional treatment are 
compared with those who were conservatively managed. 
In the next four chapters, the focus reverts to the untreated clinical course. The 
prognosis for CCM appears to be comparatively benign and clinical outcome events 
are not plentiful, which is of course very good news for the patient, albeit less good 
for the statistician. In an attempt to increase the number of outcome events, to enable 
identification of risk factors associated with ICH or FND in untreated follow-up, and 
the construction of a prognostic model, three other research centres agreed to 
collaborate and contribute data. Thus in Chapters 6–9, the individual patient data meta-
analysis and subsequent prognostic models are described, together with a subsidiary 
analysis of whether sex has an effect on recurrent ICH (or a second ICH or FND). In 
the final chapter (Chapter 10), the main strands of the thesis are discussed and 
suggestions are made for the direction that future research on this condition should 
take. 
The statistical analyses reported in this thesis were performed using IBM SPSS 
Statistics for Windows, versions 19.0 and 21.0 (Armonk, NY: IBM Corp), and Stata 










Chapter 2: Clinical background 
 
Although cerebral cavernous malformations (CCM) have been recognized as a clinical 
condition since at least the middle of the nineteenth century, when Rudolf Virchow, 
the German pathologist, described it in 1863 (Bertalanffy et al., 2002), until the mid-
1980s they could only be diagnosed conclusively either after surgery or at autopsy. 
Because CCMs cannot be visualized on angiograms, due to the very slow blood flow, 
they were often described as angiographically occult vascular malformations 
(AOVMs) or cryptic vascular malformations (Batra et al., 2009, Kim et al., 1997). 
However, the incidence of cavernous malformations has dramatically increased since 
the 1990s, with the widespread availability and usage of magnetic resonance imaging 
(MRI). The estimated annual CCM detection rate in Scotland was 0.56 (95% 
confidence interval 0.41 to 0.75) per 100,000 from 1999 to 2000 (Al-Shahi Salman et 
al., 2012), and 0.78 (95% CI 0.67 to 0.90) per 100,000 between 2006 and 2010. The 
results of a study investigating incidental findings on brain MRI suggest a CCM 




Cerebral cavernous malformations, also known as cavernomas, cavernous angiomas 
or cavernous haemangiomas, are the second most common type of intracranial 
vascular malformation (IVM) and account for about 5–15% of all IVMs (Maraire and 
Awad, 1995, Moriarity et al., 1999, Batra et al., 2009, Abla et al., 2011, Engelmann et 
al., 2011, Berg and Vay, 2011). A CCM is a small round cluster of thin-walled, dilated   
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Figure 2.1 Cerebral cavernous malformation 
 
abnormal blood vessels, packed together with no intervening brain tissue (Figure 2.1). 
Visually, the CCM is multi-lobulated and resembles a raspberry. 
The blood vessels in cavernous malformations are lined with a single endothelial cell 
layer in a similar manner to capillaries: there are no elastic or smooth muscle fibres in 
the vascular walls, and astrocytic endfeet are also absent (Kuker and Forsting, 2008, 
Batra et al., 2009, Batra et al., 2011, Bertalanffy et al., 2002). There is a slow flow of 
blood in the lesion with leaky junctions between the cells. The brain area surrounding 
the CCM often has haemosiderin staining, where small quantities of blood may have 
previously oozed out, since the structure of CCM blood vessels lacks the 
morphological basis of the blood–brain barrier. Calcification can also occur within the 
walls of the blood vessels and within the adjacent brain tissue (Batra et al., 2011); this 
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tends to be more common in people presenting with a seizure, and rarer in someone 
presenting with an intracranial haemorrhage. 
 
2.2 Characteristics of cavernous malformations 
 
The disease can take two different forms: sporadic or familial. The former is 
characterized by the presence of a single, non-hereditary lesion and is the more 
common.  Characteristics of the familial form include a higher prevalence of multiple 
lesions (50-84% in familial cases compared with less than 33% in sporadic cases) and 
also the appearance of de novo lesions (Maraire and Awad, 1995, Zabramski et al., 
1994). There is an autosomal dominant pattern of inheritance, and two genes on 
chromosome 7 and one on chromosome 3 have been discovered to be abnormal 
(Labauge et al., 2001).  
However, in this thesis, no distinction is made between the sporadic and familial form 
of the disease, and adults with either form are included in the analysis. There are 
several reasons for adopting this approach: CCM is not a common disease and there 
was a reluctance to reduce the number of people included in the study by subdividing 
the population into two unequal-sized groups, given that there is no evidence to date 
to suggest that the risk of a haemorrhage differs between the two forms of the disease. 
It would also be challenging to identify accurately all adults in the cohorts who had 
the familial form since genetic testing would be required, which in many diagnoses 
(for example, an elderly patient who has been diagnosed incidentally) would be 
inappropriate. 
 Historically, cavernous malformations were believed to be congenital lesions. In 
1994, however, Zabramski and colleagues reported that six of 21 patients in their study 
of the familial form of the disease had developed 17 new lesions that had not been 
visualized on earlier MRI (Zabramski et al., 1994). There have also been reports of 
appearances of de novo lesions following intracranial radiation, especially in children 
(Pozzati et al., 1996) and after viral infection. Thus it is now recognized that CCMs 
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are dynamic lesions: they can increase or diminish in size over time as well as appear 
de novo (Clatterbuck et al., 2000, Nimjee et al., 2006). Since clinicians in Scotland 
tend not to perform neuro-imaging routinely, unless a patient’s symptoms suggest that 
he/she would benefit from another scan, it is not possible to investigate whether 
individual lesions have increased or diminished in size over time in the Scottish 
cohorts described in this thesis. 
Cerebral cavernous malformations may be located in any region of the brain; the 
majority tend to be supratentorial, distributed in a similar proportion to neural tissue 
(Batra et al., 2009). There is, however, a possibility that the area of the brain in which 
a CCM is situated may play a part in determining the problems the CCM causes. For 
example, in the brainstem the neural functions are tightly packed; thus CCMs located 
there are adjacent to eloquent areas of the brain and so can do more damage than when 
they are located in other, non-eloquent areas of the brain.  
Patients can present with a variety of symptoms, the most common of which are 
epileptic seizure, intracranial haemorrhage (ICH), focal neurological deficit (FND), 
headache or tinnitus. Since the advent of high-resolution MRI, however, an increasing 
number of patients have been presenting  asymptomatically (Morris et al., 2009): a 
brain scan has been performed for some other reason (for example, traumatic brain 
injury) and the radiologist has also observed one (or more) incidental CCMs. In 
addition, sometimes a patient’s symptoms can only possibly (but not definitely) be 
attributed to the CCM. In both these cases, the presentation is described as ‘incidental’.  
The ability to detect the presence of asymptomatic CCMs using high-resolution MRI 
has led to the screening of other family members, if they so wish, when a patient has 
been diagnosed with the familial form of the disease; this practice also contributes to 
the large number of people with cavernous malformations presenting incidentally. As 
more people receive a CCM diagnosis incidentally, it is even more important to 
understand the untreated clinical course of the disease, since it informs decisions on 
how best the condition should be managed. 
Cavernous malformations can vary in size from a few millimetres width to 4 centi-
metres or more. Occasionally they are found in conjunction with developmental 
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venous anomalies (DVA) (or venous malformations) (Abdulrauf et al., 1999), although 
it is not unusual for the latter to be radiographically occult and only be discovered 
during surgery (Rigamonti et al., 1988, Porter et al., 1997, Abdulrauf et al., 1999).  
 
2.3 Problems associated with CCM 
 
2.3.1 Seizure 
Epileptic seizure is the most common form of symptomatic CCM presentation; 
patients who present with a seizure tend to be younger (under 40 years), are more likely 
to be male, and their cavernomas are located supratentorially. If a lesion has become 
epileptogenic, then the risk of seizures will continue, unless the cavernoma is 
surgically removed; thus patients will require lifelong anti-epileptic therapy (Bergey, 
2011, Josephson et al., 2011).  
However, the occurrence of seizures and epilepsy during follow-up is not explored in 
this thesis; adults who have undergone interventional treatment as a result of epilepsy 
are included in the treated group in Chapter 5 and the subsection on informative 
censoring in Chapter 8 below. 
 
2.3.2 Haemorrhage and focal neurological deficit 
As a result of their angioarchitecture, CCM are prone to bleed. Although the quantity 
of blood leaking out tends to be small because the blood flow is very slow, even a 
small ICH can result in a clinically significant neurological deficit (Aiba et al., 1995), 
especially when the CCM is located in the brainstem or another eloquent area.  
A major aim of this thesis is to investigate the risk of haemorrhage in adults who have 
been diagnosed with a CCM, whether they have a non-haemorrhagic or a 
haemorrhagic presentation. However, investigating haemorrhage from cerebral 
cavernous malformations is not without its challenges. In the past, different researchers 
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have used different definitions of haemorrhage and different starting points. 
Furthermore, visualization of blood on imaging requires different radiographic 
modalities at different time points. In addition, clinical practice and the quirks of 
human behaviour add to the challenge. 
 
Definition of haemorrhage 
Since CCM contain blood products at various stages of evolution, it is crucial to define 
the term ‘haemorrhage’ to avoid confusion (Porter et al., 1997, Kuker and Forsting, 
2008). The definition of symptomatic haemorrhage used throughout this thesis is that 
agreed in 2008, at a scientific workshop of the Angioma Alliance, and reproduced 
below: 
A clinical event involving both: 
Acute or subacute onset symptoms (any of headache, 
epileptic seizure, impaired consciousness, new/worsened 
focal neurological deficit referable to the anatomic 
location of the CM). 
Radiological, pathological, surgical, or rarely only 
cerebrospinal fluid evidence of recent extra- or 
intralesional haemorrhage. 
The mere existence of a hemosiderin halo, or solely an 
increase in CM diameter without other evidence of recent 
haemorrhage, are not considered to constitute haemorrhage. 
(Al-Shahi Salman et al., 2008) 
 
Radiological considerations 
The appropriate neuro-imaging modality used to detect blood depends upon when the 
suspected haemorrhage occurred.  Ideally, a CT scan should be performed within a 
week of the suspected haemorrhage for the blood to be visualized; older haemorrhages 
are visible on MRI for between two weeks and up to two or three months after the 
event. If possible, the MRI should be compared with one performed earlier, which 
does not show the abnormalities, or one taken at a later date, when the haemorrhage 
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has evolved further. Occasionally a CCM can be partially or completely obscured by 
a haemorrhage on MRI or, conversely, an ICH can obscure a CCM; therefore repeat 
scanning several months later, when the haemorrhage has broken down into its 
constituent parts, is desirable (Josephson and Al-Shahi Salman, 2011).  
 
Focal neurological deficits 
Definitions 
A non-haemorrhagic focal neurological deficit (NH-FND) is defined as ‘a new or 
worsened focal neurological deficit referable to the anatomic location of the CCM, 
which may present with other clinical features of intracranial haemorrhage, but without 
evidence of recent blood on timely brain imaging or pathological examination, or 
examination of the CSF’ (cerebrospinal fluid) (Al-Shahi Salman et al., 2008). 
Focal neurological deficit not otherwise specified (NOS-FND) is defined as a non-
haemorrhagic FND ‘where pathological investigation, CSF examination, or timely 
imaging have not been performed at all or at the correct time to establish whether 
haemorrhage, edema, or lesion growth underlie the clinical deterioration’ (Al-Shahi 
Salman et al., 2008).  
 
Potential haemorrhages 
The challenge of trying to understand and estimate the risk of haemorrhage for adults 
diagnosed with CCM is compounded by various scenarios in clinical practice that can 
result in the misclassification of a true haemorrhage as a focal neurological deficit. For 
example, patients with cavernous malformations tend to have milder deficits than 
people with, for example, arteriovenous malformations, because less blood is lost, as 
CCMs have low pressure and slow blood flow (El-Koussy et al., 2011). Thus reporting 
bias and investigation bias may lead to an underestimation of ICH: a patient may delay 
reporting seemingly minor symptoms to their general practitioner, who in turn may be 
slow to investigate because the symptoms seem mild, and the patient is known to have 
a CCM, but is being managed conservatively. As a result, the appropriate neuro-
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imaging will not be performed at the appropriate time, or possibly at all, and the 
condition will be described in the patient’s notes as a focal neurological deficit, when 
it is in fact a symptomatic intracranial haemorrhage (Josephson and Al-Shahi Salman, 
2011).  
On the other hand, CCM diagnosis itself may be subject to detection bias, since it relies 
on brain imaging of the right type being performed at the right time. Clinicians tend to 
investigate the cause of ICH symptoms in young, normotensive adults, whereas these 
symptoms in older, hypertensive adults are less likely to be further investigated, 
regardless of whether the individuals are known to harbour a cavernoma.  
Thus some NOS-FNDs are in fact ICH, but without the timely neuro-imaging to 
confirm the blood, and therefore the incidence of haemorrhage in people with 
cavernous malformations is likely to be underestimated. For this reason, reporting 
standards recommend combining proven ICH and FND into a composite outcome 
(referred to as ‘clinical event’ throughout this thesis). 
  
 








As was described in Chapter 2 above, although cerebral cavernous malformations have 
existed in the past, it is only since the advent and widespread usage of MRI that their 
conclusive diagnosis has been possible on a large scale. Before the invention of MRI, 
CCM could be diagnosed only after surgical excision of the lesion or at pathological 
examination during autopsy. Therefore before 1990 the disease literature was 
restricted to a very few CCM case studies; after this date, interest in the disease 
increased dramatically and a number of papers were published, although many of these 
concentrated on a description either of the different forms of interventional treatment 
or of the molecular structure of the disease, rather than the clinical course of the 
untreated disease.  
With the increase in detection of incidental lesions due to the widespread use of MRI, 
however, it has become imperative for clinicians to understand the natural history of 
the condition so that they are able to determine the optimum treatment for individual 
patients (Engelmann et al., 2011). Thus a number of seminal studies were published in 
the 1990s and early 2000s, describing the natural history of the condition and 
examining haemorrhage or focal neurological deficit and seizure rates. In this thesis, 
however, interest is confined to haemorrhage or focal neurological deficit in the 






A systematic search of the literature was carried out for reports of the risk of ICH or 
FND (or subsequent ICH or FND) in untreated follow-up among adults whose CCM 
diagnosis was validated by brain MRI or pathological examination. Two online data-
bases were searched – Embase, the Excerpta Medica database, and Medline, the 
National Library of Medicine database – from 1980 to August 2011 (see Table 3.1). 
The searches were limited to English or French language publications, and specific to 
human adults.  
Criteria for a study to be included in this literature review were for the sample size to 
be at least 20 patients (to avoid individual case studies); the period during which the 
patient was at risk of haemorrhage was to be calculated from the time of first 
presentation or CCM diagnosis, not from birth; and ICH was to be clearly defined. 
Other desirable study characteristics included a definite diagnosis of CCM after 
radiological or pathological examination; a specific inception point, i.e. some distinct 
time-point during the course of the disease, at which patients were recruited into the 
cohort; prospective data collection; a population-based sample in preference to a 
hospital-based one; objective pre-defined clinical outcome events to include mortality, 
ICH and a standard measure of functional outcome (for example, the modified Rankin 
scale); and patients to be assessed blind by clinicians to the prognostic factors of 
interest.  
The title of every publication identified by the electronic searches was read, and where 
the title appeared to be relevant to this study, abstracts were examined to ascertain how 
many of the above criteria were met. In addition, reference lists in selected papers 








In the Embase and Medline searches, after the language and human adult limits were 
set, 505 and 366 publications were identified respectively. After combining these two 
results, 152 duplicate records were removed, and 513 records were excluded for the 
following reasons: irrelevance, case reports, children or the study was too small (less 
than 20 adults) (see Figure 3.1). Of the 206 records remaining, 123 were eligible to be 
included in the literature review. The criterion that the period during which the patient 
was at risk of haemorrhage was to be calculated from the time of first presentation or 
CCM diagnosis, not from birth, had to be relaxed, however, as almost all studies used 
the ‘lifetime method’ of calculating the risk of ICH. 
In the literature review that follows, the main published studies have been critically 
appraised, and some of the seminal papers have been described in greater detail; the 
salient points are summarized in section 3.4. 
 
3.3.1 Critical appraisal of the literature 
Of the 21 seminal studies identified in the search, fourteen were retrospective, based 
at one or two hospitals or neurological/neurosurgery referral centres; researchers 
reviewed all the radiological images of the brain that had been performed within a 
defined period of time at the particular institution, or possibly one or two other 
collaborating centres, to identify all potential cerebral cavernous malformations. 
Clinical records were then examined retrospectively for all patients who were 
suspected of harbouring a CCM, and the patients were contacted for further follow-up. 
Researchers were predominantly interested in the prevalence of the disease and the 
number of haemorrhages in follow-up; tentative suggestions were made of any 
potential risk factors that might have been observed in their particular cohort.  
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Table 3.1 Literature search strategies 
 Embase 
1. Brain Hemangioma/ 
2. brain ventricle cavernoma/ 
3. cavernous hemangioma/ 
4. (cavernous adj5 (angioma$ or hemangioma$ or malformation$)).tw. 
5. cavernoma$.tw. 
6.  3 or 4 or 5 
7. central nervous system/ or exp brain/ or exp brain ventricle/ or exp brain artery/ 
8. exp brain tumor/ 
9. (brain$ or cerebral or intracerebral or central nervous system or intracranial or 
cerebellar or intraventricular or supratentorial).tw. 
10. 7 or 8 or 9 
11. 6 and 10 
12. 1 or 2 or 11 
13.  exp brain haemorrhage/ 
14. exp bleeding/ 
15. 13 or 14 
16. 12 and 15 
  
 Medline 
1. Hemangioma, Cavernous, Central Nervous System/ 
2. Hemangioma, Cavernous/ 
3. (cavernous adj5 (angioma$ or hemangioma$ or malformation$)).tw. 
4. cavernoma$.tw. 
5. 2 or 3 or 4 
6.  exp brain/ or central nervous system/ or exp cerebral arteries/ 
7. Exp brain neoplasms/ 
8. (brain$ or cerebral or intracerebral or central nervous system or intracranial or 
cerebellar or intraventricular or supratentorial).tw. 
9. 6 or 7 or 8 
10. 5 and 9 
11. 1 or 10 
12. exp Hemorrhage/ or exp Intracranial Hemorrhages/ 
13.  Focal neurological deficit$.tw. 
14. 12 or 13 
15. 11 and 14   
 







































Records identified through 
database searching 
(n = 1277) 
Medline 
Records identified through 
database searching 
(n = 599) 
 
Embase 
Records after limits set 
(n = 505) 
 
Records after duplicates removed 
(n = 719) 
 
Medline 
Records after limits set 
(n = 366) 
 
Records in combined database  
(n = 871) 
 
Records (n = 206) 
Literature review  n = 123 
Stereotactic radiotherapy n =   30 
Surgical excision  n =   53  
  
Records excluded (n = 513): 
Not relevant     n = 320 
Case reports     n = 171 
Children     n =   10 
Study too small     n =   12 
 
Duplicate records 
(n = 152) 
 
Figure 3.1 Flowchart of database searches for literature review 
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Unfortunately many of these studies suffered from one or more of the following 
problems. In retrospective studies, the number of patients lost to follow-up is likely to 
be greater than in prospective studies, and in some cases the length of follow-up was 
only a matter of months, which was too short a time-period for subsequent clinical 
events to occur. As several researchers have noted previously, in many cases there was 
no defined inception point, and definitions of haemorrhage were frequently vague 
(Feiz-Erfan et al., 2002, Kuker and Forsting, 2008, Josephson and Al-Shahi Salman, 
2011). Additionally, very few studies gave any indication of patient functional 
outcome or level of dependence at the end of the study period; ideally, this should be 
assessed by someone who is blinded to the prognostic features of the study, and a 
standardized disability scale should be used (Josephson and Al-Shahi Salman, 2011). 
In several studies, it was assumed that lesions were congenital and haemorrhage rates 
were calculated on the basis of lifetime risk; it is now known that CCMs are dynamic 
lesions and using the lifetime-risk method seriously underestimates the haemorrhage 
rate. Even where a prospective haemorrhage rate was calculated, some studies used 
the total number of haemorrhages during follow-up, rather than either using the first 
haemorrhage, or distinguishing between a first and recurrent bleed; including all 
haemorrhages that occurred during follow-up overestimates the risk of an individual 
suffering one or more haemorrhage. Differing haemorrhage rates can sometimes be 
explained by the fact that patients with CCMs may have been managed conservatively 
in one institution for a number of years, but have then been transferred to the study 
centre – a tertiary specialist centre – on clinical deterioration; hence the requirement 
for a specific inception point that refers to the progress of the disease, such as the date 
of first CCM diagnosis.  
Some studies reported haemorrhage rates in terms of patient-years, whereas others 
used lesion-years, and this makes comparison of rates between different studies more 
problematic, if not impossible. In addition, most studies did not account for patients 
who suffered focal neurological deficits (FNDs), which are an important cause of 
morbidity, particularly as occasionally FNDs may in reality be instances of ICH, but 
cannot be so defined because brain imaging may not have been performed at the 
appropriate time with the appropriate modality to detect blood on the scan (Josephson 
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and Al-Shahi Salman, 2011)  (see subsection 2.3.2 above). Several of the studies 
focused on a specific patient population (for example, familial CCMs or brainstem 
CCMs), so the haemorrhage rates in different studies may not be directly comparable. 
Moreover, it is not possible to compute an accurate detection rate from these studies, 
because the initial populations consisted either of hospital patients or patients who had 
been referred to a large tertiary specialist centre. Thus patients from neither group were 
representative of the general population, as they had all been referred to a medical 
establishment; any detection rate calculated from these studies would be subject to 
selection bias, and the rate of CCM in the general population would be overestimated, 
because the initial population did not include healthy subjects (Feiz-Erfan et al., 2002).  
In addition, it is likely that many studies suffered from referral bias: those adults who 
were referred to a tertiary specialist centre and who provided the data for some of the 
studies of the untreated clinical course of the disease will have a poorer prognosis than 
those who were diagnosed with CCM, but were not referred to such a centre (Al-Shahi 
and Warlow, 1999).  For this reason, further studies using prospective population-
based cohorts (such as the Scottish Intracranial Vascular Malformations Study 
(SIVMS), http://www.saivms.scot.nhs.uk/, described in Chapter 4 below) are crucial. 
Moreover, in population-based studies, mortality data will be more complete, since 
participants who die in the community, rather than in a medical establishment, will be 
recorded, whereas these community deaths will not be included in hospital-based 
studies; therefore hospital-based studies will arguably present an over-optimistic 
prognosis with regard to CCM mortality (Al-Shahi and Warlow, 1999).  
There is also the possibility of treatment bias in hospital-based studies. Individuals 
with more severe symptoms tend to be referred to a tertiary referral centre, where 
surgeons may be more likely to operate at an earlier phase in the disease, thereby 
reducing the length of conservative-management period, and thus the untreated time 
available for an event to occur. 
Nonetheless, to give an approximation of the scale of CCM incidence, several authors 
reviewed all MRI scans in their institution over a set period of time. Robinson and 
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colleagues found 66 patients with CCMs from 14,035 consecutive MRI reports, giving 
an incidence of 4.7 per 1,000 patients (Robinson et al., 1991), and Del Curling found 
32 subjects from 8,131 consecutive MRI reports, with a corresponding incidence of 
3.9 per 1,000 (Del Curling et al., 1991). These estimates are similar to the 3.9 per 1,000 
and 5.3 per 1,000 from two earlier autopsy studies (n = 4,000 and 24,535 respectively)  
(Sarwar and McCormick, 1978, Otten et al., 1989). More recently, El-Koussy and 
colleagues have reported ‘an annual incidence of 1.31 and 0.55 newly diagnosed 
symptomatic and asymptomatic cases respectively per 100,000 inhabitants’ in the 
canton of Bern (El-Koussy et al., 2011), although the authors qualify this by adding 
that it is possible that some patients from other regions of Switzerland may be included 
in this rate. 
 
Review of published studies 
Bearing in mind the potential problems described above, the studies cited below do 
give a useful insight into the condition and the most pertinent points are summarized 
below (see Tables 3.2 and 3.3 below). 
The average age at presentation leading to a CCM diagnosis was 31–42 years, although 
in Zabramski’s study on familial CCMs the average age was 25 years (Zabramski et 
al., 1994), as asymptomatic family members across the generations were also screened. 
The modes of presentation in the non-specialized studies were in the following ranges: 
ICH (9–56%), seizure (22–52%), FND (8–46%) and incidental (12–21%). However, 
these studies were based on data derived in the 1980s and 1990s for the most part; the 
percentage of patients presenting incidentally is likely to be greater since then, as the 
availability and usage of MRI has increased considerably. In the two Scottish cohorts, 
recruited between 1999 and 2010, the percentage of adults presenting incidentally was 
46% and 41% (see Tables 4.3–4.5 below). Supratentorial lesions tended to be more 
common (50–86%) than infratentorial lesions.  
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Notes 
ICH  intracranial haemorrhage; S  seizure; FND  focal neurological deficit; H  headache; I  incidental;  supra  supratentorial; infra  infratentorial.  *  Median. 
a  Age at last contact      
b  12% had multiple CCMs located in both areas. 
c   Includes patients who presented with initial episode of ICH from CCM not in brainstem.     
d   43 superficial location; 3 deep location.  
Study Recruitment 
      Age (years) 
mean       range 
Female 
(%) 
Presenting symptoms (%) 
    ICH       S      FND         H          I  
CM location (%) 
Supra         Infra 
Curling et al (1991) Bowman Gray School of Medicine, NC 37.6a 16–72a 47    9 50 22  34  19 72b   16b 
Robinson et al (1991) Cleveland Clinic Foundation, OH 34.6 0–84 45 9 52 45 30  14 84   16 
Fritschi et al (1994) Bern, CH + Barrow NI + literature 31.8 2–69 51 ― ― ― ―    0  0 100 
Zabramski et al (1994) Barrow Neurological Institute, Phoenix, AZ 25 7–51 58 ― 39 ― 52  39 92     8 
Aiba et al (1995) Niigata University, Japan ― ― 46   56 23 ― ―  21 66   34 
Kondziolka et al (1995) University of Pittsburgh, PA 37.3 4–82 51   50 23 ― 15 ― 48   52 
Kim et al (1997) Yonsei University Coll. of Medicine, Seoul 32.2 4–63 39  41  8  6  12 69   31 
Porter et al (1997) University of Toronto VM Study Group 37.5 ― 49   25 36 20  6  12 64   36 
Abdulrauf et al. (1999) Yale University School of Medicine 31.6 4–70 ―   44 22 20   0  15 64   36 
Moriarity et al (1999) Johns Hopkins Hospital, Baltimore, MD 34.6 7–78 65   13 49 46 65   2 81   19 
Porter et al (1999) Barrow Neurological Institute, Phoenix, AZ 37 3–64 62   97 ― ― ―   3   0 100 
Barker et al (2001) Massachusetts General Hospital, Boston 35* 4–63 56 100 ― ― ― ― 50   50 
Kupersmith et al (2001) Beth Israel Medical Center, NYC 37.5 6–73 59   73 ― ― 43 ―   0 100 
Labauge et al (2001) INSERM, Paris 40.8 13–65 58     0   0   0    0 100 86   14 
Hasegawa et al (2002) University of Pittsburgh, PA 37.7 4–81 44 100 ― ― ―    0 21   79 
Mathiesen et al (2003) Karolinska Institute, Stockholm ― ― ― ― ― ― ―  19   0 100 
Wang et al (2003) Beijing Neurosurgical Institute, Beijing 33.5 3–70 42 100 ― ― ―    0   0 100 
Ghannane et al (2007) Clermont-Ferrand, France 40.1 7–78 51    0 32 38 30  19 56   28 
Tarnaris et al (2008) National Hospital for Neurology, London 36.8 ― 67   57   0 24 ―  19c   0 100 
Hauck et al (2009) Southwestern Medical Center, Dallas, TX 37.5 10–77 68 ― ― ― ―    0   0 100d 
Abla et al (2011)  Barrow Neurological Institute, Phoenix, AZ 41.8 19–77 60   97 ― 2.7 ―    0.4   0 100 




R     retrospective study;     P      prospective study;      
H     hospital;      IVM   IVM study group referral unit;     L   literature;     MC   multicentre;    N    neurosurgery unit;    NO  neuro-ophthalmology unit; 
RS   radiosurgery unit 















Curling et al (1991) R  1 H 32  – – 0.3% per person-year  
Robinson et al (1991) R  1 H 66 2.2 –  0.7% per lesion-year 
Fritschi et al (1994) R brainstem 2 N + L 41 + 98 2.5 0–32 2.7% per lesion-year 21% per lesion-year 
Zabramski et al (1994) P familial 1 N 21 2.2 1–5.5 - 6.5% per patient-year 
Aiba et al (1995) R  1 N 110 4.7 –  0.4% per patient-year 22.9% per lesion-year 
Kondziolka et al (1995) R + P conservative 
management 
1 N 122 2.8 0.1–6.8 0.6% per patient-year 
2.4% per patient-yeara 
4.5% per patient-year 
5.0% per patient-yeara 
Kim et al (1997) R  1 H 62 1.9 1–4 2.3% per patient-year 3.8% per patient-year 
Porter et al (1997) R + P  1 IVM 110 3.8 –   
Abdulrauf et al. (1999) R  1 N 55 – –   
Moriarity et al (1999) P  1 N 68 5.2 – 3.1% per patient-year  
Porter et al (1999) R brainstem 1 N 100 2.9 – - 30.2% per patient-year 
Barker et al (2001) R bled at presentation 1 N 136 3.8 – - 14% per patient-year 
Kupersmith et al (2001) R brainstem 1 NO 37 4.9 0.2–23   
Labauge et al (2001) P asymptomatic familial    MC 33 2.1 0.5–4.5 4.3% per patient-year - 
Hasegawa et al (2002) R + P bled at presentationb 1 RS 82 4.3 0.2–18 - 33.9% per patient-year 
Mathiesen et al (2003) R + P brainstem + deep 1 N 68  4.6 –  2% per patient-year 7% per patient-year 
Wang et al (2003) R brainstem 1 N 137 1.8 0.5–11 6% per patient-year 60% per patient-year 
Ghannane et al (2007) R  1 N 79 total 





0.01% per patient-year 6.27% per patient-year 
Tarnaris et al (2008) R brainstem 1 N 21 6.6 0.5–20 - 5% per patient-year 
Hauck et al (2009) R symptomatic 
brainstem 
1 N 44 0.3 0–8 - 42% per patient-year 
Abla et al (2011) R brainstem, surgical 1 N 260 4.3 0–37 - 35% per patient-year 
Table 3.3 Summary of initial haemorrhage and re-haemorrhage rates in published studies 
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0 10 20 30 40 50 60 70
First/recurrent ICH not distinguished 
 
Robinson et al., 1991 None 66 
Zabramski et al., 1994 Familial 21 
Porter et al., 1997 None 110 
Moriarity et al., 1999 None 68 
Ghannane et al., 2007 None 39 
First ICH    
Aiba et al., 1995 None 48 
Kondziolka et al., 1995 None 61 
Flemming et al., 2012 None 174 
Al-Shahi Salman et al., 2012 None 96 
Mathiesen et al., 2003 Brainstem + deep 11 
Recurrent ICH    
Aiba et al., 1995 None 62 
Kondziolka et al., 1995 None 61 
Kim et al., 1995 None 28 
Barker et al., 2001 None 136 
Flemming et al., 2012 None 74 
Al-Shahi Salman et al., 2012 None 18 
Fritschi et al., 1994 Brainstem 101 
Porter et al., 1999 Brainstem 100 
Hasegawa et al., 2002 Brainstem 83 
Wang et al., 2003 Brainstem 137 
Mathiesen et al., 2003 Brainstem + deep 23 
Tarnaris et al., 2008 Brainstem 21 
Study  Selection criteria Sample size 
Rate/risk* 
Note 
The rates and risks in this figure are as reported 
in the literature; inconsistent methods were 
used in their calculation, but they are presented 
as a rough guide of the state of knowledge. 
Figure 3.2 Symptomatic intracranial haemorrhage rates during follow-up in studies of the untreated clinical course of participants diagnosed 
with cerebral cavernous malformations (point estimates and 95% confidence intervals) 
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Del Curling and colleagues conducted a retrospective study, reviewing all the MRI 
scans from the North Carolina Baptist Hospital between 1986 and 1989. From 8,131 
images, 32 patients (with 76 lesions) fulfilled their criteria for CCM diagnosis (Del 
Curling et al., 1991); 23 (72%) had supratentorial location, five (16%) infratentorial, 
and four (12%) had lesions in both locations. Only three patients had sustained a prior 
haemorrhage, and the haemorrhage rate was thus calculated as 0.25% per person-year 
of exposure or 0.1% per lesion per year, using the lifetime-risk method. They 
concluded that cerebral cavernous malformations were more common than had 
previously been believed, but recommended that the risks and benefits of surgery be 
carefully assessed for each patient before surgical excision, as the risk of haemorrhage 
was low in these patients; they also advocated that a large prospective study be 
undertaken to examine the natural history and management of the disease. 
In a similar retrospective study (n = 66), Robinson and colleagues at the Cleveland 
Clinic Foundation in Ohio reviewed 14,035 consecutive MRI scans performed there 
between 1984 and 1989. They reported six people presenting with haemorrhage, and 
a single haemorrhage occurring in 143 lesion-years of follow-up; 86% of the adults 
who had experienced a haemorrhage (n = 7) were women, and the researchers 
calculated a haemorrhage rate during follow-up of 0.7% per lesion per year (Robinson 
et al., 1991). They noted that patients with infratentorial lesions were more likely to 
present with FND (p = 0.006), whereas those with supratentorial lesions were more 
likely to present with seizure (p = 0.005). 
In a prospective study of 68 patients (44 of whom were female), followed between 
1987 and 1996 at the Johns Hopkins Hospital, Baltimore, Moriarity and colleagues 
also noted that patients with supratentorial lesions were more likely to present with 
seizure. They calculated an overall ICH rate of 3.1% per patient-year, and argued that 
prior haemorrhage was not a risk factor for ICH in follow-up (of mean duration 5.2 
years), as none of the patients who sustained an ICH in follow-up presented with an 
ICH (Moriarity et al., 1999). In addition, female patients had a significantly higher 
prospective ICH rate (4.2% per patient-year, compared with 0.9% per patient-year for 
men). They concluded that despite the fact that the surgical patients in their series had 
a good outcome, asymptomatic lesions are best managed conservatively. 
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At the University of Pittsburgh, in Pennsylvania, Kondziolka et al. prospectively 
followed 122 patients whose CCM was visualized on MRI between 1987 and 1993, 
and in whom conservative management was recommended, for a mean of 34 months 
(Kondziolka et al., 1995). In this cohort, 50% had experienced at least one prior 
haemorrhage, and 52% of lesions were located in the brainstem, basal ganglia or 
thalamus. The prospective haemorrhage rate in those who had not previously sustained 
a haemorrhage was 0.6% per patient-year, and the prospective re-haemorrhage rate 
was 4.5% per patient-year, demonstrating the fact that once a lesion has bled, the 
probability of experiencing a re-bleed is greatly increased. They found no significant 
difference in haemorrhage rate for men and women, by lesion location, or between 
patients with or without seizures, or between subjects with solitary or multiple lesions 
(no patient with multiple lesions had a haemorrhage in follow-up); the occurrence of 
a prior haemorrhage was the most important risk factor for re-haemorrhage. The 
authors did acknowledge, however, that their findings might be affected by selection 
bias, since their patients had been referred to a tertiary referral centre that specialized 
in microsurgical and radiosurgical procedures; nevertheless 61 patients in their study 
had never suffered a haemorrhage. 
In Niigata University in Japan, Aiba and colleagues conducted a retrospective study, 
with 110 patients, 56% of whom presented with a haemorrhage (Aiba et al., 1995). 
They reported a first haemorrhage rate of 0.39% per patient-year in the seizure and 
incidental groups, where there was a single bleed in 254 patient-years of follow-up, 
and a re-haemorrhage rate of 22.9% per lesion per year in those who had initially 
presented with a symptomatic haemorrhage (45 haemorrhages in a mean follow-up 
period of 4.7 years), thus demonstrating the huge effect that prior haemorrhage has on 
the re-bleed rate. They also found that younger female patients (under 40 years of age) 
had a significantly higher risk of re-bleed compared to both male groups and female 
older age-groups, and they attributed this to female hormonal factors. They observed 
that recovery from initial haemorrhage was good, even when managed conservatively, 
unless the lesions occurred in eloquent areas of the brain; however, recurrent bleeds 
did result in permanent neurological deficits. 
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Porter and colleagues analysed the data of all the patients who had been referred to the 
University of Toronto Brain Vascular Malformation Study Group between 1989 and 
1996. This is a prospective study with 173 patients at baseline (although follow-up was 
based on 110, because 63 were not considered to be eligible to be included in the study, 
as they could not contribute sufficient follow-up). Of the 173 adults, 25% presented 
with haemorrhage, 36% seizure, 20% FND and 12% incidentally. The mean follow-
up (n = 110) was 3.8 years, and an overall haemorrhage rate was calculated as 1.6% 
per patient-year (Porter et al., 1997). However, this rate includes adults who presented 
with ICH (two), FND (four) and incidentally (one), so it cannot be compared with 
other rates that are calculated as first or recurrent ICH.  
They found that CCM location – not prior haemorrhage – was the most important, and 
statistically significant, risk factor for haemorrhage: in those with supratentorial 
lesions, there was a single haemorrhage (in a thalamic lesion) during 268 patient-years 
of follow-up (0.4% per year), compared with six haemorrhages in patients with 
infratentorial lesions during 160 patient-years of follow-up (3.8% per year) (p = 
0.008). If this was re-classified as deep versus superficial, then there were seven 
haemorrhages in 170 patient-years of follow-up (4.1% per year) of lesions in deep 
locations, compared with no bleeding in 258 patient-years of follow-up in superficial 
lesions (p = 0.0003). When haemorrhage and FND (defined as ‘clinical events’) were 
examined by location, there was a single event among patients with supratentorial 
lesions (0.4% per year), whereas those with infratentorial lesions experienced 17 
events, yielding an event rate of 10.6% per year (p = 0.0001); all the events related to 
lesions in deep locations. Of the 59 patients who sustained an ICH or FND (either at 
presentation or during follow-up), 37% recovered completely, 36% had a partial 
recovery, but 27% showed no improvement at the end of follow-up. Interestingly, 
neither location, nor haemorrhagic versus non-haemorrhagic events affected the level 
of patient recovery (Porter et al., 1997).  
Porter and co-workers contacted patients who had not been seen at the clinic in the 
twelve months prior to the end of the study by telephone, in an attempt to eliminate a 
potential follow-up bias. The researchers decided a priori that only ICH (or clinical 
events) where the patient had been examined would be included in the analysis, but 
 
 
  27 
because no patient contacted by telephone had suffered an ICH (clinical event), this 
situation did not occur. This prompted their observation that patients who remain in 
good health are less likely to see their clinician and are more likely to become lost to 
follow-up. However, the authors make the interesting comment that had they not 
decided to contact these patients by telephone, these individuals would have been 
classified as lost to follow-up (Porter et al., 1997); if this situation had arisen, the 
prognosis would have appeared worse, since the data from several stable patients 
would have been missing and the denominator of patient-years of follow-up would 
have been smaller, thus resulting in an apparently greater haemorrhage risk.  
In their retrospective study of patients who had attended the neurosurgical department 
at Clermont-Ferrand between January 1990 and March 2005, Ghannane and 
colleagues reported a haemorrhage rate of 6.3% per patient-year in the 39 patients who 
did not receive surgical intervention (Ghannane et al., 2007). In a study of all cranial 
MRI scans between mid-1990 and mid-1994 at Yonsei University College of Medicine 
in Seoul, Kim et al. reported recurrent haemorrhage rates of 3.8% per patient-year or 
1.4% per lesion-year; they recommended surgical excision of lesions in patients with 
recurrent or acute progressive symptoms, and stressed the importance of complete 
removal of the lesion (Kim et al., 1997). 
Fred Barker and colleagues at Massachusetts General Hospital, Boston, investigated 
whether haemorrhages from cavernous malformations had a tendency towards 
temporal clustering (Barker II et al., 2001). They retrospectively reviewed 136 patients 
who had presented with symptomatic haemorrhage and had subsequently been treated 
surgically or with proton-beam radiosurgery between 1978 and 1995; the total follow-
up period, between first presentation and treatment, was 538 patient-years. During this 
time, 47 patients sustained a second haemorrhage and 16 had additional bleeds (12 had 
two re-bleeds, 2 three, and one person each had four and five re-bleeds), giving 
cumulative re-haemorrhage rates of 14%, 34%, 49%, 56% and 72% one, two, three, 
five or ten years after the initial haemorrhage. They discovered the monthly 
haemorrhage risk was 2% during the first 2.5 years, but that it declined spontaneously 
to less than 1% per month thereafter. They also noted that re-haemorrhage rates were 
higher in younger patients (up to 34 years), but that neither sex, lesion location, number 
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of previous haemorrhages nor time-interval between previous haemorrhages had any 
significant effect on re-haemorrhage rates. 
Hasegawa and colleagues examined the long-term results for 82 patients with high-
risk cavernous malformations who had been treated with stereotactic radiosurgery at 
the University of Pittsburgh between 1987 and 2000 (Hasegawa et al., 2002). At entry 
to the study, 76 (93%) had sustained multiple haemorrhages (range 2 to 7), and six had 
experienced a single haemorrhage but with a subsequent decline in neurological 
function; the lesions were located in critical brain areas (79% infratentorial location) 
and several patients had previously undergone surgery. The results were subdivided 
into two groups: pre-radiosurgery (time from first image-documented haemorrhage to 
radiosurgery, mean duration 4.3 years) and post-radiosurgery (mean duration 4.9 
years). Average annual ICH rates were 33.9% and 12.3% respectively; however, when 
haemorrhage rate for each individual year in the pre- and post-radiology period is 
examined, the pre-treatment haemorrhage rate starts high, but gradually decreases by 
the sixth year, and the first-year post-treatment rate is similar to the sixth-year pre-
treatment rate. The study design is somewhat questionable as the control group is the 
pre-radiosurgery group. Although the authors acknowledge Barker’s research on 
temporal clustering, they argue that their series is different as fewer of Barker’s 
patients (46%) experienced a second haemorrhage. The radiosurgical morbidity rate 
was 13.4%. The authors stress two points, however: first, the patients in this study 
were a highly select group, 93% of whom had sustained multiple haemorrhages and 
their lesions were located in areas of the brain that were associated with an 
unacceptably high surgical risk of morbidity, and second, that imaging technology is 
continually developing and hence the ability to target the lesion is improving. The 
authors suggested that younger patients who had sustained a single haemorrhage with 
major neurological deficit should possibly be considered for radiotherapy. However, 
several other clinicians have advised caution in interpreting these results (see the 
Comments, following the paper) and the need for further study (Kim et al., 1997, Porter 
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Familial cavernous malformations 
For 5.5 years, between mid-1986 and the end of 1991, Zabramski et al. studied cerebral 
cavernous malformations in six unrelated Arizona families, five of which were of 
Hispanic descent (Zabramski et al., 1994). Of 118 surviving family members, 59 were 
located and willing to participate in the screening evaluation; 31 patients (53%) were 
found to have at least one CCM on MRI, and of these, 21 people (15 symptomatic) 
agreed to take part in the prospective natural history study (mean follow-up 2.2 years). 
Three patients (two with epilepsy and one previously asymptomatic, who developed 
seizures during follow-up) had a re-bleed during follow-up, which resulted in a re-
haemorrhage rate of 6.5% per patient-year or 1.1% per lesion-year. They discovered 
that the lesions changed in size and number (17 new lesions in six patients, giving a 
growth rate of 0.4 lesions per patient-year) during the comparatively short follow-up 
period, and recommended repeat imaging using gradient-refocused MRI at annual 
intervals for symptomatic patients. 
Between December 1996 and October 1999, in a national French survey, Labauge et 
al. prospectively followed 33 clinically asymptomatic non-Hispanic patients with 
familial CCMs for a mean period of 2.1 years (Labauge et al., 2001). They confirmed 
the dynamic nature of this form of the disease and the appearance of 30 de novo lesions 
in ten patients during follow-up; they estimated a lesion growth rate as 0.4 lesions per 
patient-year. There were three haemorrhagic events: one clinically symptomatic 
(haemorrhage within the brainstem) and two asymptomatic: the symptomatic 
haemorrhage rate was 1.4% per patient-year (or 0.2% per lesion-year), and the total 
haemorrhage rate was 4.3% per patient-year (0.6% per lesion-year). They commented 
that the overall haemorrhage rate (calculated in lesion-years) in their study was similar 
to that of patients with the sporadic form of the disease; patients with the familial 
disease tend to have a higher incidence of haemorrhages because they tend to have 




Brainstem cavernous malformations 
In a retrospective study, Fritschi and colleagues reviewed 139 cases of brainstem CCM 
and found a first haemorrhage rate of 2.7% per lesion per year (using the lifetime-risk 
method), and a re-haemorrhage rate of 21% per lesion per year; there was no difference 
between the sexes (Fritschi et al., 1994). They recommended that excision of 
symptomatic brainstem lesions should only be carried out by experienced surgeons in 
a few specialist centres, and that asymptomatic lesions should be monitored regularly; 
they also stated that the probability of a good surgical outcome in the case of deep 
lesions in the brainstem that lack a superficial extension was very small, due to their 
proximity to eloquent areas.  
Randall Porter and colleagues retrospectively examined the case histories of 100 
patients with brainstem CCMs who had attended the Barrow Neurosurgical Institute 
in Arizona between 1984 and 1997 (Porter et al., 1999); 97 had presented with a 
haemorrhage, and brainstem lesions were discovered in three people incidentally. All 
of the 86 patients whose lesions were surgically excised had an associated venous 
anomaly, which was preserved in tact in 85 cases to avoid the risk of venous infarction. 
The authors observed that the natural history of brainstem CCMs is worse than that of 
CCMs in other locations: the haemorrhage rate for brainstem CCMs is higher, and 
there is an increased probability of a re-haemorrhage (which in their series was 30.2% 
per patient-year). For this reason, they recommended surgical excision in cases where 
the symptomatic lesion abuts a pial surface or is surrounded by a thin rim of brainstem 
tissue. However, they also acknowledged that conservative management may be 
appropriate for people with an asymptomatic brainstem lesion or for people who have 
made a complete recovery from a single haemorrhage. 
Mathiesen et al. prospectively followed 68 patients with brainstem or deep CCM who 
had presented at the Department of Neurosurgery at Karolinska Hospital in Stockholm 
between 1992 and 2000 (Mathiesen et al., 2003); 29 underwent microsurgery, five 
gamma knife surgery and 34 did not receive surgical intervention. The last group 
consisted of those with incidental lesions (11), those medically unfit, or with lesions 
where the risk of surgery was deemed unacceptably high. Through data linkage, the 
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authors calculated an incidence of 3.2 persons per million per year for those with 
symptomatic deep or brainstem CCMs, and 0.8 persons per million per year for 
incidental deep or brainstem CCMs in the catchment area for their institution, although 
they acknowledge that the latter figure is an underestimate of the true incidence of 
asymptomatic deep or brainstem CCMs. Analysing their data relating to the 
conservatively managed group, they concluded that incidental lesions had a low risk 
of neurological deterioration: an ICH rate of 2% per year compared with 7% per year 
in patients with symptomatic lesions. Thus they advocated that incidental brainstem or 
deep lesions should be managed conservatively, as did Wang and colleagues in Beijing 
(Wang et al., 2003). In a small study comparing six adults with brainstem lesions 
whose lesion was excised and 15 with brainstem lesions who were conservatively 
managed, Tarnaris and colleagues recommended that the ‘conservative approach 
should not be so easily overlooked’ (Tarnaris et al., 2008). 
Mathiesen’s group also stressed that timing of surgery appeared to influence the 
outcome and advised that patients should receive surgery between two and four weeks 
after ictus, but only if the surgeon was confident that total removal of the lesion was 
possible: partial removal resulted in a worse outcome than following conservative 
approach. Radiosurgery was not deemed to be an effective therapy for deep and 
brainstem lesions (Mathiesen et al., 2003, Wang et al., 2003, Hauck et al., 2009). 
Two papers have been published more recently, examining the management of 
brainstem CCM. In the first paper, Erik Hauck and colleagues retrospectively reviewed 
clinical data of all patients who had presented with a symptomatic brainstem CCM at 
the Department of Neurosurgery at the University of Texas, Southwestern Medical 
Center, between 1995 and 2007, and who had subsequently had their lesion surgically 
excised (n = 44) (Hauck et al., 2009). In the pre-treatment period, twenty people had a 
single haemorrhage and 23 at least one recurrence; the median time between first and 
second events was two years, with the risk of a recurrence being 42% per year; eight 
patients had more than two events, and the median time between the second and third 
event was only five months, with a risk of a second recurrent event being 8.6% per 
month. Although women and younger patients (under 40 years) had a shorter event-
free interval, sex and age were not statistically significant.  
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The risk of future recurrent events was reduced after surgery, but a comparison of pre- 
and post-operative scores on the modified Rankin scale did not demonstrate a huge 
improvement in patient outcome: only 30% had an improved outcome after surgery, 
whereas 70% remained the same (59%) or had a worse outcome (11%). In addition, 
there were a large number of surgical complications, and eight patients required repeat 
surgery. Weighing up both the increased risk of a haemorrhage after each successive 
event, and the fact that a patient’s pre-operative condition is a strong predictor of their 
functional outcome after surgery, with the risks of surgery, the authors ‘encourage 
neurosurgeons to consider surgery after a first event’. However, in his review of the 
paper, Christopher Ogilvy drew attention to the selection bias in the report: Hauck et 
al. only analysed patients with symptomatic brainstem lesions who had undergone 
surgery, which was a very distinct subgroup and was not representative of the 
population with brainstem lesions who had presented at the hospital. Ogilvy 
emphasized the surgical complication rate, and the fact that 70% of the sample did not 
experience an improved outcome (Hauck et al., 2009). 
In the second paper, Abla and colleagues at the Barrow Neurological Institute in 
Phoenix, Arizona, retrospectively reviewed all the adult surgical cases of brainstem 
CCMs that Robert Spetzler, the senior author, had treated between 1985 and 2009 
(Abla et al., 2011). (Some of these participants were included in the earlier paper by 
Randall Porter and colleagues (Porter et al., 1999).) Of the 260 adults (female : male 
ratio of 3 : 2), 252 (97%) had presented with either a clinical or radiographic history 
of haemorrhage, seven were suffering from progressive neurological deficits, and one 
lesion was discovered incidentally. Between presentation and surgery (mean time 4.5 
years for those with multiple bleeds), 146 of the 252 patients experienced at least one 
re-bleed: 96 had one re-bleed, 32 had two, and 18 had three or more re-bleeds, leading 
to an annual  re-bleed rate during the observation period of 35% per patient-year in 
these patients. The authors stressed that this re-haemorrhage rate was not typical of all 
patients with brainstem CCMs, as these patients had been referred to a tertiary 
specialist centre; the annual risk of haemorrhage for patients referred to the unit after 
a single haemorrhage was in the region of 15% per patient-year. After surgery, 18 
patients (6.9%) sustained 20 haemorrhages, and 12 of these patients required a second 
operation; the annual risk of post-operative haemorrhage was calculated at 2% per 
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patient. In addition, 93 patients (36%) had permanent new neurological deficits. Eight 
deaths occurred between surgery and last follow-up; however, these deaths occurred 
in the first 88 patients, and the surgical technique changed during the course of the 24 
years. The mean Glasgow Outcome Scale at admission, discharge and at last follow-
up was 4.4, 4.2 and 4.6 respectively.  
The authors concluded that in their institute surgery was offered to patients with 
symptomatic brainstem lesions that were surgically accessible, because of their 
increased risk of re-haemorrhage. However, if the symptoms are mild and the lesion 
deep-seated, then patients are observed to see whether a future bleed occurs and 
whether the lesion reaches a pial surface.  
In his Comment on the paper, Robert Solomon drew attention to the referral and 
selection bias of the study, and the fact that the neurosurgeon was exceptionally 
experienced and his results might not be replicated by a less experienced 
neurosurgeon. In Solomon’s experience the majority of patients with symptomatic 
brainstem cavernous malformations do not experience a second event, or, if they do, 
often have mild symptoms. Thus he did not agree with the authors’ conclusion that 
surgery should be offered to any patient with a surgically-accessible and symptomatic 
brainstem CCM. Solomon recommended that most patients should be conservatively 
managed and surgery should only be offered to those patients experiencing multiple 
haemorrhages and progressive neurological decline (Abla et al., 2011, Haque et al., 
2008). These differing views illustrate the fact that more research is needed, especially 
on the untreated clinical course of the condition, so that the risks of surgery can be 
weighed against the likely prognosis if conservative management is followed. 
 
Cavernous malformations with associated venous malformations 
Abdulrauf and colleagues at Yale University School of Medicine retrospectively 
compared 55 consecutive patients, who had presented over the course of four years, 
with CCMs with and without associated venous malformations (venous develop-
mental anomalies) (n = 13 and 42, respectively). They observed that women are more 
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likely to have a CCM with an associated venous malformation (Abdulrauf et al., 1999), 
and these lesions (CCM + VM) were found more frequently in patients with the 
sporadic form of the disease. Patients with mixed vascular malformations tend to have 
lesions located in the posterior fossa; they are less likely to present with seizures, but 
more likely to present with symptomatic haemorrhage, and the disease will probably 
have a more aggressive course. 
 
Haemorrhage risk 
Point estimates of haemorrhage risk have been calculated in several of the published 
accounts (see Table 3.3), and are shown in 3.2. As can be observed, there is 
considerable variation in the risks for a recurrent haemorrhage; however, some of the 
variation is a result of the method used to calculate the risk rather than disparity in the 
actual risk of haemorrhage. Some researchers have included all haemorrhages after the 
initial one as a numerator, which obviously will inflate the risk of haemorrhage. A 
more useful method for patients is to include only second bleeds, to give a risk of a 
first recurrence, and to exclude third and subsequent events. 
In a comment at the end of Moriarity and colleagues’ paper, Issam Awad puts forward 
the proposition that the neuro-imaging policy of a hospital may influence the 
haemorrhage rates of CCMs in infratentorial and supratentorial locations in that 
establishment, and even whether the rates differ between the two CCM locations 
(Moriarity et al., 1999). Awad suggests that in some centres lesions are only scanned 
during follow-up if the patient experiences certain symptoms; in this scenario, more 
serious symptoms are more likely to be associated with lesions in infratentorial 
locations than those in supratentorial locations; therefore more patients with infra-
tentorial lesions will be scanned and there is a greater chance of a symptomatic 
haemorrhage being detected in these locations. Conversely, there is a reduced chance 
of an asymptomatic haemorrhage being detected in supratentorial lesions, and this will 
affect the haemorrhage rate in this location. In centres where neuro-imaging is more 
frequent and the neuro-imaging threshold is lower, patients with lesions in either 
location will be scanned and more asymptomatic ICH will be detected: thus the 
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disparity between ICH rates in infratentorial and supratentorial locations may be less 
likely to exist in these centres. Awad argues that there does not appear to be a 
biological reason for the increased frequency of haemorrhage in infratentorial or deep 
lesions. Nevertheless, Porter and co-workers make a valid point when they assert that 
neurological deficit is of greater relevance to the patient, whether or not it is 




From the studies cited above, it can be observed that the course of the disease seems 
to be relatively benign for most people diagnosed with CCM, especially for those 
whose lesion is located in a supratentorial region. However, this research is limited to 
the risk of intracranial haemorrhage or focal neurological deficit in follow-up; for a 
small number of people with intractable epilepsy, the disease may appear to be less 
benign. In addition, patients with lesions located in the brainstem tend to have an 
increased risk of developing clinical symptoms and disability, because of the high 
density of eloquent tissue in that location (Berg and Vay, 2011).  
The probability of a fatal haemorrhage is low for adults diagnosed with CCM, whereas 
the probability of complete or good recovery following an initial haemorrhage is high; 
indeed 80% of patients experience only a transient deficit after an initial bleed (Kuker 
and Forsting, 2008). Nonetheless, several researchers have noted an increased risk of 
re-bleeding after an initial haemorrhage, and with each subsequent haemorrhage there 
is a greater probability that the patient’s outcome will deteriorate permanently; usually 
patients who sustain more than two haemorrhages from the same lesion suffer a 
persistent neurological deficit. Moreover the prognosis for brainstem lesions is worse, 
with a re-bleed rate greater than 5% per patient-year (Kuker and Forsting, 2008, 
Josephson and Al-Shahi Salman, 2011).  
 In their review, Maraire and Awad commented that most cerebral cavernous 
malformations are diagnosed between the ages of 20 and 50 years: patients who 
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present before they reach the age of 30 are more likely to be male, whereas women 
tend to present between the ages of 30 and 60 (Maraire and Awad, 1995). Patients who 
are younger than 40 years at presentation tend to suffer seizures, whereas focal 
neurological deficits and haemorrhage are more common in older patients and children 
(Requena et al., 1991, Maraire and Awad, 1995, Ebrahimi et al., 2009). However, El-
Koussy and colleagues report no such sex-related modes of presentation in their large 
retrospective study of patients who were seen at Inselspital, a tertiary care centre and 
part of the University of Bern, in Switzerland, over the course of twenty years (n = 
347) (El-Koussy et al., 2011). Patients with lesions in infratentorial locations are more 
likely to present with FND, whereas those with supratentorial lesions are more likely 
to present with seizure (Robinson et al., 1991, Moriarity et al., 1999, Batra et al., 2009). 
There is a certain level of disagreement among authors regarding risk predictors for 
haemorrhage. Robinson, Aiba, Abdulrauf, Moriarity and Wang all agree that women 
are more likely to experience a re-bleed than men, and Aiba also reports that younger 
women (under 35 years) have an increased risk of haemorrhage (Robinson et al., 1991, 
Aiba et al., 1995, Abdulrauf et al., 1999, Moriarity et al., 1999, Wang et al., 2003). On 
the other hand, Fritschi, Kondziolka, Porter, and Kuker and Forsting specifically state 
that there is no sex difference (Fritschi et al., 1994, Kondziolka et al., 1995, Porter et 
al., 1997, Kuker and Forsting, 2008), and Engelmann et al. write: ‘based on more 
recent evidence, it is now generally accepted that CMs behave similarly in both 
genders’ (Engelmann et al., 2011). Interestingly, data from the first Scottish cohort 
very definitely opposed this view; however, data from the second cohort are consistent 
with it (see Chapters 4 and 8 below).  
Several researchers, including Aiba, Kupersmith and Zabramski, state that younger 
patients (under 35 years) have an increased risk of experiencing bleeds or re-bleeds 
(Zabramski et al., 1994, Aiba et al., 1995, Kupersmith et al., 2001). Robinson and 
colleagues, however, could find no evidence in their study that haemorrhage rates 
differed between younger and older patients (Robinson et al., 1991).  
Prior haemorrhage was observed as a risk factor by Aiba and Kondziolka, although 
Moriarity categorically stated that it was not a risk factor in his study (Aiba et al., 1995, 
Kondziolka et al., 1995, Moriarity et al., 1999). Phillip Porter and colleagues found 
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that most people who experience haemorrhage or a focal neurological deficit in follow-
up had already experienced a prior haemorrhage or FND, but they did not find an 
association with sex; they explicitly stated that ‘lesion location, and not previous 
haemorrhage, is the most important factor in predicting haemorrhage or events’ (Porter 
et al., 1997). They observed 18 haemorrhages and FNDs during follow-up in patients 
with deep lesions (17 infratentorial and one thalamic), and no events in patients with 
superficial lesions. Moriarity and co-workers reported that patients with infratentorial 
lesions were significantly more likely to present with FND than patients with a 
supratentorial lesion (p = 0.003) (Moriarity et al., 1999). In their study on temporal 
clustering, Barker et al. suggested that the risk of a lesion re-bleeding was elevated for 
2.5 years immediately following the bleed, then it reverted spontaneously to a lower 
level (Barker II et al., 2001). In his Comment at the end of Moriarity’s paper, Issam 
Awad suggests that some of the discrepancy among researchers regarding re-
haemorrhage rate may be due to the fact that surgeons in different medical 
establishments operate at different stages in the clinical course. Some will decide to 
excise a lesion soon after the initial haemorrhage, thereby providing a very short 
window for a re-haemorrhage to occur and hence a potentially lower risk of re-
haemorrhage at that institution, whereas others will be more cautious and allow a 
longer time to elapse, during which the individual may re-bleed (Awad in (Moriarity 
et al., 1999)). 
No researchers observed a statistically significant association between lesion size and 
risk of haemorrhage (although Kupersmith and co-workers commented that lesions 
that were larger than 1 cm in diameter were associated with a higher risk of bleeding) 
(Kupersmith et al., 2001). Neither CCM multiplicity, nor the form of the disease 
(sporadic versus familial), nor seizure at presentation were associated with an 
increased risk of haemorrhage. 
Several authors stated in their conclusions that a larger, prospective study with a longer 
follow-up period was required (Del Curling et al., 1991, Fritschi et al., 1994, Maraire 
and Awad, 1995, Yoon et al., 1998, Abdulrauf et al., 1999, Hauck et al., 2009). In 
1999, a prospective, population-based study began recruitment – the Scottish 
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Intracranial Vascular Malformation Study (SIVMS) (http://www.saivms.scot.nhs.uk/) 




This chapter is based on the literature search and review that I included in my first-
year report (November 2011). In September 2014, I updated the two database searches 
to check for publications in the intervening period (2010–current). I found 185 records 
in the Embase search and 122 in the Medline search. The combined searches contained 
27 duplicate records, and a further 229 records that were not relevant (genetic studies, 
case reports or less than 20 sample size, imaging reports, or children, or too 
specialized) were deleted. Of the 51 remaining records, eleven examined the untreated 
clinical course (including our paper and two from our collaborators at the Mayo Clinic) 
and four functional outcome (two of which were abstracts in conference proceedings). 
However, I discovered no new information about the risk of haemorrhage in untreated 
follow-up. I had previously read four of the eleven papers and a fifth was a reprint of 
a paper published in the 1990s; two Chinese papers were restricted to brainstem 
lesions, and were an update of an earlier paper (Wang et al., 2003); and a small series 
of 29 surgical patients were described in a Brazilian paper (De Araujo Jr et al., 2011).  
With the benefit of hindsight, were I to embark on a review of the literature again, I 
would create more tables in greater detail, before starting the reading, to facilitate a 
more systematic means of note-taking. However, I would stress that my intention was 
to provide a concise review of the literature available at the time, rather than to 
undertake a full-blown systematic review.  
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Untreated clinical course 11 
ICH     1 
Functional outcome    4 
Antithrombotic therapy   2 
Pregnancy     4 
Surgical excision  13 
Stereotactic radiosurgery 10 
Treatment comparison   3 
Familial     1 
Other     2 










Chapter 4: Estimated risk of intracranial 
haemorrhage or focal neurological deficit in 




Until the end of the 1990s, apart from a small prospective population-based study in 
Olmsted County, Minnesota (Brown et al., 1996), all cavernous malformation data 
were derived from hospital-based and often retrospective studies, and were often based 
on post-mortem examination. As discussed in Chapter 3 above, this introduced many 
forms of bias, including selection bias and case-ascertainment bias, since people with 
asymptomatic CCMs or mild cases would not have been seen in hospital, and only 
those with more severe symptoms would probably have been referred to a tertiary 
neurological centre, where most research groups are based. Thus prospective, 
population-based studies of people with cerebral cavernous malformations were 
needed so that the prevalence of the condition in a stable population could be 
estimated, and its clinical course and various treatments could be studied (van Beijnum 
et al., 2008). 
It is important to note that in this thesis the description ‘prospective population-based 
study’ has a more restrictive meaning than in common epidemiological usage. For 
example, the Scottish Intracranial Vascular Malformation Study is frequently 
described as a prospective population-based study, because it recruits all adults 
resident in Scotland (i.e. population-based, rather than patients from a particular 
hospital or group of hospitals) who have received a first-in-a-lifetime intracranial 
vascular malformation diagnosis that has been validated by brain MRI or pathological 
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examination within two five-year time-periods. The date of presentation or date of 
diagnosis is set as the study inception, and all follow-up from this point onwards is 
prospective. It should be borne in mind, however, that the population from which the 
cohort is recruited must have either had a brain MRI or undergone brain surgery, in 
addition to being resident in Scotland during the study recruitment period.  
There are other people in Scotland who have some form of intracranial vascular 
malformation (of which CCM is one type) that is quiescent, who have never needed to 
have a brain MRI for any other cause, and who are therefore unaware of their 
underlying condition; although these individuals are asymptomatic and have the 
disease, their condition has not – yet – been diagnosed (and indeed may never be 
diagnosed). Brain MRI, however, is increasingly being used as an investigative tool 
for people who have suffered a traumatic brain injury, migraine sufferers, people with 
other symptoms or underlying medical conditions, and healthy research volunteers. It 
is estimated that about 1 person in 625 who have a brain MRI will receive an incidental 
CCM diagnosis, even though they have not experienced any symptoms related to the 
disease. Therefore it is crucial that more research is conducted on the risk of future 
ICH or FND for people with CCM who present incidentally, so that clinicians and 
future patients can make decisions on a management plan after incidental CCM 
diagnosis, informed by the likely course of the untreated cavernous malformation.  
Although randomized controlled trials (RCTs) are the optimum means of assessing 
treatment effects, prospective population-based studies nevertheless play a part in 
generating effect estimates and planning RCTs. Longitudinal observational cohort 
studies benefit from a long follow-up period; for example, in the case of SIVMS, 
everyone in the earlier cohort has a minimum of eleven years of follow-up to date. To 
answer accurately the question of how the untreated clinical course of the disease 
progresses, a minimum length of follow-up of at least two decades is likely to be 
required, and ideally follow-up will continue for the duration of the cohort members’ 
lifetime. Longitudinal cohort studies are also useful for comparing long-term patient 
outcome after interventional treatment and conservative management.   
 
 




4.2.1 Study questions 
In this chapter, clinical and functional outcomes of Scottish residents who were 
diagnosed with cerebral cavernous malformation between 1999 and 2010 are 
investigated. The following questions are addressed. 
1. What are the estimated five-year risks of first and second intracranial 
haemorrhages definitely due to CCM?  
2. What are the estimated five-year risks of first and second clinical events 
(intracranial haemorrhage or focal neurological deficit), definitely or possibly 
due to CCM? 
3. Which baseline characteristics modify the risk of ICH or FND occurring within 
five years of CCM diagnosis? 
4. Over the course of five years, from the time of the first clinical event, how does 
the level of dependency compare for adults who have had a single clinical event 
and for those who have had a recurrence? 
 
4.2.2 Scottish Audit of Intracranial Vascular Malformations  
Since Scotland is a geographically distinct area, with its own health service and a fairly 
stable population of 5.06 million in 2001 (annual influx was 0.3% between 2000 and 
2001), which was large enough to support a register of cavernous malformations, it 
seemed an ideal location in which to set up a prospective population-based study. Thus 
the Scottish Intracranial Vascular Malformation Study (SIVMS) was established in 
1998 to enable researchers to investigate the clinical course of the most common 
intracranial vascular malformations. SIVMS is the research arm of the Scottish Audit 
of Intracranial Vascular Malformations (SAIVMs, http://www.saivms.scot.nhs.uk/ ), 
which is a National Health Service clinical audit of all adults living in Scotland at the 
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time of receiving a first-ever diagnosis of any type of intracranial vascular 
malformation (IVM) during two five-year periods: 1999–2003 and 2006–2010 (Al-
Shahi et al., 2003a, Cordonnier et al., 2008).  
Multiple overlapping sources of case ascertainment were used to identify all adults 
diagnosed with an intracranial vascular malformation in Scotland within these two 
time-periods. The major source was a collaborative nationwide neuroscience network 
of physicians, surgeons, radiologists and pathologists who were affiliated with the 
clinical neurosciences and neuro-imaging facilities in Scotland. Clinicians in similar 
specialties who worked in hospitals in Newcastle and Carlisle were also approached, 
to ensure that any patients living close to the Scottish/English border who attended 
English hospitals were not missed. In addition, the Information Services Division 
(ISD) provided hospital discharge and death certificates relating to patients with an 
ICD-10 (International Classification of Diseases, 10th revision) code for an IVM, and 
in the first year all 3,700 general practitioners (GPs) in Scotland were contacted to 
ascertain whether they had any patients who were not already known to SIVMS. No 
new adults were recruited from the GP survey, so this was not repeated (Al-Shahi et 
al., 2003b, Al-Shahi Salman, 2005). 
Although recruitment to SAIVMs ended on 31 December 2010, all participants in the 
audit are followed up annually, for an indefinite length of time, using multiple 
overlapping sources. On the anniversary of IVM diagnosis, each participant’s GP is 
contacted to report their patient’s functional outcome on the Oxford Handicap Scale 
(OHS) (Bamford and Sandercock, 1989). In addition, GP medical notes and hospital 
notes are reviewed in an annual surveillance, and some participants agree to complete 
annual questionnaires on their functional outcome (based on the Barthel Index, Short-
Form 36, and Hospital Anxiety and Depression Scale), with additional questions 
relating to the occurrence of nose bleeds, epilepsy, stroke and whether the participant 
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4.2.3 Study design 
As described above, SIVMS is a prospective, population-based observational cohort 
study that aims to include all adults who were permanently resident in Scotland at the 
time of a first-in-a-lifetime definite diagnosis of any of the three major intracranial 
vascular malformations: brain arteriovenous malformation, dural arteriovenous fistula 
and cerebral cavernous malformations. All participants included in this analysis were 
aged 16 years or over when they received a first-ever CCM diagnosis that had been 
validated by brain imaging (MRI) or pathological examination.  
 
4.2.4 Procedures 
For this analysis, inception is taken as the date of a participant’s initial presentation 
that resulted in a medical investigation and a subsequent CCM diagnosis. For patients 
whose CCM was asymptomatic, inception was taken as the date of the medical 
consultation that led to the clinical investigation as a result of which a CCM was 
diagnosed.  
The follow-up period was five years after inception. The period of time between the 
date of presentation and the date of diagnosis is considered to be retrospective, and 
time from date of diagnosis onwards is prospective. Although more follow-up was 
available for the earlier cohort and also for some adults in the second cohort, a decision 
was taken to truncate follow-up at five years to encourage the standardization of 
outcomes and follow-up length, in order to facilitate comparison with other studies. 
This topic is discussed in greater depth in Chapter 6 (subsection 6.6.2) below. 
In cases where the patient presented with several symptoms, the dominant type of 
clinical event was reported as the presenting event: for example, in the case of someone 
who presented with a headache, an epileptic seizure and an intracranial haemorrhage, 
the haemorrhage would be recorded as the type of presentation, since the other 
conditions are symptomatic of haemorrhage. 
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Distinctions were drawn between intracranial haemorrhage, non-haemorrhagic focal 
neurological deficit (where there is no evidence of recent blood on timely brain 
imaging or pathological examination) and focal neurological deficit not otherwise 
specified (where neither neuro-imaging of the appropriate modality nor pathological 
examination had been performed at all or at the correct time to be able to distinguish 
recent blood), according to published criteria (Al-Shahi Salman et al., 2008), for 
clinical events both at presentation and in follow-up. These outcome events were 
categorized as being either definitely due to the CCM or possibly due to the lesion 
(there being no other adequate explanation).  
Initial presentation was categorized as ‘incidental’ if an adult was asymptomatic (for 
example, an MRI might have been performed after a traumatic head injury) or if their 
symptoms (e.g. headache, tinnitus or other neurological deficit) could not be ascribed 
to the underlying cavernoma. Initial presentation was classified as epileptic seizure if 
the seizure was neither symptomatic of a concomitant intracranial haemorrhage nor 
more likely to be due to another cause.   
 
4.2.5 Data extraction 
For this investigation, two anonymized datasets per cohort were extracted from the 
SAIVMs database: one outcome was first intracranial haemorrhage attributable to a 
cerebral cavernous malformation that occurred after presentation, and the second was 
intracranial haemorrhage or focal neurological deficit, attributable or possibly 
attributable to a cerebral cavernous malformation, that occurred after presentation. 
Each dataset was imported as a flat-form datasheet into SPSS via MS Excel. 
At this stage, however, data were displayed so that each row represented a cavernous 
malformation, whereas the intention of the analysis was to create a model that would 
predict outcome for the patient, rather than according to the CCM. In addition, it would 
create statistical problems if the analyses were performed with individual lesions as 
the observational unit, rather than patients: in the former case, the assumption of 
independence of observations would no longer be valid, as the same patient 
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characteristics would be represented multiple times for those patients who had more 
than one cavernous malformation. Therefore the four datasheets needed to be de-
duplicated so that each row represented a single adult.  
When an adult harbouring multiple lesions presented symptomatically, with a seizure, 
haemorrhage or focal neurological deficit, the mode of clinical presentation was 
attributed to the symptomatic lesion, and the row relating to this lesion was used in 
this analysis; the rows pertaining to the other lesions were deleted, after inspection that 
no other information relating to the adult was included in them. On the other hand, 
when an adult with multiple lesions presented asymptomatically or their CCM 
diagnosis was incidental, then brainstem location took precedence as the primary CCM 
location, and the rows for the other lesions were deleted.  
The basis for this decision to include brainstem lesions in the analysis in preference to 
lesions in other locations, in cases where a primary lesion could not be detected and at 
least one brainstem CCM was present, was the hypothesis that brainstem location was 
a predictor of intracranial haemorrhage or focal neurological deficit since lesions 
located in the brainstem are adjacent to eloquent areas of the brain and can thus do 
more damage than when they are situated in other parts of the brain. If this decision 
were to result in an over-classification of brainstem lesions among patients with 
multiple lesions, then it is possible that the association between brainstem location and 
ICH or FND in follow-up might be weakened. The number of patients (and lesions) 
affected by this classification compromise should be reported to ascertain the scale of 
the potential problem. In cases where adults harboured multiple lesions, but none were 
located in the brainstem and none had undergone interventional treatment, a random 
row was selected to represent that adult. 
Data completeness for each cohort was quantified as total actual data obtained as a 
percentage of total potential data (Clark et al., 2002). 
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Composition of the datasets 
The composition of the datasets used for the analyses reported in this chapter is 
described in the following two subsections. In Table 4.1, datasets are labelled 
according to the cohort, the mode of clinical presentation (or whether an outcome event 
has previously occurred in follow-up, for those adults presenting incidentally or with 
a seizure), and the outcome event in the analysis. Reference will be made to this table 
and Figures 4.1–4.2, in the next two subsections, in an attempt to clarify the 
composition of each dataset and which research question they are addressing. 
 
Time to first ICH attributable to CCM 
For each cohort, the first analysis investigated either the estimated risk of experiencing 
a first ICH attributable to a CCM within five years of presentation (or until the date of 
first intervention, if the management strategy included interventional treatment), for 
those who had presented with a seizure or incidentally (i.e. datasets A and E in Table 
4.1), or the estimated risk of a recurrent ICH attributable to a CCM within five years 
of presentation (or until date of intervention), for those who had suffered a prior ICH 
due to a CCM, either at presentation or within five years of untreated follow-up 
(datasets C and G in Table 4.1). Figure 4.1 displays which adults are included in this 
outcome graphically.  
Thus the dataset for each cohort was formed by merging datasheets for each of the 
following four groups:   
(i) those who presented with a seizure or incidentally (sets A and E); 
(ii) those who presented with an ICH attributable to a CCM (sets C and G); 
(iii) those who presented with a seizure or incidentally, and suffered an ICH due to 
a CCM within five years of untreated follow-up (included in sets C and G); 
and 
(iv) those who presented with an FND, and suffered an ICH due to a CCM within 
five years of untreated follow-up (included in sets C and G).   
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Figure 4.1 Adults included and outcomes for first analysis, ICH attributable to CCM 
 
 
Those who presented with an FND, but did not experience an ICH attributable to a 
CCM within five years of untreated follow-up were not included in this analysis. This 
decision was taken because there was potential uncertainty whether the FND at 
presentation was actually an ICH, either without the correct neuro-imaging having 
been performed or because the CCM obscured the blood on the imaging. A small 
number of people were included in both outcomes – i.e. first and recurrent ICH: 
namely those who presented with an FND, seizure or incidentally, but suffered an ICH 
due to a CCM during a maximum of five years’ untreated follow-up.  
 
Table 4.1 Composition of datasets used to answer research questions 
 
Presentation: 
     Outcome: 
Cohort 
Incidental + seizure 
presentation 
 
1st ICH    1st ICH + FND 




ICH + FND presentation 
/ in follow-up 
 
Recurrent ICH + FND 
Cohort 1  
1999–2003 
set A set B set C set D 
Cohort 2  
2006–2010 





   
   
 Incidental + seizure 
presentation 
Sets A + E 
1st ICH attributable to 
CCM 
 ICH due to CCM presentation  
 Incidental + seizure presentation, with 
1st ICH due to CCM in follow-up 
 FND presentation, with 1st ICH due to 
CCM in follow-up 
Sets C + G 
 





Time to first clinical event 
In this analysis the outcome was broadened to include haemorrhages that were possibly 
due to a CCM, in addition to focal neurological deficits, due or possibly due to CCM; 
these are subsequently referred to as ‘clinical events’ in this thesis.  
There are several reasons for including focal neurological deficits in this analysis. 
First, the effect of a non-haemorrhagic FND can have a similar degree of severity on 
a patient’s functional outcome as the effect of an ICH. Second, as discussed in Chapter 
2 above (section 2.3.2), diagnosis of an ICH is dependent on the appropriate neuro-
imaging modality being performed at an appropriate time: blood can only be detected 
using CT within a week of the bleed, after which MRI is required, and sometimes an 
ICH can be obscured on a scan by the CCM and haemosiderin ring. Third, if patients 
and their clinicians have agreed on a strategy of conservative management, patients 
may be reluctant to report minor symptoms that may actually indicate a small 
symptomatic haemorrhage to their doctors, and similarly doctors may decide not to 
proceed to investigate minor or transient symptoms, when a cavernous malformation 
has previously been diagnosed (Josephson and Al-Shahi Salman, 2011). Thus it is 
apparent that the distinctions between the classification of a haemorrhage and a focal 
neurological deficit can on occasion be rather blurred, and symptoms that have been 
diagnosed as FND might in reality be small ICH. 
In this analysis, the estimated risk of suffering a first ICH or FND due or possibly due 
to CCM for those adults who presented with a seizure or incidentally (i.e. sets B and 
F of Table 4.1) was compared with the estimated risk of suffering a recurrent ICH or 
FND for those who had suffered a prior clinical event, either at presentation or within 
five years of untreated follow-up (sets D and H of Table 4.1). The two groups are 
displayed graphically in Figure 4.2.  
The dataset for each cohort was again formed by merging datasheets for each of the 
following three groups:   
(i) those who presented with a seizure or incidentally (sets B and F in Table 4.1); 
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(ii) those who presented with an ICH or FND attributable or possibly attributable 
to a CCM (sets D and H); and 
(iii) those who presented with a seizure or incidentally, and suffered a clinical event 
due or possibly due to a CCM within five years of untreated follow-up 
(included in sets D and H). 
Again, a small number of people were included in both outcomes – i.e. first and 
recurrent clinical events: those who presented with a seizure or incidentally, but 
suffered a clinical event due or possibly due to a CCM during a maximum of five 
years’ untreated follow-up.  
 
    
 
Figure 4.2 Adults included and outcomes for the analysis of clinical event attributable 






   
   
 Incidental + seizure 
presentation 
Sets B + F 
 
1st ICH/FND, due or 
possibly due to CCM 
 ICH/FND due or possibly due to CCM 
presentation  
 Incidental + seizure presentation, with 
1st ICH/FND due or possibly due to 
CCM in follow-up  
Sets D + H 
2nd ICH/FND, due or 




4.2.6 Statistical analysis 
Descriptive analysis 
First, tables of baseline characteristics, stratified by mode of clinical presentation, were 
created for the individual cohorts and both cohorts combined. The tables for the two 
individual cohorts were compared to ascertain whether any changes had occurred over 
the course of the twelve-year recruitment period.  
At baseline, CCM location was categorized into four groups: brainstem (in the 
midbrain, pons or medulla), cerebellar, deep (in the thalamus, basal ganglia or 
choroid), or lobar (in the cortex or subcortical areas of the cerebral hemispheres). 
However, in the survival analyses, CCM location was dichotomized into brainstem 
CCM versus other location. 
 
Time-to-event analysis 
Throughout this thesis, time-to-event data, rather than continuous data, are analysed, 
since what is of interest is the length of time that elapses between the start of follow-
up and the occurrence of a specific outcome (for example, ICH) over a period of time. 
For the data in Chapters 4 and 5, the start of follow-up is the date of first presentation 
that leads to a first-ever CCM diagnosis. Not all adults in the study will experience the 
endpoint of interest (i.e. ICH), but they may nevertheless be known to have survived 
for a certain period of time event-free; in this study, for example, they may have 
undergone interventional treatment, become lost to follow-up (withdrawn from the 
study), or have died, or have reached the end of follow-up (five years from presentation 
date, in this analysis), without having suffered a haemorrhage. In all these scenarios, 
the individual is considered to have been (right) censored at the earliest occurrence of 
treatment, withdrawal or death, and although these censored adults have not 
experienced the outcome of interest, they are still able to contribute valuable data until 
the time of censoring.  
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Survivor function and hazard function 
The two main functions used to describe time-to-event data are the survivor function 
and the hazard function (Collett, 2003). The survivor function, S(t) is defined as the 
probability that an individual survives from the start of follow-up to at least as long as 
time t:  








P[death in interval (𝜏,𝜏+∆𝜏)]
∆𝜏
), 
and ∆𝜏 is a very small time interval (Machin et al., 2006).  
The hazard function, h(t), represents the instantaneous rate of dying at time t, 








The survivor function, hazard function and probability density function can be 






















= 𝐻(𝑡) = − log 𝑆(𝑡) 
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or 
𝑆(𝑡) = exp [−𝐻(𝑡)]. 
𝐻(𝑡) is the cumulative hazard. The survivor function and hazard function are estimated 
from the observed survival data. 
 
Kaplan-Meier estimate of the survivor function 
There are two main non-parametric methods used for analysing time-to-event data: the 
actuarial, life-table method and the Kaplan-Meier method (Collett, 2003). The former 
is well-suited when the actual times of the event are unknown, which is not the case in 
this thesis; therefore the Kaplan-Meier method is used throughout the three analyses, 
and is briefly described below. 
The basic concept underlying the Kaplan-Meier estimated survival method is that the 
probability of surviving for a complete year is the probability of surviving for the 365th 
day, given that an individual has already survived 364 days (Machin et al., 2006). This 
can be written as: 
𝑆(365) =  𝑝1 ×   𝑝2 × …  × 𝑝364 × 𝑝365 
where 𝑝1is the probability of surviving at least one day after presentation, 
𝑝2 is the conditional probability of surviving a second day, having already survived 
the first day,  
and 𝑝3 is the conditional probability of surviving a third day, having already survived 
the second day, etc. 
The probability of survival to time t is thus: 
𝑆(𝑡) =  𝑝1 ×  𝑝2 × …  × 𝑝𝑡−1 × 𝑝𝑡. 
For any time t, 
𝑝𝑡 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑓𝑜𝑙𝑙𝑜𝑤𝑒𝑑 𝑓𝑜𝑟 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 (𝑡 − 1) 𝑑𝑎𝑦𝑠 𝑎𝑛𝑑 𝑤ℎ𝑜 𝑠𝑢𝑟𝑣𝑖𝑣𝑒 𝑑𝑎𝑦 𝑡
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If there are n individuals in the study, with survival times t1, t2, t3,…, tn, and there are 
r deaths, since probably not all n people will die, and some may die on the same day 
(so r ≤ n), then the death times can be ordered such that t1 < t2 < t3 <…< tr (Collett, 
2003, Machin et al., 2006). At time (𝑡𝑖 − 𝛿), an infinitesimal interval before time ti, 
there are ni individuals alive (including those who are just about to die) and di die at 
time ti. The probability of a death occurring between time (𝑡𝑖 − 𝛿) and time ti is  








When an individual is censored at exactly the same time as a death occurs, the death 
is considered to take place first. When there are no deaths, i.e. between time ti and time 
(𝑡𝑖+1 − 𝛿), the probability of survival is 1. Under the assumption that each death is 
independent, the Kaplan-Meier (or product-limit) estimate of the survivor function for 
the period between time tk and time (𝑡𝑘+1 − 𝛿), and all the earlier intervals, is  
𝑆(𝑡) = ∏ (
𝑛𝑖−𝑑𝑖
𝑛𝑖
)𝑘𝑖=1 .   
The estimates of S(t) can be drawn in a Kaplan-Meier plot, which is a distinctive step 
function, as the estimated survival probabilities remain constant between adjacent 
deaths, and then decrease at the time of each death.  
 
Comparison of two survival curves 
The Kaplan-Meier plot is very useful when comparing the survival curves of two (or 
more) groups of individuals, for example, examining whether progression to five years 
of presentation is similar for men and women. The log-rank test is a non-parametric 
hypothesis test that is used to ascertain whether there is a difference between the two 
survival curves, and the basic premise underlying this test is that, if the two survival 
distributions actually are identical, then deaths (the outcome events) should be 
distributed between the two groups in proportion to the number of individuals at risk, 
(Collett, 2003, Machin et al., 2006). The log-rank test has the advantage that it uses all 
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the data for the entire duration of follow-up, rather than comparing the two curves at a 
single point in time. On each day (or whatever time unit is used) that a death (event) 
occurs, for each group the number of individuals at risk and the number of deaths 
(events) on that day are calculated; these are the observed values. As for the standard 
χ2 test, the number of expected deaths is calculated for each group, and the difference 
between observed and expected values are calculated for each group. There are several 












where 𝑂𝐴 and 𝑂𝐵 are the sums of the observed values for groups A and B on each day 
of death (event) respectively, and similarly 𝐸𝐴 and 𝐸𝐵 are the sums of the expected 
values for groups A and B on each day of death (event) (Machin et al., 2006). As a 
check, if performing this calculation by hand 
𝑂𝐴 + 𝑂𝐵 = 𝐸𝐴 + 𝐸𝐵. 
This log-rank statistic is then compared with the χ2 distribution with 1 degree of 
freedom (for a two-group comparison) to obtain the level of significance. 
 
SIVMS data 
For the analyses of recurrent ICH, follow-up started at presentation date for those who 
presented with an ICH or at date of first ICH in follow-up, for those with a non-
haemorrhagic presentation. Similarly, in the analyses for recurrent clinical event 
definitely or possibly due to CCM, follow-up started at presentation for those who 
presented with ICH or FND, or at date of first clinical event for those who presented 
with a seizure or incidentally. 
The focus of this analysis is the untreated clinical course of cerebral cavernous 
malformations, and the outcomes are either (i) first ICH definitely due to CCM or (ii) 
first ICH or FND, definitely or possibly due to CCM. Follow-up is censored at the 
earliest occurrence of first interventional treatment, in addition to death unrelated to 
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CCM, or last available follow-up. Therefore the length of follow-up for those who had 
an outcome event within five years of presentation was the time that elapsed between 
presentation and the event, and for those who did not have an outcome event, the length 
of follow-up was calculated as the time between presentation and censoring or the end 
of follow-up (which was truncated at five years). 
Kaplan-Meier survival curves were used both to estimate the five-year risk of a clinical 
outcome (Kirkwood and Sterne, 2003, Machin et al., 2006), and together with log-rank 
tests, to test whether there was a difference between the two groups (i.e. those who 
presented incidentally or with a seizure and those who presented with a haemorrhagic 
presentation).   
Given the size of these two cohorts, there were unlikely to be sufficient outcome events 
to build a prognostic model. However, Kaplan-Meier plots, stratified by (i) sex and (ii) 
CCM location, were produced to investigate in an exploratory analysis the effect of 
these two binary baseline characteristics on the progression to ICH or clinical event. 
These two variables were selected, in that order, as possible predictors of ICH or FND, 
on account of their clinical significance and existing evidence base (Robinson et al., 
1991, Aiba et al., 1995, Kondziolka et al., 1995, Moriarity et al., 1999, Josephson and 
Al-Shahi Salman, 2011, Al-Shahi Salman et al., 2012, Flemming et al., 2012), in 
addition to their completeness, accuracy and reliability.   
 
Level of dependence after a first clinical event 
As described in section 4.2.2 above, as part of the SIVMS follow-up, participants’ 
general practitioners are contacted annually, at around the time of the anniversary of 
CCM diagnosis, to rate their patients’ functional outcome using the Oxford Handicap 
Scale (Bamford and Sandercock, 1989). The Oxford Handicap Scale (OHS) is a six-
point evaluation of the level of patient handicap, developed from the modified Rankin 
Scale (van Swieten et al., 1988); the OHS ranges from 0 (no handicap) to 5 (severe 
handicap: patient totally dependent and requires constant attention, day and night), 
although it is frequently informally extended to include grade 6, dead (see Table 5.1).  
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In this study, annual OHS ratings were examined for those patients who had 
experienced a first clinical event, either at presentation or during follow-up if they had 
presented with a seizure or incidentally. For the eight adults in the first cohort and the 
three in the second who presented with a seizure or incidentally, but suffered an ICH 
or FND within five years or presentation, their OHS ratings were adjusted so that the 
first rating they contributed to year one of follow-up was the first that was given after 
their first clinical event. If more than 18 months elapsed between the clinical event and 
the subsequent OHS score, then the score was included in the following year.  
Patients were divided into two groups: those who experienced a second clinical event 
during five-year follow-up, and those who did not. Stacked bar charts for each group 
were created, showing the percentage of adults ranked on each OHS grade; the bar 
charts covered presentation and each of the five years of follow-up. As a sensitivity 
analysis, an additional stacked bar chart with the inclusion of those who had undergone 
interventional treatment was created for each cohort. 
 
4.3 Results  
 
4.3.1 Baseline characteristics 
In the five years between 1999 and 2003, 141 adults who were aged 16 years or over 
and resident in Scotland were diagnosed with a definite first-time cerebral cavernous 
malformation that was validated by magnetic resonance imaging or pathological 
examination, and between 2006 and 2010, 166 adults received a similar definite first 
CCM diagnosis. Five adults in the earlier and one in the later time-period were 
diagnosed incidentally at autopsy, however, and these individuals were not included 
in the analysis. Therefore the earlier cohort consists of 136 adults, and the later one of 
165 participants. The six adults who were diagnosed after death all presented 
incidentally; their baseline characteristics are displayed in Table 4.2. Data 
completeness for the first and second cohorts was 96.3% and 90.6% respectively.   
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Baseline characteristics of the two cohorts, stratified by mode of initial clinical 
presentation, are displayed in Tables 4.3 and 4.4 below. Over 40% of adults presented 
incidentally, and of those with symptomatic lesions, about half presented with a 
seizure, and the other half with either an ICH or FND. The percentage with FND 
presentation was 15% in 1999–2003, compared with 6% in 2006–2010; however, the 
median age for FND presentation among adults in the first cohort was substantially 
younger than that in the second cohort (40 versus 57 years).  
Age at presentation increased slightly in the second cohort: median age in the first 
cohort was 40 years (interquartile range 31–52), compared with 46 years (IQR 33–60) 
in the later group, and this increase was observed across all types of presentation. To 
avoid multiple testing, the two cohorts were combined into a single datafile (see Table 
4.5): adults presenting incidentally were significantly older (median age 48.5 years, 
IQR 39–59) than those with a symptomatic presentation (median 38 years, IQR 30–
53) (Mann-Whitney, p < 0.001).  
The percentage of women in the first cohort was 59%, but this decreased to 49% in the 
second, although there was a preponderance of women when the two cohorts were 
combined (53%).  
Characteristic 1999–2003 cohort 2006–2010 cohort 
Total 5 1 
Sex   
  Male 4 1 
  Female 1 0 
Age (median, IQR) 78 (52–82) 48 
Multiplicity   
  Single 4 1 
  Multiple 1 0 
CCM location   
  Brainstem 2 1 
  Lobar 3 0 
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Table 4.3 SIVMS 1999-2003: baseline characteristics and events in follow-up 
 
*One adult experienced an ICH as a second event, having had an FND earlier in follow-up. 
 
    
   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 136 
Incidental 
(n = 62, 46%) 
Seizure 
(n = 36, 27%) 
ICH 
(n = 17, 13%) 
FND 
(n = 21, 15%) 
 n % n % n % n % n % 
Age at presentation (median, 
IQR) 
46 34–55 34 26–46 35 29–46 40 32–59 40 31–52 
Sex           
   Male 23 37% 22 61%  5 29%     6 29% 56 41% 
   Female 39 63% 14 39% 12 71%   15 71% 80 59% 
Primary CCM location           
   Lobar 44 71% 36 100%   7 41%   5 24% 92 68% 
   Deep   4   7%   0    0%   1   6%   4 19%   9   7% 
   Cerebellum   9 15%   0    0%   5 29%   4 19% 18 13% 
   Brainstem   5   8%   0    0%   4 24%   8 38% 17 13% 
Single or multiple CCMs           
   Single 56 90% 24 67% 14 82% 18 86% 112 82% 
   Multiple   6 10% 12 33%   3 18%   3 14%  24 18% 
1st clinical event in follow-up           
   1st ICH   2   3%   0 0%   3 18%    2* 10%    7*   5% 
   1st FND   5   8%   1 3%   2 12%   9 43%  17 13% 
   No event  in 5-year follow-up 55 89% 35 97% 12 71% 10 48% 112 82% 
Length of censored follow-up   
(years) (median, IQR) 
5.0 5.0–5.0 5.0 1.4–5.0 2.1 0.8–5.0 3.6 0.8–5.0 5.0 1.6–5.0 
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   Characteristic 
Type of symptom leading to CCM diagnosis  
Total 
n = 165 
Incidental 
(n = 68, 41%) 
Seizure 
(n = 52, 32%) 
ICH 
(n = 35, 21%) 
FND 
(n = 10, 6%) 
 n % n % n % n % n % 
Age (median, IQR) 53 42–62 37 29–51 42 32–60 57 52–60 46 33–60 
Sex           
   Male 31 46% 32 62% 18 51%   4 40% 85 52% 
   Female 37 54% 20 39% 17 49%   6 60% 80 49% 
Primary CCM location           
   Lobar 52 77% 51 98% 18 51%   3 30% 124 75% 
   Deep   1   2%   0   0%   3   9%   0   0%   4   2% 
   Cerebellum   8 12%   0   0%   2   6%   1 10% 11   7% 
   Brainstem   7 10%   1   2% 12 34%   6 60% 26 16% 
Single or multiple CCMs           
   Single 58 85% 43 83% 26 74%   9 90% 136 82% 
   Multiple 10 15%   9 17%   9 26%   1 10% 29 18% 
1st clinical event in follow-up           
   ICH   0   0%   1   2%   9 26%   1 10% 11   7% 
   FND   1   2%   1   2%   2   6%   2 20%   6   4% 
   No event in follow-up 67 99% 50 96% 24 69%   7 70% 148 90% 
Length of censored follow-up 
(years) (median, IQR) 
4.6 3.9–5.0 5.0 4.0–5.0 3.4 0.3–5.0 5.0 3.5–5.0 4.8 3.4–5.0 
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Table 4.5 SIVMS combined cohorts: baseline characteristics and events in follow-up 
*One adult experienced an ICH as a second event, having had an FND earlier in follow-up.  
   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 301 
Incidental 
(n = 130, 43%) 
Seizure 
(n = 88, 29%) 
ICH 
(n = 52, 17%) 
FND 
(n = 31, 10%) 
 n % n % n % n % n % 
Age at presentation (median, 
IQR) 
48 39–59 36 26–48 38 32–57 50 36–60 44 32–57 
Sex           
   Male 54 42% 54 61% 23 44% 10 32% 141 47% 
   Female 76 59% 34 39% 29 56% 21 68% 160 53% 
Primary CCM location           
   Lobar 96 74% 87 99% 25 48%   8 26% 216 72% 
   Deep   5   4%   0   0%   4   8%   4 13% 13   4% 
   Cerebellum 17 13%   0   0%   7 14%   5 16% 29 10% 
   Brainstem 12   9%   1   1% 16 31% 14 45% 43 14% 
Single or multiple CCMs           
   Single 114 88% 67 76% 40 77% 27 87% 248 82% 
   Multiple   16 12% 21 24% 12 23%   4 13%  53 18% 
1st clinical event in follow-up           
   1st ICH     2   3%   1 1% 12 23%   3*   7%  18*   6% 
   1st FND     6   5%   2 2%   4   8% 11 36%  23   8% 
   No event  in 5-year follow-up 122 93% 85 97% 36 69% 17 58% 260 86% 
Length of censored follow-up   
(years) (median, IQR) 
5.0 4.1–5.0 5.0 3.4–5.0 2.6 0.4–5.0 5.0 1.5–5.0 5.0 2.6–5.0 
 
 
  63 
In both cohorts, however, adults who presented with a seizure tended to be both male 
and young (under 40 years) (36% in the first cohort and 44% in the second). In the first 
cohort, 71% of adults presenting with either an ICH or FND were women, but this 
decreased to 51% in the second cohort. Among the other baseline characteristics, CCM 
multiplicity was identical in both cohorts (82% had single lesions), and the percentage 
of brainstem CCMs was similar (13% and 16% respectively). In both cohorts, about 
70% of adults with brainstem cavernous malformations presented with either ICH or 
FND. 
The main difference between the two cohorts is the length of available follow-up, 
which is explored in greater detail in Chapter 7. In the earlier cohort, all adults who 
were censored at last communication - that is, they experienced neither ICH, FND, 
interventional treatment, nor death in follow-up – had a minimum of 7.8 years of 
follow-up (although, as previously stated, in this study five years was stipulated to be 
the maximum length of follow-up). In the later cohort, the minimum length of follow-
up for the equivalent group was 2.2 years; median follow-up was 5.5 years (IQR 4.3 
to 7.1 years). However, in Table 4.3, adults in the first cohort presenting with seizure, 
ICH or FND appear to have less follow-up (lower quartile and median) than those in 
the second cohort (Table 4.4); this is because more people in the first cohort were 
censored for interventional treatment (e.g. 29% of those presenting with seizure in the 
first cohort underwent surgical excision, compared with 6% in the later cohort).  
 
Brainstem classification compromise 
In the 1999–2003 cohort, five of the 17 adults with a brainstem CCM had multiple 
lesions. Of the five, three presented incidentally and CCM location was designated 
brainstem because that was a putative predictor. Only one of these three adults 
experienced an FND in follow-up, which was in fact attributable to the brainstem 
lesion. In the 2006–2010 cohort, eight of the 26 adults with brainstem CCM had 
multiple lesions, and again three of these presented incidentally. However, in this 
cohort, none of these three experienced a clinical event during follow-up.  
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In total, 29 people are known to have died since being recruited into the two cohorts: 
21 in the earlier cohort and eight in the later. However, 19 people died within the five-
year follow-up period: twelve in the earlier group and seven in the later (see Table 
4.6). The median age at death was slightly younger for the earlier cohort (59 years, 
IQR 50–73 years, compared with 62 years, IQR 61–72). Three deaths were due to 




(n = 12) 
2006–2010 cohort 
(n = 7) 
Age at death, median (IQR) 59.6 50–73 62.9 61–72 
Time after presentation (yrs)   2.0 0.9–2.5   2.4 0.9–4.0 
Cause of death     
  Due to CCM 3 25% 0   0% 
  Due to other cause 9 75% 5 71% 
  Unknown 0   0% 2 29% 
Interventional treatment in follow-up 2 17% 0   0% 
ICH in follow-up 1   8% 0   0% 
FND in follow-up 2 17% 0   0% 
Sex     
  Male   6 50% 3 43% 
  Female   6 50% 4 57% 
Presentation     
  Incidental   6 50% 5 71% 
  Seizure   3 25% 1 14% 
  ICH or FND   3 25% 1 14% 
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Subsequent events in untreated follow-up 
In the earlier cohort, 136 adults were diagnosed with a cerebral cavernous 
malformation within the five-year period. During untreated follow-up (to a maximum 
length of five years) 18 individuals suffered a single clinical event, three experienced 
two events and one three events. Another adult experienced her fourth event about two 
months after undergoing a haematoma evacuation (the original planned CCM excision 
was aborted). The number of events that occurred during untreated follow-up in each 
cohort, stratified by mode of presentation, is displayed in Table 4.7 below. 
Similarly, in the later cohort, 165 adults received a first-ever CCM diagnosis between 
2006 and 2010 inclusively, and 17 experienced at least one clinical event in the 
untreated follow-up period. Again, a few participants experienced subsequent events: 
two suffered two events and three people had three events (see Table 4.7).  
 
4.3.2 ICH attributable to CCM 
First cohort, 1999–2003 
In the first cohort, 98 adults presented with a seizure or incidentally (set A in Table 4.1 
and 4.9; see the first analysis in Table 4.8, and the flowchart in Figure 4.3). Of these, 
two adults who presented incidentally suffered a haemorrhage attributable to the CCM 
during the five-year follow-up period (one of which was fatal). The Kaplan-Meier 
estimated five-year risk of a first intracranial haemorrhage, attributable to a CCM, 
among those who presented incidentally or with a seizure was 2.4% (95% CI 0% to 
5.7%). 
Set C in Tables 4.1 and 4.9 consists of the two adults with non-haemorrhagic 
presentation who suffered a first ICH in follow-up, and two adults who presented with 
a focal neurological deficit and also had a similar ICH in follow-up, together with the 
17 who initially presented with a haemorrhage. The adults in set C are included in the 
estimated risk of a second ICH attributable to CCM during follow-up (see Table 4.8).   
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Table 4.7 Clinical events in untreated follow-up 
 
Original mode of 
presentation 





3rd event after 
presentation 
4th event after 
presentation 
SIVMS, 1999–2003     
60 incidental 1 ICH* (fatal)    
 1 ICH* 1 ICH*   
 1 FND*    
 4 FND† 1 FND†   
2 FND†     
36 seizures 1 FND†    
21 FND* 1 ICH* 1 ICH*   
 8 FND* 1 ICH* 1 ICH* 1 FND* 
 1 FND†    
17 ICH* 3 ICH* 1 ICH*  1 FND†  
 2 FND*    
SIVMS, 2006–2010     
66 incidental 1 FND† 1 FND† 1 FND†  
2 FND†     
52 seizures 1 ICH*    
 1 FND†    
10 FND* 1 ICH* 1 FND*   
 1 FND*    
 1 FND†    
35 ICH* 9 ICH* 2 ICH* 1 FND*  
 1 FND*    
 1 FND† 1 FND† 1 FND†  
Notes 
*Event definitely attributable to CCM. †Event possibly attributable to CCM.    
 
   67 
Table 4.8 Composition of datafiles used for analyses of untreated clinical course 
*These adults are re-entered into the analysis with a different outcome.   †Includes adult who presented incidentally and had a fatal first ICH 2 years later.  
Analysis Cohort Included nincluded Set Event in follow-up nevents Outcome 
ICH due to CCM SIVMS, 1999–2003 Incidental + seizure presentation 98 A 1st ICH   2 1st ICH 
  ICH presentation 17 
C 
1st ICH   3 
2nd ICH 
  
Incidental*, seizure* + FND presentation, 
with a 1st ICH in follow-up 
   4† 2nd  ICH   3 
  Total 119†     8  
ICH due to CCM SIVMS, 2006–2010 Incidental + seizure presentation 120 E 1st ICH   1 1st ICH 
  ICH presentation   35 
G 
1st ICH   9 
2nd ICH 
  
Incidental*, seizure* + FND presentation, 
with a 1st ICH in follow-up 
    2 2nd  ICH   0 
  Total 157   10  
ICH/FND due or 
possibly due to 
CCM 
SIVMS, 1999–2003 Incidental + seizure presentation  98 B 1st ICH/FND   8 1st clinical event 
 ICH + FND presentation  38 
D 
1st ICH/FND 15 
     2nd clinical event  FND possibly due to CCM presentation*    2 1st ICH/FND   0 
 
Incidental* + seizure* presentation, with a 
1st ICH/FND in follow-up 
    8† 2nd  ICH/FND   2 
  Total  144†   25  
ICH/FND due or 
possibly due to 
CCM 
SIVMS, 2006–2010 Incidental + seizure presentation 118 F 1st ICH/FND   3 1st clinical event 
 ICH + FND presentation   45 
H 
1st ICH/FND 14 
     2nd clinical event  FND possibly due to CCM presentation*     2 1st ICH/FND   0 
  
Incidental* + seizure* presentation, with a 
1st ICH/FND in follow-up 
    3 2nd  ICH/FND   1 





Figure 4.3 Flowchart showing which adults in the first cohort entered the analysis of first ICH definitely attributable to CCM 
 
  
Clinical event at presentation First event in follow-up Second event 
62 incidental + 
36 seizure 
17 1st ICH* 
1st ICH*, n = 2 
(1 fatal) 
2nd ICH*, n = 6 n = 1 
n = 3 
 
2 FND with 1st ICH 
in follow-up  
n = 2 
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Six adults suffered a second ICH during the five-year follow-up period: three adults 
who presented with an ICH, one who presented incidentally and two who presented 
with FND. The Kaplan-Meier estimated five-year risk of a second ICH was 40.8% 
(95% CI 14.2% to 67.3%).  
If the two adults who presented with FND are excluded from the analysis to second 
ICH (on the grounds that the 21 adults who presented with an FND might in reality 
have had an ICH, and therefore should be excluded from the analysis, due to 
uncertainty), then four recurrent ICH occurred, and the Kaplan-Meier estimated risk 
of a second ICH definitely due to CCM decreases to 31.9% (95% CI 4.5% to 59.3%).  
In Figure 4.4, a Kaplan-Meier plot displays the estimated progression to first or second 
intracranial haemorrhage definitely attributable to CCM within five years of untreated 
follow-up. As can be observed, the risk of a second ICH is significantly greater than 
that of a first ICH (log-rank χ2(1) = 31.3, p < 0.0001). Of the eight haemorrhages that 
occurred during follow-up, one was fatal; this occurred to a 50-year-old man with a 




Table 4.9 Number of adults and outcomes in follow-up for each set 
  
Presentation: 
     Outcome: 
 
Cohort 
Incidental + seizure 
presentation 
 
1st ICH     1st ICH + FND 
ICH 
presentation 
or in follow-up 
 
Recurrent ICH 
ICH + FND 
presentation or in 
follow-up 
 
Recurrent ICH + FND 
Cohort 1  
1999–2003 
set A 
n = 98 
2 ICH 
set B 
n = 96 
2 ICH + 6 FND  
set C 
n = 21 
6 ICH 
set D 
n = 48 
5 ICH + 12 FND 
    
Cohort 2  
2006–2010 
set E 
n = 120 
1 ICH 
set F 
n = 118 
1 ICH + 2 FND 
set G 
n = 37 
9 ICH 
set H 
n = 50 
10 ICH + 5 FND 
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Number of adults at risk (number of ICH in preceding year) 
First ICH 98 88(0) 82(1) 77(1) 77(0) 76(0) 
Second ICH 21  12(3)   8(2)   7(0)   7(0)   6(1) 
 
Figure 4.4 Kaplan-Meier plot of estimated progression to first or second intracranial 




Second cohort, 2006–2010 
Of 120 adults with non-haemorrhagic presentation in the later cohort, a man who 
presented with a seizure was the only adult to experience a haemorrhage due to CCM 
during follow-up (set E in Tables 4.1 and 4.9; see second analysis in Table 4.8 and 
Figure 4.5). The Kaplan-Meier estimated five-year risk of a first ICH due to CCM was 













Figure 4.5 Flowchart showing which adults in the second cohort entered the analysis of first ICH definitely attributable to CCM 
Clinical event at presentation First event in follow-up Second event 
68 incidental + 
52 seizure 
35 1st ICH* 
1st ICH*, n = 1 2nd ICH*, n = 9 
n = 9 
 
1 FND with 1st ICH 
in follow-up  
Notes 
*Event definitely related to CCM. 
Broken line implies that no adults with 
that specific first event in follow-up 
have a recurrent event. 
72 
In this cohort, a woman who presented with an FND and suffered an ICH due to CCM 
in follow-up, together with the man who had a first ICH after seizure presentation, 
were included with the 35 adults with initial ICH presentation in the analysis to second 
ICH due to CCM (set G in Tables 4.1 and 4.9; see the second analysis in Table 4.8 
above, and the flowchart in Figure 4.5). Nine participants, all of whom presented with 
an ICH, suffered a subsequent ICH due to CCM within five years of presentation; two 
of these adults had a subsequent haemorrhage later in follow-up (see Table 4.7 above). 
No haemorrhage in this cohort was fatal. The Kaplan-Meier estimated five-year risk 
of a recurrent ICH due to CCM during untreated follow-up was 26.6% (95% CI 11.5% 
to 41.8%); if the adult who presented with an FND and suffered an ICH in follow-up 
is removed from the analysis, this estimate increases to 27.1% (95% CI 11.8% to 
42.5%). 
A Kaplan-Meier plot of the progression to first and second ICH is presented in Figure 
4.6; again, the estimated risk of a second ICH is significantly greater than that of a first 
(log-rank χ2(1) = 30.2, p < 0.0001).  
In Figure 4.7, the Kaplan-Meier plots for the two cohorts are combined. It should be 
borne in mind that 53 people in the second cohort (34% of adults included in this 
analysis) have less than five years follow-up, due to the recruitment period of the 
cohort; however, only three adults have less than 2.5 years follow-up, and most 
outcomes tend to occur in the first half of the follow-up period. In addition, three 
people (two from the first cohort and one from the second) have been re-entered into 
the analysis, as they presented with a seizure or incidentally, suffered a first ICH, and 
then were included in the second ICH analysis (see Table 4.8, and Figures 4.3 and 4.5). 
The plots for both analyses are very similar; about 5% of each cohort suffers a recurrent 
haemorrhage within five years of follow-up.  
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Number of adults at risk (number of ICH in preceding year) 
First ICH 120 115(0) 111(1) 107(0) 91(0) 63(0) 





Figure 4.6 Kaplan-Meier plot of progression to first or second ICH definitely due to 
CCM in SIVMS cohort 2006–2010  
 
 





















 Figure 4.7 Kaplan-Meier plot of progression to first or second ICH definitely due to 
CCM, stratified by SIVMS cohort 
 
  
Number of adults at risk (number of ICH in preceding year) 
A   21   12(3)     8(2)     7(0)       7(0)   6(1) 
B   37   25(7)   23(0)   21(1)     19(1) 12(0) 
C   98   88(0)   82(1)   77(1) 77(0) 76(0) 
D 120 115(0) 111(1) 107(0) 91(0) 63(0) 
A 1999–2003 cohort, 2nd ICH 
B 2006–2010 cohort, 2nd ICH 
C 1999–2003 cohort, 1st ICH 
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4.3.3 Clinical event due or possibly due to CCM 
The outcome in the following two subsections is either intracranial haemorrhage or 
focal neurological deficit that is definitely or possibly attributable to CCM; it is 
referred to as clinical event in the text. Clinical event is the primary outcome in this 
chapter, as it is arguably of most relevance to patients: the level of functional impair-
ment after an FND can be equally as severe as after an ICH and, as has been mentioned 
earlier, it is also possible that some events in the cohorts that were recorded as FND 
would have been recorded as ICH, had appropriate neuro-imaging been performed at 
the appropriate time.  
 
First cohort, 1999–2003 
In the first cohort, 98 adults presented with a seizure or incidentally, eight of whom 
then suffered a first clinical event within the five-year follow-up period (two ICH and 
six FND) (set B in Tables 4.1 and 4.9; see third analysis in Table 4.8 above, and Figure 
4.8). These eight, together with two adults who were recorded as incidental, since their 
FND symptoms at presentation were only possibly due to CCM, plus the 38 adults 
who presented with an ICH or FND were included in the analysis to second clinical 
event in follow-up (set D in Tables 4.1 and 4.9). In this group there were 17 clinical 
event outcomes: five ICH, six FND and six non-haemorrhagic FND.  
The Kaplan-Meier estimated five-year risk of a first clinical event, due or possibly due 
to CCM, among those with seizure or incidental presentation was 9.4% (95% CI 3.2% 
to 15.6%), and the similar risk of a second clinical event among those who had suffered 
a prior event at presentation or follow-up was 42.2% (95% CI 26.7% to 57.7%). As 
can be observed in the Kaplan-Meier plot (see Figure 4.9), the risk of a clinical event 
within five years of presentation was significantly greater for those who had already 
experienced a clinical event at presentation or earlier in follow-up (log-rank χ2(1) = 
20.2, p < 0.0001). 
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Figure 4.8 Flowchart showing which patients in SIVMS, 1999–2003 were included in the recurrent ICH or FND definitely or possibly 
attributable to CCM
Clinical event at presentation First event in follow-up Second event 
 
n = 1 (ICH) 
 
n = 10 (1 ICH + 9 FND) 












1st FND†, n = 1  
1st FND*, n = 1 
1st ICH*, n = 1 (non-fatal) 
1st ICH*, n = 1 (fatal) 
2nd ICH* or FND*† 
 n = 17: 
ICH* n = 5 
FND* n = 10 
FND†    n = 2 
1st FND†, n = 4 
n = 5 (3 ICH + 2 FND) 
Notes 
*Event definitely related to CCM. 
†Event possibly related to CCM. 
Broken line implies no adults with that 













Figure 4.9 Kaplan-Meier estimate of progression to first or second intracranial 
haemorrhage or focal neurological deficit, definitely or possibly due to CCM, in 
SIVMS, 1999–2003 
  
Number of adults at risk (number of ICH or FND in preceding year) 
1st clinical event 96 83(4) 77(1) 71(2) 71(0) 70(1) 
2nd clinical event 48 33(8) 27(4) 23(3) 22(1) 20(1) 
Log-rank (Mantel Cox), χ2(1) = 20.2, p < 0.0001 
 
y = 0 
 
1st clinical event 
 




Second cohort, 2006–2010 
Of 118 adults who presented with a seizure or incidentally, three suffered a first 
clinical event due or possibly due to CCM within five years of presentation (set F in 
Tables 4.1 and 4.9; see final analysis in Table 4.8 above, and Figure 4.10 below). These 
three adults joined the two who were recorded as incidental presentation, but had a 
focal neurological deficit that was possibly due to the CCM, and the 45 who presented 
with a haemorrhage or FND that was due to the CCM as the included participants for 
a second outcome (set H in Tables 4.1. and 4.9). In this group of 50 adults, fifteen 
experienced a second clinical event (ten ICH, two FND and three non-haemorrhagic 
FND).  
The Kaplan-Meier estimated risk of a first clinical event due or possibly due to a CCM 
within five years of untreated follow-up for an individual presenting initially with a 
seizure or incidentally was 2.7% (95% CI 0% to 5.7%); a similar risk for an individual 
who had already experienced a clinical event due or possibly due to a CCM at 
presentation or during earlier follow-up was 33.5% (95% CI 19.5% to 47.5%). The 
Kaplan-Meier plot for estimated progression to a first or second clinical event is 
displayed in Figure 4.11; the estimated risk of a subsequent clinical event is 




In Figure 4.12, the Kaplan-Meier plots for both cohorts are displayed. The Kaplan-
Meier estimated annual risk of either an intracranial haemorrhage or clinical event for 
both cohorts is presented in Table 4.10. Broadly speaking, the hazard rate for both ICH 
and clinical event tends to diminish after the first three years of follow-up; however, it 
is not yet known whether this trend continues in the long term. 
 












Figure 4.10 Flowchart showing which patients in SIVMS, 2006–2010 were included in the recurrent ICH or FND definitely or possibly 
attributable to CCM  
Clinical event at presentation  First event in follow-up Second event 
n = 3 (1 ICH + 2 FND) 
n = 11 (9 ICH + 2 FND) 











1st FND†, n = 1  
 
2nd ICH* or FND*† 
 n = 15: 
ICH* n = 10 
FND* n = 2 
FND†    n = 3 
 
1st FND†, n = 1  
 
1st ICH*, n = 1 
Notes 
*Event definitely related to CCM. 
†Event possibly related to CCM. 
Broken line implies no adults with that specific 






























Figure 4.11 Kaplan-Meier estimate of progression to first or second intracranial 






Number of adults at risk (number of ICH or FND in preceding year) 
1st clinical event 118 112(1) 108(1) 104(1) 88(0) 61(0)  
2nd clinical event   50   37(8)   34(2)   30(2) 25(3) 17(0)  
Log-rank (Mantel Cox), χ2(1) = 31.7, p < 0.0001 
 
y = 0, reference 
 
1st clinical event 
 















 A  1999–2003 cohort, 2nd ICH or FND 
 B  2006–2010 cohort, 2nd ICH or FND 
 C  1999–2003 cohort, 1st ICH or FND 
 D  2006–2010 cohort, 1st ICH or FND  
 
Figure 4.12 Kaplan-Meier plot of estimated progression to first or second clinical 
event definitely or possibly due to CCM, stratified by SIVMS cohort  
Number of adults at risk (number of ICH or FND in preceding year) 
A 48   33(8)   27(4)   23(3) 22(1) 20(1) 
B 50   37(8)   34(2)   30(2) 25(3) 17(0) 
C 96   83(4)   77(1)   71(2) 71(0) 70(1) 
D 118 112(1) 108(1) 104(1) 88(0) 61(0) 







Table 4.10 Annual estimated risk of outcome events within five years of presentation 
Analysis Year SIVMS, 1999–2003  
Hazard rate            95% CI 
SIVMS, 2006–2010 
Hazard rate            95% CI 
ICH only      
   1st ICH 1 -  -  
 2 1.2 0 to 3.5 0.9 0 to 2.6 
 3 1.3 0 to 3.7 -  
 4 -  -  
 5 -  -  
      
   2nd ICH 1 18.2 0 to 38.7 22.6 6.0 to 39.2 
 2 20.0 0 to 47.6 -  
 3 -  4.5 0 to 13.5 
 4 -  5.0 0 to 14.8 
 5 15.4 0 to 45.4 -  
Clinical event      
   1st clinical event 1 4.5 0.1 to 8.8 0.9 0 to 2.6 
 2 1.3 0 to 3.7 0.9 0 to 2.7 
 3 2.7 0 to 6.4 0.9 0 to 2.8 
 4 -  -  
 5 1.4 0 to 4.2 -  
         
  2nd clinical event 1 19.8 6.1 to 33.4 18.4 5.7 to 31.1 
 2 13.3 0.3 to 26.4 5.6 0 to 13.4 
 3 12.0 0 to 25.6 6.3 0 to 14.9 
 4 4.4 0 to 13.2 10.9 0 to 23.2 
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4.3.4 Putative predictors of clinical event 
At the time of data extraction, sex and CCM location were proposed as putative 
predictors of clinical event, since there were insufficient outcomes in each cohort to 
support more than two covariates (Harrell et al., 1984, Concato et al., 1995, Peduzzi 
et al., 1995). Cox regression analysis was not possible because the proportional 
hazards assumption did not hold; however, exploratory univariate analyses were 




In the earlier cohort, 32 women and 16 men experienced a first clinical event; of the 
17 recurrent events within five years of presentation, 16 occurred to women. The 
Kaplan-Meier estimated five-year risk of a recurrent clinical event for women 
diagnosed with CCM who had either presented with a clinical event or experienced 
one in follow-up was 55.6% (95% CI 37.1% to 74.0%), compared with a similar 
estimated five-year risk for men of 7.7% (95% CI 0% to 22.2%) (see Table 4.11). 
 
 Table 4.11 Kaplan-Meier estimated five-year risk of a recurrent clinical event  
Sex 
5-year risk 
Estimate        95% CI 




Estimate    95%CI 
 (%)             (%) 
1999–2003       
 Female 55.6 37.1 to 74.0  Brainstem 57.1 31.2 to 83.1 
 Male   7.7   0.0 to 22.2  Other location 33.7 15.3 to 52.2 
2006–2010       
 Female 34.8 13.7 to 55.9  Brainstem 64.5 40.9 to 88.1 
 Male 32.4 13.7 to 51.0  Other location 13.6    1.1 to 26.0 
Both cohorts      
 Female 47.0 32.8 to 61.2  Brainstem 60.8 43.4 to 78.2 




Number of adults at risk (number of ICH or FND in preceding year) 
Women 24 18(2) 17(1) 15(2) 12(2) 9(0)  
Men 26 19(6) 17(1) 15(0) 13(1) 8(0)  
Figure 4.13 Kaplan-Meier plots showing estimated progression to second ICH or FND, 
stratified by sex: (A) 1999–2003 cohort and (B) 2006–2010 cohort  
Number of adults at risk (number of ICH or FND in preceding year) 
Women 32 22(7) 17(4) 14(3) 13(1) 11(1)  








y = 0 
(A) 
(B) 
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Thus, in the earlier cohort, women had a significantly greater estimated risk of a 
recurrent clinical event (log-rank, χ2(1) = 6.2, p = 0.013); this is demonstrated 
graphically in the Kaplan-Meier plot in Figure 4.13(A). This increased risk, however, 
was not observed in the later cohort: here, 24 women and 26 men experienced a first 
event, and 7 women and 8 men suffered a recurrence (see Figure 4.13(B) and Table 
4.11). The corresponding Kaplan-Meier estimated five-year risks of a recurrent clinical 
event were 34.8% (95% CI 13.7% to 55.9%) for women and 32.4% (95% CI 13.7 to 
51.0%) for men. 
When the two cohorts were pooled, 23 women (of 56 who had experienced at least one 
clinical event) suffered a recurrence compared with nine men (of 42). The 
corresponding Kaplan-Meier estimated five-year risks for women and men were 
47.0% (95% CI 32.8% to 61.2%) and 24.2% (95% CI 10.3% to 38.1%) respectively 
(Figure 4.14 and Table 4.11). Although women in the pooled SIVMS cohorts had a 
greater estimated risk of recurrence than men, this increased risk did not achieve 




Figure 4.14 Kaplan-Meier plot showing estimated progression to second ICH or FND, 
stratified by sex: both cohorts 
Number of adults at risk (number of ICH or FND in preceding year) 
Women 56 40(9) 34(5) 29(5) 25(3) 20(1) 
Men 42 30(7) 27(1) 24(0) 22(1) 17(0) 
Men 
y = 0 
Women 






Of the 48 individuals in the earlier cohort who experienced a first clinical event at 
presentation or during follow-up, 14 adults had a brainstem CCM and 34 had a lesion 
in another location; eight participants with a brainstem CCM and nine with a CCM in 
a different area of the brain suffered a recurrence within five years of presentation (see 
Figure 4.15 (A) and Table 4.11). Although the Kaplan-Meier estimated risk of a second 
clinical event was increased for those with brainstem cavernomas in this cohort, this 
increase did not achieve statistical significance (log-rank χ2(1) = 2.0, p = 0.162). The 
Kaplan-Meier five-year estimated risk for a second clinical event for adults with a 
brainstem lesion was 57.1% (95% CI 31.2% to 83.1%), and the corresponding risk for 
adults with a non-brainstem lesion was 33.7% (95% CI 15.3% to 52.2%). 
In the later cohort, 11 of the 19 adults with brainstem lesions suffered a recurrence, 
compared with four of the 31 with lesions in other locations (see Figure 4.15 (B)). 
Those who harboured a brainstem CCM had an increased risk of a recurrent clinical 
event (log-rank χ2(1) = 10.0, p = 0.002): the Kaplan-Meier five-year estimated risk of 
a recurrence for an adult with a brainstem CCM was 64.5% (95% CI 40.9% to 88.1%), 
and a similar risk for a non-brainstem CCM was 13.6% (95% CI 1.1% to 26.0%) (see 
Table 4.11). 
When both cohorts were pooled, 19 of the 33 participants with brainstem CCMs 
experienced a second event, compared with 13 of the 65 adults with lesions in other 
parts of the brain. As can be observed in Figure 4.16, those with a brainstem lesion 











Number of adults at risk (number of ICH or FND in preceding year) 
Brainstem 14 11(3)   8(3)   7(1)   6(1)   6(0) 
Other location 34 22(5) 19(1) 16(2) 16(0) 14(1) 
  
Number of adults at risk (number of ICH or FND in preceding year)  
Brainstem 19 14(4) 12(2)  9(2)  4(3)  2(0)  
Other location 31 23(4) 22(0) 21(0) 21(0) 15(0)  
Figure 4.15 Kaplan-Meier plots showing estimated progression to second ICH or FND, 
stratified by CCM location: (A) 1999–2003 cohort and (B) 2006–2010 cohort  
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Figure 4.16 Kaplan-Meier plot showing estimated progression to second ICH or FND, 
stratified by CCM location: both cohorts 
 
 
Sex and CCM location 
In this subsection, the composition of the two cohorts in terms of the two putative 
predictors is explored, with a view to examining the potential for confounding. In 
Table 4.12, each cohort is split into two groups – those who experienced a recurrence 
and those who did not – and the percentage of each sex and CCM location is given for 
these two groups, and for the entire cohort in the final two rows. In both cohorts, about 
40% of those who suffer a recurrence are female with a brainstem lesion; this group 
comprises 25% of the earlier cohort and 18% of the later cohort.   
Number of adults at risk (number of ICH or FND in preceding year) 
Brainstem 33 25(7) 20(5) 16(3) 10(4)   8(0)  
Other location 65 45(9) 41(1) 37(2) 37(0) 29(1)  
Log-rank (Mantel Cox), χ2(1) = 10.33, p = 0.001 
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Table 4.12 Cohort composition: two putative predictors, stratified by outcome event 
 All figures in this table are percentages.  
 
 
The percentage of brainstem lesions among those who do not suffer a recurrence is 
similar (19% and 23%). However, the sex distribution in this subgroup differs among 
the two cohorts: 16% women and 3% men have brainstem lesions, but suffer no 
recurrent event within five years in the earlier cohort, compared with 9% women and 
14% men in the later cohort. 
In Table 4.13, the composition of each cohort and the pooled cohorts is examined with 
respect to the two putative predictors. For example, men with non-brainstem lesions 
form 29% of the earlier cohort and 32% of the later cohort: no men in this subgroup 
suffer a recurrence in the earlier cohort, whereas three men (i.e. 19% of the male, non-
brainstem group) have recurrences in the second. In both cohorts, 50% of men with 
brainstem lesions suffer a recurrence (one in the 1999–2003 cohort, and five in the 
2006–2010 cohort), and 58% of women with brainstem lesions in the earlier cohort 
and 67% in the later have a recurrence. However, in the first cohort, nine women with 
a non-brainstem lesion (45%) experience a recurrence, in comparison with one woman 
(7%) in the later cohort.   
Description 
1999–2003 cohort 
Brainstem   Other  
 2006–2010 cohort 
Brainstem   Other 
 Pooled cohorts 
Brainstem  Other 
Recurrence      
 Female 41 53  40   7  41 31 
 Male   6   0  33 20  19   9 
No recurrence         
 Female 16 36    9 40  12 38 
 Male   3 45  14 37    9 41 
Total cohort         
 Female 25 42  18 30  21 36 
 Male   4 29  20 32  12 31 
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Table 4.13 Cohorts, stratified by putative predictors 
Characteristic 
Earlier cohort 
Number                Events 
    n         %*               n         %† 
 Later cohort 
Number                Events 
        n       %*             n        %† 
 Pooled cohorts 
Number                Events 
      n        %*            n        %† 
Female, brainstem CCM 12 25% 7 58%    9 18% 6 67%  21 21% 13 62% 
Male, brainstem CCM   2 4% 1 50%  10 20% 5 50%  12 12%   6 50% 
Female, non-brainstem CCM 20 42% 9 45%  15 30% 1 7%  35 36% 10 29% 
Male, non-brainstem CCM 14 29% 0 0%  16 32% 3 19%  30 31%   3 10% 
Total 48 100% 17 35%  50 100% 15 30%  98 100% 32 33% 
 
Notes 
*Percentage of total cohort. 
†Percentage of characteristic that has a clinical event within five years of presentation: i.e. 58% of women with a brainstem lesion in the earlier cohort suffered a 
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4.3.5 Functional outcome at the end of follow-up 
In this subsection, the level of dependence of adults who have experienced at least one 
intracranial haemorrhage or focal neurological deficit, definitely or probably due to 
CCM, is examined. The functional outcome of those who have experienced a single 
event is compared with those who have suffered at least two events, and the baseline 
characteristics for adults in both groups in each cohort are displayed in Table 4.14. 
Again, the adults in the first cohort are about seven years younger, but there is no age 
difference between the groups within the cohorts. About a fifth of adults who 
experienced a single event harbour brainstem lesions, but 47% of adults who suffered 
a second event in the earlier cohort have a brainstem CCM, compared with 73% in the 
later cohort.  About 80% of adults in all groups have a solitary lesion. Approximately 
equal numbers of each sex experienced a single event; however, in the earlier cohort 
94% of adults who suffered a second event were women, but this decreased to 47% in 
the later cohort.  
 
 
Table 4.14  Comparison of baseline characteristics among adults who experience at 
least one clinical event in follow-up, stratified by cohort and single or recurrent event  
 Scotland, 1999–2003 
Single event         Recurrence 
n = 30      %        n = 17        % 
Scotland, 2006–2010 
Single event         Recurrence 
n = 35        %           n = 15     % 
Age in years 
(median, IQR) 
39 30–56 38 31–54 46 32–61 46 33–58 
Male 14 47% 1   6% 18 51% 8 53% 
Female 16 53% 16 94% 17 49% 7 47% 
Brainstem CCM 6 20% 8 47% 8 23% 11 73% 
Other location 24 80% 9 53% 27 77% 4 27% 
Single CCM 24 80% 14 82% 27 77% 12 80% 
Multiple CCM 6 20% 3 18% 8 23% 3 20% 
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As described in subsection 4.2.2 above, at the time of presentation, each participant’s 
functional outcome is assessed, using the Oxford Handicap Scale, and then, in 
subsequent years at around the anniversary of CCM diagnosis, SIVMS contacts each 
participant’s general practitioner to request a new OHS rating. In the first cohort, of 
the 47 adults alive after a first clinical event, nine were censored in the first two years 
of follow-up, after interventional treatment (seven in the single-event group and two 
in the recurrence group); another two (both in the recurrence group) were censored at 
treatment later in follow-up, and four people in this cohort died, one death of which 
was attributable to CCM.   
In the second cohort (n = 50), ten participants were censored for treatment – six in the 
single-event group and four in the second – and a further two were censored for 
treatment in later years (one in each group). Two adults died during the first two years. 
In addition, 13 adults did not have OHS scores for all five years of follow-up, since 
their initial presentation was after June 2008.   
In Figures 4.17–4.20, OHS scores for presentation and the five years of follow-up are 
displayed as stacked bar charts for each cohort, stratified by clinical-event group, 
which is determined by whether the participant has experienced a single or a second 
event. Figures 4.17–4.18 refer to adults in the earlier cohort and Figures 4.19–4.20 to 
adults in the later cohort. In Figures 4.17 and 4.19, participants are censored at the time 
of interventional treatment, and therefore the populations included in these figures are 
identical to those in the analyses in subsection 4.3.3. Figures 4.18 and 4.20 act as 
sensitivity analyses and include all adults – irrespective of whether or not they have 
received interventional treatment. Completeness of follow-up was quantified by 
expressing total follow-up obtained as a percentage of the total follow-up that could 
potentially have accrued (Clark et al., 2002). Thus completeness for OHS scores at 
presentation and the first five years was 89.7% in the earlier cohort and 84.3% in the 
later cohort, after adjustment for the years in the latter cohort when follow-up was not 
possible.   
OHS scores 0–1 (shown in blue) represent favourable outcome (no or minor symptoms 
with no interference to lifestyle), and OHS 2–5 (the orange bars) represent unfavour-
able outcome, ranging from a minor to severe handicap.    
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Figure 4.17 Dependence measured on the Oxford Handicap Scale for survivors of first and second intracranial haemorrhage or focal 
neurological deficit in SIVMS, 1999–2003 (adults censored at time of interventional treatment)   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
First ICH/FND, presentation (n = 30)
First ICH/FND, year 1 (n = 16)
First ICH/FND, year 2 (n = 18)
First ICH/FND, year 3 (n = 21)
First ICH/FND, year 4 (n = 16)
First ICH/FND, year 5 (n = 18)
Second ICH/FND, presentation (n  = 17)
Second ICH/FND, year 1 (n  = 12)
Second ICH/FND, year 2 (n  = 11)
Second ICH/FND, year 3 (n  = 11)
Second ICH/FND, year 4 (n  = 12)
Second ICH/FND, year 5 (n  = 11)




Figure 4.18 Dependence measured on the Oxford Handicap Scale for survivors of first and second intracranial haemorrhage or focal 
neurological deficit in SIVMS, 1999–2003 (including adults who have undergone interventional treatment)   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
First ICH/FND, presentation (n = 30)
First ICH/FND, year 1 (n = 20)
First ICH/FND, year 2 (n = 25)
First ICH/FND, year 3 (n = 27)
First ICH/FND, year 4 (n = 22)
First ICH/FND, year 5 (n = 24)
Second ICH/FND, presentation (n = 17)
Second ICH/FND, year 1 (n = 14)
Second ICH/FND, year 2 (n = 13)
Second ICH/FND, year 3 (n = 14)
Second ICH/FND, year 4 (n = 16)
Second ICH/FND, year 5 (n = 14)
OHS 0 OHS 1 OHS 2 OHS 3 OHS 4 OHS 5
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Figure 4.19 Dependence measured on the Oxford Handicap Scale for survivors of first and second intracranial haemorrhage or focal 
neurological deficit in SIVMS, 2006–2010 (adults censored at time of interventional treatment)  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
First ICH/FND, presentation (n = 35)
First ICH/FND, year 1 (n = 20)
First ICH/FND, year 2 (n = 22)
First ICH/FND, year 3 (n = 24)
First ICH/FND, year 4 (n = 21)
First ICH/FND, year 5 (n = 15)
Second ICH/FND, presentation (n = 15)
Second ICH/FND, year 1 (n = 7)
Second ICH/FND, year 2 (n = 11)
Second ICH/FND, year 3 (n = 11)
Second ICH/FND, year 4 (n = 11)
Second ICH/FND, year 5 (n = 8)
OHS 0 OHS 1 OHS 2 OHS 3 OHS 4
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Figure 4.20 Dependence measured on the Oxford Handicap Scale for survivors of first and second intracranial haemorrhage or focal 
neurological deficit in SIVMS, 2006–2010 (including adults who have undergone interventional treatment) 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
First ICH/FND, presentation (n = 35)
First ICH/FND, year 1 (n = 26)
First ICH/FND, year 2 (n = 28)
First ICH/FND, year 3 (n = 29)
First ICH/FND, year 4 (n = 25)
First ICH/FND, year 5 (n = 21)
Second ICH/FND, presentation (n = 15)
Second ICH/FND, year 1 (n = 10)
Second ICH/FND, year 2 (n = 14)
Second ICH/FND, year 3 (n = 14)
Second ICH/FND, year 4 (n = 14)
Second ICH/FND, year 5 (n = 11)
OHS 0 OHS 1 OHS 2 OHS 3 OHS 4
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Three adults in the earlier cohort were rated OHS 0 at presentation. In both cohorts, 
counterintuitively, those who did not have a subsequent event tended to have a worse 
OHS rating at presentation than those who suffered another clinical event during 
follow-up (about 20% in the single-event groups are rated OHS 0–1 compared with 
53% [earlier cohort] and 40% [later cohort] in the recurrent group). The worst grade 
for either cohort at presentation is OHS 4, occurring in both single-event groups and 
OHS 3 for those who suffered a second event.  
During follow-up, OHS scores among those censored at the time of interventional 
treatment range from 0 to 3 in both cohorts, although in several years the lowest score 
is OHS 2. When those who received interventional treatment are included, one adult 
in the single-event group of the first cohort was rated OHS 5 in year 2 (in 2003, the 
year after treatment; between 2008 and 2013, however, he alternated between OHS 0 
and 1), and a woman in the recurrence group of the same cohort was rated OHS 4 in 
year 4 (in 2005; again, her level of dependence improved subsequently, and since 2008 
she has been rated OHS 2, whenever a rating has been received).  
The distribution of OHS scores for those who experience a single event is similar in 
both cohorts: over the five years of untreated follow-up, the percentage who are rated 
OHS 0–1 ranges from about 70% (in the first year after presentation) to about 80% 
(after five years). The number of adults who suffered a second event and received an 
OHS score during untreated follow-up is small in both cohorts (between seven and 
twelve), so percentages are rather unreliable. In the first cohort, 50–60% are rated OHS 
0–1 each year, with the exception of year 2, where 73% are rated as having a 
favourable outcome. In the later cohort, 36–50% are rated OHS 0–1 in four years; four 
years after the first event 64% are rated as having a favourable outcome.  
In summary, of those adults whose level of dependence was graded during follow-up 
in either cohort, about two-thirds of all survivors of an intracranial haemorrhage or 
focal neurological deficit (63–72%) have a favourable outcome, with no interference 
to lifestyle; about a quarter (19–30%) have some restrictions to lifestyle, but are able 
to look after themselves (OHS 2), and 3–16% have a moderate handicap, with 






The Scottish Intracranial Vascular Malformation Study (SIVMS) was meticulously 
designed to minimize potential sources of bias (Al-Shahi et al., 2003a, Al-Shahi et al., 
2003b, Al-Shahi Salman, 2005). By adopting a prospective, population-based design, 
recall and selection biases were minimized: recall bias is a problem in retrospective 
studies, and hospital-based studies tend to include the more seriously ill patients, 
whereas those patients whose lesions only have very mild side-effects and are treated 
by primary-care providers, and also those individuals in the community who die 
suddenly as a result of a haemorrhage tend to be missed. A clear inception point of 
symptom onset leading to a first-ever CCM diagnosis was adopted. Multiple 
overlapping sources of case ascertainment were used to identify adults with cerebral 
cavernous malformations, and two neuro-radiologists independently reviewed the 
original diagnostic imaging to confirm CCM diagnosis; strict diagnostic criteria and 
outcome definitions were applied to avoid detection and misclassification biases; 
neuro-imaging, pathology reports and case notes were reviewed to determine mode of 
initial clinical presentation; multiple overlapping sources of follow-up were – and 
continue to be – used to avoid information bias; assessors used all the clinical, 
radiological and pathological information available and were masked to potential 
prognostic features (sex and CCM location) to prevent bias in outcome assessment. 
Nevertheless, it is possible that the number of haemorrhages that occurred over the 
five-year period was underestimated, since haemorrhages can occur with a seizure and 
not every adult who suffers a seizure is referred for neuro-imaging.  
 
Composition of cohorts 
The composition of the second cohort is slightly older across all presentation types, 
but this is unlikely to be accounted for by the fact that no recruitment occurred during 
the years 2004 and 2005. Although a seemingly plausible explanation for the increased 
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age of the second cohort might be that some adults who would have been diagnosed 
in these two years were diagnosed a few years later, this does not appear to be borne 
out by the recruitment pattern in the second cohort. When year of diagnosis in the 
second cohort is examined, the least number of adults were diagnosed in 2006, and the 
largest numbers in the final two years (37 and 40 respectively).  
Examining the composition of both cohorts, those presenting incidentally and with 
FNDs tend to be older. This may be consistent with the theory that it is more common 
to investigate possible haemorrhagic symptoms in young, normotensive adults 
(Josephson and Al-Shahi Salman, 2011). This suggestion is further supported by the 
fact that there are fewer adults recorded with an FND presentation in the second cohort 
(6% compared with 15%), and those who are recorded have a median age of 57 years 
(IQR 52–60), compared with a median age of 40 years (IQR 32–59) in the first cohort.  
It is conceivable that general practitioners increased the number of patients they 
referred for neuro-imaging over the course of the two recruitment periods; this might 
account also for the increase in the percentage of adults presenting with seizure and 
ICH in the later cohort. It is also plausible that, over the course of the two recruitment 
periods, clinicians may have begun to refer slightly older patients with haemorrhagic 
symptoms for neuro-imaging; this might account for the older age-group presenting 
with FND in the second cohort, since some of those with FND presentation in the first 
cohort might in fact have been haemorrhagic presentation, had the appropriate neuro-
imaging been performed at the appropriate time. It is also possible, however, that MRI 
has become more sensitive over the study period and it has therefore become easier 
for neuro-radiologists to detect blood on the imaging in the later period.   
These two cohorts were drawn from the same population at different time periods, but 
were analysed separately, both in this and later chapters. This decision was taken for 
three reasons. First, separate analyses enabled a comparison of the number of outcome 
events that occurred over the two time-periods, at what stage in the follow-up period 
they occurred, and the consequent estimated risks of each event, since recruitment in 
the first cohort was between 1999 and 2003, and in the second between 2006 and 2010. 
It was not known whether MRI sensitivity had increased sufficiently during this period 
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to have had an effect on the number of clinical events detected. Second, the data 
pertaining to the earlier cohort were analysed in 2011, before any follow-up could be 
accrued for the final year of recruitment in the later cohort. Finally, the first cohort had 
a minimum of nine years follow-up (although this was truncated to five years in the 
analyses), whereas not every member of the second cohort was able to contribute the 
full five years of follow-up, because recruitment ended on 31 December 2010. 
 
Haemorrhage and focal neurological deficit in follow-up 
The estimated five-year risk of a recurrent intracranial haemorrhage definitely 
attributable to CCM was significantly greater than the similar risk for a first 
haemorrhage, in both cohorts. However, it should be borne in mind that the number of 
haemorrhages in the five-year follow-up period was very small: two (one) ICH among 
those who presented incidentally or with a seizure in the first (second) cohort, and six 
(nine) ICH among those who presented with a haemorrhage or had experienced one 
earlier in follow-up in the first (second) cohort.  
Furthermore, most haemorrhages occurred within the first eighteen months of follow-
up, and the estimated annual risk appeared to decrease over the course of the five years. 
In a similar manner, the estimated risk of a second clinical event due or possibly due 
to CCM was significantly greater than the risk of a first event, and again the annual 
risk diminished over time.  
The long-term risk of an ICH/FND in untreated follow-up remains uncertain: in the 
first cohort, a single participant experienced a clinical event in untreated follow-up 
more than five years after initial presentation (two non-haemorrhagic FNDs possibly 
due to CCM, 11.5 and 12.7 years after presentation). Therefore it would appear that 
the data from the earlier Scottish cohort support Barker and colleagues’ hypothesis 
that clinical events tend to cluster in time for a period of two or three years, and then 
the risk reverts to baseline (Barker II et al., 2001). 
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Sex as a predictor in the earlier cohort 
Another difference between the two cohorts is the percentage of women who presented 
with ICH or FND: 71% in the first cohort and 51% in the second. The data in the first 
cohort were analysed more than two years before the data in the second cohort, and 
therefore for this intervening period it seemed very probable that sex was a predictor 
of a recurrent clinical event in follow-up: sixteen women and a single man from the 
first cohort experienced a recurrent event, and women had an increased risk of a second 
event (log-rank χ2(1) = 6.21, p = 0.013) (see Figure 4.13(A)). In addition, biological 
mechanisms appeared to support this result, as it has been proposed previously that a 
CCM might respond to an increase in hormones during pregnancy, contraception or 
hormone replacement therapy (Robinson et al., 1991, Aiba et al., 1995, Abdulrauf et 
al., 1999, Moriarity et al., 1999, Wang et al., 2003, Pozzati et al., 1996). When the 
second cohort were analysed, however, the progression to second event was similar 
for both sexes, and indeed for the first four years, men appeared to have a slightly 
increased risk of a second event (Figure 4.13(B)).  
The medical records of the women in the earlier cohort who had experienced at least 
one clinical event were examined in greater depth, in an attempt to investigate whether 
oral contraception, pregnancy or hormone replacement therapy might have played a 
part in this increased risk. Nothing conclusive could be discovered, partly because the 
number of women who had experienced at least one clinical event was small (n = 32), 
and the women ranged in age from 23 years at presentation to 82 (median 39 years, 
interquartile range 33–58 years). With hindsight, it would appear that the fact that 
almost everyone who had a recurrence in the first cohort was female was an example 
of this cohort being located in the extreme tail of a theoretical sampling distribution, 





The functional outcome for participants in both cohorts with a single event was high 
over the first five years of follow-up, with over two-thirds being rated OHS 0–1. 
Among those who experienced at least two events within five years, 50–60% in the 
first cohort and 40–50% in the second cohort were rated OHS 0–1.  
However, this dichotomization into favourable versus unfavourable outcome is 
sometimes split so that favourable outcome includes OHS 2 (minor handicap: some 
restrictions, but able to look after self) (Bamford and Sandercock, 1989). If this 
dichotomization – OHS 0–2 versus OHS 3–5 – is used, then in most years at least 85% 
of adults, and in some years 100%, achieved a favourable outcome. This illustrates 
that, in general, the level of morbidity associated with cerebral cavernous 
malformation is low; none the less, it must be borne in mind that for a few less 
fortunate individuals, this is not the case and they experience OHS levels of 4 or 5.  
Functional outcome is a valuable measure for clinicians to employ when describing to 
newly diagnosed adults the untreated course of the condition. Five years after 
diagnosis, over 50% of adults who survived two clinical events had a favourable 
outcome (OHS 0–1) (and this extends to 100%, if favourable outcome is broadened to 
include OHS 2).  
  
Concluding comment 
Fortunately, comparatively few members of either cohort suffered a clinical event 
within five years of untreated follow-up. However, from a statistical point of view, the 
infrequency of outcome events created problems for modelling the untreated course of 
the disease, and it was impossible to build a prognostic model using the data from the 
first cohort alone. Thus several other research groups were invited to collaborate, so 
that an individual patient data meta-analysis could be undertaken; this is described in 
Chapters 6–9 below.   
 




Chapter 5: Comparison of outcome among 
treated and conservatively managed adults in 




As was discussed in Chapter 2, with the increased availability and usage of magnetic 
resonance imaging (MRI) over the past 25 years, and with more sophisticated neuro-
imaging techniques continually being developed, more people have received a first-
ever diagnosis of cerebral cavernous malformation. In particular, during this period an 
increasing number of people who are asymptomatic have been diagnosed incidentally; 
for example, of the 141 adults resident in Scotland who received a first definite CCM 
diagnosis between 1999 and 2003, 67 (48%) were diagnosed incidentally.  
As a result of this increase in diagnosis, clinicians frequently encounter a dilemma of 
how best to treat patients with CCM: whether to advise surgery to remove the lesion, 
on the one hand, with the attendant risks of morbidity and death; or whether to 
advocate conservative management, and thereby expose the patient to a lifetime risk 
of haemorrhage or focal neurological deficit. This situation is particularly challenging 
in the case of adults with hitherto asymptomatic lesions. To date, very few comparative 
studies have been undertaken that investigate the outcome of those who undergo 
interventional treatment for their cavernous malformations and those who are 
conservatively managed.    
For an individual with a non-haemorrhagic presentation who has not undergone any 
interventional treatment, the five-year risk of a first ICH due to CCM is estimated to 
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be 2.4% (95% CI 0% to 5.7%), and the five-year estimated risk of a recurrence is 
29.5% (95% CI 4.1% to 55.0%) (see Chapter 4 above) (Al-Shahi Salman et al., 2012). 
Moreover, as was observed in Chapter 4, the risk of a recurrent haemorrhage appears 
to decrease within five years of the initial haemorrhage (Barker II et al., 2001, Al-
Shahi Salman et al., 2012, Flemming et al., 2012). In addition, the volume of an 
intracranial haemorrhage due to a cavernous malformation tends to be small (average 
volume is approximately 1.8 cm3), due to CCM angioarchitecture, and functional 
outcome after the haemorrhage tends to be good (Cordonnier et al., 2008, Moultrie et 
al., 2014).  
In this chapter, after a brief synopsis of the available research, the functional outcome 
of all adults in Scotland who received a cavernous malformation diagnosis between 
1999 and 2003 is examined. 
 
5.2 Recent research 
 
There have been very few published studies comparing outcome after CCM excision 
with conservative management. Most studies that do exist tend to have one or more 
flaws: small sample size, short follow-up periods, a highly-selected patient base (for 
example, patients with brainstem CCM or CCM in eloquent areas of the brain) 
(Tarnaris et al., 2008, Huang et al., 2010, Menon et al., 2011, Wostrack et al., 2012).  
In a recent review of the literature concerning intractable epilepsy among patients 
diagnosed with CCM, the authors concluded ‘a large proportion of recent studies on 
surgery for CCM-associated epilepsy are not using criteria and definitions for the 
classification of epilepsy and outcome that are commonly used by epileptologists or 
epilepsy surgeons. This results in limited usefulness of a large part of the literature’ 
(von der Brelie and Schramm, 2011). Furthermore, several studies were published over 
fifteen years ago; neuro-imaging, neuro-navigation, electrophysiological monitoring, 
and microsurgical and radiosurgical techniques have all improved in the ensuing 
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period, and therefore a comparison of conservative and surgical management of CCM 
that was undertaken more than fifteen years ago is of limited relevance.  
Recinos et al. published a summary of advantages and disadvantages of conservative 
and surgical treatment, according to type of presentation and CCM location (Recinos 
et al., 2011). In a recent systematic review of comparative studies (Poorthuis et al., 
2013), Poorthuis and colleagues found sixteen observational studies comparing either 
surgical excision or stereotactic radiosurgery with conservative management: five 
studies investigated adults with a CCM who had experienced a prior haemorrhage, and 
eleven investigated patients with a CCM who suffered epileptic seizures. Of these 
sixteen studies, only two in the latter group demonstrated a ‘dramatic effect’ (i.e. less 
than 1% probability that both groups of observations came from the same population, 
and a rate ratio greater than 10) (Glasziou et al., 2007), and these latter two were 
considered to be at high risk of bias (Poorthuis et al., 2013). The authors concluded 
that ‘there is a need for large studies of CCM treatment with a concurrent control 
group, ideally with randomized treatment allocation’ (Poorthuis et al., 2013).  
In a systematic review and meta-regression analysis on CCM interventional treatment, 
Poorthuis and colleagues identified 63 cohorts, 49 of which reported on neurosurgery 
(2,684 patients with 6,707 patient-years of follow-up) and 14 on stereotactic 
radiosurgery (740 patients with 3,322 patient-years of follow-up), eleven using 
Gamma Knife and three using a linear accelerator (Poorthuis et al., 2014). However, 
the length of follow-up for these studies was comparatively short (median length 2.3 
years, 95% CI 0.1 to 8.1 years), and only three of the 63 studies fulfilled the 
researchers’ criteria for being classified as ‘high-quality’ studies, which was too few 
to conduct their planned sensitivity analysis. They concluded that:  
‘The reported risks of CCM treatment (and the lower risks of 
neurosurgical excision over time, from recently bled CCMs, 
and for CCMs outside the brainstem) compare favourably with 
the risks of recurrent haemorrhage from CCM. Long-term 
effects, especially important for stereotactic radiosurgery, are 






5.3.1 Research aim 
The primary aim of this chapter is to answer the following research question: how does 
the functional outcome of adults diagnosed with CCM who have undergone 
interventional treatment compare with those who have been managed conservatively 
over the course of a five-year follow-up period? It should be emphasized that no prior 
hypothesis was formulated at the beginning of this study as to whether interventional 
treatment would improve or worsen the functional outcome of adults diagnosed with 
CCM.  
 
5.3.2 Study design 
This is a comparative study, nested in a prospective, population-based observational 
cohort study of the management of adults with cavernous malformations. The adults 
who received CCM excision (cases) and the adults who were conservatively managed 
(controls) were concurrent.   
 
5.3.3 Participants  
All adults in the first cohort of the Scottish Intracranial Vascular Malformation Study 
(presenting between 1999 and 2003) who had received a definite CCM diagnosis and 
who were alive at presentation were included in this analysis. The period at risk was 
dichotomized into treated and untreated follow-up. Patients were classified as being 
managed conservatively, if they had not received interventional treatment for their 
cavernous malformation within five years of initial presentation, or as treated, if they 
had undergone surgical intervention or stereotactic radiosurgery within five years of 
initial presentation. It was necessary to specify a time window in which treatment had 
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occurred to ensure that there was a sufficient period of time for follow-up after 
treatment. Treatment strategy was decided by local clinicians. 
 
5.3.4 Inception and follow-up 
Methods of case ascertainment, follow-up, and definitions of ICH and FND have been 
described in Chapter 4 above. The inception point for the conservatively managed 
group was the date of initial presentation, which was the date of symptom onset – or 
the date of medical presentation, if the patient was asymptomatic – that directly led to 
a diagnosis of cavernous malformation. For the treated group, inception was the date 
of first intervention within five years of initial presentation. 
As described in Chapter 4, each year, on the anniversary of the date of diagnosis, a 
postal questionnaire is sent to every general practitioner, seeking an assessment of the 
patient’s functional outcome, using the Oxford Handicap Scale (OHS), which is 
derived from the modified Rankin scale. The Oxford Handicap Scale ranges from 0 
(‘no handicap: no change to lifestyle’) to 5 (‘severe handicap: totally dependent; 
requires constant attention day and night’) and 6 (death) (Bamford and Sandercock, 
1989) (see Table 5.1). 
 
5.3.5 Statistical analysis 
Baseline characteristics 
As in Chapter 4, in the descriptive analysis, mode of initial clinical presentation was 
categorized into four groups: ICH, FND, seizure or incidental; and CCM location was 
categorized as brainstem (in the midbrain, pons or medulla), cerebellar, deep (in the 
thalamus, basal ganglia or choroidal), or lobar (all other locations). However, in the 
univariate and multivariable analyses, mode of clinical presentation was dichotomized 
as ICH or FND at presentation versus incidental or seizure at presentation, and location  
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 Table 5.1 The Oxford Handicap Scale 
  
Reference: (Bamford and Sandercock, 1989). 
 
as brainstem versus all other locations. CCM multiplicity was grouped as single versus 
multiple. When comparing baseline characteristics between treatment groups, 
parametric methods of analysis were used where data were normally distributed, and 
non-parametric methods where they were not; odds ratios (together with 95% 
confidence intervals) were used to compare categorical variables; and exact tests 
where cell counts were less than five.   
 
Follow-up 
Treated follow-up was defined as all available follow-up from the date of a first 
intervention (that occurred within the first five years of follow-up), until the first 
outcome event or censoring. Untreated follow-up was divided into two groups: (i) all 
available follow-up from inception date until the first outcome event or censoring at 
five years for those adults who did not have an intervention within five years of 
presentation; or (ii) all available follow-up from inception until the date of a first 
intervention that occurred within five years of first presentation. Censoring occurred 
at the earliest occurrence of death unrelated to CCM, last available follow-up or five 
years after the start of follow-up. 
Handicap Lifestyle Grade 
None No change 0 
Minor symptoms No interference 1 
Minor handicap Some restrictions, but able to look after self  2 
Moderate handicap Significant restriction; unable to lead a totally 





Unable to live independently, but does not 
require constant attention 
4 
Severe handicap Totally dependent; requires constant attention 
day and night 
5 
Dead Dead 6 
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The untreated clinical course in the treated group was described – that is, the number 
of people who experienced a clinical event, whether due to the CCM or unknown 
cause, between presentation and intervention dates – but not included in the statistical 
analysis. If a participant had either an intracranial haemorrhage or new focal 
neurological deficit, due or possibly due to CCM, in this untreated period, then the 
dataset was adjusted so that the individual ‘presented’ with the last event before 
intervention (thus the primary mode of clinical presentation, age at presentation and 
possibly the CCM location could be changed). Deaths and their causes that occurred 
within 30 days of treatment were also described. 
 
Primary outcome 
The primary outcome of this analysis was ‘sustained poor outcome’, which was 
defined as two successive OHS scores ≥ 2, occurring within five years of the start of 
follow-up (after presentation date for the conservatively managed group and after 
intervention date for the treated group) (see Table 5.2 for a demonstration of the 
method used to calculate sustained poor outcome). An OHS score of 2–6 was 
determined as ‘poor outcome’, since OHS 2 is defined as ‘minor handicap: some 
restrictions, but able to look after self’ and, in general, cavernous malformations tend 
to have low morbidity. If a participant’s OHS scores were missing for the next one or 
two years after a first score of OHS 2–5, but the first available score was also OHS 2–
6, then this outcome was included in the definition of sustained poor outcome (see 
Table 5.2). Both OHS scores that contributed to the outcome measure occurred during 
the follow-up period, or the sixth year after inception; that is, the initial, baseline OHS 
score was not used to determine the primary outcome. 
The annual functional outcome for the treated group was adjusted to ensure that the 
first OHS scores to be used for this group occurred between 5 and 18 months after the 
date of first intervention, and at approximate annual intervals thereafter.  
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Table 5.2 Calculation of sustained poor outcome 
OHS ratings 
Comments 
Presentation Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
0 0 0 3 2 1 1 Sustained poor outcome occurred:  
start date for treated group: 
start date for conservatively managed group: 
 
year 3 
midway between years 2 
and 3 
1 2 0 2 1 3 1 Sustained poor outcome did not occur : 
No successive OHS 2–6 ratings  
1 - 2 - - 2 3 Sustained poor outcome occurred:  
start date for treated group: 




presentation and year 2  
No OHS ratings available in years 3 and 4, so first OHS 2–6 rating in year 
2 carries over to second OHS 2–6 rating in year 5 
1 2 1 - - 2 3 Sustained poor outcome occurred:  
start date for treated group: 




midway between years 2 
and 5 
Year 1 rating followed by OHS 1 in year 2, so year 5 is the first of two 
successive OHS 2–6 ratings 
3 2 1 - - 2 3 Sustained poor outcome occurred:  
start date for treated group: 




midway between years 2 
and 5 
Presentation rating not included in sustained poor outcome calculation  
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For the conservatively managed group, however, unless the participant died within the 
first year of follow-up, the first possible OHS score was at least one year after the date 
of presentation, since questionnaires requesting OHS ratings were sent to family 
doctors annually on the anniversary of the presentation date. To avoid an apparent 
artificial time-lag between treated and conservatively managed groups, the start date 
of sustained poor outcome for the untreated group was calculated so that it occurred 
midway within the observation period (i.e. midway between the last OHS score 0–1 
and the first OHS score 2–6) (see Table 5.2), with the rationale that sustained poor 
outcome is a gradual process rather than a specific event that happens on a particular 
day.   
 
 Secondary explanatory outcome  
The secondary – explanatory – outcome was a composite endpoint of symptomatic 
cerebral infarction, intracranial haemorrhage or new focal neurological deficit (Al-
Shahi Salman et al., 2008). Cerebral infarction was defined by clinical signs of focal 
or global neurological disturbance that developed rapidly and lasted for 24 hours or 
longer, with the proviso that this diagnosis was supported by appropriate neuro-
imaging or pathological examination. These three events were independently 
classified as definitely attributable to a CCM, possibly attributable to a CCM (due to 
lack of a more plausible explanation) or attributable to CCM treatment. A sensitivity 
analysis was undertaken for the secondary outcome: events that were definitely 
attributable to a CCM or attributable to surgery were included, and events possibly 
attributable to a CCM were excluded from the analysis. 
 
Analysis 
Kaplan-Meier survival curves (one minus Kaplan-Meier estimate) for the primary and 
secondary outcomes, each plot stratified by treatment group, were constructed to 
display the cumulative proportion of each group that experienced the outcome; log-
rank tests were used to compare the two curves.  
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For both primary and secondary outcomes, four predictors of interest among the 
baseline characteristics were pre-specified in the following order: age at start of 
follow-up (or treatment); primary mode of clinical presentation; CCM location; and 
sex. The fifth predictor was treatment group. These variables were selected on account 
of their clinical relevance; their known or hypothesized relevance in the medical 
literature; and the accuracy, reliability and completeness of data collection. 
Cox proportional hazards regression was used in the univariate analyses for both 
primary and secondary outcomes, to determine the unadjusted hazard ratios for each 
potential predictor, if the proportional hazards assumptions were satisfied (Machin et 
al., 2006). This model is expressed in terms of the hazard function, ℎ(𝑡), which is the 
instantaneous rate of an event happening at time t, given that it has not occurred up to 
time t: 
ℎ(𝑡) = ℎ0(𝑡)exp (𝑏1𝑥1) 
where ℎ0(𝑡) is the baseline or underlying hazard function, when the covariate, 𝑥1, has 
the value of 0, and 𝑏1 is the regression coefficient; values for ℎ0(𝑡) and 𝑏1 are 
estimated from the data.  
In the multivariable analyses for each outcome, Cox regression was again used and the 
model took the form  
ℎ(𝑡) = ℎ0(𝑡)exp (𝑏1𝑥1 +  𝑏2𝑥2 + ⋯ + 𝑏𝑝𝑥𝑝) 
where 𝑥1 to 𝑥𝑝  are the covariates in the model, and 𝑏1 to 𝑏𝑝 are the regression 
coefficients, which are all estimated from the data. For both outcome measures, hazard 
ratios were adjusted by any factors imbalanced at baseline and/or known to influence 
CCM prognosis. However, because the main objective was to examine the impact of 
treatment on outcome, rather than to create a model, the rule that the number of 
predictors entered into the analysis should be governed by the number of outcome 
events was relaxed (Harrell et al., 1984, Concato et al., 1995, Peduzzi et al., 1995), and 
all pre-specified covariates were entered into the analyses.   
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The sample size for this analysis was not pre-specified; however, the aim was to 
identify every new definite diagnosis of CCM (i.e. validated by MRI or pathological 
examination) within a five-year period in a single country, and to accumulate at least 




5.4.1 Treatment groups 
Between 1999 and 2003, 141 adults resident in Scotland received a first-ever definite 
diagnosis of cerebral cavernous malformation, which was validated by MRI (n = 135) 
or pathological examination, following surgical excision (n = 1) or autopsy (n = 5) (see 
Figure 5.1). The five participants who were diagnosed at autopsy were not included in 
the analysis, since they did not contribute any follow-up. In addition, when the analysis 
was undertaken (summer 2012), the diagnosis of two adults had not been confirmed 
as definite; therefore these participants were not included in this analysis. In fact, these 
two patients were conservatively managed, suffered neither intracranial haemorrhage 
nor focal neurological deficit in follow-up, and their Oxford Handicap Scale (OHS) 
scores were unavailable until the year 2009/2011 (which was more than five years after 
presentation); since then one has a consistent score of 0, and the other scored a single 
2 and has since alternated between 0 and 1. 
During the first five years of follow-up, 25 adults (19%) underwent microsurgical 
CCM treatment, no one received stereotactic radiosurgery, and 109 adults (81%) were 
conservatively managed. Two adults underwent surgery more than five years after 
presentation; they are included in the conservatively managed group as they each had 
five years of untreated follow-up. Although a potential five-year period between 
presentation and intervention had been specified, all 25 adults in the treated group had 
surgery within three years of presentation. The median time between presentation and 
intervention was 10 months (IQR 4.7–16.1 months), and only two people had surgical 



















Figure 5.1 Flowchart of adults included in the analysis  
Adults diagnosed at 
autopsy 
n = 5 
SIVMS CCM cohort, 1999–2003 
Adults with a definite CCM 
diagnosis 
n = 141 
 Adults with definite 
CCM diagnosis 
confirmed after July 
2012 
n = 2 
n = 2 
 
Treated participants 
 Treated within 5 years of first 
presentation  
 Follow-up starts at date of 
intervention 
n = 25  
Conservatively managed participants 
 All untreated adults and adults who 
were treated more than 5 years after 
first presentation 
 Follow-up starts at presentation 
date: 
n = 109 
Sustained poor outcome in 
follow-up (2 successive OHS 
scores 2–5) 
n = 13 
Sustained poor outcome in 
follow-up (2 successive OHS 
scores 2–5) 
n = 40 
 
Clinical event (ICH or FND) in 
follow-up 
n = 8; events: 9 
 
Clinical event (ICH or FND) in 
follow-up 
n = 17; events: 21 
 
Adults included in the analysis  
Adults with a definite CCM, 
alive at diagnosis 
n = 134 
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In the treated group, 21 adults underwent surgical excision of their lesion: 20 had a 
single CCM excised, and another participant had two lesions excised on different 
occasions. Two of the remaining four adults had a partial resection, and in one case 
the lesion was excised six weeks later (follow-up started at partial resection for both 
participants). Another two adults underwent haematoma evacuation, one of whom had 
a subsequent excision nine months later; for the latter participant, follow-up began 
immediately after the excision of his lesion.  
 
5.4.2 Baseline characteristics 
Baseline characteristics of the cohort, stratified by treatment group, are shown in Table 
5.3. A male : female sex ratio of 2 : 3 was identical in both groups. A larger percentage 
of the untreated group harboured a brainstem lesion (15% vs 4%), but fewer people 
who were conservatively managed had multiple lesions (16% vs 24%). Comparing 
symptoms that led to a CCM diagnosis in the two groups, a larger percentage of the 
treated group presented with haemorrhage (32% vs 9%) and seizure (40% vs 23%), 
and conversely fewer presented incidentally (12% vs 51%). Two adults in the treated 
group, however, initially presented incidentally, but one experienced a haemorrhage 
and the other a focal neurological deficit in the period of untreated follow-up between 
presentation and intervention; presentation type and age at presentation for these two 
participants were adjusted to take account of these clinical events in untreated follow-
up.  
When type of presentation was dichotomized into ICH and FND versus incidental and 
seizure, a larger percentage of adults in the treated group presented with an intracranial 
haemorrhage or focal neurological deficit (48% vs 26%) (χ2(1) = 4.84, p = 0.033).   
However, those who were conservatively managed tended to be almost a decade older 
at the time of presentation (median age 43 years vs 34 years in the treated group) 
(Mann-Whitney test, p = 0.004). Despite these baseline imbalances, the dichotomized 
OHS scores at presentation were similar in both groups: 44% in the treated group had 
an OHS score 0–1 compared with 51% in the conservatively managed group.   
116 
Table 5.3 Baseline characteristics of adults who presented with a definite diagnosis of cerebral cavernous malformation in Scotland, 1999-
2003, stratified by treatment group 
Characteristic 
Treated group, 
n = 25 
n                         % 
 Conservatively managed 
group, n = 109 
n                     % 
Statistical tests 
Sex:       
Female 15 60%  64 59% Female vs male: OR = 1.06 (0.44–2.56) 
Male 10 40%  45 41%  
Age at presentation* (median, 
IQR) 
34 26.5, 41.5 
 
43 33.5, 53.0 
Mann-Whitney U test (p = 0.004) 
CCM location:       
Lobar 19 76%  71 65% Brainstem vs other location: 
Cerebellum   4 16%  14 13% OR = 0.24 (0.03–1.92) 
Deep   1   4%    8   7%  





Single vs multiple: OR = 0.59 (0.20–
1.68) 
Single 19 76%  92 84%  
Multiple   6 24%  17 16%  
Mode of clinical presentation*      ICH + FND vs incidental + seizure: 
Incidental   3 12%  56 51% OR = 2.67 (1.09–6.53) 
Seizure 10 40%  25 23% χ2(1) = 4.84 (p = 0.033) 
Intracranial haemorrhage   8 32%  10   9%  
Focal neurological deficit   4 16%  18 17%  





OHS 0–1 vs OHS 2–6:  
0–1   11 44%  55 51% OR = 0.77 (0.32–1.85) 
2–5  14 56%  54 50%  
*Mode of clinical presentation and age at presentation have been adjusted for the six adults who experienced an ICH or FND before they underwent surgery. 
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5.4.3 Primary outcome 
The primary outcome of this analysis was sustained poor outcome, a functional 
outcome measure defined as two successive Oxford Handicap Scale scores 2–5 (see 
Table 5.2). Of the 25 adults who underwent surgery, 13 (52%) had a period of 
sustained poor outcome within five years of the intervention, compared with 40 adults 
(37%) in the conservatively managed group (n = 109) who had a similar period of 
sustained poor outcome within five years of presentation.   
As can be seen in the Kaplan-Meier survival plot in Figure 5.2, there was no strong 
evidence that progression to a period of sustained poor outcome differed between the 
two groups during the five years of follow-up (log-rank test (Mantel-Cox) χ2(1) = 1.85, 
p = 0.17). Although there is a suggestion of a trend in favour of conservative 
management, it is possible that this might become less apparent if the length of follow-
up were increased. In the univariate Cox regression analysis to compare the effect of 
treatment (surgical excision versus conservative management) on functional outcome, 
the hazard ratio (HR) was 1.54 (95% confidence interval 0.82 to 2.88). It should be 
noted, however, that this progression to sustained poor outcome was unadjusted for 
potential confounders and, as can be seen from Table 5.3, there were clear differences 
between the two treatment groups at presentation. In Table 5.4, the number of adults 
who progressed to sustained poor outcome, stratified by treatment group and baseline 
characteristic, is displayed. The corresponding adjusted results are presented in Table 
5.9 in section 5.4.5. 
The spectrum of dependence, measured on the Oxford Handicap Scale, is shown in   
Figure 5.3 and illustrates fluctuations in functional outcome over the follow-up period. 
The OHS score at presentation date is displayed for both groups, together with the 
annual OHS scores of adults whose family doctors participated in the study during the 
five-year follow-up period (which started from presentation for the conservatively 
managed group and from the date of intervention for the treated group). In several 
instances of missing annual OHS scores, family doctors responded to the annual 
questionnaire that they felt unable to rank functional outcome of their patient on the 






Adults at risk (events in previous year)    
Treated   25 20(5) 15(5) 12(2) 11(1) 11(0)  
Untreated 109   88(21) 82(6)   72(10) 69(3) 68(0)  
 
 




Figure 5.2 Kaplan-Meier estimate of progression to sustained poor outcome (primary 
outcome), stratified by treatment group, during five years of prospective follow-up 
CCM excision 
Conservative management 
CCM excision vs conservative management 
Hazard ratio = 1.54 (95% CI 0.82 to 2.88) 
Log-rank (Mantel-Cox), χ2(1) = 1.85, p = 0.17 
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CCM excised (tx) 
Sustained poor outcome 




 Conservatively managed (cm) 
Sustained poor outcome 





Treatment group  13 52% 25  40 37% 109 
         
Mode of presentation ICH/FND 5 42% 12  10 36% 28 
Other 8 62% 13  30 37% 81 
         
CCM location Brainstem 1 100%   1    9 56% 16 
Other 12 50% 24  31 33% 93 
         
Sex Male   5 50% 10  21 47% 45 
Female   8 53% 15  19 30% 64 
         
CCM multiplicity Single   9 47% 19  31 34% 92 
Multiple   4 67%   6    9 53% 17 
         
OHS rating at 
presentation 
0–1   6 55% 11  10 18% 55 
2–5   7 50% 14  30 56% 54 
Age-group at 
presentation 
< 40 years   7 41% 17  13 28% 47 
40+ years   6 75%   8  27 44% 62 
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Figure 5.3 Dependence, measured on the Oxford Handicap Scale, for adults with CCM diagnosis, from date of presentation: five-year 
follow-up period from presentation for conservatively managed group and from intervention for CCM excision group 
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The Oxford Handicap Scale is frequently dichotomized into favourable outcome, 
which may be categorized as OHS 0–1 (or 0–2), versus unfavourable outcome, OHS 
2–6 (or 3–6); hence in Figure 5.3, the blue bars represent OHS scores 0–1 and the 
orange bars OHS 2–6. Both treated and conservatively managed groups had a similar 
distribution of scores at presentation. For each of the five years of follow-up, however, 
at least 40% (range 41–55%) of the conservatively managed group received an OHS 
rating of 0, whereas a lower percentage (between 23% and 48%) of the treated group 
were allocated OHS score 0. When OHS scores of 0–1 were considered, the difference 
between the two groups was less pronounced, particularly in years 4 and 5 of follow-
up.  
 
Completeness of OHS ratings 
As was described in section 5.3.5 above, the primary outcome measure of sustained 
poor outcome was computed using the annual Oxford Handicap Scale ratings that were 
reported by participants’ family doctors each year. The level of completeness for these 
ratings is shown in Table 5.5 below; the mean level of completeness over the six years 
is similar for both treatment groups (85%). 
 










n                   % 
CCM excision 
n                   % 
1 70 64% 19 76% 
2 95 87% 23 92% 
3 99 91% 22 88% 
4 96 88% 21 84% 
5 95 87% 22 88% 
6 100 92% 21 84% 
Mean 93 85% 21 84% 
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5.4.4 Secondary outcome 
The secondary outcome was a composite endpoint – the first occurrence in follow-up 
of intracranial haemorrhage, new focal neurological deficit or cerebral infarction; this 
was considered as a potential explanatory outcome. There were 42 clinical events – 
intracranial haemorrhage or new focal neurological deficit – after initial presentation, 
but no occurrences of infarction in this cohort.  
Eight adults (32%) in the treated group (three of whom had had at least one clinical 
event between presentation and intervention), and 17 (16%) in the untreated group 
experienced a clinical event in follow-up (see Table 5.6). Three FNDs, however, 
occurred more than five years after presentation (one to an adult in the conservatively 
managed group, who had a lobectomy more than seven years after presentation, and 
two within six weeks to an adult who had undergone surgical excision 6.5 years 
previously). The number of adults who experienced a clinical event during five-year 
follow-up, stratified by treatment group and baseline characteristic or measurement, is 
presented in Table 5.7. 
 
Conservatively managed group 
Among the participants who were conservatively managed (see Table 5.6, two suffered 
a single haemorrhage, a third experienced two haemorrhages and the fourth adult two 
haemorrhages and a focal neurological deficit; all haemorrhages were attributable to 
the CCM. The median time to first haemorrhage in the conservatively managed group 
was 1.6 years, with an interquartile range of 0.9–3.6 years. In addition, 13 participants 
experienced at least one focal neurological deficit (median time to first FND: 1.5 years, 
IQR: 0.6–2.3 years). Eight FNDs were attributable to the CCM, and five were possibly 
due to the lesion; one adult experienced two FNDs, both possibly due to the CCM. 
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Earlier events before 
intervention 
Subsequent events 
after recurrencea  
Treated ICH procedure  1  – 1 adult x 1 FND 
 FND IVM  1  1 adult x 1 FND + 2 ICH – 
  FND procedure  6  1 adult x 1 ICH – 
     1 adult x 1FND – 
       
Conservatively managed ICH IVM  4 1 fatal – – 
     – 1 adult x 1 ICH 
     – 1 adult x 1 ICH + 1 FND 
 FND IVM  8 – – – 











a In addition, two other women experienced events more than six years after the start of follow-up: 
one was in the conservatively managed group, but had an excision more than seven years after presentation and suffered an FND due to the 
procedure;  











Clinical event in follow-up 




 Conservatively managed 
Clinical event in follow-up 









ICH/FND 4 33% 12  11 39% 28 
Other 4 31% 13    6   7% 81 
         
CCM location Brainstem 1 100%   1    8 50% 16 
Other 7 29% 24    9 10% 93 
         
Sex Male 4 40% 10    3   7% 45 
Female 4 27% 15  14 22% 64 
         
CCM multiplicity Single 3 16% 19  14 15% 92 
Multiple 5 83%   6    3 18% 17 
         
OHS at presentation 0–1 3 27% 11    7 13% 55 
2–5 5 36% 14  10 19% 54 
Age-group at 
presentation 
< 40 years 5 29% 17    7 15% 47 
40+ years 3 38% 8  10 16% 62 
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Treated group 
In the treated group, one adult sustained a haemorrhage two days after surgery (and 
over two years later experienced a non-haemorrhagic focal neurological deficit), and 
seven adults experienced a focal neurological deficit: four the day after first 
intervention, one the day following excision of a second lesion, one 8 days after 
surgery, and one two months later. Seven of the clinical events in this group could be 
attributed to the intervention; the eighth participant had a focal neurological deficit 
attributable to the CCM two months after a haematoma evacuation, following three 
previous events (FND and 2 ICH) in untreated follow-up (see Table 5.6). 
 
Untreated follow-up period in treated group 
In the period between presentation and first intervention, six adults (24%) suffered at 
least one clinical event (see Table 5.8): three participants experienced a single FND; a 
fourth sustained a single ICH; a fifth sustained two ICH; and the sixth suffered a single 
FND, followed by two ICH. For these six adults, the date of the last event before 
excision was taken as ‘presentation’ date: baseline characteristics of age and type of 
presentation were adjusted to the final event before treatment.  
 
 








Adults Type of clinical event(s) 
3 Single FND 
1 Single ICH 
1 Two ICH 




The Kaplan-Meier survival curve for progression to first clinical event in follow-up is 
shown in Figure 5.4. There was a greater risk of a first event in follow-up for the treated 
group (log-rank test (Mantel-Cox) χ2(1) = 5.88, p = 0.015), and the hazard ratio was 
2.71 (95% confidence interval 1.17 to 6.29). It is striking, however, that clinical events 
in the treated group occurred within a few days of surgery, whereas events in the 
conservatively managed group occurred throughout the five years of follow-up. 
 
Univariate and multivariable analyses 
Four potential confounders, based on baseline imbalance and epidemiological 
evidence, were pre-specified: age at presentation, mode of clinical presentation, CCM 
location and sex. Univariate Cox regression was performed to obtain a hazard ratio for 
treatment group and each confounder in order to observe the effect of each on the 
primary and secondary outcomes (Table 5.9).  
For the primary outcome, in which the difference in time to sustained poor outcome 
was examined, none of the five variables achieved significance, although the hazard 
ratio for increasing age (at presentation or at final event preceding treatment) per year 
was 1.015 (95% CI 0.998 to 1.03).  
However, when time to first clinical event (the secondary outcome) was examined, 
three variables achieved significance: treatment group, prior clinical event and CCM 
location. The hazard ratio for treatment (CCM excision versus conservative manage-
ment) was 2.71 (95% CI 1.17 to 6.29); the hazard ratio for presentation (ICH or FND 
versus other presentation) was 4.03 (95% CI 1.81 to 8.97); and the hazard ratio for 
CCM location (brainstem versus other location) was 4.46 (95% CI 1.96 to 10.12). 
  
 




Figure 5.4 Kaplan-Meier estimate of progression to ICH/FND (secondary outcome), 
stratified by treatment group, during five years of prospective follow-up 
 
Cox regression was used to investigate the effect of treatment on both functional and 
clinical outcome, after adjusting for the four potential confounders, and these results 
are also summarized in Table 5.9 (right column). These results should be interpreted 
with a degree of caution, however, since the proportional hazards assumption could 
not be assessed, due to the paucity of events in the analysis.  
Adults at risk (events in previous year) 
CCM excision   25   16(8) 15(0) 14(0) 14(0) 14(0) 
Conservative 
management 
109 100(7) 95(4) 88(3) 87(1) 85(2) 
CCM excision 
Conservative management 
CCM excision vs conservative management 
Hazard ratio = 2.71 (95% CI 1.17 to 6.29) 
Log-rank (Mantel Cox), χ2(1) = 5.88, p = 0.015 
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Table 5.9 Univariate and multivariable analyses of first progression to the first occurrence of a primary or secondary outcome during five 





















The analyses for the primary outcome have been conducted using the adjusted time-period: sustained deterioration for the untreated group is deemed to have occurred 
in the middle of the period between the date of the last OHS 0–1 score and the first of at least two consecutive OHS 2–6 scores.   
 Univariate analyses 
HR  (95% CI) 
Multivariate analyses 
HR  (95% CI) 
Primary outcome – sustained poor outcome 
Excision vs conservative management 1.54 (0.82 to 2.88) 2.19 (1.12 to 4.29) 
Increasing age (at presentation or at final event preceding 
treatment), per 10 years 
1.16 (0.98 to 1.37) 1.23 (1.02 to 1.48) 
ICH or FND at presentation vs incidental or seizure 0.88 (0.48 to 1.59) 0.68 (0.35 to 1.30) 
Brainstem vs other location 1.77 (0.89 to 3.53) 2.51 (1.18 to 5.34) 
Female vs male 0.64 (0.37 to 1.09) 0.56 (0.32 to 0.97) 
   
Secondary outcome – clinical event   
Excision vs conservative management 2.71 (1.17 to 6.29) 3.60 (1.29 to 10.03) 
Increasing age (at presentation or at final event preceding 
treatment), per 10 years 
1.03 (0.79 to 1.33) 1.10 (0.81 to 1.48) 
ICH or FND at presentation vs incidental or seizure 4.03 (1.81 to 8.97) 2.12 (0.85 to 5.26) 
Brainstem vs other location  4.46 (1.96 to 10.12)  4.15 (1.52 to 11.37) 
Female vs male 1.87 (0.78 to 4.48) 1.27 (0.51 to 3.16) 
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After adjusting for increasing age at presentation (or at final event preceding 
treatment), ICH or FND versus incidental or seizure at presentation, brainstem versus 
other location, and female versus male, the hazard for progression to sustained poor 
outcome for those whose lesions were excised was more than twice that for those who 
were conservatively managed (HR = 2.19, 95% CI: 1.12 to 4.29). Thus adjusting for 
these potential confounders and imbalances at baseline has resulted in a slightly 
increased hazard ratio, which now also achieves significance (univariate HR = 1.54, 
95% CI 0.82 to 2.88).  
Similarly, after adjusting for the four potential confounders, the hazard for progression 
to first clinical event in follow-up for those who received surgery was more than three 
times that for those who were conservatively managed (HR = 3.60, 95% CI: 1.29 to 
10.03). Again, the size of the hazard ratio after adjustment was made for baseline 
imbalances and potential confounders has slightly increased from the univariate value 
of 2.71 (95% CI 1.17 to 6.29). 
 
Deaths  
Thirteen participants died during the five-year follow-up period. Among the ten deaths 
in the conservatively managed group, two were attributable to IVM and eight to other 
causes; in the treated group, one death was attributable to the cavernous malformation 
and two to other causes. There were no deaths within thirty days of treatment. The 
median age at death was 60 years (interquartile range 50 to 73 years): this was 
substantially younger for those whose cavernous malformation was excised (51 years) 




5.4.6 Sensitivity analyses 
In the sensitivity analyses for the secondary outcome, progression to intracranial 
haemorrhage or new focal neurological deficit, events that were possibly attributable 
to a CCM were excluded from the analysis. This resulted in five clinical events – all 
new FND – being removed from the original analysis. Although one of these adults 
had a second event in follow-up, this FND was also probably due to the CCM, and so 
excluded from the sensitivity analysis. All excluded FND occurred to adults who had 
been managed conservatively. Therefore, in this sensitivity analysis: 
(i) 25 adults had a CCM excised:  
8 had an event within 5 years of excision; 
17 had no event within 5 years of excision; 
(ii) 109 adults were managed conservatively: 
12 had an event in 5-year follow-up period;   
97 had no event in 5-year follow-up period.  
 
The results of the univariate and multivariable analyses are presented in Table 5.10. In 
the univariate analysis, treatment, CCM location and ICH/FND presentation are still 
statistically significant, with hazard ratios slightly increased, as would be expected. In 
addition, in the multivariable analysis, ICH/FND presentation is also statistically 
significant, together with treatment and CCM location (which were before). The 
unadjusted and adjusted hazard ratios for treatment versus conservative management 
are larger than in the original analysis, since all the events excluded in the analysis 
were in the conservatively managed group.  
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Table 5.10 Sensitivity analysis: univariate and multivariable analyses of progression 
to first clinical event during five years of follow-up 
Secondary outcomea – clinical 
event 
Univariate hazard ratio 
(95% CI) 
Multivariable adjusted 
hazard ratio (95% CI) 
Excision vs conservative 
management 
3.78    (1.54 to 9.26)   5.54    (1.78 to 17.23) 
   
Increasing age above mean, per 10 
years 
1.01  (0.76 to 1.36) 1.14  (0.81 to 1.61) 
   
Presentation with haemorrhage or 
FND 
  6.12    (2.35 to 15.94) 3.03    (1.05 to 8.76) 
   
Brainstem CCM location   5.09    (2.08 to 12.50)   5.17    (1.67 to 16.01) 
   
Female 1.69    (0.65 to 4.41) 0.98    (0.35 to 2.71) 






In this prospective, population-based observational cohort study of the management of 
adults with cavernous malformations, interventional treatment was a predictor of 
progression to sustained poor outcome, after adjustment had been made for factors 
imbalanced at baseline (increasing age and intracranial haemorrhage or focal 
neurological deficit at presentation) and/or potentially related to CCM prognosis 
(brainstem lesion and sex). Progression to sustained poor outcome was not adequately 
explained by progression to first clinical event in follow-up. 
 
5.5.1 Strengths  
Study design 
The main strength of this study is its meticulous study design and multiple attempts to 
minimize several potential sources of bias (see subsections 4.2.2 and 5.3.4 above). 
Prospective recruitment to the cohort was restricted to newly diagnosed cases of 
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cerebral cavernous malformation in a stable adult population in 1999 of 4.08 million 
inhabitants (Scotland), using multiple overlapping sources of case ascertainment, to 
counter potential selection bias. Strict diagnostic criteria and outcome definitions were 
employed in an attempt to avoid detection and misclassification biases.  
Prospective follow-up was undertaken using multiple overlapping sources at annual 
intervals and is still continuing; 100% completeness of baseline data and 97% 
completeness of follow-up was achieved over the five-year duration of this study; 
assessors were blinded to potential prognostic features; and functional outcome was 
measured on a validated scale. In addition, because a single study population was 
stratified during follow-up into concurrent treated and conservatively managed groups, 
problems that would arise from comparing different geographical populations 
originating from different ethnic backgrounds at different time periods have been 
avoided. This study represents current clinical practice, and can be compared at a 
future date with a second cohort of adults from the same geographical area, who were 
diagnosed with cerebral cavernous malformation between 2006 and 2010 inclusive.  
 
5.5.2  Limitations 
Non-random treatment allocation 
The main weakness of this study is the fact that, since it is an observational study, there 
is potential confounding of results by certain imbalances at presentation: the treated 
group were younger and more likely to present with haemorrhage or focal neurological 
deficit than the conservatively managed group. From a clinical perspective, it is not 
surprising that the treated group contains younger patients with more severe 
symptoms, since this group is most likely to derive the greatest future benefit from 
interventional treatment with the least risk, as its members probably have fewer 
comorbidities and a longer life expectancy. It should be noted, however, that rankings 
on the OHS were similar in both groups at presentation.  
In an attempt to limit the problem of confounding, multivariable analysis was used to 
adjust for the imbalances in the baseline characteristics (see Table 5.9 for the hazard 
 
  133 
ratios and 95% confidence intervals). Randomization of treatment allocation, however, 
is required as it is the only effective method of ensuring that no systematic difference 
exists among patients in either treatment group before the treatment is started (Hlatky 
et al., 1988, Byar, 1991). Although in this study adjustment has been made for baseline 
characteristics that are suspected or known to affect outcome, it is possible that other 
– unobservable or unknown – factors may exist (for example, genetic factors), that 
have an effect on outcome; randomization increases the probability that such factors 
would be evenly distributed among treatment groups.  
 
Size of treated group 
Further limitations of this study are the small size of the treated group (19%), which 
reflects current clinical practice in Scotland, and the comparatively short follow-up 
period. Both of these shortcomings, however, can be addressed in the future, since the 
second cohort of adults, diagnosed between 2006 and 2010 inclusive, is being 
followed, and follow-up still continues for the first cohort. 
 
Oxford Handicap Scale ratings 
Different time points for two treatment groups 
A potential problem with the primary outcome measure is that the Oxford Handicap 
Scale ratings for the two treatment groups start at different time points. Although the 
OHS rating occurs annually, those who have received interventional treatment receive 
their first rating at some point between 5–18 months after surgery, whereas those who 
have been conservatively managed are rated sometime after the approximate 
anniversary of their diagnosis. To avoid the spurious implication that progression to 
sustained poor outcome was about six months slower for conservatively managed 
participants, a date midway between last OHS score 0–1 and first OHS score 2–6 was 
calculated and used for the start date of sustained poor outcome. This approach was 
justified since sustained deterioration tends to be a gradual process and is thus unlikely 
to occur on a specific date.  
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The fact that the time between intervention and first OHS rating is not fixed can also 
lead to potential difficulties: for example, a patient may have a first OHS score 2–5 at 
three months after intervention, which is ignored according to our criteria, and a 
second rating which is also OHS 2–5, followed by subsequent ratings that are OHS  
0–1. In this example, the patient is deemed not to have suffered sustained poor 
outcome; however, had the first score, three months after surgery, been used, then this 
patient would have been included in the subgroup that experienced a period of 
sustained poor outcome. 
 
Influence of a patient’s comorbidity on OHS rating 
Another potential problem associated with the primary outcome measure in this study 
is that a general practitioner’s annual OHS rating of his/her patient’s functional 
outcome may be unduly influenced by the individual’s comorbidity. In theory, the 
OHS rating represents an annual assessment of the level of independence that an adult 
diagnosed with a cavernous malformation enjoys. In practice, however, it represents a 
single snapshot once a year of how a general practitioner assesses his/her patient’s 
functional outcome. It may not take into account any of the patient’s other health 
problems. For example, an asymptomatic patient may be diagnosed incidentally with 
a cavernous malformation at the time of an MRI for traumatic brain injury; in 
subsequent years, his OHS rating may signify poor functional outcome, but this may 
conceivably be due to disability resulting from the brain injury rather than to problems 
associated with the presence of a cavernous malformation. This problem is more likely 
to affect older patients, since the risk of suffering from many diseases, e.g. 
cardiovascular disease, cancer, etc., tends to increase with age.  
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5.5.3 Other points 
Possibility of subsequent improved outcome 
It should also be noted that although 13 adults (52%) in the treated group and 40 (37%) 
in the conservatively managed group experienced a period of sustained poor outcome 
within the first five years of follow-up, there is a suggestion that this is not necessarily 
a permanent state and that improvement may be possible at a later date. Taking two 
successive OHS scores 0–1 as evidence of a period of sustained improvement, 
following the period of sustained poor outcome, 14 (26%) of the 53 adults who 
suffered a period of sustained poor outcome subsequently enjoyed a period of 
sustained improvement later during the course of seven years of follow-up. In terms 
of treatment groups, nine of the 40 adults (23%), who were conservatively managed 
and had a period of sustained poor outcome, subsequently enjoyed a period of good 
outcome; similarly, five of the 13 participants (38%) whose lesion was excised and 
had a period of poor outcome showed sustained good outcome. The number of adults 
in either group is too small, however, to permit any meaningful conclusions being 
drawn from this treatment-group stratification, beyond a demonstration that a period 




In this chapter an exploratory observational study comparing outcomes of adults who 
either opted for CCM excision or conservative management is described. The strengths 
and limitations of the study were presented in subsections 5.5.1 and 5.5.2 above, and 
need to be assessed carefully. On the one hand, the adults were drawn from a 
prospective population-based cohort study that was very carefully designed to 
minimize several sources of potential bias, and follow-up was assiduously 
accumulated; on the other hand, the lack of randomization of the two groups is a 
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serious flaw in the study design. In addition, although the two treatment groups were 
concurrent, the number of adults who received interventional treatment was relatively 
small (n = 25).  
For these reasons, the results of this study should be treated with a great deal of caution. 
They would appear to imply that complications within days of interventional surgery 
may outweigh the benefits of excision. Furthermore, although none of the adults whose 
CCMs were excised without early surgical complications suffered a subsequent ICH 
or FND within five years of surgery, their level of dependence, as measured by Oxford 
Handicap Scale scores – especially in the fourth and fifth years since surgery – was 
similar to that of the group who were conservatively managed. (Figure 5.3 suggests 
that the treated group, if anything, may have a slightly inferior outcome to the untreated 
group.) Additionally, cases have been reported of new CCMs growing after excision 
and subsequently bleeding. It is also possible, however, that adults in the 
conservatively managed group may suffer a subsequent ICH or FND more than five 
years after presentation, although results in SIVMS and other research suggest that 
clinical events tend to cluster in the early years and decline later. 
However, the lack of treatment randomization, the small size of the surgery group, and 
the fact that dependence levels in either group may be due to the effects of 
comorbidities rather than CCM militate against drawing a clear conclusion from this 
study, other than to repeat the case for a randomized controlled trial (RCT). As is 
discussed in Chapter 10 below, recruitment to a potential RCT in this area will 
certainly not be without its difficulties, as individuals may understandably be reluctant 
to leave the decision to undergo neurosurgery purely to chance. In the meantime, the 
recommended guidelines for the management of adults with CCMs – whether the 
CCMs were incidentally detected with no clinical events in follow-up, CCMs that have 
caused one or more than one ICH or FND – is to decide management on a case-by-













Over the past two decades, a number of papers describing the clinical course of 
untreated cavernous malformations have been published (Robinson et al., 1991, 
Zabramski et al., 1994, Aiba et al., 1995, Kondziolka et al., 1995, Kim et al., 1997, 
Porter et al., 1997, Moriarity et al., 1999, Porter et al., 1999, Barker II et al., 2001, 
Hasegawa et al., 2002, Mathiesen et al., 2003, Wang et al., 2003, Ghannane et al., 
2007, Al-Shahi Salman et al., 2012, Flemming et al., 2012, Schneble et al., 2012). 
Unfortunately, many of these studies suffer from one or more biases, as was discussed 
in Chapter 3 above (section 3.3.1): most were hospital-based studies, which are 
susceptible to selection bias; many were retrospective studies, which suffer from 
information bias; and in many cases detection and misclassification biases were likely, 
as diagnostic criteria were not clearly specified and outcome events, especially 
intracranial haemorrhage (Al-Shahi Salman et al., 2008), were undefined.   
In addition, studies that limit outcome to intracranial haemorrhage may be at risk of 
detection bias, as outlined in Chapter 2 above (section 2.3.2). There is a tendency for 
clinicians to investigate the cause of a haemorrhage in young, normotensive adults, 
whereas older, hypertensive adults are less likely to be investigated, especially if they 
are known to harbour a cavernous malformation, and thus the possibility exists that a 
small haemorrhage may be missed. Patients with cavernous malformations who are 
being treated conservatively may be more reluctant to report minor symptoms to their 
clinicians, who in turn may be more reluctant to arrange radiographic investigation, 
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even though the symptoms may in some cases reflect a small symptomatic 
haemorrhage, which would have been detected, had the appropriate neuro-imaging 
been undertaken. In some instances, of course, the reverse may be true: some patients 
being treated conservatively may report minor symptoms more frequently, if they are 
anxious about the management of their disease, in the hope that the treatment decision 
may be changed. 
Diagnosis of a haemorrhage also relies on timely neuro-imaging using the appropriate 
modality: for example, a haemorrhage can only be detected on a CT scan if it is 
performed within a week of the event; if more than a week has elapsed between the 
haemorrhage and the CT scan, the blood can no longer be detected, even though a 
haemorrhage occurred. Thus for the reasons described above, some researchers 
combine outcomes of intracranial haemorrhage and focal neurological deficit into a 
composite endpoint of ‘clinical event’ (Porter et al., 1997, Al-Shahi Salman et al., 
2012).  
The main limitations of previously published studies, however, have been small 
sample size and short follow-up; this has resulted in some studies being underpowered 
with an insufficient length of follow-up for infrequent outcomes to occur.  
 
6.2 Risk of intracranial haemorrhage after cerebral 
cavernous malformation diagnosis 
 
Comparison of the risks of ICH between these studies is problematic for several 
reasons. First, some research groups restricted inclusion in their study to selected 
participants: for example, those patients who initially presented with a haemorrhage 
or FND that led to their eventual CCM diagnosis; or individuals who had the familial 
form of the disease, and who frequently have multiple lesions; or individuals with a 
CCM in a specific anatomical location. The risk of ICH or FND in follow-up is likely 
to be different for each group.  
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Second, different statistical methods have been used to calculate risk of ICH or FND 
in untreated follow-up in most of the studies. In many papers, authors calculated the 
risk of ICH assuming that the CCM is congenital, whereas it is now accepted that 
lesions do occur de novo during lifetime (Zabramski et al., 1994, Kattapong et al., 
1995, Detwiler et al., 1997, Nimjee et al., 2006). In some studies, the risk per lesion 
was estimated rather than that per patient. In other studies, the total number of ICH in 
follow-up rather than the first ICH in follow-up was used to calculate an annual rate; 
it was also assumed that the annual rate is constant over time, which appears not to be 
the case, as some studies have evidence of a gradual diminishing of risk over time 
(Barker II et al., 2001, Al-Shahi Salman et al., 2012). 
Furthermore, the risk of haemorrhage is affected by the increased availability of more 
sophisticated neuro-imaging techniques over the past twenty years; not only are more 
symptomatic cavernous malformations being detected, but intracranial haemorrhages 
can also be detected more reliably since the development of haemosiderin-sensitive 
MRI sequences (Josephson and Al-Shahi Salman, 2011). 
 Overall, the annual rates of first-ever ICH (0.3% to 2.0%) have been lower than 
recurrent ICH (6.2% to 18.3%) from the same lesion, but neither of these rates has 
been estimated with precision (Al-Shahi Salman et al., 2012, Flemming et al., 2012).  
 
6.3 Aims of an individual patient data meta-analysis 
 
Most studies have consistently identified the occurrence of a prior haemorrhage as a 
risk factor for an adult developing a subsequent haemorrhage. Studies have varied, 
however, in whether putative risk factors such as patient sex, CCM location or CCM 
multiplicity have influenced the risk of ICH. Therefore, the patient’s and clinician’s 
dilemma about whether, when and how to treat a cavernous malformation would be 
informed by more precise estimation of the clinical course of untreated cavernous 
malformations, the identification of prognostic factors, and the derivation and evalu-
ation of a prognostic model. By collaborating with other research groups and 
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conducting an individual patient data meta-analysis, it was possible to use consistent 
methods of analysis for all patients across studies and to investigate two outcomes: 
ICH alone and a composite outcome of ICH and new focal neurological deficit.  
The aims of this study were to improve the precision of previous estimated risks of 
first ICH after CCM diagnosis (and also the composite outcome of first or recurrent 
ICH or FND), and to identify prognostic factors for such an outcome after diagnosis. 
Finally, if it were appropriate, a prognostic model based on several covariates would 
be developed and evaluated / validated.  
 
6.3.1 Study questions 
The rationale for this individual patient data meta-analysis was to help the clinician 
when explaining a CCM diagnosis to a patient and to inform their decision on an 
appropriate management strategy for the disease. This study aims to answer the 
following three questions: 
1. What is the estimated risk of an untreated adult suffering an ICH (or a clinical 
event, that is, either an ICH or FND) within five years of CCM diagnosis? 
2. Which baseline characteristics modify the risk of ICH (or clinical event) 
occurring within five years of CCM diagnosis? 
3. Is it possible to predict, at the time of diagnosis, an individual’s risk of a 




After conducting a systematic review, described elsewhere (Al-Shahi Salman et al., 
2012), thirteen suitable studies were identified that could provide detailed individual 
patient data regarding clinical outcome (ICH or FND) between diagnosis and either 
CCM treatment or last follow-up. A protocol was sent to each research group, together 
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with an invitation to participate in an individual patient data meta-analysis. The 
invitation was also extended to two research groups whose studies were unpublished 
at the time (Flemming et al., 2012, Schneble et al., 2012). 
 
6.4.1 Study and participant eligibility 
Our criteria for study eligibility for inclusion in this collaboration were that each study 
should have a minimum sample size of 50 adults; the period at risk should begin either 
at first CCM diagnosis or the symptoms leading to CCM diagnosis, thereby enabling 
calculation of an event risk from diagnosis (not retrospective ‘lifetime risk’); 
symptomatic ICH should be included as an objective, pre-defined clinical outcome; 
and outcome events should be able to be quantified per patient during the follow-up 
period. 
The minimum sample-size criterion was dictated by time and patient-number 
constraints. It is very time-consuming to liaise with different research groups, 
understand data collection methods and clean datafiles, and as the two outcomes (ICH 
and FND) are comparatively uncommon, a minimum study size was stipulated to 
maximize the chance of obtaining datasets with at least some outcome events and 
thereby avoid spending a disproportionate length of time with very small datasets that 
would make a minimal contribution to the study.  
As mentioned above, many of the early studies describing the natural history of 
cavernous malformations calculated the risk of haemorrhage over the course of an 
individual’s life-time. However, this method of calculation underestimates the risk of 
haemorrhage, because it is now recognized that cavernous malformations are dynamic 
lesions that can appear de novo, as well as increase or diminish in size over time 
(Zabramski et al., 1994, Pozzati et al., 1996, Nimjee et al., 2006, Flemming et al., 
2011). Even among individuals in whom no new lesions have developed, calculation 
of haemorrhagic risk from the date of diagnosis is more appropriate, since in many 
cases a lesion will have been latent for many years and will suddenly become active, 
resulting in an event that leads to its diagnosis. 
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In addition, the following individual inclusion criteria were specified: each participant 
should be aged 16 years or older and have received a definite CCM diagnosis, 
validated by brain MRI; and participants should not have received interventional 
treatment – surgical excision or stereotactic radiotherapy – by the time of diagnosis.  
 
6.5  Procedures 
 
The following baseline data were requested from collaborating studies: patient sex, 
date of birth, date and mode of clinical presentation leading to CCM diagnosis, date of 
earliest radiographic-definite CCM diagnosis, number and location of CCM, and 
presence of associated developmental venous anomalies. Dates of all clinical outcome 
events (ICH or FND) during follow-up, dates and types of any interventional 
treatment, and date and cause of death were also requested.  
As in previous chapters, distinctions were made between intracranial haemorrhage, 
non-haemorrhagic focal neurological deficit (where there is no evidence of recent 
blood on timely brain neuro-imaging or pathological examination) and focal 
neurological deficit not otherwise specified (where neither neuro-imaging of the 
appropriate modality nor pathological examination had been performed at all or at the 
correct time to be able to distinguish recent blood), according to published criteria (Al-
Shahi Salman et al., 2008), for clinical events both at presentation and in follow-up 
(see section 2.3.2). Initial presentation was categorized as ‘incidental’ if an adult was 
asymptomatic or if their symptoms (e.g. headache or tinnitus) could not be ascribed to 
the underlying cavernous malformation. Initial presentation was classified as epileptic 
seizure if the seizure was neither symptomatic of a concomitant intracranial 
haemorrhage nor more likely to be due to another cause.   
Unlike in the previous two chapters, the inception point for this study was taken as the 
date of first-in-a-lifetime diagnosis of a cavernous malformation, and the follow-up 
period was five years. The two primary outcome events were symptomatic ICH alone 
and a composite endpoint of symptomatic ICH or new FND. The composite outcome 
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(referred to forthwith as a ‘clinical event’) is important, because both ICH and FND 
have a similar level of morbidity for the patient, and in certain circumstances an 
outcome labelled FND may, in reality, be an ICH, but not categorized as such, either 
because the appropriate neuro-imaging was not performed or because the imaging 
failed to detect any blood (Al-Shahi Salman et al., 2008). 
 
6.6 Statistical analysis 
 
6.6.1 Preparing the data for analysis 
A protocol and a separate detailed statistical analysis plan were developed and agreed 
with all the participating centres before data analysis began (see Appendices B and E). 
The data from each study were checked carefully for internal consistency and 
agreement with any relevant published reports, and any queries were referred back to 
the original research group for clarification.  Individuals in each cohort were checked 
to ensure that they met the eligibility criteria to be included in the study. Datafiles for 
each cohort were created in identical format to enable the data for individual cohorts 
to be merged into a single large dataset. 
In instances where adults harboured multiple cavernomas, a single primary location 
was attributed to the symptomatic lesion; however, where an adult presented 
asymptomatically with multiple cavernous malformations, brainstem location took 
precedence (see sections 4.2.5 and 4.3 above). Location of cavernoma was categorized 
as brainstem (in the midbrain, pons or medulla), cerebellar, deep (in the thalamus, 
basal ganglia or choroidal), or lobar (in the cortex or subcortical areas of the cerebral 
hemispheres) in the baseline characteristics, but in the univariate and multivariable 
analyses the covariate was dichotomized to brainstem versus other location. Similarly, 
mode of presentation has four categories at the baseline level (ICH, FND, seizure or 
incidental), but was dichotomized to presentation with ICH or FND versus other 




During the process of cleaning each dataset, problems of missing data were addressed 
by contacting the clinician responsible for providing the data. In the statistical analysis 
plan, it was reported that in cases where missing data could not be resolved they would 
be imputed, if appropriate.  
 
6.6.2 Descriptive analysis 
As a first stage, tables of baseline characteristics were compiled for each individual 
cohort and also for the pooled cohorts; these were stratified by mode of clinical 
presentation, to enable the similarity of each cohort at inception to be assessed. In time-
to-event analyses, the primary outcome was ICH and the secondary outcome was 
clinical event; follow-up data were censored for each adult at the time of the earliest 
occurrence of the treatment, death or last follow-up; if censoring had not already 
occurred, follow-up was truncated at five years after CCM diagnosis.  
The decision to truncate follow-up at five years was influenced by several factors. A 
reasonable length of follow-up was required for each cohort to provide an opportunity 
for outcome events to occur, since intracranial haemorrhage and focal neurological 
deficit are not common events. However, there is some evidence that clinical events 
tend to cluster within a few years of diagnosis, and then the event rate declines (Barker 
II et al., 2001, Al-Shahi Salman et al., 2012). In an ideal study, all cohorts would have 
a pre-determined fixed length of follow-up; unfortunately, this was not possible in this 
study, as the end of the recruitment period for the second Scottish cohort was 31 
December 2010. Thus five years seemed an optimum compromise between being a 
sufficient length of time to enable the majority of clinical events occurring in follow-
up to be captured, on the one hand, and being a reasonable target length for studies to 
achieve. It is hoped that five years might become a standard follow-up period to enable 
comparison of present results with those of future studies.  
 
  145 
It should be noted that the possibility of the occurrence of informative censoring 
cannot be excluded, since a neurosurgeon may discern that a patient’s condition is 
worsening and thus decide to excise the CCM before an intracranial haemorrhage or 
focal neurological deficit actually occurs. Censoring at interventional treatment is 
discussed at greater length in section 8.3 in Chapter 8 below. 
 
6.6.3 Identification of risk factors 
Five predictors of haemorrhage or clinical event within a five-year follow-up period 
were pre-specified on account of their clinical significance and existing evidence base 
(Robinson et al., 1991, Aiba et al., 1995, Kondziolka et al., 1995, Moriarity et al., 
1999, Josephson and Al-Shahi Salman, 2011, Al-Shahi Salman et al., 2012, Flemming 
et al., 2012), in addition, to their completeness, accuracy and reliability. Mode of 
clinical presentation and CCM location were core predictors; sex, CCM multiplicity 
(multiple versus solitary) and age were putative predictors. In addition, CCM size and 
associated developmental venous anomaly were pre-specified as exploratory 
predictors, if they had been recorded by sufficient cohorts.  
In both the univariate and multivariable analyses, age was treated as a continuous 
variable, since categorization of a continuous variable results in loss of information, 
power and precision (Royston et al., 2006). To enable survival plots to be inspected 
for age, the pooled cohort was divided into three, approximately equal, age-groups.  
Kaplan-Meier survival curves, stratified by each of the five pre-specified covariates in 
turn, displayed the cumulative proportion of the cohort that experienced each of the 
outcome events over five years of follow-up (Kirkwood and Sterne, 2003, Machin et 
al., 2006). The log-rank test was used to compare the survival plots for each predictor.  
Cox proportional hazards regression was used in the univariate analyses to determine 
the unadjusted hazard ratios for each predictor of both intracranial haemorrhage and 
clinical event within five-year follow-up (Machin et al., 2006). Assuming the 
proportional hazards assumption was not violated, multivariable Cox proportional 
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hazards regression would be used to model the risk of a future ICH (and ICH or FND, 
where the data were available) for an adult with CCM during untreated follow-up 
(Harrell et al., 1996, Machin et al., 2006). In the multivariable analyses for each 
outcome event, the two core predictors – mode of clinical presentation and CCM 
location – were entered into the model first, and then each putative predictor – sex, 
CCM multiplicity and age – was added in turn to ascertain whether any of them added 
statistically significant prognostic information over and above the two core predictors.  
 
6.6.4 Study design of IPDMA 
In a meta-analysis the results of several similar studies are combined into a single 
summary statistic (with confidence interval). The rationale for undertaking an 
individual patient data meta-analysis (IPDMA) is to synthesize the available evidence 
concerning the clinical course of untreated cerebral cavernous malformations to 
improve the estimated risk of an intracranial haemorrhage within five years of CCM 
diagnosis, and to identify risk factors for this outcome.  
Although meta-analyses can be performed using aggregate data (summary statistics), 
it is more satisfactory to use individual patient data in time-to-event analyses since the 
researcher is not only interested in whether an outcome occurred, but at what point in 
the follow-up period it occurred. Also, when individual patient data are used, the 
researcher is able to compare participant characteristics across studies and investigate 
heterogeneity (Tudur Smith, 2004). In addition, as was outlined above (in section 6.2), 
the risk of an intracranial haemorrhage has not been estimated in a standardized 
manner in the other studies reported in the systematic review (Al-Shahi Salman et al., 
2012), and therefore it would not be appropriate to carry out a meta-analysis using 
aggregate data from these studies.  
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Theory: meta-analysis 
Two-stage vs one-stage approach  
Before undertaking an individual patient data meta-analysis, thought must be given to 
which model should be used – whether fixed effect or random effects – and whether 
the meta-analysis should be carried out in one or two stages. In the two-stage approach, 
data for each study are analysed independently, using the same method of analysis, to 
produce summary statistics, together with confidence intervals (first stage). The 
summary statistics calculated for each study (i.e. aggregate data) can then be 
synthesized according to standard meta-analysis techniques (second stage).  
In the one-stage approach, individual patient data from all the studies in the meta-
analysis are pooled and a single model, stratified by study, is fitted (Riley et al., 2010). 
However, the one-stage method relies on a much stronger assumption of homogeneity 
among studies than the two-stage method, and it is also more challenging to implement 
for time-to-event data, especially when the random-effects model is used (Bowden et 
al., 2011), since hierarchical regression models would be required (Stewart et al., 
2012).   
In the present study, the two-stage meta-analysis method was adopted, as it would be 
beneficial to be able to inspect the hazard ratios in individual studies as well as the 
pooled cohorts. Indeed, this approach is arguably more transparent than the one-stage, 
especially when considerable heterogeneity between studies is likely: not only were 
patients in the cohorts located in different countries, with different health-care systems, 
but some studies were hospital-based whereas others were population-based.  
 
Fixed-effect model 
In the fixed-effect model, it is assumed that no heterogeneity exists between studies 
and that there is one underlying true parameter value (or common effect size, hence 
the name ‘fixed effect’) for all the studies; any differences in observed estimates of the 
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parameter can be attributed solely to sampling variation  (Deeks et al., 2001, Kirkwood 
and Sterne, 2003, Borenstein et al., 2009). The summary estimate of the pooled log 
hazard ratio is a weighted average of the log hazard ratios from each of the k individual 
studies:   
log(HR𝐹) =  







where log(HR𝐹) is the log hazard ratio under the fixed-effect model (in which it is 
assumed that the mean hazard ratio is the same for each study in the meta-analysis), 
and log(HR𝑖)  is the log hazard ratio for study i. The relative weight, 𝑤𝑖, is calculated 
as the inverse of the sampling variance of the mean of study i; therefore studies with 
greater precision have a smaller variance and greater weight, and so have greater 
influence in the meta-analysis. Conversely, studies that have a wider dispersion and 
larger variance, and are thus less precise, have a lower weight and consequently less 
influence in the meta-analysis.  
 
Random-effects model 
By contrast, in the random-effects model it is assumed that heterogeneity does exist 
between studies. Thus the true parameter (e.g. log hazard ratio) for each study will 
vary around an overall average value, and is assumed to be part of a random sample 
from a normal distribution, i.e.      
log(HR𝑖) ~ 𝑁(log(HR𝑅) , 𝜏
2 ) 
where the mean, log(HR𝑅), is the true ‘overall’ log hazard ratio, and the between-study 
variance is 𝜏2 . In addition, for each study, the observed effect will be different to the 
true effect, due to sampling error. Therefore in the random-effects model, the distance 
between the true mean parameter value and the observed summary statistic is 
composed of two parts: the true variation in effect sizes (between-study variability) 
and the variation due to sampling error (i.e. chance) (within-study variability) (Tudur 
Smith, 2004, Borenstein et al., 2009).  
The random-effects summary estimate of the log hazard ratio is 
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log(HR𝑅) =  
∑ [𝑤𝑖








∗ is the weight assigned to study i in the random-effects model: 
𝑤𝑖
∗ =  
1
𝑣𝑖 +  𝜏2
 
and 𝑣𝑖  is the within-study variance for study i (and is therefore equal to 𝑤𝑖
−1) 
(Kirkwood and Sterne, 2003, Borenstein et al., 2009, Thompson et al., 2010, Tudur 
Smith, 2004). The standard error of the random-effects summary estimate is the square 
root of the inverse of the sum of the adjusted weights: 






The between-studies variance, 𝜏2, is estimated using the DerSimonian and Laird 
method (also known as the method of moments) (DerSimonian and Laird, 1986): 
𝜏2  = 𝜏𝐷𝐿




where, in a meta-analysis with k studies, Q is the test statistic for the χ2 test of 
heterogeneity with k - 1 degrees of freedom, df, i.e. 

















In random-effects models, the intention is that by allocating weights, both sources of 
variance should be minimized. The range of the weights assigned to studies is narrower 
than for a fixed-effect model, and the sum of the weights is always equal to 100%. 
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Therefore smaller studies tend to exercise a greater influence in random-effects models 
than in the fixed-effect models (and conversely larger studies are less influential), 
because in a random-effects model the mean of a distribution of effects, rather than a 
single effect, is being estimated.  
Compared with fixed-effect models, the summary estimate in random-effects models 
tends to be more conservative, with a wider confidence interval; this reflects the fact 
that in the random-effects model there is greater uncertainty because, in addition to the 
sampling variation, the true effect is assumed to vary between studies (Kirkwood and 
Sterne, 2003, Borenstein et al., 2009). 
 
Cerebral Cavernous Malformation study 
In the present study, two-stage random-effects meta-analyses were performed for each 
of the five a priori predictors. The random-effects model was used because of the 
probability that clinical heterogeneity existed between the studies. The metan 
command in Stata, which uses the DerSimonian-Laird method (DerSimonian and 
Laird, 1986), was used to perform the meta-analyses in this thesis (Bradburn et al., 
2009, Harris et al., 2009).  
Forest plots displayed the unadjusted hazard ratios for each cohort and an unadjusted 
hazard ratio for the pooled study. The meta-analyses were repeated, this time using the 
adjusted hazard ratios; hazard ratios for the two core predictors were adjusted for each 
other, and the hazard ratios for each of the three putative predictors were adjusted for 
the two core predictors.   
 
6.6.5 Heterogeneity 
Heterogeneity is an important consideration, both from the clinical and statistical 
perspectives, and in this study there are three potential sources. A first source of 
heterogeneity is in the study design (methodological heterogeneity): adults in a 
population-based study may be more likely to present incidentally than adults in a 
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hospital-based study. To account for this source of heterogeneity, the total dataset was 
stratified by study design – that is, population-based cohort versus hospital based 
cohort.  
A second source of heterogeneity may be found in the baseline characteristics of 
participants (clinical heterogeneity), and of particular concern in this study are patient 
age, sex, mode of clinical presentation, CCM location and multiplicity, as these may 
influence outcome. For example, patients in a tertiary referral neurosurgery unit may 
be more likely to harbour brainstem lesions, and patients in an institute specializing in 
genetics may be more likely to have the familial form of the disease, with multiple 
lesions, than patients in general hospitals or the community. 
A third type of heterogeneity that might exist between the cohorts is due to the 
variation in the true effect size between studies (statistical heterogeneity); this might 




The sources of observed variation in effect size can be split into two components: first, 
observed effects that vary due to within-study error (i.e. when all studies have the same 
– i.e. true – effect size and thus heterogeneity does not exist), and second, the real 
heterogeneity in effect size (when the effect size varies between studies) (Borenstein 
et al., 2009). 
Several tests have been devised to discern the extent of heterogeneity in meta-analysis. 
Until recently, a frequently used test for heterogeneity was the Cochran’s Q test, which 
is the weighted sum of squares of deviations (as given in the subsection above Theory: 
meta-analysis):    
𝑄 =  ∑ 𝑤𝑖
𝑘
𝑖=1
[log(HR𝑖)  −  log(HR𝐹)]
2 
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The null hypothesis is that there is a fixed effect shared by all (k) studies, and the test 
statistic, Q, is compared with a χ2 distribution with (k – 1) degrees of freedom.  
The Q test, however, is not reliable at detecting true heterogeneity between studies, 
since it lacks power when the meta-analysis consists of a small number of studies or 
small studies that contain large within-study variance (Hardy and Thompson, 1998, 
Deeks et al., 2001, Higgins et al., 2003, Borenstein et al., 2009, Huedo-Medina et al., 
2006). Thus a p-value greater than 0.05 does not necessarily imply homogeneity;  
indeed, some authors recommend using a 10% cut-off for significance testing to assess 
heterogeneity (i.e. p < 0.1), but that in turn creates problems by increasing the risk of 
a type I error (Higgins et al., 2003). Another parameter used to quantify heterogeneity 
is τ2, the variance of the true effect sizes or between-study variance (see subsection 
Theory: meta-analysis above). 
The 𝐼2 index measures the percentage of total variation in study estimates that is due 
to true (between-study) heterogeneity, rather than chance (Higgins and Thompson, 
2002):   
𝐼2 =  (
𝑄 − 𝑑𝑓
𝑄
)  × 100% 
The range of possible values for 𝐼2 lies between 0% and 100%, so if the degrees of 
freedom (k – 1) are greater than Q, then 𝐼2 is set at 0%. When 𝐼2 is equal to 0%, there 
is no observed heterogeneity; the level of heterogeneity increases as the value of 𝐼2 
increases.  
An advantage of using 𝐼2 is that it is independent of the number of studies in the meta-
analysis. 𝐼2 is the ratio of excess (𝑄 − 𝑑𝑓) to total (𝑄) dispersion, and can be 
considered as a measure of inconsistency across study findings since it reflects the 
extent of the overlap of confidence intervals (Higgins and Thompson, 2002, Higgins 
et al., 2003, Huedo-Medina et al., 2006, Borenstein et al., 2009, Bowden et al., 2011). 
Higgins and Thompson (2003) include guidance for calculating the standard error of 
𝐼2, which they use to calculate 95% uncertainty intervals. Higgins and co-authors have 
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tentatively suggested that for 𝐼2 values of 25%, 50% and 75%, heterogeneity might be 
considered to be respectively mild, moderate and high (Higgins et al., 2003). 
 
6.6.6 Sensitivity analysis 
Sensitivity analyses were undertaken. For the outcome of ICH, all the cohorts were 
pooled, and the univariate and multivariable Cox regression analyses were repeated on 
the entire dataset, stratified by the covariate ‘study’. For the composite outcome of 
clinical event (ICH or FND), the cohorts where FND was recorded were pooled and 
the Cox regression analyses were repeated as above, stratified by ‘study’.   
 
6.6.7 Building a prognostic model 
The level of heterogeneity between the cohorts was examined for each covariate, and 
possible reasons were proposed to explain its existence. If heterogeneity between 
cohorts were sufficiently modest to enable a prognostic model to be built, patient data 
in all cohorts would be pooled to form a single dataset (Altman et al., 2009, 
Hemingway et al., 2013, Riley et al., 2013, Steyerberg et al., 2013, Steyerberg, 2009). 
Ideally, this pooled dataset should be split in half, with one half being used to develop 
the model and the other to evaluate or validate it. However, as outcome events for this 
condition are comparatively uncommon, it would be unlikely that there would be 
sufficient events in each portion to build or evaluate a model. If it were not possible to 
use one or more cohorts in developing the model, then these could possibly be used to 
validate it (Altman et al., 2009, Debray et al., 2012, Moons et al., 2012b, Moons et al., 
2012a, Steyerberg et al., 2013).   
Assuming the proportional hazards assumption were not violated, multivariable Cox 
proportional hazards regression would be used to model the risk of a future ICH (and 
ICH or FND, if the data were available) occurring within five years of CCM diagnosis 
during untreated follow-up. This model is expressed in terms of the hazard function, 
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ℎ(𝑡), which is the instantaneous rate of an event happening at time t, given that it has 
not occurred up to time t: 
ℎ(𝑡) = ℎ0(𝑡)exp (𝑏1𝑥1 +  𝑏2𝑥2 + ⋯ + 𝑏𝑝𝑥𝑝) 
ℎ0(𝑡) is the baseline or underlying hazard function, when all the covariates have the 
value of 0; 𝑥1 to 𝑥𝑝  are the covariates in the model; and 𝑏1to 𝑏𝑝 are the regression 
coefficients; values for ℎ0(𝑡), 𝑏1and 𝑏𝑝 are all estimated from the data (Harrell et al., 
1996, Machin et al., 2006).   
Pre-specified covariates in the model would be selected for their clinical significance: 
covariates of a priori interest were listed above, namely, ICH/FND at presentation, 
brainstem location, age (as a continuous variable), lesion multiplicity, and sex. Other 
potential covariates include lesion size and associated developmental venous anomaly. 
Initially, the two core predictors were entered into the model first and then each 
putative predictor was added in turn to examine its impact on the outcome. The Wald 
test was used to assess the contribution of each covariate, and whether it should be 
included in the final model. The Wald test is based on the ratio of the regression 







where W has a χ2 distribution, with one degree of freedom. 
Since there is inconsistency in the literature about the role of sex as a putative risk 
factor for ICH or FND, the four other a priori covariates were forced into the model 
on account of their clinical significance, regardless of their statistical significance in 
the univariate analyses; the analysis was re-run with sex included, to ascertain its effect 
on the outcome. 
If heterogeneity between the cohorts were substantial, but the proportional hazards 
assumption were not violated, then the Cox proportional hazards regression would be 
stratified by a ‘study’ covariate, with covariates of a priori interest included in the 
model (Hosmer et al., 2008, Steyerberg, 2009, Fibrinogen, 2009).  
 
  155 
 
 
6.6.8 Prognostic index 
If appropriate, a prognostic index would be developed to enable classification of the 
patients into three groups: low-, medium- and high-risk of experiencing an intracranial 
haemorrhage (or clinical event) within five years of diagnosis. The index would take 
the form: 
prognostic index score =  𝑏1𝑥1 + 𝑏2𝑥2 + ⋯ + 𝑏𝑝𝑥𝑝 
where, again, 𝑥1 to 𝑥𝑝 are the covariates, and 𝑏1 to 𝑏𝑝 the regression coefficients, 
estimated from the data (Machin et al., 2006). 
One of the main reasons for creating this index would be for its use as an aid for 
clinicians at the time of CCM diagnosis: to enable them to advise patients of their 
estimated five-year risk of ICH (ICH or FND) following diagnosis, if they were 
conservatively managed. Therefore the covariates in the index must be readily 
available at time of diagnosis. It is also essential to ensure that the levels for each 
variable are ordered in the same direction, probably from tending towards a good 
prognosis (low code) to tending towards a bad prognosis (high code). If this form of 
coding is used, then a high score in the prognostic index will indicate a poor prognosis.  
After the covariates have been selected and a suitable model obtained, the next step 
would be to simplify the regression coefficients of the model. This is normally 
achieved by finding a common factor and then rounding each coefficient to the nearest 
integer, or by dividing all the regression coefficients by the smallest coefficient and 
then rounding. Finally, a prognostic index would be developed by calculating a 
prognostic score for each adult in the dataset.  
A frequency distribution of the individual scores would be examined, and two cut-off 
points would be used to separate the dataset into high-, medium- and low-risk 
categories (Machin et al., 2006, Leonard et al., 1991). The cut-off points can either be 
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determined at arithmetically convenient points, or by selecting, for example, the lower 
and upper quartiles for the 25% with worst prognosis, and 25% with the best prognosis, 
respectively. A Kaplan-Meier plot, stratified by these three risk categories, would then 
be examined to determine the degree of discrimination achieved by the index.  
 
6.6.9 Subsidiary analysis 
In the original analysis of the earlier Scottish cohort (Al-Shahi Salman et al., 2012), 
the four adults who had a recurrent haemorrhage in follow-up were all women, and 16 
of the 17 adults who experienced a recurrent clinical event in follow-up were women; 
with this in mind, the possibility of exploring the influence of sex on recurrent 
haemorrhage and/or focal neurological deficit in a subsidiary analysis was pre-
specified in the statistical analysis plan. (It should be noted, however, that in the 
original analyses, inception was date of presentation, whereas in this study inception 
is date of diagnosis.) 
Two new datasets were created: the first consisted of adults who had either presented 
with an intracranial haemorrhage or experienced one within five years of diagnosis, 
after presenting with a focal neurological deficit, seizure or incidentally, and the 
outcome was a (recurrent) ICH within five years of diagnosis. The second dataset 
included participants who had either presented with an ICH or FND or had suffered 
one within five years of diagnosis, after presenting with a seizure or incidentally, and 
the outcome event in this dataset was clinical event. Kaplan-Meier survival curves, 
stratified by sex, were inspected and the log-rank test was used to compare the curves 
for each sex. 
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Chapter 7: Cohorts included in the individual 
patient data meta-analysis 
 
7.1 Introduction  
 
Thirteen research groups were identified in a systematic review (Al-Shahi Salman et 
al., 2012) and invited to join the collaboration (see Appendix C). One group agreed to 
collaborate and successfully shared their data; three groups agreed to collaborate, but 
the data-sharing stage was never reached; one group was difficult to contact, and when 
this was eventually achieved, the research group had disbanded and the data were not 
available; another group no longer had access to the original data; and seven did not 
respond to several invitations. Among the twelve teams who did not share their data, 
six cohorts (544 patients) were highly selected: one was a small study of adults with 
familial cavernous malformations (21 subjects), two cohorts only included patients 
who had bled at presentation (218 adults), and three cohorts studied adults with 
brainstem cavernomas (305 patients). Inclusion of these six cohorts would have 
skewed the results, since mode of clinical presentation and CCM location are both core 
predictors of ICH or FND outcome.  Of the remaining six cohorts (n = 527), five 
groups published their studies on or before 1997.  
In addition to those research teams identified in the systematic review, several other 
well-known active research groups were contacted and invited to join the collabor-
ation. In total, data were received from five cohorts: three research groups based at 
tertiary-care referral centres (Toronto Western Hospital, Canada; Mayo Clinic, 
Rochester, MN, USA; and Hôpital Lariboisière, Paris, France), in addition to data from 
a single prospective population-based group with two different time-windows for 
recruitment (Scottish Intracranial Vascular Malformation Study).   
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Type of study Type of patients 
Robinson 1991 66 Retrospective; hospital-
based 
 
Zabramski 1994 21 Prospective; hospital-
based 
Familial CCM 
Aiba 1995 110 Retrospective; hospital-
based 
 





Kim 1997 62 Retrospective; hospital-
based 
 
Porter* 1997 110 Retrospective + 
prospective; brain IVM 
unit 
 
Moriarity 1999 68 Prospective; hospital-
based 
 
Porter 1999 100 Retrospective; hospital-
based 
Brainstem 
Barker 2001 136 Retrospective; hospital-
based 
Bled at presentation 
Hasegawa 2002 82 Retrospective + 
prospective; radiosurgery 
unit  
High-risk, bled at 
presentation; pre-
treatment 
Mathiesen 2003 68 Retrospective + 
prospective; hospital-
based 
Brainstem + deep 
Wang 2003 137 Retrospective; hospital-
based 
Brainstem 
Ghannane 2007 79 Retrospective; hospital-
based 
 
Flemming* 2012 292 Retrospective; tertiary-
care referral centre 
 
Schneble* 2012 87 Retrospective; tertiary-











*These studies accepted the invitation to collaborate. 
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7.2 Hospital-based cohorts 
 
7.2.1 Mayo Clinic 
Mayo Clinic is a tertiary-care referral centre situated at Rochester, Minnesota, USA; 
it provides integrated medical care not only for inhabitants of Rochester and the state 
of Minnesota, but also for individuals from all other US states and many countries 
throughout the world. Although the Mayo Clinic in Minnesota owns two hospitals for 
exclusive use of Mayo Clinic patients, most people with a CCM diagnosis are treated 
on an outpatient basis.  
The Mayo Clinic cohort is a retrospective, hospital-based cohort. Clinicians searched 
the radiographic database and identified all patients with a CCM diagnosis, validated 
by MRI, who had attended the Mayo Clinic between 1989 and 1999, whether as an 
inpatient or outpatient (Flemming et al., 2012). Medical records were then scrutinized, 
and demographic and clinical information was recorded on standardized forms and 
entered into the computerized database for the CCM study.  
The study inception point was time of CCM diagnosis, and follow-up was collected 
retrospectively. Between 2000 and 2003, the principal investigator undertook a clinical 
review of all the patients in the study: details of occurrence of symptomatic 
haemorrhage due to the CCM, pregnancy since diagnosis, surgery or stereotactic 
radiotherapy since diagnosis, and use of antithrombotic medication were all recorded 
in the study database; focal neurological deficit that occurred in follow-up, however, 
was not recorded. Because the Mayo Clinic is a tertiary-care referral centre, patients 
who had not been seen within six months of the clinical review were sent a postal 
questionnaire and then contacted by telephone for details of further follow-up; where 
available, medical records and radiographic film from other medical institutions were 
examined for follow-up information, which was duly recorded. Relatives of deceased 
patients were contacted for details about the cause of death on the death certificate.   
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In this cohort, haemorrhages that occurred in follow-up were categorized into three 
groups: definitive prospective, probable prospective and undocumented prospective. 
A definitive prospective haemorrhage was defined as ‘a new clinical event (focal 
deficit, seizure or severe headache) in association with radiographic evidence of acute 
haemorrhage or autopsy data suggesting acute haemorrhage’ (Flemming et al., 2012). 
A probable prospective haemorrhage was defined as a clinical event that suggested an 
intracerebral haemorrhage, but which was recorded in medical records obtained from 
a medical institution outwith the Mayo Clinic medical record system and the films 
were not available to Mayo Clinic clinicians to view. Finally, an undocumented 
prospective haemorrhage was an acute clinical event, but neither imaging report nor 
film was available to the researchers; often the information was acquired directly from 
the patient, and there was nothing documented in the patient’s medical records about 
the episode. In this meta-analysis, only definitive and probable prospective 
haemorrhages were included in the analysis.  
 
7.2.2 Toronto Western Hospital 
Toronto Western Hospital is a tertiary-care referral centre situated close to the centre 
of the most populous city in Canada. It is a world leader in neuroscience and was one 
of the first hospitals in Canada to use gamma knife radiotherapy. In 1989, the Toronto 
Brain Vascular Malformation Study Group was formed and research on the natural 
history of cerebral cavernous malformations was published in 1997 (Porter et al., 
1997). Most of the patients included in the Toronto Brain Vascular Malformation 
Study Group live in the Greater Toronto Area; the remaining patients predominantly 
live within Ontario, as it is very rare for a patient from a different Canadian province 
to be treated in the unit (Ronit Agid: personal communication). 
All the patients in the Toronto cohort included in this study were referred to the 
Toronto Brain Vascular Malformation Study Group between 1989 and 2007; a very 
small number were diagnosed between 1987 and 1988. In all cases, the diagnosis of 
cerebral cavernous malformation was validated by brain MRI and, where available, 
pathological examination. Demographic and medical history was recorded by 
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clinicians on standardized data collection forms at the time of consultation. In 1993, 
the CCM database was computerized, using Microsoft Access software, and in 2000 
an electronic patient record (EPR) system and the medical-imaging technology PACS 
(picture archiving and communication system) were set up. 
Clinicians recorded both intracranial haemorrhage and non-haemorrhagic focal 
neurological deficit in follow-up.  Haemorrhage was defined ‘radiologically as acute 
or subacute blood located outside the hemosiderin ring or an increase in lesion size by 
20% or more in diameter on serial imaging with associated mass effect and/or edema’. 
An event ‘refers to neurological deterioration, defined as subjective worsening (new 
or increased neurological symptoms) accompanied by objective worsening of 
neurological findings, with or without radiologically proven hemorrhage’ (Porter et 
al., 1997). In this cohort, no information on patient vital status was available. 
Follow-up for patients in this cohort was prospective, but organized irregularly and 
only available if they attended an outpatient clinic appointment or were admitted to 
Toronto Western Hospital. Until about 2007, many patients were reviewed annually 
for several years, but some asymptomatic patients were seen only once. Around 2007, 
however, a decision was taken to abandon the annual review. Therefore patients 
referred to the clinic after this date have not been included in the present study, since 
their inclusion would almost certainly bias the meta-analysis: those patients recruited 
after 2007 who have follow-up are more likely either to have more problems related 
to their CCM diagnosis or be considered to be at greater risk of future events (to justify 
being reviewed) than those who have not been reviewed.  
 
7.2.3 Hôpital Lariboisière, Paris  
Hôpital Lariboisière in Paris is a tertiary-care referral centre, and all the patients in this 
cohort attended the Centre de Référence pour les maladies rares des Vaisseaux du 
Cerveau et de l’Oeil (CERVCO, the French national reference centre for rare 
neurovascular diseases of the eye and brain), located at the hospital. CERVCO 
provides a diagnostic service for hereditary neurovascular diseases for all French and 
162 
some European hospitals, and several research groups located there are conducting 
research on genetic neurovascular diseases. Because the genetic form of the disease is 
characterized by individuals harbouring multiple lesions, it is to be expected that this 
cohort will have a disproportionately high number of adults with multiple CCMs. 
In October 2008, a database was set up and patients with a CCM diagnosis were 
enrolled into a prospective study; patients were reviewed at least annually, and more 
frequently, if the severity of their condition required it. Pre-specified demographic, 
clinical, genetic and radiological data were collected for patients with CCM. For adults 
who had been diagnosed before the database was set up, data at diagnosis and any 
clinical events that occurred in follow-up before October 2008 were collected 
retrospectively (Schneble et al., 2012).  
The time of inception for this cohort was date of diagnosis. In this study, only CCM-
related haemorrhages, defined according to the Angioma Alliance guidelines (Al-
Shahi Salman et al., 2008), were recorded in follow-up. 
 
7.3 Population-based studies 
 
Two cohorts from the Scottish Intracranial Vascular Malformation Study (SIVMS), 
recruited between 1999 and 2003 (first cohort), and 2006 and 2010 (second), were 
included in this study. A description of how these cohorts were recruited is given in 
Chapter 4 above. It should be noted, however, that for the analyses in this part of the 
thesis, the point of inception for these studies is taken not as the date of presentation, 
as in Chapters 4 and 5, but as the date of diagnosis, so that consistency is maintained 
among all studies. 
Although these two cohorts originated from the same population, they were analysed 
separately for two reasons. First, the length of follow-up period was not identical: 
participants in the earlier cohort had the potential to contribute five years of follow-
up, whereas those diagnosed at the end of the final year in the later cohort were only 
able to contribute a maximum of 2.5 years follow-up because recruitment ended on 31 
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December 2010, and the cut-off date for data entry of follow-up was 19 July 2013 (see 
section 8.1 in Chapter 8). Second, neuro-imaging techniques are continuing to develop 
and become more sophisticated, and it was proposed that the individuals included in 
the second cohort might have slightly different characteristics to those in the first 
cohort. For example, in the first cohort 13% presented with an intracranial 
haemorrhage and 16% with a focal neurological deficit, whereas the corresponding 
percentages in the second cohort were 19% and 6% respectively, which might suggest 





The format of the original datasets for each cohort, data-cleaning methods that were 
employed and any difficulties that were encountered in the process are described in 
this section. Prior to requesting data from the four collaborating research groups, 
personalized questionnaires were sent to the clinicians and statisticians at each team, 
in an attempt to discover the form their data took and whether they would be suitable 
for inclusion in an individual patient data meta-analysis. (For copies of the 
questionnaires, please see Appendix D.)  
 
7.4.1 Hospital-based cohorts 
The data collected in the three hospital-based cohorts are systematically different to 
the data in the population-based cohorts. In the hospital-based cohorts, data have been 
collected in a much more haphazard manner, based on clinicians retrospectively 
reviewing case notes from patients who have attended clinic appointments, whereas 
the population-based cohorts are part of a national audit of intracranial vascular 
malformations that was set up for a specific purpose and for which follow-up is 




Mayo Clinic data 
A copy of the anonymized dataset pertaining to the paper published in 2012 (Flemming 
et al., 2012) was received in November 2012. Three SAS files were included on the 
CD-ROM: one contained the data; a second the variable names and their coding on the 
four standardized case report forms; and the third was the value labels for the items in 
the case-report forms. All three files could be opened in IBM SPSS Statistics.  
All queries relating to the data were referred back to the principal investigator, who 
was able to resolve all problems. For each participant, mode of presentation was re-
examined and a new variable was created which was identical to that used in the 
Scottish cohorts. During the data-cleaning process, analyses were undertaken to 
replicate the tables in the paper published in 2012, and this was successfully achieved.  
 
Data from Toronto Western Hospital 
At the request of the Toronto clinical research co-ordinator, a dummy dataset in 
Microsoft Excel was sent to Toronto as an example of the format and variables 
required. The anonymized data were received in a Microsoft Excel spreadsheet in 
September 2012, and subsequently imported into IBM SPSS Statistics. 
 
Missing data  
In the Toronto datafile, there were three potential dates for inception: (i) ‘date of onset 
of symptoms leading to CCM diagnosis’; (ii) ‘date of earliest radiographic-definite 
CCM diagnosis’; and (iii) ‘date of first attendance at the Vascular Malformation Clinic 
at Toronto Western Hospital’, each of which had a number of missing values. The 
decision to use date of CCM diagnosis as inception was motivated by the fact that this 
date was most readily available in the other cohorts and, of the three possible dates in 
the Toronto data, it had the smallest number of missing values. Date of diagnosis was 
available for 318 (out of 345) participants, and all three dates were available for 228 
adults.  
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Table 7.2 Time between symptom-onset, diagnosis and referral for all participants in 
the Toronto cohort with three dates (n = 228) 
 
The difference in time between symptom-onset, diagnosis and referral was calculated 
for the 228 adults, and median and interquartile range for each time-period are 
presented in Table 7.2. For the 14 adults where the symptom-onset date was available, 
this date was used for inception, as it was closer to date of diagnosis than date of 
referral (in Table 7.2). However, where neither symptom-onset nor diagnosis dates 
were available (n = 13), date of referral to Toronto Western Hospital was used as 
inception. 
Unfortunately, deaths and thus mortality status were unavailable in this cohort, due to 
the method of data collection, which was driven by clinic attendance rather than by the 
research group requesting data at regular intervals from family doctors.  
Although research from this group had been published previously (Porter et al., 1997), 
an earlier dataset had been used; thus analyses from this publication could not be 
replicated. 
 
Data from Hôpital Lariboisière, Paris  
In response to a request for an anonymized datafile of patients with an MRI-validated 
CCM diagnosis and a minimum of one year follow-up, a Microsoft Excel spreadsheet 
of patients was received in June 2013; this was then imported into IBM SPSS 
Statistics. 
Time period Median (years) Interquartile range  (years) 
Between symptom onset and diagnosis 0.06 0 to 0.37 
Between diagnosis and referral  0.14 0 to 0.36 
Between symptom onset and referral 0.35 0.06 to 1.02 
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Although the datafile received was purported to be that used in the paper published in 
2012 (Schneble et al., 2012), the analyses could not be accurately reproduced. In the 
first instance, it was not obvious which of the patients had been included in the paper 
(104 were included in the datafile, but only 87 in the paper). Second, although the 
differences in baseline characteristics were small, the number of intracranial 
haemorrhages within five years of diagnosis was four (which was confirmed by the 
final author of the paper), with a fifth occurring in the sixth year, rather than the nine 
stated in the paper. Thus there were several discrepancies with what had previously 
been reported and the data that were received. 
 
7.4.2 Population-based cohorts 
The SIVMS database is stored in Microsoft Access, and an analysis application has 
been programmed to enable data extraction. Two anonymized datafiles were extracted 
from this database: the first, on 27 September 2013, for the 1999–2003 cohort, and the 
second, on 24 September 2013, for the 2006–2010 cohort. These extractions were 
exported via Microsoft Excel and imported into IBM SPSS Statistics. 
 
7.4.3 Data completeness  
Missing values  
Upon pooling the five cohorts, the complete dataset consisted of 988 adults. After the 
five datasets had been checked and cleaned, there were no missing values for the 
following variables: date of birth, age at diagnosis, sex, mode of clinical presentation, 
CCM location and CCM multiplicity. For the two exploratory predictors, 5% of the 
values for associated developmental venous anomaly and more than 72% for CCM 
size were missing; however, there was uncertainty about whether the neuro-
radiographers had consistently recorded the presence of associated developmental 
venous anomaly in some cohorts, and therefore it was not possible to include these two 
variables in the main analysis.  
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Date of diagnosis was missing for 27 adults in one cohort, but it was possible to 
substitute date of symptom onset leading to CCM diagnosis for 14 adults, and date of 
first attendance at study centre for the remainder (see subsection 7.4.1 above). 
 
Follow-up: completeness and maturity 
Total follow-up, after censoring at first clinical event, intervention or death, and 
truncating at five years, was 3,232 patient-years. Using the Clark et al. equation for 
quantifying data completion – total observed follow-up as a percentage of the total 
potential follow-up – total observed follow-up represents 80% completeness of total 
potential follow-up (4,042 patient-years) (Clark et al., 2002). It should be recalled, 
however, that recruitment to the second Scottish cohort only finished on 31 December 
2010, and therefore for some adults in that cohort it was possible to contribute only a 
maximum of 2.5 years; thus 100% completeness for five-year follow-up is not possible 
in this study (see end of section 8.1 below). 
In an attempt to assess follow-up maturity (Machin et al., 2006), the length of follow-
up for those who were censored  in the original analysis was calculated: the median 
time was 4.24 years (interquartile range 1.95 to 5 years). By reversing the coding of 
the variable for outcome versus censored, a Kaplan-Meier plot of the proportion who 
still remained on follow-up was produced (see Figure 7.1). The estimated median 
length of follow-up for those who were originally censored was 4.51 years (95% 
confidence interval 4.44 to 4.57 years), and almost 47% of participants in the study 
were able to contribute data for the entire five-year follow-up period. 
Of 96 adults in the entire study who did not experience an ICH or FND within five 
years of diagnosis and who had less than six months’ follow-up, six died, 63 received 







Figure 7.1 Kaplan-Meier 'follow-up plot' for participants in the five cohorts 
 
 
7.5 Baseline characteristics of individual cohorts 
 
7.5.1 Mayo Clinic cohort  
In the original datafile, 292 patients had received a CCM diagnosis and had attended 
Mayo Clinic between 1989 and 1999, and 32 haemorrhages had been recorded. Some 
of these patients, however, did not meet the inclusion criteria for this study and their 
records were therefore removed from the datafile: for example, eight were treated on 
the day of diagnosis, three had no follow-up, five were treated before diagnosis and so 
were therefore not ‘untreated’, and nine were younger than 16 years of age at diagnosis 
(see the flowchart in Figure 7.2). In terms of number of outcomes, the four ICH that 
                      Number at risk     
988 820 693 585 477 397 
x = 4.51 
y = 0.5 
y = 0.467  
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were undocumented were removed, three ICH were lost because the patients had 
previously received treatment, another three occurred to patients who had been 
diagnosed in childhood, and two were lost through truncation of follow-up at five years 
after diagnosis. Hence in the present study, the Mayo Clinic cohort consisted of 267 
adults, who had 20 haemorrhages within five years of diagnosis.  
The baseline characteristics of this cohort are presented in Table 7.3. Slightly more 
than half were female (n = 143, 54%); of the symptoms that led to a CCM diagnosis, 
about a third (n = 98, 37%) presented incidentally, a quarter with ICH (n = 64, 24%), 
29 (11%) with focal neurological deficit, and 76 (29%) with a seizure.  The median 
age at diagnosis was 46 years (interquartile range 31–62 years), ranging from 40 years 
for those who presented with a seizure to 55 years for those presenting incidentally. 
Approximately a fifth of the cohort had multiple lesions (n = 49, 18%); a quarter of 
the primary lesions were located in the brainstem (n = 63, 24%), and of those with a 
brainstem CCM, 81% (n = 51) presented with an ICH or FND. 
About a quarter of the cohort (n = 73, 27%) received interventional treatment (either 
surgical excision or stereotactic radiotherapy) during the total follow-up period 
available: of these, almost a half (n = 35, 48%) presented with a seizure, a third (n = 
26, 36%) with an ICH, 10 (14%) with an FND, and 2 (3%) incidentally. Twenty adults 
(7.5%) had an ICH within five years of diagnosis: eleven (55%) had presented with an 
ICH, four each (20%) with a seizure or FND, and one adult incidentally.  
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*No MR imaging or report available 
Summary 
Patients   n = 267 
First ICH in follow-up:  20 events    
2 adults suffered an ICH 5.25 and 6.95 years after diagnosis 
 
       
Mayo Clinic data 
Dataset received November 2012 
n = 292 
Events (CH) = 32 Undocumented* events: n = 4 
Patients: n = 292 
Events:  n = 28 
 
 Tx date = dx date: n = 8 
 No follow-up: n = 3 
Events: n = 2  
 
Patients: n = 281 
Events: n = 26 
Patients aged <16 years at dx: 
n = 9 
Events: n = 3  
1st tx before dx date: n = 5 
Events: n = 1  
 
Patients    Events 
n = 267     n = 22 
 
First ICH in five-year follow-up 
 Presented incidentally or with seizure:   5 ICH 
 Presented with ICH:     11 ICH 
 Presented with FND:       4 ICH 
 
Censored 
ICH occurring > 5 years after 
diagnosis: n = 2 
Patients: n = 276 
Events: n = 25 
 
 
Figure 7.2 Flowchart showing composition of cohort from Mayo Clinic, Rochester, MN 
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Table 7.3 Mayo Clinic cohort: baseline characteristics 
*Management is over the entire follow-up period provided, not truncated at five years.  
 
   Characteristic 
Type of symptom leading to CCM diagnosis Total 
n = 267 
 
Incidental 
(n = 98, 37%) 
Seizure 
 (n = 76, 28%)  
ICH  
(n = 64, 24%) 
FND  
(n = 29, 11%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR) 55 34–69 40 29–52 44 29–56 50 40–67 46 31–62 
Sex           
   Male 46 47% 39 51% 24 38% 15 52% 124 46% 
   Female 52 53% 37 49% 40 63% 14 48% 143 54% 
Primary CCM location           
   Lobar 56 57% 74 97% 24 38%   2   7% 156 58% 
   Deep 20 20%   1 1%   7 11%   6 21%   34 13% 
   Cerebellum 11 11%   0 0%   2   3%   1   3%   14   5% 
   Brainstem 11 11%   1 1% 31 48% 20 69%   63 24% 
Single or multiple CCMs           
   Single 85 87% 61 80% 50 78% 22 76% 218 82% 
   Multiple 13 13% 15 20% 14 22%   7 24%   49 18% 
Management*           
   Surgery/radiosurgery   2   2% 35 46% 26 41% 10 35% 73 27% 
   Conservative management 96 98% 41 54% 38 59% 19 66% 193 73% 
1st clinical event in follow-up           
   ICH   1   1%   4   5% 11 17%   4 14%   20   7% 
   No event  in follow-up 97 99% 72 95% 53 83% 25 86% 247 93% 
Length of censored follow-up 
(years) (median, IQR) 
5.0 1.9–5.0 3.9 1.1–5.0 2.7 0.4–5.0 5.0 0.8–5.0 4.5 1.1–5.0 
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7.5.2 Toronto cohort 
Between 1989 and 2008, some 569 patients with cavernous malformations attended a 
clinic at the Toronto Western Hospital; of these, however, only 381 individuals were 
reported to have both an initial assessment and a minimum of one year follow-up, and 
these patients formed the Toronto cohort in this study. In August 2012, a research 
clinician at Toronto Western Hospital searched the hospital electronic patient record 
system and the neuroradiology imaging database for follow-up for these 381 
participants. Data pertaining to separate clinical events in follow-up were extracted 
onto a spreadsheet to ensure that the Toronto data were in a format compatible with 
other datasets in this meta-analysis.  
During the data-cleaning process, a number of records were removed from the dataset 
(see the flowchart in Figure 7.3). In two cases, the diagnosis was not in fact CCM, and 
one record had minimal data; 11 people were diagnosed during childhood (aged less 
than 16 years); six adults received treatment on or before the date of diagnosis, and 
another less than a week after diagnosis; and fifteen individuals, who were diagnosed 
before 1 January 1987, had uncertain diagnosis dates (n = 8) or were diagnosed 
between 1976 and 1986 (n = 4), or the data seemed unreliable (for example, no notes 
in EPR and no imaging available) (n = 3). After these records were deleted, the cohort 
from Toronto Western Hospital consisted of 345 adults, who experienced 24 
haemorrhages within five years of follow-up, and 55 clinical events (23 ICH and 32 
FND).  
The baseline characteristics of this cohort are presented in Table 7.4 below. For 
approximately half of the cohort, the symptoms that led directly to CCM diagnosis 
were either ICH (n = 116, 34%) or FND (n = 59, 17%); a fifth of the cohort presented 
with a seizure (n = 69, 20%) and the remainder incidentally (n = 101, 29%). This cohort 
consisted of more women (n = 194, 56%), and the median age at diagnosis was 42 
years (interquartile range 33–54 years), which ranged from 36 years for those 
presenting with a seizure to 46 years for those presenting incidentally. There was a 
larger percentage of people with multiple lesions in the Toronto cohort (n = 79, 23%) 
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than in the cohort from the Mayo Clinic (18%). Again, the percentage of adults with 
primary brainstem lesions was greater in the Toronto cohort (n = 102, 30%) than in 
the Mayo Clinic (24%): 84 (82%) of those with a brainstem lesion presented with 
either an ICH or FND, and 14 people with a brainstem lesion presented incidentally.  
A smaller percentage of the Toronto cohort received interventional treatment (n = 40, 
12%) over the course of the entire follow-up period, compared with the Mayo Clinic 
cohort (27%), and of these, 31 (78%) presented with an ICH or FND. Among the 24 
people who experienced a first haemorrhage within five years of diagnosis, 18 (75%) 
presented with an ICH and 5 (21%) presented with FND; among those who suffered 
an FND in the first five years of follow-up (n = 32), 14 each (44%) presented with ICH 




  Toronto cohort 
Data received September 
2012 
(n = 381) 
Deleted: 
 CCM not diagnosed (n = 2) 
 Minimal data (n = 1) 
Toronto cohort 
(n = 378) 
Deleted: 
 < 16 years at inception (n = 11) 
 Inception date before 1 
January 1987    (n = 15) 
 Intervention before / on 
inception (n = 6) 
 < 1 week of untreated follow-
up available (n = 1)  
Toronto cohort 
(n = 345) 
First ICH / clinical event in 5-year untreated follow-up 
 Presented incidentally or seizure: n = 170 
ICH: n = 1;  
clinical event: n = 5 (1 ICH + 4 FND) 
 Presented with ICH: n = 116 
ICH: n =18 (17 1st event; 1 2nd event) 
clinical event: n = 31 (17 ICH + 14 FND) 
 Presented with FND: n = 59 
ICH: n = 5  
clinical event: n = 19 (5 ICH + 14 FND) 
 
Summary 
Number of adults:      345 
Number of 1st ICH in five-year follow-up:    24* 
Number of 1st clinical events in five-year follow-up:   55 (23 ICH + 32 FND) 
Figure 7.3 Flowchart showing composition of final Toronto cohort 
 
*One adult experienced an ICH as a second event, having suffered an FND earlier in follow-up. 
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Table 7.4 Toronto cohort: baseline characteristics  
*Management is over the entire follow-up period provided, not truncated at five years.  
†One adult experienced an ICH as a second event, having had an FND earlier in follow-up. 
  
     Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 345 
Incidental 
(n = 101, 29%) 
Seizure 
 (n = 69, 20%) 
ICH  
(n = 116, 34%) 
FND  
(n = 59, 17%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR) 46 35–55 36 27–48 40 34–52 44 34–57 42 33–54 
Sex           
   Male 39 39% 35 51% 48 41% 29 49% 151 44% 
   Female 62 61% 34 49% 68 59% 30 51% 194 56% 
Primary CCM location           
   Lobar 67 66% 62 90% 44 38% 16 27% 189 55% 
   Deep   9   9%   2   3% 13 11%   6 10%   30   9% 
   Cerebellum 11 11%   1   1%   7   6%   5   9%   24   7% 
   Brainstem 14 14%   4   6% 52 45% 32 54% 102 30% 
Single or multiple CCMs           
   Single   80 79% 52 75% 91 78% 43 73% 266 77% 
   Multiple   21 21% 17 25% 25 22% 16 27%   79 23% 
Management*           
   Surgery/radiosurgery   1   1%   8 12% 25 22%   6 10%   40 12% 
   Conservative management 100 99% 61 88% 91 78% 53 90% 305 88% 
1st clinical event in 5-year follow-up   3   3%   2   3% 31 27% 19 32% 55 16% 
    1st ICH    0   0%   1   1%   18* 16%   5   9%   24†   7% 
    1st FND   3   3%   1   1%  14 12% 14 24% 32   9% 
1st clinical event in total follow-up   3   3%   2   3% 40 35% 24 41% 69 20% 
Length of follow-up (median, IQR) 3.4 1.8–5.0 4.7 2.1–5.0 2.6 1.2–4.5 4.3 1.5–5.0 3.2 1.5–5.0 
176 
 
7.5.3 Cohort  from Hôpital Lariboisière, Paris 
The initial datafile from Hôpital Lariboisière contained 104 patients, but 23 records 
were removed because of minimal data available (1), no follow-up (18), CCM was 
diagnosed in childhood (1), intervention on or before diagnosis (2), and diagnosed 
before 1 January 1987 (1). Hence the final cohort consisted of 81 adults, who had four 
haemorrhages within five years of diagnosis (see flowchart in Figure 7.4). 
The baseline characteristics for this cohort are displayed in Table 7.5. More than half 
the adults presented incidentally (n = 47, 58%); of the remainder, 14 (17%) presented 
with an FND, and equal numbers with seizure and haemorrhage (n = 10, 12%). The 
cohort consists of more women (n = 47, 58%) than men, and the percentage of adults 
with multiple lesions is larger than in the other cohorts (n = 27, 33%). The 
comparatively large number of adults who harbour multiple lesions is unsurprising, 
since much of the research in identifying genes responsible for the familial form of the 
disease, which is characterized by the presence of multiple lesions, has been conducted 
in a unit attached to Hôpital Lariboisière. 
The median age at diagnosis is 42 years (interquartile range 28–59 years), ranging 
from a median of 35 years for those presenting with an ICH to 49 years for those 
presenting incidentally. Seventeen patients (21%) have brainstem lesions: of these, 8 
(47%) presented incidentally and 9 with either ICH or FND. Four patients received 
interventional treatment for their lesion (two presenting incidentally and two with an 
ICH). The median length of follow-up for this cohort is 2.2 years (interquartile range 
0.7–4.2), which is shorter than that for the other cohorts.  
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Figure 7.4 Flowchart showing composition of cohort from Hôpital Lariboisière, Paris 
 
Summary 
Participants    n = 81 
First ICH in five-year follow-up:  n =   4  
A fifth adult suffered an ICH 5.25 years after diagnosis 
  
Paris cohort 
Data received June 2013 
(n = 104) 
Deleted: 
 No follow-up (n = 18) 
 Minimal data (n = 1) 
Paris cohort 
 (n = 85) 
Deleted: 
 < 16 years at inception 
(n = 1) 
 Inception date before 
1 January 1987  (n = 1) 
 Intervention before / 
on inception (n = 2) 
Paris cohort 
 (n = 81) 
First ICH in five-year follow-up 
 Presented incidentally or seizure: n = 58 
ICH: n = 3 
 Presented with ICH: n = 10 
ICH:  n = 1 
 Presented with FND: n = 14 
ICH:  n = 0  
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Table 7.5 Paris cohort: baseline characteristics 
                                                                                                                                                                                                                                                                                                                           
*Management is over the entire follow-up period provided, not truncated at five years.   
 
   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 81 
Incidental 
(n = 47, 58%) 
Seizure 
 (n = 10, 12%)  
ICH  
(n = 10, 12%) 
FND  
(n = 14, 17%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR) 49 29–61 41 25–59 35 23–42 40 34–63 42 28–59 
Sex           
   Male 20 43% 5 50% 4 40% 5 36% 34 42% 
   Female 27 57% 5 50% 6 60% 9 64% 47 58% 
CCM location           
   Brainstem 8 17% – – 6 60% 3 21% 17 21% 
   Other location 39 83% 10 100% 4 40% 11 79% 64 79% 
Single or multiple CCMs           
   Single 28 60% 8 80% 8 80% 10 71% 54 67% 
   Multiple 19 40% 2 20% 2 20% 4 29% 27 33% 
Management*           
   Surgery/radiosurgery  2   4%  –  0% 2 20% – –  4   5% 
   Conservative management 45 96% 10 100% 8 80% 14 100% 77 95% 
1st clinical event in follow-up           
   ICH  3   6% – – 1 10% – –  4    5% 
   No event  in follow-up 44 94% 10 100% 9 90% 14 100% 77 95% 
Length of censored follow-up (years) 
(median, IQR) 
2.2 1.0–4.0 2.0 0.4–3.7 2.0 0.4–4.0 2.2 0.5–4.9 2.2  0.7–4.2 
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7.5.4 First Scottish cohort 
Figure 7.5 displays the flowchart for this cohort, with inception now changed to date 
of diagnosis. In the five-year period between 1999 and 2003, 141 residents in Scotland 
(aged 16 years or over), received a first-ever CCM diagnosis, validated by magnetic 
resonance imaging (MRI) or pathological examination. Five adults were diagnosed at 
autopsy, and another was diagnosed after their lesion had been surgically excised.  
Between presentation and diagnosis, three adults in this cohort, all of whom presented 
with FND, each suffered a recurrent FND; however, as follow-up in this study starts 
at time of diagnosis, these events are not included in the analysis, but merely reported 
for information. Similarly, outcome events that occur more than five years after 
diagnosis are excluded from analysis; in this cohort there is only one occurrence: an 
adult who presented incidentally, but suffered her first FND 11.5 years after diagnosis, 
and then a recurrent FND nine months later. Therefore the earlier Scottish cohort 
consists of 135 adults, seven of whom had a first ICH within five years of diagnosis, 
and twenty had a first clinical event (six ICH and fourteen FND). 
The baseline characteristics for this cohort are displayed in Table 7.6. Of 135 adults in 
the cohort, almost half presented incidentally (n = 62, 46%), a quarter with a seizure 
(n = 35, 26%), 17 (13%) with a haemorrhage, and 21 (16%) with an FND. There are 
80 women (59%) in the cohort, and the median age at diagnosis was 41 years 
(interquartile range 32–53 years), ranging from a median of 34 years for those who 
presented with a seizure to 46 years for those presenting incidentally. In this cohort, 
24 individuals (18%) had multiple lesions; only 17 adults (13%) had a primary 
brainstem lesion, and of these eight (47%) presented with an FND, four (24%) with an 
ICH, and 5 (29%) incidentally. Of the 23 who received surgical intervention, 10 (43%) 
presented with seizure. Seven people had a first ICH within five years of diagnosis 
(two each presenting incidentally or with an FND, three with an ICH); twenty suffered 
a first clinical event in the same period (one presented with a seizure, five an ICH, and 
seven each with FND or incidentally).  
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Figure 7.5 Flowchart showing composition of first Scottish cohort 
Scotland, 1999-2003 cohort 
Data extracted September 2013 
(n = 141) 
Deleted 
CCM diagnosed at autopsy (n = 5) 
Scotland, 1999-2003 cohort 
 (n = 136) 
Deleted 
Adults with surgical intervention 
on date of diagnosis (n = 1) 
Scotland, 1999-2003 cohort 
 (n = 135) 
First ICH / clinical event in 5-year follow-up 
 Presented incidentally or seizure:  n = 97 
ICH:  n = 2 
clinical event: n = 8 (2 ICH + 6 FND) 
 Presented with ICH:  n = 17  
ICH:  n = 3 
clinical event: n = 5 (3 ICH + 2 FND)  
 Presented  with FND: n = 21 
 ICH:  n = 2 
 clinical event: n = 7 (1 ICH + 6 FND)   
Between presentation and diagnosis 
 3 adults, all presenting with FND, 
each had a first event – FND – in 
this period 
 no interventions 
 no deaths 
Summary 
Participants      n = 135 
Events in 5 years of follow-up 
First ICH in follow-up:     7 ICH (1 fatal) 
First clinical event in follow-up:    20 events (6 ICH + 14 FND) 
Events between presentation and diagnosis 
3 adults had an FND  
Events more than 5 years after diagnosis 
1 adult presenting incidentally: 1st FND 11.5 years after diagnosis; 2nd 
FND 0.75 years later 
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Table 7.6 Scotland, 1999–2003: baseline characteristics 
*Management is over entire follow-up period provided, not truncated at five years.  
†One adult experienced an ICH as a second event, having had an FND earlier in follow-up 
   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 135 
Incidental 
(n = 62, 46%) 
Seizure 
(n = 35, 26%) 
ICH 
(n = 17, 13%) 
FND 
(n = 21, 16%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR) 46 34–56 34 26–46 35 29–46 42 33–62 41 32–53 
Sex           
   Male 23 37% 21 60%   5 29%     6 29% 55 41% 
   Female 39 63% 14 40% 12 71%   15 71% 80 59% 
Primary CCM location           
   Lobar 43 69% 35 100%   7 41%   5 24% 90 67% 
   Deep   4   7%   0 0%   1   6%   4 19%   9   7% 
   Cerebellum 10 16%   0 0%   5 29%   4 19%   19 14% 
   Brainstem   5   8%   0 0%   4 24%   8 38%   17 13% 
Single or multiple CCMs           
   Single 56 90% 23 66% 14 82% 18 86% 111 82% 
   Multiple   6 10% 12 34%   3 18%   3 14%   24 18% 
Management*           
   Surgery/radiosurgery   5   8% 10 29%   6 35%   2 10%   23 17% 
   Conservative management 57 92% 25 71% 11 65% 19 90% 112 83% 
1st clinical event in follow-up           
   1st ICH   2   3%   0 0%   3 18%    2† 10%      7†   5% 
   1st FND   5   8%   1 3%   2 12%   6 29%   14  10% 
   No event  in 5-year follow-up 55 89% 34 97% 12 71% 14 67% 115 85% 
Length of censored follow-up   
(years) (median, IQR) 
5.0 5.0–5.0 5.0 1.1–5.0 1.9 0.3–5.0 5.0 0.9–5.0 5.0 1.4–5.0  
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7.5.5 Second Scottish cohort 
In the five-year period between 2006 and 2010, 166 adults resident in Scotland 
received a first-ever CCM diagnosis, which was validated by MRI or pathological 
examination (see flowchart in Figure 7.6). One adult was diagnosed at autopsy, and 
five others were removed from the datafile, as their lesions were discovered after 
surgical excision: thus the second Scottish cohort consists of 160 adults, who had a 
total of seven ICH and six FND within five years of diagnosis.  
Baseline characteristics are given in Table 7.7 below. In contrast to the earlier Scottish 
cohort, in the later one men (n = 83, 52%) slightly outnumbered women (n = 77, 48%), 
and the median age at diagnosis was five years older, at 46 years (interquartile range 
34–60 years), ranging from 38 years for people presenting with seizures to 58 for those 
with FND. A quarter of the cohort presented with either ICH (n = 31, 19%) or FND (n 
= 10, 6%), a third (n = 52, 33%) with seizure, and the remainder incidentally (n = 67, 
42%). Nearly a fifth (n = 29, 18%) harboured multiple lesions, and a sixth (n = 25, 
16%) had primary brainstem lesions, 17 (68%) of whom presented with either an ICH 
or FND, and 7 (28%) incidentally. Only 11 (7%) patients had received interventional 
treatment for their lesions during the total follow-up period available, but this figure is 
probably artificially low because of the short length of follow-up for many individuals 
in this cohort (see section 7.3 above, and subsection 4.3.1 in Chapter 4). Of the thirteen 
adults who suffered a clinical event, ten (77%) experienced an initial ICH or FND 
which led subsequently to CCM diagnosis.  
  
 





Participants      n = 160 
Events in 5 years of follow-up 
First ICH in follow-up       7 ICH  
First clinical event in follow-up:    13 events (7 ICH + 6 FND) 
Events between presentation and diagnosis 
2 adults had an ICH between presentation and diagnosis, and no further 
events in follow-up 
Scotland, 2006–2010 cohort 
Data extracted September 
2013 
(n = 166) 
Deleted: 
CCM diagnosed at autopsy (n = 1) 
Scotland, 2006–2010 cohort 
 (n = 165) 
Deleted: 
Adults with surgical intervention 
on date of diagnosis (n = 5) 
Scotland, 2006–2010 cohort 
 (n = 160) 
First ICH / clinical event in five-year follow-up 
 Presented incidentally or seizure: n = 119 
ICH:    n = 1 
clinical event:   n = 3 (1 ICH + 2 FND) 
 Presented with ICH: n = 31 
ICH:    n = 5 
clinical event:   n = 7 (5 ICH + 2 FND) 
 Presented with FND: n = 10 
ICH:     n = 1  
clinical event:   n = 3 (1 ICH + 2FND) 
 
Between presentation and diagnosis 
 3 adults, all presenting with CH, 
each had a first event – CH – in this 
period; 
1 also had a CH and FND after 
diagnosis 
 no interventions 
 no deaths 
Figure 7.6 Flowchart showing composition of second Scottish cohort 
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Table 7.7 Second Scottish cohort: baseline characteristics 
*Management is over the entire follow-up period provided, not truncated at five years. 
 
   Characteristic 
Type of symptom leading to CCM diagnosis  
Total 
n = 160 
Incidental 
(n = 67, 42%) 
Seizure 
(n = 52, 33%) 
ICH 
(n = 31, 19%) 
FND 
(n = 10, 6%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR) 54 43–63 38 29–52 44 32–60 58 52–61 46 34–60 
Sex           
   Male 31 46% 32 62% 16 52%   4 40% 83 52% 
   Female 36 54% 20 39% 15 48%   6 60% 77 48% 
Primary CCM location           
   Lobar 51 76% 51 98% 15 48%   3 30% 120 75% 
   Deep   1   2%   0 0%   3  10%   0   0%     4   3% 
   Cerebellum   8 12%   0 0%   2   7%   1 10%   11   7% 
   Brainstem   7 10%   1 2% 11 36%   6 60%   25 16% 
Single or multiple CCMs           
   Single 57 85% 43 83% 22 71%   9 90% 131 82% 
   Multiple 10 15%   9 17%   9 29%   1 10%   29 18% 
Management*           
   Surgery/radiosurgery   2   3%   3   6%   6 19%   0   0%   11   7% 
   Conservative management 65 97% 49 94% 25 81% 10 100% 149 93% 
1st clinical event in follow-up           
   ICH   0   0%   1 2%   5 16%   1 10%     7   4% 
   FND   1   2%   1 2%   2   7%   2 20%     6   4% 
   No event in follow-up 66 99% 50 96% 24 77%   7 70% 147 92% 
Length of censored follow-up  
(years) (median, IQR) 
3.6 2.9–4.9 4.1 2.9–5.0 3.0 1.8–4.1 3.5 2.5–5.0 3.9 2.9–5.0 
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As described in the previous chapter, this individual patient data meta-analysis 
comprises five cohorts, with a total size of 988 adults. However, although all five 
studies recorded the number of intracranial haemorrhages experienced during follow-
up, only three studies (the two Scottish cohorts and Toronto) recorded focal 
neurological deficits in follow-up, and therefore the number of adults in the analysis 
of the outcome ‘clinical event’ was 640. If the six highly selected cohorts that were 
originally invited to join the collaboration are excluded (see Table 7.1 above), the 
present study (n = 988) includes 65% of the more general potential cases that were 
previously identified.  
The flowcharts for each individual study (Figures 7.2–7.6 above) illustrate how the 
final number of participants was achieved for each cohort; this is summarized for the 
entire study in Figure 8.1 below. In the hospital-based cohorts, 292 adults were 
diagnosed with a cerebral cavernous malformation between March 1984 and August 
1998, and 267 people were eligible to form the Mayo Clinic cohort; 381 adults were 
diagnosed between 1 January 1987 and mid-December 2007, and 345 form the 
Toronto Western Hospital cohort; and of 104 individuals diagnosed between August 
1994 and August 2011, 81 adults are included in the Paris cohort. Patients did not 
necessarily receive a first diagnosis at these three institutions; however, if they were 
diagnosed elsewhere, then they were referred subsequently to one of these three 
institutions, either as out- or inpatients.  
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Exclusion Data received Data included in study 
   
   
   
   
   
 
 
Figure 8.1 Flowchart showing composition of cohorts included in the study  
Mayo Clinic 
292 patients 
No follow-up: n = 3 
Treated before/at diagnosis: n = 13 +  
3 events 
Patients < 16 years at diagnosis: n = 9 + 
3 events 
Events censored > 5 years after 
diagnosis: 2 events 
No MRI/CT for events: 4 events  
Mayo Clinic 
267 patients 
20 ICH  
CCM not diagnosed: n = 2 
Minimal data: n = 1 
Intervention before/at diagnosis: n = 6 
Inception before 1 January 1987: n = 15 
< 1 week follow-up: n = 1 
Patients < 16 years at diagnosis: n = 11 






No follow-up: n = 18 
Minimal data: n = 1 
Intervention before/at diagnosis: n = 2 
Inception before 1 January 1987: n = 1 









Diagnosed at autopsy: n = 5 






Diagnosed at autopsy: n = 1 







Five cohorts pooled 
988 patients: 62 ICH 
Three cohorts pooled (Toronto + 2 Scottish cohorts) 
640 patients: 88 events (36 ICH and 52 FND) 
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By contrast, in a prospective population-based study within two five-year time-spans 
in a single country – Scotland – 135 adults were alive at the time of receiving a first-
ever CCM diagnosis between 1999 and 2003, and had not undergone interventional 
treatment for their lesion at the time of diagnosis, and similarly 160 adults between 
2006 and 2010. Although these two cohorts originated from the same population, the 
decision was taken to analyse them separately. (The rationale behind this decision was 
discussed in section 7.3 of Chapter 7 above.) 
Therefore this individual patient data meta-analysis includes 693 participants from 
three hospital-based studies located in three different countries, and 295 adults from 
two cohorts of a nationwide population-based study that were recruited over two 
different periods of  time.  
 
Follow-up in the second Scottish cohort 
Between 2006 and 2010, 160 adults resident in Scotland were diagnosed with a 
cerebral cavernous malformation: of these, thirteen had a clinical event within five 
years of diagnosis; twelve were censored at the time of interventional treatment, if they 
had not experienced a prior clinical event; and six died within five years of diagnosis 
(a seventh died in the sixth year).  
The remaining participants in the cohort (n = 129) were censored at last contact or five 
years after diagnosis, whichever occurred first. For this subsection of the cohort, the 
length of follow-up available ranged from a minimum of 1.75 years to a maximum of 
7.5, with forty adults (31%) having the full five-year period and 30 (23%) having 
between 1.75 and 3 years; the median length of follow-up was 4 years (interquartile 




Figure 8.2 Follow-up for adults censored at last contact in second Scottish cohort 
 
 
8.2 Baseline characteristics 
 
Baseline characteristics for each individual cohort, stratified by mode of clinical 
presentation, were presented in Chapter 7 (Tables 7.3–7.7). In this chapter, the baseline 
characteristics of the five-cohort and three-cohort pooled studies are displayed in Table 
8.1(a) and (b) respectively, and graphs of the five pre-specified predictors, grouped by 
study, are presented in Figures 8.3–8.7.  
In Table 8.2, the composition of the five cohorts and the two pooled studies is 
examined: percentages are presented to enable a comparison of the distribution of 
baseline characteristics in each individual cohort, together with the median age and 
length of untreated follow-up available. 
n = 129 
Median: 4.0 years 
IQR: 3.0 to 5.6 years 
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Table 8.1 Pooled cohorts: baseline characteristics, interventions and first clinical events, stratified by mode of presentation 
(a) Intracranial haemorrhage analysis (five pooled cohorts) 
 
 
   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 988 
Incidental 
(n = 375, 38%) 
Seizure 
 (n = 242, 25%)  
ICH  
(n = 238, 24%) 
FND  
(n = 133, 14%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR)   50 36-61   38 27-50   40 32-53   48 36-61 44 32-57 
Sex           
   Male 159 42% 132 55%   97 41%   59 44% 447 45% 
   Female 216 58% 110 46% 141 59%   74 56% 541 55% 
Primary CCM location           
   Lobar 256 68% 232 96%   94 40%   37 28% 619 63% 
   Deep   34   9%     3 1%   24  10%   16 12%   77   8% 
   Cerebellum   40 11%     1  0.4%   16   7%   11    8%   68   7% 
   Brainstem   45 12%     6 3% 104 44%   69 52% 224 23% 
CCM multiplicity           
   Single 306 82% 187 77% 185 78% 102 77% 780 79% 
   Multiple   69 18%   55 23%   53 22%   31 23% 208 21% 
Management (w/in 5 years of diagnosis)          
   Surgery/radiosurgery       9   2%     47 19%   43 18%    8   6% 107 11% 
   Conservative management   366 98%   195 81% 195 82% 125 94% 881 89% 
1st clinical event in follow-up      6   2%     6 3%   38 16%   12   9%   62   6% 
Length of censored follow-up   
(years) (median, IQR) 




Table 8.1 contd 


























   Characteristic 
Type of symptom leading to CCM diagnosis 
Total 
n = 640 
Incidental 
(n = 230, 36%) 
Seizure 
 (n = 156, 24%)  
ICH  
(n = 164, 26%) 
FND  
(n = 90, 14%) 
 n % n % n % n % n % 
Age at diagnosis (median, IQR)   48 37-58   36 27-48   40 33-53 48 35-59   43 33-56 
Sex           
   Male   93 40%   88 56%   69 42% 39 43% 289 45% 
   Female 137 60%   68 44%   95 58% 51 57% 351 55% 
Primary CCM location           
   Lobar 161 70% 148 95%   66 40% 24 27% 399 62% 
   Deep   14   6%     2   1%   17 10% 10 11%   43   7% 
   Cerebellum   29 13%     1   1%   14     9% 10 11%   54   8% 
   Brainstem   26 11%     5   3%   67 41% 46 51% 144 23% 
CCM multiplicity           
   Single 193 84% 118 76% 127 77% 70 78% 508 79% 
   Multiple   37 16%   38 24%   37 23% 20 22% 132 21% 
1
st
 clinical event in 5-yr follow-up  11   5%     5   3%   43 26% 29 32%   88 14% 
   ICH    2   1%     2   1%   25 15%   7   8%   36   6% 
   FND    9   4%     3   2%    18 11% 22 24%   52   8% 
Length of censored follow-up   
(years) (median, IQR) 
  4.2 2.4-5.0     4.8   2.2-5.0    2.6 1.1-4.4   4.3 1.5-5.0     3.9   1.9-5.0 
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Table 8.2 Comparison of composition of five cohorts and pooled studies: baseline characteristics (percentages) 
 
 
Age (years) Sex Presentation 
Brainstem 
Multiplicity Follow-up (years) 
median IQR Male Female Incidental Seizure ICH FND Single Multiple median IQR 
Mayo Clinic 46 31–62 46 54 37 29 24 11 24 82 18 4.5 1.1–5.0 
Toronto 42 33–54 44 56 29 20 34 17 30 77 23 3.2 1.5–5.0 
Paris 42 28–59 42 58 58 12 12 17 21 67 33 2.2 0.7–4.2 
Scotland, 
1999-2003 
41 32–53 41 59 46 26 13 16 13 82 18 5.0 1.4–5.0 
Scotland, 
2006-2010 
46 34–60 52 48 42 33 19 6 16 82 18 3.9 2.9–5.0 
Total:              
   5 cohorts 44 32–57 45 55 38 25 24 14 23 79 21 3.9 1.5–5.0 
   3 cohorts 43 33–56 45 55 36 24 26 14 23 79 21 3.9 1.9–5.0 
 





Figure 8.3 Boxplot of age at diagnosis, by mode of presentation, stratified by study  
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Median age for the entire study is 44 years (interquartile range 32 to 57 years), ranging 
from 38 years for seizure presentation to 50 years for incidental presentation (see Table 
8.1(a)). Comparing individual cohorts (Table 8.2), median age ranges from 41 years 
(Scotland, 1999–2003) to 46 years (Scotland, 2006–2010 and Mayo Clinic). 
There is a slight predominance of women (n = 541, 55%), both in total and in ICH, 
FND and incidental presentations, but this trend is reversed in seizure presentation, 
where the number of men is 132 (55%). Among the individual cohorts, the percentage 
of women ranges from 48% (Scotland, 2006–2010) to 59% (Scotland, 1999–2003).  
With regard to mode of clinical presentation, a quarter presented with intracranial 
haemorrhage (n = 238, 24%) and seizure (n = 242, 25%), 133 with focal neurological 
deficit (14%), and 375 (38%) incidentally. The percentage presenting incidentally 
ranged from 29% (Toronto) to 58% (Paris), with seizure from 12% (Paris) to 33% (the 
later Scottish cohort), with ICH from 12% (Paris) to 34% (Toronto), and with FND 
from 6% (the later Scottish cohort) to 17% (both Toronto and Paris). 
Almost a quarter of the pooled cohort had a primary brainstem cavernous 
malformation (n = 224, 23%), 77% of whom (n = 173) presented with ICH or FND. 
In the individual cohorts, brainstem location ranged from 13% (Scotland, 1999–2003) 
to 30% (Toronto). About a fifth of the entire study had multiple lesions (n = 208, 21%); 
this ranged from 18% (Scotland, both cohorts and Mayo Clinic) to 33% (Paris). 
Hôpital Lariboisière is a national reference centre for rare neurovascular diseases of 
the eye and brain, and also specializes in research on the genetic form of the disease, 
in which form individuals tend to have multiple CCM; therefore it is of little surprise 
that the Paris cohort has a large percentage of multiple lesions.  
The median length of censored follow-up available for the entire study was 3.9 years 
(interquartile range 1.5 to 5.0 years); the median length for those presenting with ICH 
was 2.7 years, but the other presentations had medians of at least 4 years. Median 




Figure 8.4 Frequency distribution of mode of clinical presentation, stratified by study 
 
 
Figure 8.5 Frequency distribution of CCM location, stratified by study 
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Figure 8.6 Frequency distribution of CCM multiplicity, stratified by study 
 
 
Figure 8.7 Frequency distribution of sex, stratified by study 
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8.3 Censoring at interventional treatment 
 
In this study, patients who had not suffered a previous haemorrhage or FND during 
follow-up were censored at first treatment date, if they underwent interventional 
treatment – whether surgical excision or stereotactic radiotherapy – for their CCM. To 
investigate the possibility of informative censoring, as described in Chapter 6 above, 
follow-up of those participants who were censored for treatment has been explored in 
greater depth. 
In the pooled cohort, 157 participants (16%) received some form of interventional 
treatment for their cavernoma: however, 37 had treatment after experiencing at least 
one clinical event within five years of diagnosis, and 13 had treatment more than five 
years after diagnosis (see Figure 8.8). The remaining 107 participants (11%) were 
censored for interventional treatment during the five-year follow-up period; of these 
47 presented with epilepsy and 60 presented with an intracranial haemorrhage, focal 
neurological deficit or incidentally. The percentage of each cohort censored for 
treatment (within five years of CCM diagnosis) ranged from 4.6% (Toronto) to 21% 
(Mayo Clinic) (see Table 8.5 below). 
A breakdown of the length of follow-up available before interventional treatment, 
stratified by mode of presentation, is shown in Table 8.3. Of those censored for 
treatment during the five-year follow-up period, 92 (86%) had less than two years of 
follow-up: 63 (59%) had less than six months’ follow-up, and 14 (13%) had between 
six months and a year.  
Informative censoring is less of a potential problem for patients who present with a 
seizure and subsequently undergo interventional treatment than for those who are 
treated after a non-seizure presentation, since the decision for surgery with a seizure 
presentation is predominantly informed by intractable epilepsy rather than by the risk 
of future intracranial haemorrhage.  
 




Number who presented initially 
with a seizure: 
n = 47 
Total number of patients in 
cohort: 
n = 988 
Number treated within five years 
of diagnosis, who have not 
experienced a clinical event 
before treatment: 
n = 107 
Number who have been treated and 
who have not experienced a clinical 
event before treatment: 
n = 120 
Number who undergo 
interventional treatment 
during follow-up: 
n = 157 
Number who do not receive 
interventional treatment during 
follow-up: 
n = 831 
Number treated after a 
clinical event in follow-up: 
n = 37 
 
Number treated five or more 
years after CCM diagnosis: 
n = 13 
 
Number who presented 
initially with an ICH or FND 
or incidentally: 
n = 60 
Figure 8.8 Flowchart of those receiving interventional treatment 
198 
Table 8.3 Length of follow-up before treatment, stratified by mode of presentation 
Mode of 
presentation 
Length of follow-up (years) Total 
< 0.5  0.5–0.99  1–1.99 2–2.99 3–3.99 4–4.99 
Seizure 20 5 12 4 2 4 47 
Incidental   7 1   0 1 0 0   9 
ICH 32 6   3 2 0 0 43 
FND   4 2   0 0 0 2   8 
Total 63 14 15 7 2 6 107 
 Cells contain number of adults. 
 
Participants whose data are most likely to be affected by competing risks and therefore 
prone to informative censoring are those who presented initially with an ICH or FND 
and have less than two years of follow-up; these 47 participants form 4.8% of the entire 
study (see Table 8.3). After re-examining the five datafiles for any indication of a 
reason for interventional treatment, it would appear that 51 participants had treatment 
related to epilepsy, 33 to ICH or FND, and 23 for undisclosed reasons (see Table 9.2).  
In Table 8.4, baseline characteristics and length of follow-up are presented for 
participants who were treated within five years of diagnosis and with no prior clinical 
event occurring since diagnosis, and for the adults in the remainder of the study; the 
two groups are further subdivided by whether or not they initially presented with a 
seizure. Those who presented with a seizure tended to be younger than those with other 
presentations, but those who received interventional treatment were significantly 
younger than those who did not (Mann Whitney test, p < 0.0001). In both treatment 
groups, slightly more men presented with a seizure, and the overall sex ratio was 
similar in both groups. In addition, lesion location and multiplicity were similar in both 
treatment groups.  
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Table 8.4 Comparison of treated and untreated groups, stratified by seizure and non-seizure presentation 
*Censored for interventional treatment within five years of diagnosis, no prior clinical event in follow-up. 







n = 47 (44%) 
Other 
presentation 
n = 60 (56%) 
Total 
n = 107 
Presented with 
seizure 
n = 195 (22%) 
Other 
presentation 
n = 686 (78%) 
Total 
n = 881 
Age at diagnosis    median 37.5 39.1  37.5 38.8  47.6 45.2 
IQR (30.3–47.1) (29.3–46.2) 29.8–46.8 (27.5–51.8) (35.0–60.7) 33.3–58.9 
Sex Male 24 (51%) 20 (33%) 44 (41%) 108 (55%) 295 (43%) 403 (46%) 
 Female 23 (49%)  40 (67%) 63 (59%)   87 (45%) 391 (57%) 478 (54%) 
Presentation  Incidental  –   9 (15%)   9 (8%) – 366 (53%) 366 (42%) 
 ICH or 
FND  
– 51 (85%) 51 (48%) – 320 (47%) 320 (36%) 
CCM location  Brainstem – 20 (33%) 20 (19%)   6 (3%) 198 (29%) 204 (23%) 
 Cerebellum   1 (2%)   7 (12%)   8 (8%) –   60 (9%)   60 (7%) 
 Deep –   7 (12%)   7 (7%)   3 (2%)   67 (10%)   70 (8%) 
 Lobar 46 (98%) 26 (43%) 72 (67%) 186 (95%) 361 (53%) 547 (62%) 
CCM multiplicity Single  37 (79%) 51 (85%) 88 (82%) 150 (77%) 542 (79%) 692 (79%) 
 Multiple  10 (21%)   9 (15%) 19 (18%)   45 (23%) 144 (21%) 189 (22%) 















Mode of presentation differed significantly between treatment groups (χ2 (2) = 49.4, p 
< 0.0001): greater percentages presented with (i) ICH or FND and (ii) seizure in the 
treated group (48% and 44% respectively) compared to the conservatively managed 
group (36% and 22%). Conversely, the percentage presenting incidentally was 
significantly greater in the untreated group (42% versus 8%). The median length of 
follow-up was greatly reduced in the treated group: 0.3 years compared to 4.4 years in 
the conservatively managed group (Mann Whitney test, p < 0.0001). 
 
8.4 Risk of ICH or FND in five-year follow-up 
 
In the five-cohort analysis of risk of intracranial haemorrhage, 62 adults (6.3%) 
suffered a first ICH within five years of diagnosis – three of which were fatal – and in 
the three-cohort clinical-event analysis, 88 adults (13.8%) experienced either an ICH 
(n = 36) or an FND (n = 52). The contributions of each cohort to the two outcomes, 
together with the number who received interventional treatment within five years of 
diagnosis, are presented in Table 8.5. The number of haemorrhages in each cohort, as 
a percentage of its total population, was very similar and ranged from 4.4% (the later 
Scottish cohort) to 7.5% (Mayo Clinic).   
To illustrate the distribution of outcome events among cohorts, Kaplan-Meier plots of 
the times to ICH and clinical event are presented in Figures 8.9 and 8.10. In Figure 
8.9, the three hospital-based cohorts all have a greater cumulative risk of ICH over the 
five-year period than the two population-based cohorts; however, the scale of the y-
axis has been magnified to enable the different cohort curves to be discerned more 
easily, and therefore the difference is not as great as might initially appear. 
In Figure 8.10, progression to first haemorrhage or focal neurological deficit is very 
similar for the first Scottish cohort and the Toronto cohort, especially in the first three 
years, whereas the proportion of the second Scottish cohort who suffer a clinical event 
is smaller. This pattern is also apparent in Table 8.6, where the estimated risks of first 
haemorrhage (clinical event) in each cohort and for the pooled cohorts are presented: 
these range from 5.4% (second Scottish cohort) to 9.8% (Mayo Clinic).
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Table 8.5 Five cohorts: size, outcome events and number treated within five years of diagnosis  
Cohort Adults 
      Treated 
   n          % 
     1st ICH 
      (n = 988) 
       n           % 
             1st clinical event (n = 640) 
 
n % ICH FND 
Mayo Clinic 267 56 21.0%  20 7.5%  – – – – 
Toronto 345 16   4.6%  24 7.0%  55 15.9% 23 32 
Paris   81   4   4.9%    4 4.9%  – – – – 
Scotland, 1999–2003 135 19 14.1%    7 5.2%  20 14.8% 6 14 
Scotland,  2006–2010 160 12    7.5%    7 4.4%  13   8.1% 7   6 
Pooled cohorts: 
   Five cohorts 








































Note The scale of the y-axis has been magnified (proportion from 0 to 0.14 only) to enable the plots for each cohort 
to be inspected.  
 
 
Figure 8.9 Kaplan-Meier plot comparing estimated risk of first intracranial 
haemorrhage, stratified by study cohort  
Number of adults at risk (number of ICH in preceding year) 
Scotland, 
1999–2003  
135 113(2) 102(4) 101(0) 101(0)   97(1) 
Scotland, 
2006–2010 
160 145(2) 135(1) 105(2)   66(2)   40(0) 
Mayo Clinic 267 204(9) 176(5) 157(4) 144(2) 126(0) 
Toronto 345 301(12) 238(6) 189(3) 144(2) 120(1) 







  203 
 
 
Number of adults at risk (number of clinical events in preceding year) 
Scotland, 
1999–2003  
135 109(9)   97(5)   93(3)   92(1)   88(2) 
Scotland, 
2006–2010 
160 145(3) 135(5) 105(2)   66(3)   40(0) 
Toronto 345 301(23) 238(13) 189(10) 144(5) 120(4) 
 
Note The scale of the y-axis has been magnified (proportion from 0 to 0.24 only) to enable the plots for each cohort 




Figure 8.10 Kaplan-Meier plot comparing estimated risk of first clinical event 







The Kaplan-Meier estimated risk of an intracranial haemorrhage (clinical event) in 
five-year follow-up has been calculated for the two core and three putative predictors; 
the risk is given for individual cohorts and for the pooled cohorts. For example, in 
Table 8.7, the Kaplan-Meier estimated risk of an ICH within five years of diagnosis 
for an adult presenting with an ICH or FND ranged from 4.2% (Paris) to 20.7% (Mayo 
Clinic), with a pooled-cohort estimated risk of 17.7% (95% confidence interval 13.1% 
to 22.3%), whereas the Kaplan-Meier estimated risk for an adult presenting with a 
seizure or incidentally (‘other’ presentation) varied from 0.6% (Toronto) to 10.8% 
(Paris), with the pooled-cohort estimated risk of 2.6% (95% CI 1.2% to 4.1%). 
Similarly, in Table 8.8, the estimated risk of an ICH when the cavernous malformation 
is located in the brainstem ranged from 18.4% (Scotland, 1999–2003) to 34% 
(Scotland, 2006–2010), with a pooled-cohort risk of 21.1% (95% CI 14.9% to 27.2%), 
in contrast to the substantially lower risk when the CCM was located in another area 
of the brain (lowest: 0.8% in Scotland, 2006–2010; highest: 7.2% at Mayo Clinic; 
pooled-cohort estimate: 4.4%, 95% CI 2.6% to 6.1%). The tables for the other three 
putative predictors of haemorrhage and the five predictors of clinical event are located 
in Appendix F at the end of the thesis (see Tables A.1–A.8).  
 
Table 8.6 Kaplan-Meier estimated risk of haemorrhage and clinical event within five 
years of diagnosis, stratified by study  
Cohort Risk of ICH 
Estimate              95% CI 
Risk of clinical event 
Estimate              95% CI 
Mayo Clinic 9.8% 5.7 to 14.0 – – 
Toronto 9.0% 5.4 to 12.6 20.5% 15.4 to 25.6 
Paris 8.8% 0.1 to 17.5 – – 
Scotland, 1999–2003 6.1% 1.7 to 10.5 17.1% 10.2 to 24.0 
Scotland, 2006–2010 5.4% 1.4  to  9.4  9.6% 4.6 to 14.7 
Pooled 8.1% 6.1 to 10.1 17.0 13.6 to 20.3 
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Table 8.7 Estimated risk of intracranial haemorrhage within five years of CCM diagnosis, by initial presentation 














  5 
20.7% 
  4.3% 
11.2 to 30.1 
0.6 to 7.9 
0.048 
0.019 





  1 
17.7% 
  0.6% 
10.8 to 24.6 
   0 to 1.8 
0.035 
0.006 




  1 
  3 
  4.2% 
10.8% 
0 to 12.2 
0 to 22.6 
0.041 
0.060 




  5 
  2 
15.9% 
 2.5% 
3.0 to 28.8 
0 to 5.9 
0.066 
0.017 




  6 
  1 
19.8% 
  0.9% 
5.1 to 34.5 
0 to 2.7 
0.075 
0.009 
       







  2.6% 
13.1 to 22.3 






Table 8.8 Estimated risk of first intracranial haemorrhage within five years of CCM diagnosis, by lesion location 
















  7.2% 
8.6 to 30.5 
2.9 to 11.5 
0.056 
0.022 







  4.5% 
11.1 to 29.9 
1.3 to 7.6 
0.048 
0.016 







  3.1% 
0 to 50.8 
0 to 9.2 
0.131 
0.031 







  4.2% 
0 to 37.3 
0.1 to 8.2 
0.096 
0.020 







  0.8% 
10.4 to 57.7 
0 to 2.4 
0.121 
0.008 
       







  4.4% 
14.9 to 27.2 
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8.5 Univariate analysis 
 
8.5.1 Kaplan-Meier plots 
For each outcome event, five different Kaplan-Meier plots were produced, each plot 
stratified by a different a priori predictor in turn. Four plots comparing the estimated 
risk of first haemorrhage (clinical event), stratified by the two core predictors, for the 
pooled cohorts are displayed in Figures 8.11–8.12 below; plots for the individual 
cohorts, and also for the putative predictors, are presented in the Appendix G at the 
end of the thesis (Figures A.1–A.13).  Age was categorized into three groups – 35 
years or younger, 36–53 years, or 54 years or older – solely to enable a visual 
examination of the effect of different age-groups on the clinical outcome.  
After examining each plot, a statistically significant difference could be discerned 
when comparing the estimated risk of progression to a haemorrhage (clinical event) 
between those presenting with an ICH or FND and those presenting incidentally or 
with a seizure in four of the cohorts (see Figure 8.11, and Figures A.1–A.2 in Appendix 
G), and those with a brainstem location (see Figure 8.12, and Figures A.3–A.4 in 
Appendix G) compared to those with another CCM location in all five studies. 
The log-rank test results are given in Tables 8.9 and 8.10 below, for initial presentation 
and lesion location respectively in the time to first haemorrhage, and in Tables A.9–
A.18 in Appendix F for the other predictors. For the other three putative predictors 
(age, sex and CCM multiplicity), no consistent difference was apparent (see Figures 
A.5–A.13 in Appendix G). In the pooled cohorts, fewer of those in the oldest age-
group at diagnosis (54 years or older) appeared to have a haemorrhage or FND over 
five years; however, this difference was only statistically significant when the five 
cohorts were pooled and the log-rank test for trend was used (χ2(1) = 5.05, p = 0.025). 
Indeed, the order of the youngest group and the middle group was reversed in the three-













Number of adults at risk (number of ICH in preceding year) 
ICH or FND at 
presentation: 
371 281(25) 233(11) 188(7) 154(5) 126(2) 
Other 
presentation: 
617 539(1) 460(6) 397(3) 323(2) 271(0) 
 
Number of adults at risk (number of ICH in preceding year) 
ICH or FND at 
presentation: 
254 201(28) 163(19) 126(13)    94(8)    76(4) 
Other 
presentation: 
386 354(7) 307(4) 261(2) 208(1) 172(2) 
ICH or FND at presentation 
Other presentation 
 
y=  0, reference 
ICH or FND at presentation 
Other presentation  
 
y = 0, reference  
 
Figure 8.11 Kaplan-Meier plots comparing estimated risk of (a) first ICH and (b) first 
ICH or FND, stratified by presentation: ICH or FND presentation vs other presentation 
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Number of adults at risk (number of ICH in preceding year)  
Brainstem: 224 170(21) 137(9) 114(3)   92(5)   72(0) 




Number of adults at risk (number of ICH in preceding year)  
Brainstem: 144 114(22)   90(13)   68(7)   47(9)   36(2) 
Other location: 496 441(13) 380(10) 319(8) 255(0) 212(4) 
 
 
Figure 8.12 Kaplan-Meier plot comparing estimated risk of (a) first ICH and (b) first ICH 










Other location  




8.5.2 Cox proportional hazards regression 
The original intention, as outlined in Chapter 6 above and the statistical analysis plan, 
was to treat age in the survival analysis as a continuous variable, to avoid the loss of 
information, power and precision that results when a categorized variable is used 
(Royston, 2006). In order to do this, however, the linearity assumption had to be 
investigated – that is, whether the influence of age on the outcome variable can be 
considered to be linear. To check this assumption, age was categorized into three 
groups, as described in subsection 8.5.1 above. Two plots were examined: first, a Cox 
regression was undertaken, using age as a categorical variable, and the regression 
coefficients were plotted against the corresponding age-group (Machin, 2006); and 
second, the log minus log plots for this regression were inspected, to ascertain whether 
the distance between the three curves was approximately equal. 
The resulting graphs seemed a little ambiguous. Furthermore, when age had been 
categorized into three equal-sized groups in the analysis for clinical event, the log 
minus log curves were not ordered. Therefore, to check that this was not an artefact, 
age was re-grouped into four categories (30 years or younger, 31–45 years, 46–60 
years, and 61 years or older), and the analysis was repeated. This time the results were 
more clear-cut: the line plot resembled a Z-shape, rotated by about 40 degrees; and in 
the log minus log plots (Figure 8.13), the curves crossed several times, but after about 
18 months, the two younger age-groups and two older age-groups separated, although 
the curves within these two groups crossed at least twice. Given these conflicting 
results, it was decided to treat age as a categorical variable with three levels, as in the 
subsection above: that is, 35 years or younger; 36–53 years; 54 years or older.   
The unadjusted and adjusted hazard ratios for the two core pre-specified predictors for 
time to first ICH are presented in Tables 8.9 and 8.10; Tables A.9–A.18 (in Appendix 
F) display the hazard ratios for the three pre-specified putative predictors and the five 
pre-specified predictors (two core and three putative) for time to first clinical event.   
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Table 8.9 Analysis of time to first ICH within five years of diagnosis, stratified by clinical presentation (ICH or FND at presentation vs other 
presentation, i.e. seizure or incidental) 
aHazard ratio from univariate analysis.  b Hazard ratio is adjusted for CCM location.  












95% CI p 
Mayo Clinic ICH or FND 93 15 
16.97 <0.0001 6.37 2.3–7.5 <0.0001 5.07 1.6–15.8 0.005 
Other 174 5 
Toronto  ICH or FND 175 23 
22.67 <0.0001 25.64 3.5–189.9 0.001 17.00 2.2–131.1 0.007 
Other 170 1 
Paris ICH or FND 24 1 
0.05 0.826 0.78 0.1–7.5 0.826 0.30 0.03–3.1 0.317 
Other 57 3 
Scotland, 
1999–2003 
ICH or FND 38 5 
7.96 0.005 7.46 1.4–38.5 0.016 5.51 0.9–32.4 0.059 
Other 97 2 
Scotland, 
2006–2010 
ICH or FND 41 6 




ICH or FND 371 50 
58.84 <0.0001 7.96 4.2–15.0 <0.0001 4.85 2.4–9.7 <0.0001 





ICH or FND 371 50 
55.89 <0.0001 8.03 4.2–15.2 <0.0001 4.95 2.5–9.9 <0.0001 
Other 617 12 
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Table 8.10 Analysis for time to first ICH within five years of diagnosis, stratified by CCM location (brainstem vs other location) 
aHazard ratio from univariate analysis.  b Hazard ratio is adjusted for presentation.












95% CI p 
Mayo Clinic brainstem 63 10 
9.94 0.002 3.72 1.5–8.9 0.003 1.59 0.6–4.3 0.356 
other 204 10 
Toronto brainstem 102 16 
19.98 <0.0001 5.58 2.4–13.0 <0.0001 2.65 1.1–6.3 0.027 
other 243 8 
Paris brainstem 17 3 
6.07 0.014 10.04 1.04–96.8 0.046 14.59 1.4–150.1 0.024 
other 64 1 
Scotland, 
1999–2003 
brainstem 17 3 
5.58 0.018 5.06 1.1–22.6 0.034 2.40 0.5–12.1 0.289 
other 118 4 
Scotland, 
2006–2010 
brainstem 25 6 




brainstem 224 38 
63.08 <0.0001 6.13 3.7–10.2 <0.0001 3.06 1.8–5.4 <0.0001 





brainstem 224 38 
59.13 <0.0001 6.05 3.6–10.2 <0.0001 3.08 1.8–5.4 <0.0001 
other 764 24 
 
  213 
The results for the univariate analyses are summarized in Table 8.11 and 8.12. In the 
univariate analyses for each outcome event, the hazard ratios for CCM location were 
statistically significant for every cohort, although the hazard ratio for progression to 
haemorrhage ranged from 3.7 (Mayo Clinic) to 41.0 (second Scottish cohort); when 
the cohorts were pooled, and stratified by ‘study’, the hazard ratio was 6.1 (95% CI 
3.6 to 10.2, p < 0.0001) (Table 8.10 and 8.11). For mode of clinical presentation, the 
unadjusted hazard ratios for four of the cohorts were statistically significant and ranged 
from 6.4 (Mayo Clinic) to 25.6 (Toronto); the pooled hazard ratio, stratified by ‘study’, 
was 8.0 (95% CI 4.2 to 15.2, p < 0.0001) (Table 8.9 and 8.11). Similarly, the hazard 
ratios for the two core predictors in the analysis for progression to first clinical event 
were statistically significant (see Table 8.12, and Tables A.13–A.14 in Appendix F). 
By contrast, none of the hazard ratios for the three putative predictors were statistically 
significant for either outcome event.  
 
 
Figure 8.13 Complementary log plot for time to first intracranial haemorrhage, 
stratified by four levels of age-group, to test for linearity
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Hazard ratio        95% CI 
 Univariate analysis, 
stratified by ‘study’ 
Hazard ratio        95% CI 
 Random-effects meta-analysis  
Hazard ratio               95% CI 
Presentation (ICH/FND vs other) 7.96 4.2–15.0  8.03 4.2–15.2  7.39 2.9–19.2 
Location (brainstem vs other) 6.13 3.7–10.2  6.05 3.6–10.2  5.72 3.2–10.3 
Age: ≤ 35 years vs ≥ 54 years 









   
Sex (female vs male) 0.81 0.5–1.3  0.80 0.5–1.3  0.8 0.5–1.4 
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Hazard ratio        95% CI 
 Univariate analysis, 
stratified by ‘study’ 
Hazard ratio        95% CI 
 Random-effects meta-analysis  
Hazard ratio               95% CI 
Presentation (ICH/FND vs other) 8.24 4.8–14.2  8.24 4.7–14.3  7.95 4.3–14.6 
Location (brainstem vs other) 6.26 4.1–9.6  6.23 4.0–9.7  7.00  3.3–15.0 
Age: ≤ 35 years vs ≥ 54 years 









   
Sex (female vs male) 1.16 0.8–1.8  1.13 0.7–1.7  1.20 0.6–2.4 
CCM multiplicity (multiple vs 
solitary) 









8.6 Multivariable analysis 
 
In the multivariable analysis, the hazard ratios of the two core predictors were adjusted 
for each other, and the three putative predictors were each adjusted for the two core 
predictors. These results are summarized in Table 8.13; more detailed results are 
presented in the extreme right columns of Tables 8.9 and 8.10 (for the two core 
predictors in the progression to first ICH analysis), and in Tables A.9–A.18 in 
Appendix F (the three putative predictors for the time to ICH analysis, and the two 
core and three putative predictors for the time to clinical event analysis).  
The pooled adjusted hazard ratios for the two core predictors, clinical presentation and 
CCM location, each stratified by ‘study’, were 4.95 (95% CI 2.5 to 9.9) and 3.08 (95% 
CI 1.8 to 5.4) respectively for the risk of haemorrhage, and 5.20 (95% CI 2.9 to 9.4) 
and 3.32 (95% CI 2.1 to 5.3) respectively for the risk of clinical event. 
As with the univariate analysis, the pooled hazard ratios for the two core predictors 
were statistically significant for both risk of haemorrhage and risk of clinical event; 
the adjusted hazard ratios for the three putative predictors, however, did not achieve 
statistical significance. This demonstrates that none of the three putative predictors – 
age, sex and CCM multiplicity – added statistically significant prognostic information 




Two-stage random-effects meta-analyses were carried out for each of the five pre-
specified predictors, and for each primary outcome; the forest plots for the two core 
predictors for both outcomes are displayed in Figures 8.14–8.18. In the case of the 
three putative predictors, two-stage random-effects meta-analyses were undertaken 
both for each unadjusted predictor and also for the predictor after adjusting for 
presentation and location (see Figures A.14–A.19 in Appendix G).  
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Table 8.13 Summary of results for the multivariable analyses for both outcome events 
Analysis Predictor Category 
Adjusted hazard ratio* 
Estimate                   95% CI 
ICH only Core predictors – adjusted for each other 
    
 Presentation ICH/FND presentation 4.95   2.5–9.9 
 Location Brainstem 3.08 1.8–5.4 
     
 Putative predictors – adjusted for two core predictors 
  
 Sex Female 0.69 0.4–1.1 
 Multiplicity Multiple 1.42 0.8–2.5 
 Age ≤ 35 years 2.34 1.2–4.6 
  36–53 years 1.61 0.8–3.2 
    
ICH/FND Core predictors – adjusted for each other 
    
 Presentation ICH/FND presentation 5.20 2.9–9.4 
 Location Brainstem 3.32 2.1–5.3 
     
 Putative predictors – adjusted for two core predictors 
    
 Sex Female 0.88 0.6–1.4 
 Multiplicity Multiple 0.82 0.5–1.4 
 Age ≤ 35 years 1.86 1.0–3.4 
  36–53 years 2.41 1.4–4.3 
 
Note 
*Adjusted hazard ratios are for the pooled cohorts, stratified by ‘study’. 
 
 
When the five cohorts were pooled, the unadjusted hazard ratio for the effect of mode 
of clinical presentation on occurrence of first haemorrhage was 7.4 (95% confidence 
interval 2.9 to 19.2); the test for heterogeneity was not significant (χ2 = 6.26, with 4 
degrees of freedom, p = 0.18); the estimate of between-study variance, τ2, was 0.42, 
and the 𝐼2 index was 36% (Figure 8.14), which indicates that some heterogeneity 
exists. However, the Parisian cohort was very small (n = 81) with only four 
haemorrhages occurring within five years of diagnosis; it acts as a clinical outlier, as 
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disproportionately more adults have the familial form of the disease, since the hospital 
is a national referral centre. When this cohort was excluded, the overall hazard ratio 
for the other four studies was 9.2 (95% CI 4.4 to 19.3): again, the test for heterogeneity 
was not significant (χ2(3) = 2.13, p = 0.55), but now τ2 = 0 and 𝐼2 = 0%, indicating that 
no heterogeneity was observed (see Figure 8.15).  
Similarly, in the forest plot for the effect of CCM location on the occurrence of first 
ICH in five-year follow-up (Figure 8.16), the pooled (unadjusted) hazard ratio was 5.7 
(95% CI 3.2 to 10.3). The test for heterogeneity was not significant (χ2(4) = 4.49, p = 
0.344) and τ2 = 0.052. The 𝐼2 value of 10.8% suggests that little variability exists 
between the studies that cannot be ascribed to chance. 
The results are similar in the three-cohort meta-analyses of the two core predictors (see 
Figures 8.17 and 8.18). The unadjusted hazard ratio for mode of presentation was 7.95 
(95% CI 4.3 to 14.6); the test for heterogeneity was not significant (χ2(2) = 2.19, p = 
0.344), τ2 = 0.026, and 𝐼2 = 8.9%. The unadjusted hazard ratio for CCM location was 
7.00 (95% CI 3.3 to 15.0); the test for heterogeneity was not significant (χ2(2) = 4.60, 
p = 0.10), and τ2 = 0.255; however, the 𝐼2 value of 56.5% would suggest that there is 
high heterogeneity among these cohorts. The high value of 𝐼2 can be attributed to the 
fact that there were only three cohorts in this meta-analysis. In the meta-analyses of 
the three putative predictors for haemorrhage (clinical event), none of the hazard ratios 
achieved statistical significance (see Figures A.14–A.19 in Appendix G). 
 
8.7.1 Sensitivity analyses 
In the sensitivity analyses for the effect of mode of presentation and CCM location on 
the occurrence of intracranial haemorrhage, the equivalent unadjusted hazard ratios for 
the pooled cohort, stratified by ‘study’, were 8.03 (95% CI 4.2 to 15.2, p < 0.0001) 
and 6.05 (95% CI 3.6 to 10.2, p < 0.0001) respectively (see Tables 8.9 and 8.10 above 
for detailed results, and Tables 8.11 and 8.12 above for summarized results).  
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Heterogeneity 
χ2(4) = 6.26, p = 0.18 
Estimate of between-study variance, τ2 = 0.4212 
Variation in effect size attributable to heterogeneity, I2 = 36.1% 
Test of effect size = 1, z = 4.11, p < 0.0001 
 
Figure 8.14 Forest plot displaying a random-effects meta-analysis of the effect of mode of presentation (unadjusted) on the occurrence of 
first ICH in five-year follow-up  





























χ2(3) = 2.13, p = 0.55 
Estimate of between-study variance, τ2 = 0 
Variation in effect size attributable to heterogeneity, I2 = 0% 
Test of effect size = 1, z = 5.86, p < 0.0001 
 
Figure 8.15 Forest plot displaying a random-effects meta-analysis of the effect of presentation (unadjusted) on occurrence of first ICH in five-
year follow-up, when the smallest cohort is excluded  
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Heterogeneity 
χ2(4) = 4.49, p = 0.344 
Estimate of between-study variance, τ2 = 0.0515 
Variation in effect size attributable to heterogeneity, I2 = 10.8% 
Test of effect size = 1, z = 5.86, p < 0.0001 
 
Figure 8.16 Forest plot displaying a random-effects meta-analysis of the effect of CCM location (unadjusted) on occurrence of first ICH in 
five-year follow-up  





























χ2(2) = 2.19, p = 0.344 
Estimate of between-study variance, τ2 = 0.0262 
Variation in effect size attributable to heterogeneity, I2 = 8.9% 
Test of effect size = 1, z = 6.72, p < 0.0001 
 
Figure 8.17 Forest plot displaying a random-effects meta-analysis of the effect of mode of presentation (unadjusted) on the occurrence of 
first ICH or FND in five-year follow-up  
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Heterogeneity 
χ2(2) = 4.60, p = 0.100 
Estimate of between-study variance, τ2 = 0.2549 
Variation in effect size attributable to heterogeneity, I2 = 56.5% 
Test of effect size = 1, z = 5.00, p < 0.0001 
 
Figure 8.18 Forest plot displaying a random-effects meta-analysis of the effect of CCM location (unadjusted) on occurrence of first ICH or 
FND in five-year follow-up
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Random-effects model
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Indeed, the confidence interval for the hazard ratio in each forest plot was slightly 
wider than that in the equivalent sensitivity analysis, although the level of agreement 
was generally good (see Tables A.9–A.15 in Appendix F).   
 
8.7.2 Heterogeneity between cohorts 
In Table 8.14, the baseline characteristics of the hospital-based cohorts are compared 
with those of the population-based cohorts to assess whether any heterogeneity exists 
in the study design. With regard to age, sex and CCM multiplicity, both groups are 
very similar. In the hospital-based cohorts, a larger proportion present with ICH or 
FND (42%, compared with 27% in the population-based cohorts), whereas a greater 
percentage of adults in the population-based cohorts present with seizure (29% 
compared with 22% in the hospital-based cohorts) and incidentally (44% and 35% 
respectively). Thus the hospital-based cohorts include a greater percentage of people 
with one or more potential risk factors.  
In the ICH-only meta-analyses, the test of heterogeneity was only significant for the 
effect of multiplicity (unadjusted and adjusted): χ2(3) = 7.95, p = 0.047 and χ2(3) = 
8.90, p = 0.031 respectively. (The Parisian cohort was not included in these two meta-
analyses because only adults with multiple lesions suffered a haemorrhage, and 
therefore a hazard ratio could not be obtained for that cohort.) However, the 𝐼2 index 
ranged from 0% (sex, adjusted for presentation and CCM location; and age 
unadjusted), indicating that no heterogeneity was observed, to over 60% (multiplicity, 
unadjusted and adjusted), which suggests that most of the variability across studies 
was due to heterogeneity rather than chance. Two meta-analyses – unadjusted present-
ation and age, adjusted for presentation and location – had respective 𝐼2 values of 36% 
and 28%, indicating that in these meta-analyses mild heterogeneity existed between 
cohorts. 𝐼2 values for all meta-analyses are displayed in Table 8.15.  
In the meta-analyses for clinical event, only three cohorts recorded this outcome, and 
the test of heterogeneity was not significant for any of the predictors. An 𝐼2 value of 
0% was recorded for sex (adjusted for the two core predictors), unadjusted CCM 
multiplicity, and age (both unadjusted and adjusted). 𝐼2 was equal to 9% for unadjusted   
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Table 8.14 Comparison of baseline characteristics of pooled cohorts: hospital-based 
cohorts versus population-based cohorts 
 
 
a CCM location only categorized as brainstem versus other location for one cohort. 
 
 
presentation, which indicates that little variability exists between cohorts that cannot 
be explained by chance. However, a moderate level of inconsistency existed between 
cohorts for unadjusted sex (𝐼2 = 45%), adjusted CCM multiplicity (𝐼2 = 51%) and 
unadjusted location (𝐼2 = 57%) (see Table 8.15).  
Characteristic 
Hospital-based cohorts 
(n = 693, 70%) 
 
n                   % 
Population-based cohorts 
n = 295, 30%) 
 
n                          % 
Age (median, IQR) 44 32–58 44 33–57 
Sex     
   Male 309 45% 138 47% 
   Female 384 55% 157 53% 
Presentation     
   Incidental 246 35% 129 44% 
   Seizure 155 22% 87 29% 
   ICH 190 27% 48 16% 
   FND 102 15% 31 11% 
Primary CCM locationa     
   Lobar – – 210 71% 
   Cerebellum – – 13 4% 
   Deep – – 30 10% 
   Brainstem 182 26% 42 14% 
CCM multiplicity     
   Single 538 78% 242 82% 
   Multiple 155 22% 53 18% 
226 




I2 = 0% 
Very little 
1% ≤ I2 < 10% 
Mild 
10% ≤ I2 < 25% 
Moderate 
25% ≤ I2 < 50% 
High 
I2 >50% 
ICH only      
 Presentation, unadjusted 0%a   36.1%b  
 Location, unadjusted   10.8%   
 Sex, unadjusted   11%   
 Sex, adjusted 0%     
 Multiplicity, unadjusted     62.3% 
 Multiplicity, adjusted     66.3% 
 Age, unadjusted 0%     
 Age, adjusted    28.2%  
ICH or FND      
 Presentation, unadjusted  8.9%    
 Location, unadjusted     56.5% 
 Sex, unadjusted    44.9%  
 Sex, adjusted 0%     
 Multiplicity, unadjusted 0%     
 Multiplicity, adjusted     50.8% 
 Age, unadjusted 0%     
 Age, adjusted 0%     
a Four cohorts, exc. Paris    b Five cohorts.
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8.8 Prognostic model  
 
After completing the multivariable analysis and meta-analyses, a prognostic model 
was built for the estimated five-year risk of an intracranial haemorrhage (clinical 
event) at time of diagnosis (see the statistical analysis plan in Appendix E below). Due 
to the comparatively small number of outcome events, and the fact that a two-stage 
meta-analysis was being undertaken, the decision was taken to rely on clinical insight 
and prior knowledge, derived from the literature, to inform the model-building process, 
rather than to use stepwise selection. This decision was made to avoid the model being 
data-driven and over-fitted.  
The default prognostic model was based on including the two core predictors that were 
known to affect the progression to a clinical outcome event. Previously, it was 
envisaged that the hazard ratios of one or more of the putative predictors would also 
be significant, and therefore at least one putative predictor would be a candidate for 
inclusion in the default model. For this reason, each of the three putative predictors 
was added, in turn, to the default model (i.e. the Cox regression was performed three 
times, with a different putative predictor being added into the analysis on each 
occasion), to ascertain whether any of them added further prognostic information. 
However, even after adjusting for the two core predictors, none of the three putative 
predictors achieved statistical significance. Consequently, because only the hazard 
ratios of the two core predictors were significant, the model-building process that was 
actually undertaken was much simpler than that described in both the statistical 
analysis plan and Chapter 6 above. Furthermore, because only two binary covariates 
were included in the model, the previously planned prognostic index was not created. 
Therefore, as a result of the multivariable analysis, described above in section 8.6, each 
model contained the two core predictors: ICH or FND presentation (versus other 
presentation) and brainstem location (versus other location) (see Tables 8.16 and 8.17). 
For each outcome, over 55% of the cohort was in the low-risk, baseline group (other 
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presentation and other location) and about 18% in the high-risk – ICH or FND 
presentation, brainstem CCM – group.  
For both models, the analysis was undertaken twice: first, without taking the fact that 
the data was pooled from five different cohorts (unstratified analysis), and second, 
including ‘study’ as a stratification. However, the results were very similar (see Tables 
A.19–A.20 in Appendix F below). In the following two subsections, the unstratified 
results are used. 
 
8.8.1 Model A: four-level model 
In the first model, two binary covariates – mode of clinical presentation and CCM 
location – were entered into a multivariable Cox regression. There are four levels for 
this model:   
(i) incidental or seizure presentation (‘other’ presentation), primary CCM not 
located in the brainstem (i.e. ‘other’ location): this is the baseline or reference 
group; 
(ii) incidental or seizure presentation, primary CCM located in the brainstem; 
(iii) ICH or FND presentation, other location;   
(iv) ICH or FND presentation, brainstem location.  
For both outcomes (ICH or clinical event), individuals in groups (ii) to (iv), who have 
one or two risk factors, have a worse prognosis than those in the reference group.  
For example, the hazard that an adult with a brainstem lesion who presents incidentally 
or with a seizure might suffer a haemorrhage within five years of diagnosis is more 
than three times that for an adult with a similar presentation, but whose lesion is in a 
non-brainstem location (HR = 3.1; 95% CI 1.8 to 5.4). For an adult presenting with an 
ICH or FND and a non-brainstem lesion, the comparable hazard is almost five times 
the baseline hazard (HR = 4.9; 95% CI 2.4 to 9.7). However, the hazard ratio for an 
adult with both risk factors – brainstem CCM, ICH or FND presentation – is almost 
15 relative to an adult in the baseline category (HR = 14.9; 95% CI 4.3 to 51.8) (see 
Table 8.16).  
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ICH only    
ICH/FND presentation, brainstem location 173 18% 36 14.9 4.3 to 51.8 25.7% 18.3 to 33.2 
ICH/FND presentation, other location 198 20% 14   4.9 2.4 to 9.7  10.6% 5.2 to 16.1 
Other presentation, brainstem location   51   5%   2   3.1 1.8 to 5.4   5.5% 0 to 12.9 
Other presentation, other location 566 57% 10   1.0 -   2.4% 0.9 to 3.8 
ICH or FND    
ICH/FND presentation, brainstem location 113 18% 48 16.3 5.7 to 46.3 50.7% 40.1 to 61.4 
ICH/FND presentation, other location 141 22% 24    5.1 2.8 to 9.1 22.4% 14.2 to 30.6 
Other presentation, brainstem location   31   5%   5    3.2 2.0 to 5.1 22.9% 3.7 to 42.2 
Other presentation, other location 355 56% 11    1.0 -   3.7% 1.5 to 5.9 
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n                % 









ICH only        
Two risk factors 173 18% 36 14.3 7.1 to 28.8 25.7% 18.3 to 33.2 
One risk factor 249 25% 16   4.0 1.8 to 8.7   9.5% 4.9 to 14.1 
No risk factors 566 57% 10   1.0    2.4% 0.9 to 3.8 
ICH or FND        
Two risk factors 113 18% 48 18.0 9.4 to 34.8 50.7% 40.1 to 61.4 
One risk factor 172 27% 29   6.1 3.1 to 12.2 22.3% 14.8 to 29.8 
No risk factors 355 56% 11   1.0  3.7% 1.5 to 5.9 
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The prognosis is similar when comparing the risk of an ICH or FND within five years 
of diagnosis: the hazard for those who have both risk factors is more than 16 times that 
for those in the reference group (HR = 16.3; 95% CI 5.7 to 46.3) (see Table 8.16). 
 
Model A: linear predictors  
Expression 8.1 below represents the linear predictor for the estimated five-year risk of 
an intracranial haemorrhage at time of diagnosis, in untreated follow-up, and 
expression 8.2 represents the equivalent linear predictor for the five-year risk of a 
clinical event in untreated follow-up (see also Table 8.18 below). In expression 8.1, 
1.12 is the log hazard ratio for CCM location, and 1.58 is the log hazard ratio for mode 
of presentation; similarly, in expression 8.2, the coefficients are the respective log 
hazard ratios for each predictor. 
𝟏. 𝟏𝟐𝒙𝟏 + 𝟏. 𝟓𝟖𝒙𝟐       8.1 
𝟏. 𝟏𝟔𝟐𝒙𝟏 + 𝟏. 𝟔𝟐𝟕𝒙𝟐       8.2 
where 𝑥1 = 0, if the CCM is not located in the brainstem (i.e. ‘other location’), and 
 𝑥1 = 1, if the CCM is located in the brainstem; and  
 𝑥2 = 0, if mode of presentation is seizure or incidental, and 
 𝑥2 = 1, if ICH or FND presentation.   
  
8.8.2 Model B: three-level model 
In the second model, the two groups with a single risk factor have been combined, as 
their hazard ratios are similar; thus the three levels of this model are no, one and two 
risk factors (see Table 8.17). The rationale for developing this model is twofold: first, 
a three-level model will provide more stable estimates in the category with the fewest 
members (other presentation, brainstem location); and second, the three-level model 
might be more practical for clinical use, as it is slightly simpler. (See section 9.1.1 
below for a discussion concerning the two models.)
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Estimate          95% CI 
Linear predictor 
ICH only Presentation ICH or FND 1.580 0.351 20.22 4.85 2.438–9.665  
  Other    1.00   
 Location Brainstem 1.120 0.285 15.44 3.06 1.753–5.357  
  Other       
        1.58 * presentation + 1.12 * location 
         
ICH or FND Presentation ICH or FND 1.627 0.299 29.69 5.09 2.834–9.134  
  Other    1.00   
 Location Brainstem 1.162 0.235 24.34 3.20 2.014–5.070  
  Other    1.00   
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Hazard ratio  
Estimate               95% CI 
Linear predictor 
ICH only Risk factor Two 2.66 0.36 55.28 14.28 7.09–28.79  
  One 1.38 0.40 11.63 3.96 1.80–8.72  
  None    1.00   
        1.38 * risk factor 
         
ICH or FND Risk factor Two 2.89 0.34 74.64 18.05 9.36–34.7  
  One 1.81 0.35 26.10 6.11 3.05–12.22  
  None    1.00   





As in Model A, for both outcomes, the group with no risk factors is the baseline. The 
hazard ratio that an individual with a single risk factor might suffer an intracranial 
haemorrhage within five years of diagnosis is 4.0 (95% CI 1.8 to 8.7) relative to those 
in the reference group, and for an adult with two risk factors, the hazard ratio is more 
than 14 compared to the reference group (HR = 14.3, 95% CI 7.1 to 28.8). Similarly, 
the hazard for a person with a single risk factor suffering either a haemorrhage or focal 
neurological deficit within five years of diagnosis is over six times that for someone 
with no risk factors (HR = 6.1, 95% CI 3.1 to 12.2), and for an individual with both 
risk factors this hazard increases to 18 (95% CI 9.4 to 34.8). 
 
Model B: linear predictors  
Expression 8.3 represents the linear predictor for the estimated five-year risk of a first 
intracranial haemorrhage at time of diagnosis, in untreated follow-up, and expression 
8.4 represents the equivalent linear predictor for the estimated five-year risk of a 
clinical event in untreated follow-up (see also Table 8.19).  
𝟏. 𝟑𝟕𝟓𝒙𝟏 + 𝟐. 𝟔𝟓𝟗𝒙𝟐      8.3 
𝟏. 𝟖𝟎𝟗𝒙𝟏 + 𝟐. 𝟖𝟗𝟑𝒙𝟐      8.4 
where 𝑥1 = 0 and 𝑥2 = 0, represents no risk factors, 
 𝑥1 = 1 and 𝑥2 = 0, represents one risk factor, and 
𝑥1 = 0 and 𝑥2 = 1, represents two risk factors. 
However, in this model, there is a single predictor with three levels, so the two linear 
predictors for Model B can be simplified, as shown in Table 8.19, by writing them as 
 1.38 × (number of risk factors)   ICH  
and 
 1.81 × (number of risk factors)   clinical event. 
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8.8.3 Proportional hazards assumptions 
Log-minus-log plots were inspected to check that the proportional hazards assump-
tions for both models are valid (Figure 8.19). In the plots for time to first intracranial 
haemorrhage and first clinical event in five-year follow-up in model A (Figure 8.19a 
and c), three of the four curves were parallel; however, there were insufficient outcome 
events in the brainstem location/other presentation group to enable a meaningful curve 
to be plotted. (In Figure 8.19c the brainstem location/other presentation curve cut two 
of the parallel curves, but this is almost certainly an artefact due to paucity of outcome 
events.) Therefore it is not possible to obtain very robust estimates in the four-way 
split, because one category had very few outcome events. In contrast, the three curves 
were parallel for both outcomes in Model B (Figure 8.19b and d).   
 
8.8.4 Discrimination 
Originally, I had assumed that the model would include at least one putative predictor, 
in addition to the two core predictors; if this had been the case, then a prognostic index 
would have been created, as described in Chapter 6 above (subsection 6.6.8). However, 
as the model contained only two binary predictors, the study population was 
automatically divided into four groups (or three, if the two groups with a single risk 
factor were combined), without creating a prognostic index. In order to assess the level 
of separation between predictors, Kaplan-Meier plots were produced for each outcome 




(a) ICH: by mode of clinical presentation and CCM location (Model A) 
 
(b) ICH: by risk factor (Model B) 
 
ICH/FND presentation, brainstem location 
ICH/FND presentation, other location 
Other presentation, brainstem location 
Other presentation, other location 
Two risk factors 
One risk factor 
No risk factors 
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(c) Clinical event: by mode of clinical presentation and CCM location (Model A) 
 
(d) Clinical event: by risk factor (Model B) 
 
Figure 8.19 Test of the proportional hazards assumption, using log minus log plots, 
for intracranial haemorrhage (a) by presentation and location and (b) risk factor, 
and for clinical event (ICH or FND) by presentation and location and (d) risk factor 
ICH/FND presentation, brainstem location 
Other presentation, brainstem location 
 
Other presentation, other location 
ICH/FND presentation, other location 
 
Two risk factors 
One risk factor 




For this model, a Kaplan-Meier plot was produced for each outcome (ICH or clinical 
event), stratified by the four levels: (i) other presentation and other CCM location 
(baseline reference group), (ii) other presentation and brainstem location, (iii) 
ICH/FND presentation and other location, and (iv) ICH/FND presentation and 
brainstem location (see Figures 8.20 and 8.21). As can be observed, for each outcome 
there are clear differences in the risk of progression to an ICH (clinical event) among 
the four groups, and those with the two risk factors have a statistically significant 
higher risk than those with a single or no risk factor (ICH only, log-rank test: χ2(1) = 
79, p < 0.0001; ICH or FND, log-rank test: χ2(1)  = 114, p < 0.0001).  
There is a wide gap between those with the worst prognosis (a brainstem CCM and 
ICH or FND presentation) and the next-worse prognosis group (ICH or FND 
presentation with a lesion in a different location) for both outcomes, but in the Kaplan-
Meier plot for composite outcome, the survival curves for those who present with an 
ICH/FND, with a lesion in another location, and those with a brainstem CCM and 
incidental or seizure presentation are quite close and cross over twice. This latter fact 
adds weight to the proposition to create a model with three levels – no risk factors, one 
or two risk factors – as developed in model B.  
For each risk group, the Kaplan-Meier estimated risk of a first ICH (clinical event) 
within five years of diagnosis, together with 95% confidence intervals, is presented in 
Figure 8.22. The estimates for each outcome for the baseline group, represented in 
black, are ranged to the left of the figure, with values between 0% and 6%; estimates 
for the group who have both risk factors (shown in red) are situated to the right of the 
figure, reflecting the increased risk of a haemorrhage (clinical event). 
The Kaplan-Meier estimated risk of haemorrhage within five years of diagnosis for 
those in the Paris cohort who have a brainstem lesion and present incidentally or with 
a seizure is greater than for those in the same cohort who have both risk factors, but 
the confidence intervals for the former estimate are so large that that point estimate is 
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 Number of adults at risk (number of ICH in preceding year):   
 ICH/FND, brainstem 173 125(21) 101(8) 82(3) 65(4)   57(0)   
 ICH/FND, other location 198 156(4) 132(3) 106(4) 89(1)   69(2)   
 Other presentation, brainstem   51   45(0)   36(1)   32(0) 27(1)   15(0)   
 Other presentation, other 
location 
566 494(1) 424(5) 365(3) 296(1)  256(0)   
Legend 
A  ICH/FND presentation, brainstem location 
B  ICH/FND presentation, other location 
C  Other presentation, brainstem location 





y = 0, reference 
Logrank test (Mantel-Cox) χ2(1) = 79.1, p < 0.0001 
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 Number of adults at risk (number of ICH in preceding year):   
 ICH/FND, brainstem 113 86(20) 66(13) 48(6) 31(8) 27(1)   
 ICH/FND, other location 141 115(8) 97(6) 78(7) 63(0) 49(3)   
 Other presentation, brainstem   31 28(2) 24(0) 20(1) 16(1) 9(1)   
 
Other presentation, other 
location 
355 326(5) 283(4) 241(1) 192(0) 163(1)   
Legend 
A  ICH/FND presentation, brainstem location 
B  ICH/FND presentation, other location 
C  Other presentation, brainstem location 





y = 0, reference 
Logrank test (Mantel-Cox) χ2(1) = 113.9, p < 0.0001 
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0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No risk factors 95% confidence interval
One risk factor - brainstem 95% confidence interval
One risk factor - ICH/FND presentation 95% confidence interval
Two risk factors 95% confidence interval
Legend
 






0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100%
No risk factors 95% confidence interval
One risk factor - brainstem 95% confidence interval
One risk factor - ICH/FND presentation 95% confidence interval
Two risk factors 95% confidence interval
Legend
 
(B) Estimated risk of first ICH or FND in five-year follow-up
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rendered meaningless. However, the Paris cohort is different to the other cohorts: it is 
much smaller; there are comparatively fewer haemorrhages in follow-up; and a greater 
percentage of adults harbour multiple lesions, as the hospital specializes in the familial 
form of the disease. 
 
Model B 
Again, Kaplan-Meier plots were used to investigate the degree of separation between 
the three groups – no risk factors, one or two risk factors – for each outcome, and the 
survival curves are displayed in Figures 8.23 and 8.24. Progression to first ICH 
(clinical event) is very different, depending on how many risk factors are present, and 
the log-rank test is statistically significant for both outcomes (intracranial 
haemorrhage: χ2(1) = 85, p < 0.0001; clinical event: χ2(1) = 124, p < 0.0001). For the 
composite outcome (ICH or FND, see Figure 8.24), the three curves are slightly more 
evenly spaced than for the single outcome (ICH, Figure 8.23), although the distance 
between the curves for none and one risk factor is smaller than that between one and 
two risk factors. 
The Kaplan-Meier estimated risk of a first haemorrhage (clinical event) in five-year 
follow-up is presented in Figure 8.25; apart from the Paris cohort, the separation into 
three groups is very good, especially for the composite outcome. 
 
 




  Number of adults at risk (number of ICH in preceding year):   
  Two risk factors 173 125(21) 101(8) 82(3) 65(4) 57(0)   
  One risk factor 249 201(4) 168(4) 138(4) 116(2) 84(2)   
  No risk factors 566 494(1) 424(5) 365(3) 296(1) 256(0)   
           
Figure 8.23 Kaplan-Meier plot of estimated risk of ICH within five years of diagnosis, stratified by risk factors  
Legend 
A  Two risk factors 
B  One risk factor 




y = 0, reference 





  Number of adults at risk (number of ICH or FND in preceding year):   
  Two risk factors 113   86(20)   66(13)   48(6)   31(8)   27(1)   
  One risk factor 172 143(10) 121(6)   98(8)   79(1)   58(4)   
  No risk factors 355 326(5) 283(4) 241(1) 192(0) 163(1)   
           
Figure 8.24 Kaplan-Meier plot of estimated risk of ICH or FND within five years of diagnosis, stratified by risk factors 
Legend 
A  Two risk factors 
B  One risk factor 




y = 0, reference 
Logrank test (Mantel-Cox) χ2(1) = 124.0, p < 0.0001 
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0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No risk factors 95% confidence interval
One risk factor 95% confidence interval
Two risk factors 95% confidence interval
Legend
 






0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No risk factors 95% confidence interval
One risk factor 95% confidence interval
Two risk factors 95% confidence interval
Legend
 
(B) Estimated risk of first ICH or FND in five-year follow-up
246 
 
8.9 Subsidiary analysis 
 
In the analysis of the effect of sex on the recurrence of an intracranial haemorrhage 
within five years of CCM diagnosis, 262 adults from the five cohorts either presented 
with a haemorrhage (n = 238, 91%) or suffered one within five years of diagnosis 
(twelve adults presented with an FND, six with a seizure and six incidentally). Of 
these, 44 participants (17%) – 23 women (15%) and 21 men (19%) – had a recurrent 
haemorrhage within five years of diagnosis.  
A comparison of the baseline characteristics of those who experienced a recurrent 
haemorrhage within five years of diagnosis and those who suffered a single 
haemorrhage, either at diagnosis or within five-year follow-up, is presented in columns 
2–6 of  Table 8.20. All the characteristics have a similar distribution in the two groups, 
with the exception of CCM location: 68% of those who have a recurrent ICH have a 
brainstem lesion, whereas only 39% have a brainstem lesion in the group who do not 
experience a recurrence within five years of diagnosis. 
A Kaplan-Meier plot showing time to recurrent haemorrhage, stratified by sex, is 
displayed in Figure 8.26(a); there was no statistically significant difference in the risk 
of haemorrhage between the two sexes (log-rank test χ2(1) = 0.91, p = 0.34). 
Similarly, in the three cohorts where focal neurological deficits in follow-up were 
recorded, 272 adults either presented with an intracranial haemorrhage or a focal 
neurological deficit (n = 256, 94%) or experienced an event within five years of CCM 
diagnosis (11 presented incidentally and five with a seizure). In this analysis, 76 adults 
(28%) suffered a recurrent ICH or FND within five years of diagnosis: 31 men (26%) 
and 45 women (29%). The baseline characteristics of those who suffered a recurrent 
ICH or FND and those who did not are compared in columns 7–11 of Table 8.20. 
Again, there is a similar distribution within the two groups with the exception of CCM 
location: 65% of those who experience a recurrence have a brainstem lesion, compared 
to 36% of those who do not.  
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In the stratified Kaplan-Meier survival plot for time to recurrent clinical event, the 
estimated risk of an event in five-year follow-up did not differ significantly between 
men and women (log-rank test, χ2(1) = 0.08, p = 0.77; see Figure 8.26(b)). 
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Table 8.20 Baseline characteristics of adults who have experienced an ICH (ICH or FND), stratified by recurrence 
 Recurrent ICH, five cohorts  Recurrent ICH or FND, three cohorts 
Recurrence 
n        %    
No recurrence 
n        %    
Total Recurrence 
n        %    
No recurrence 
n        %    
Total 
Age at diagnosis (median, 
IQR) 
42 33-50 40 30–53 40, 31–53 41 34-51 43 33–57 43, 34–55 
Sex           
    Male 21 48%   89 41% 110 31 41% 87 44% 118 
    Female 23 52% 129 59% 152 45 59% 109 56% 154 
Mode of clinical presentation           
    Incidental   1 2%    5 2%   6   4   5%   7   4% 11 
    Seizure   1 2%    5 2%   6   0   0%   5   3%     5 
    ICH 38 86% 200 92% 238 43 57% 121 62% 164 
    FND   4 9%     8 4%  12 29 38% 63 32%   92 
CCM location           
    Brainstem 30 68%  85 39% 115 49 65% 70 36% 119 
    Other location 14 32% 133 61% 147 27 36% 126 64% 153 
CCM multiplicity           
    Single 32 73% 168 77% 200 63 83% 146 75% 209 
    Multiple 12 27%   50 23%   62 13 17%   50 26%   63  
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 Number of adults at risk (number of ICH in preceding year) 
 Female  152 113(9) 93(7) 74(4) 59(2) 47(1)  
 Male 110   83(11) 63(3) 45(4) 33(1) 29(2)  
         
 
 Number of adults at risk (number of ICH/FND in preceding year) 
 Female  154 122(16) 102(13) 82(8) 63(6) 51(2)  
 Male 118   95(13)  75(7) 55(6) 41(3) 33(2)  
         
Figure 8.26 Kaplan-Meier plots comparing estimated risk of recurrent (a) ICH or (b) 





Logrank test (Mantel-Cox) χ2(1) = 0.91, p  = 0.34 
 












Chapter 9: Discussion 
 
9.1 Prognostic model 
 
9.1.1 Model  A or B? 
In this study, two risk factors have been identified that are associated with an increase 
in an adult’s likelihood of experiencing an intracranial haemorrhage (or clinical event) 
within five years of diagnosis, assuming no interventional treatment has occurred: ICH 
or FND presentation (versus other presentation) and brainstem CCM location (versus 
other location). Conversely, the three putative risk factors – age, sex and CCM 
multiplicity – do not appear to add any statistically significant prognostic information 
to the model.  
In the previous chapter (section 8.8), two versions of a prognostic model that was fitted 
to the data were described. Model A had four levels: (i) baseline, no risk factors (i.e. 
other presentation and other location); (ii) other presentation, brainstem location; (iii) 
ICH/FND presentation, other location; and (iv) ICH/FND presentation, brainstem 
location. In Model B, levels (ii) and (iii) were combined to form the following levels: 
(a) no risk factor; (b) one risk factor; and (c) two risk factors.  
The motivation for creating a prognostic model is to stratify the risk of an intracranial 
haemorrhage (clinical event) within five years of diagnosis for adults who have not 
received interventional treatment for their cerebral cavernous malformation. In Figures 
8.20–8.21 (Model A) and 8.23–8.24 (Model B), Kaplan-Meier plots were examined to 
assess the ability of each model to discriminate between the various risk groups. 
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Although these plots illustrate the fact that adults who possess both risk factors have a 
considerably greater risk of experiencing either outcome, the four-level model 
discriminates less well between adults in the other three groups. (Note that in Table 
8.16 above, the 95% confidence intervals for the estimated five-year risk overlap in 
the groups who have no or one risk factor, for both outcome events.) In contrast, there 
is a good level of separation between the three trajectories in Model B, demonstrating 
a very different prognosis for each risk group (see also Table 8.17). 
This difficulty in achieving robust estimates in the four-level model arises because, in 
the five-cohort analysis of time to ICH, there are only two (out of 62) outcome events 
in one category (those who present incidentally or with a seizure, but have a brainstem 
lesion). In Model B, an assumption has been made that adults who have a single risk 
factor – whether ICH/FND presentation or brainstem CCM – have the same risk of 
progressing to a haemorrhage or clinical event. If clinicians are able to accept this 
assumption – even though, from a clinical view, an adult with a brainstem CCM 
presenting with a seizure or incidentally is very different to an adult with a CCM in 
another (i.e. non-brainstem) location presenting initially with an ICH or FND – then 
Model B would be the better model to adopt, since it provides more robust estimates, 
because each category has an adequate number of outcome events with which to 
estimate the risk.  
When the composition of the other presentation / brainstem location group was 
examined more closely, it was discovered that the group consists of 51 adults (5.2%), 
two of whom suffered a haemorrhage within five years of diagnosis. However, both 
these adults were in the Parisian cohort, the composition of which differs from the 
other four cohorts (see sections 8.7 above and 9.2.1 below). This provides further 
evidence that Model B should be adopted, since the estimated risk of ICH would be 
zero, if the Parisian cohort were to be excluded from the study, as there would be no 
outcome events in the other presentation / brainstem location group. 
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9.1.2 Uses of the model 
As was apparent in Figures 8.23 and 8.24, Model B provides a good level of separation 
for the three risk groups, and results for this model were presented in Table 8.17. The 
estimated risk of an intracranial haemorrhage within five years of diagnosis, with no 
interventional treatment, can be stratified thus: 
 no risk factors   2.4% (95% CI 0.9 to 3.8)  
 one risk factor   9.5% (95% CI 4.9 to 14.1) 
 two risk factors  25.7% (95% CI 18.3 to 33.2) 
With model B, the 95% confidence intervals for the point estimate (five-year risk) for 
each risk group do not overlap, demonstrating a complete separation of risk groups; 
this is also true for the clinical event analysis (see Table 8.17).  
The likelihood ratio statistic (LR) was used to test the predictive ability of each of 
Models A (the four-group model) and B (the risk-factor model) (using the −2 log 
likelihood, 𝐿𝐿1 ) against the null model (with no predictors, and the −2 log likelihood, 
𝐿𝐿0 ), where 
𝐿𝑅 = −2(𝐿𝐿0 − 𝐿𝐿1). 
The −2 log likelihood, 𝐿𝐿0 value for the null model was 820.93 and the −2 log 
likelihood, 𝐿𝐿1  for models A and B was 748.50 and 749.22 respectively. Therefore 
the likelihood ratio statistics for Models A and B were equal to 72.43 and 71.71, each 
with two degrees of freedom (as there were two covariates in Model A and three levels 
of risk factor in Model B). However, Model B is not nested within Model A, so the 
likelihood ratio test cannot be used (Harrell et al., 1984, Machin et al., 2006). There is 
no significant difference between the fit of the two models (although both are an 
improvement on the null model), but Model B is preferred because it is the simpler 
model and demonstrates a slightly better separation of the risk groups. 
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A major advantage of model B is its simplicity, which is of benefit to both the clinician 
and the patient. For the clinician, the model can be used as an adjunct in describing the 
prognosis to patients at the time of diagnosis of cerebral cavernous malformation, if 
the lesion is conservatively managed. More importantly, for the patient, the results of 
the model are easy to understand and may help to give them some sense of perspective 
about their disease and its prognosis. Information is available at the time of diagnosis 
about an estimated risk of haemorrhage (or clinical event) occurring within five years 
of diagnosis, if the lesion is conservatively managed, given the presence or absence of 
the two risk factors. However, it must be borne in mind that the model relates only to 
the risk of a haemorrhage or focal neurological deficit in untreated follow-up; the risk 
of epileptic seizures, which can also be very debilitating, is not included in this model. 
In addition to providing the patient with more information about the likely progression 
of the disease, the result of this study may influence the decision of how the disease 
should be managed (see subsection below). For a patient with a lesion located in the 
lobar area of the brain who presents incidentally (i.e. a patient in the reference group 
who has no risk factors), the estimated risk of a haemorrhage or focal neurological 
deficit within five years is sufficiently low that a decision to undergo interventional 
treatment would be an unlikely choice of management, given the risks that are related 
to brain surgery, unless the patient suffered intractable epilepsy. However, if the 
patient has a brainstem lesion and presented with a haemorrhage (i.e. has both risk 
factors), then the increased risk of a subsequent haemorrhage or focal neurological 
deficit within five years, compared to the baseline risk, may be sufficient to render the 
prospect of neurosurgery, with its various associated risks, less unappealing, especially 
as several researchers have emphasized the risk of permanent neurological deficit after 
two or more bleeds (Aiba et al., 1995, Porter et al., 1999, Kuker and Forsting, 2008, 
Recinos et al., 2011). 
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Adults treated during follow-up 
During the five-year follow-up period, 107 adults (10.8%) were censored at the time 
of interventional treatment, before they had experienced either outcome, as was 
described in section 8.3 above. In Table 9.1, these adults are examined, according to 
their risk group and initial mode of clinical presentation. Although over 50% of those 
who were treated are in the low-risk group (i.e. no risk factors), 47 adults presented 
with a seizure and thus were more likely to be undergoing surgical excision as a result 
of intractable epilepsy. Only eight adults who presented incidentally (1.4% of those 
who had neither risk factor) were censored for treatment. By contrast, 19 adults who 
possessed both risk factors (11.0% of this high-risk group) were censored for 
treatment.   
  
Table 9.1 Adults censored for treatment, stratified by risk group 
Risk groups 
Risk group 














One risk factor 249 25.2% 33 13.3%   
Brainstem 
location 
 51 5.2%  1  2.0% 
Incidental  1 
ICH/FND 
presentation 










n Number of adults in five-cohort study (n = 988). 
nR Number of adults in each risk group. 




9.2 The study 
 
9.2.1 Strengths 
Three main strengths are associated with this study: the size of the cohort, the length 
of follow-up, and the consistency of the results across studies. To my knowledge, this 
is the largest collaborative study to explore the risk of intracranial haemorrhage 
(clinical event) in newly diagnosed adults who have not received interventional 
treatment for their cavernous malformation.  
 
Study size 
To have sufficient power for the potential inclusion of the five putative predictors in a 
prognostic model, sixty outcome events (haemorrhages) were required, as age is 
analysed as a categorical variable (Concato et al., 1995, Peduzzi et al., 1995, Harrell 
et al., 1996). Fortunately for the patient, however (if not the statistician), outcome 
events are not particularly common for adults with this condition.  In the five cohorts 
included in this study, 62 outcome events (ICH) were observed; the percentage of 
adults who experienced a haemorrhage in the five-year follow-up period varied 
between 4.4% (the later Scottish cohort) and 7.5% (Mayo Clinic). In addition, although 
cerebral cavernous malformation does not qualify as a rare disease, it is not particularly 
common: the annual population-based first-CCM detection rates in Scotland between 
1999 and 2003 (2006 and 2010) were 0.69 (0.78) per 100,000 adults. Therefore to 
achieve the requisite number of outcome events within a reasonable time-period, a 
collaborative study was required, with the inevitable differences in patient population 
and study protocol that would ensue.   
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Consistency of results across studies 
As a consequence of the potential for clinical heterogeneity among the different patient 
populations, random-effects meta-analyses were undertaken. This method of meta-
analysis has an additional source of uncertainty compared with the fixed-effect 
method, and this uncertainty is reflected in the fact that the confidence intervals are 
wider for random-effects than fixed-effect meta-analysis. In reality, there was no 
statistically significant heterogeneity between the cohorts, and this was particularly the 
case if the Paris cohort was excluded (for example, compare Figures 8.14 and 8.15). 
In sensitivity analyses, the results of the meta-analyses were compared with the results 
obtained when the pooled cohort was stratified by ‘study’; the smaller the amount of 
heterogeneity existing between cohorts, the closer the confidence interval in the meta-
analysis was to that in the stratified cohort.  
Despite the fact that all the cohorts were from observational studies rather than trials, 
and thus there were potential differences in the patient populations, there was a high 
level of consistency in the results: namely, a brainstem location was found to be a 
statistically significant risk factor in all five cohorts, and ICH or FND presentation was 
statistically significant in the four larger cohorts. The hazard ratios for the effect of 
lesion location on occurrence of haemorrhage ranged from 3.7 (95% CI 1.6 to 8.9) 
(Mayo Clinic) to 41.0 (95% CI 4.9 to 342.3) (the later Scottish cohort) (see Figure 
8.16), and hazard ratios for presentation ranged from 0.8 (95% CI 0.1 to 7.5) (Paris) to 
25.6 (95% CI 3.5 to 190.0) (Toronto) (Figure 8.14). As was demonstrated in section 
8.7 above, however, the smaller cohort from Paris contained a larger proportion of 
adults with the familial form of the disease, because the French National Reference 
Centre for Rare Neurovascular Diseases of the Eye and Brain is located at Hôpital 
Lariboisière, whereas the other cohorts comprised mostly adults with the sporadic 
form. Thus if the Paris cohort were excluded on grounds of its small size and highly 
selected status, the range of hazard ratios for the effect of presentation on occurrence 
of haemorrhage became 6.4 (95% CI 2.3 to 17.6) (Mayo Clinic) to 25.6 (95% CI 3.5 
to 190.0) (Toronto) (Figure 8.15).  
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Although the two core predictors were statistically significant in the majority of the 
individual-cohort analyses, it was only by pooling the data into a large single cohort 
that a more precise estimate of the effect of these two risk factors could be achieved 
for each outcome event in the pooled cohort. For example, the pooled estimate for the 
effect of location on occurrence of haemorrhage was 5.7 (95% confidence interval 3.2 
to 10.3); the equivalent estimate for presentation was 7.4 (95% CI 2.9 to 19.2), and if 
the hazard ratio is based on the four larger cohorts, the pooled estimate is 9.2 (95% CI 
4.4 to 19.3). 
 
Length of follow-up 
Another strength of this study is the length of follow-up. Among the five pooled 
cohorts the median length of follow-up was 3.9 years (interquartile range 1.5–5.0 
years). Although the target of five years was not achieved, 50% of the patients 
contributed almost four years’ follow-up, during which period the majority of 
haemorrhages and focal neurological deficits are likely to occur.  
The decision to truncate follow-up at five years was taken for several reasons. 
Primarily, the follow-up period for a study of this nature needs to be sufficiently long 
to enable outcome events to occur; however, the results of previous studies have 
suggested that after a certain period of time, the risk of a first intracranial haemorrhage 
or focal neurological deficit decreases (Al-Shahi Salman et al., 2012). In addition, five 
years’ follow-up seemed potentially to be a length of time that most studies could 
achieve. Even in the second Scottish cohort, where recruitment ended on 31 December 
2010 and therefore five years’ follow-up for everyone in the study was not possible, 
the  median length of follow-up was 3.9 years (interquartile range 2.9–5.0 years), 
which compared favourably with two of the other cohorts. A third reason motivating 
five-year truncation was a desire to encourage a standardized length of follow-up for 
future studies, to enable inter-study comparison.  
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External validity 
The fact that this study is a collaboration of four research groups from four different 
countries is important, since this will increase the external validity of the result. Two 
of the cohorts were population-based, representing all known instances of a first CCM 
diagnosis in a single country within two five-year periods. In contrast, the other three 
studies were hospital-based: Toronto Western Hospital is a tertiary neurosurgical 
referral centre, which might be expected to see a disproportionately large number of 
more severe cases. Research groups at Hôpital Lariboisière in Paris specialize in rare 
vascular diseases of the brain and are involved with much research into the genetic 
aspects of the disease; this is reflected in the composition of the Parisian cohort, since 
this cohort includes a larger percentage of adults with multiple cavernous 
malformations (a feature of the genetic form of the disease). The Mayo Clinic is a 
tertiary-care referral centre that attracts patients from all over the world, in addition to 
those who live in the immediate geographical vicinity of its Minnesota location. 
Despite these different backgrounds, the five cohorts were broadly similar at baseline 
(see Tables 8.1 and 8.2 above), the level of heterogeneity was small, and there was a 
very high level of consistency across the results.   
 
9.2.2 Limitations 
There are, however, limitations to this study. First, there appears to be a lack of similar 
cohorts, and in particular prospective population-based studies. It was difficult to 
identify other research groups who had collected data in a similar manner, and who 
were willing to collaborate. Several groups who had published their results in the 
1990s, at a time when the use of MRI was becoming more widespread and 
consequently the detection of CCMs more frequent, were contacted and invited to join 
this collaboration. Unfortunately, however, as described in section 7.1 above, a number 
of these groups had since disbanded or the data were no longer available. 
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Because of the challenges relating to the recruitment of studies to collaborate in this 
individual patient data meta-analysis, it was not possible to split the dataset into two 
groups, and use one to develop the model and the other to validate it. Therefore before 
the model can be used in clinical practice, it should be validated on a different dataset. 
Another limitation is the paucity of data concerning the occurrence of focal 
neurological deficit in follow-up. Only three cohorts were able to contribute data for 
this outcome, which is unfortunate because the effects of an FND can be as devastating 
to the patient and family as those of an ICH. However, this is a common consequence 
of using secondary data, since the data have originally been collected for specific, but 
frequently different purposes. Nevertheless, the situation contributed to a tension in 
the study embodied in the following analysis dilemma: on the one hand, there were 
more cohorts, but with fewer outcome events (haemorrhages) available for analysis, 
whereas on the other hand, fewer cohorts contributed data, but more outcome events 
(ICH or FND) could be included in the analysis. 
 
Informative censoring 
As discussed in Chapter 8 above (section 8.3), 107 participants (10.8%) underwent 
treatment within five years of diagnosis and before a potential haemorrhage occurred, 
and thus are at risk of informative censoring.  However, as shown in Table 9.2, at least 
51 adults (47.7%) received interventional treatment as a result of intractable epilepsy, 
and were perhaps less at risk of experiencing a haemorrhage if they had been 
conservatively managed throughout the entire follow-up period.  
As illustrated in Table 8.3, the 47 participants (4.8%) who presented with an ICH or 
FND, and in addition had less than two years of follow-up, are at greatest risk of 
informative censoring. However, when the baseline characteristics of those adults who 
were treated during follow-up, and before an event could occur (n = 107), were 
compared with the remainder of the study (n = 881) (see Table 8.4), the treated group 
were significantly younger (median age 37.5 years versus 45.2 years respectively, 
Mann Whitney test, p < 0.0001); in addition, they were more likely to present with an 
ICH or FND (48% versus 36%) or seizure (44% versus 22%) (χ2(2) = 49.4, p < 0.0001).   
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Mayo Clinic 56 35 13 8 
Toronto 16   2   7 7 
Paris   4   2  – 2 
Scotland, 1999–2003 19   8   6 5 
Scotland, 2006–2010 12   4   7 1 
     
Total 107 51 33 23 
 
 
The median length of follow-up in the treated group was also very much shorter: 0.3 
years compared with 4.4 years in the conservatively managed group (Mann Whitney 
test, p < 0.0001). The two groups were similar with regard to sex ratio, lesion location 
and multiplicity. 
 
9.2.3 Difficulties encountered when undertaking an individual 
patient data meta-analysis 
Liaising with different study groups 
Several challenges are encountered when undertaking an individual patient data meta-
analysis, and the researcher must balance the requirement, on the one hand, of 
producing the meta-analysis within as short a time-period as is feasible, with the 
difficulties of trying to include the maximum number of studies, on the other. For 
example, a mean time of about 16 months elapsed between informal discussions about 
participating in the project to receipt of the datafile. 
In an ideal situation, the project should be planned as a prospective study, with each 
research group following the same protocol, similar to a multi-centre trial. 
Unfortunately, however, this is an unrealistic scenario, especially for a study that is 
examining the clinical course of an uncommon disease, since the time required to 
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undertake such a study could be of the order of fifteen years and it would be 
prohibitively expensive. Therefore the researcher is forced to compromise and 
undertake a retrospective study, often using data that have been collected for a different 
purpose; as a consequence, this can restrict the scope of the project. Examples of this 
problem are the fact that focal neurological deficits were only recorded in three of the 
five cohorts, and the date of death was unavailable in another study. 
It can be challenging and time-consuming for the coordinator of a meta-analysis to 
make sense of datasets from other research groups. In this study, for example, it was 
essential that definitions of intracranial haemorrhage and inception were the same 
among the studies to ensure that the same outcomes were being analysed. Fortunately, 
as a result of previous conflicting definitions of ICH and FND, a scientific workshop 
of the Angioma Alliance had been devoted to developing a consensus statement on the 
clinical and imaging features of CCM haemorrhage, and this subsequent definition and 
reporting guidelines were published in Stroke in 2008 (Al-Shahi Salman et al., 2008). 
The four studies in this meta-analysis all adhered to this definition.  
Inevitably, a large amount of the researcher’s time is spent liaising with different 
groups to clarify issues arising from the data, some of which will not be possible to 
resolve since the original researchers may no longer be working in the field or available 
to respond to queries, if several years or even decades have elapsed between the study 
being conceived and their data being used for a secondary purpose.  
 
9.2.4 Other issues 
Age of data and neuro-imaging availability 
The date of diagnosis for patients in the five cohorts in this study range over a period 
in excess of twenty years, from 1984 to 2011; about 50% were diagnosed before 2000. 
The patients in the two largest cohorts were diagnosed earlier, between 1984 and 1998 
(Mayo Clinic, n = 267) and between 1987 and 2007 (Toronto, n = 345).  
Although there has been a huge development in magnetic resonance imaging (MRI) 
techniques during this period, even in 1982–83 T1-weighted and T2-weighted spin-
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echo sequences were available for use in the detection of cavernous malformations. 
T2 imaging sequences were used by Mayo Clinic (Kelly Flemming, personal 
communication). T2-weighted gradient-echo imaging (T2*GRE) is now considered to 
be the gold standard imaging sequence for detecting cavernous malformations, 
especially tiny lesions (Campbell et al., 2010, Lin and Abdalla, 2011), as it has 
increased sensitivity to haemorrhagic by-products. However, the length of time that 
has elapsed between the first patients in this study receiving a CCM diagnosis and the 
present day may not have had such a detrimental effect as might perhaps be envisaged. 
Nevertheless, it is possible that the neuro-imaging modalities available in the first 
years of this study were not sufficiently sensitive to detect an asymptomatic 
haemorrhage occurring during follow-up, which would be routinely detected if it were 
scanned now. 
 
Age as a predictor 
As described in Chapters 6 and 8 above, the original intention had been to treat age as 
a continuous variable, to avoid unnecessary loss of information, power and precision 
(Royston et al., 2006). However, after testing the linearity assumption and discovering 
that it did not hold, it was necessary to treat age as a categorical variable.  
Initially, Kaplan-Meier plots were produced with age split into three equal-sized 
groups; when the categorization was adjusted to enable the split to occur at a whole 
number, the log-rank test changed from being just statistically significant (p = 0.048) 
to non-significant (p = 0.082) for the unstratified five-cohort pooled analysis. To check 
whether this was an artefact, age was split into four categories; when the Kaplan-Meier 
plot was examined, no ordering was observed between the age-splits.  
Univariate and multivariable analyses were undertaken twice, with age as both three- 
and four-category variables; in the meta-analysis age was treated as a continuous 
variable. However, regardless of whether it was treated as a categorical or continuous 




Potential bias arising from observational studies 
Unlike randomized controlled trials, observational studies are prone to bias and 
confounding (Hlatky et al., 1988, Byar, 1991, Riley et al., 2010). Nonetheless various 
methods were adopted in this meta-analysis to try to minimize potential problems of 
bias and confounding. First, pre-determined criteria for inclusion of studies, including 
minimum study size, patient eligibility, and definitions of inception and outcome 
events, were specified in the study protocol and statistical analysis plan.  
Although there were difficulties acquiring data from previously published studies, 
which could lead to retrieval bias, at the time of informal discussion at the beginning 
of this project, only one study included in this meta-analysis had been previously 
published; indeed most of the data subsequently received from this study referred to 
patients who were diagnosed after the original study had been published, and therefore 
were not included in the original study. Thus at the start of this project the results of 
individual studies were unknown, and even when three of the studies were later 
published, the methods of statistical analysis differed and comparisons of results could 
not be made.  
  
 




Chapter 10: Concluding comments and future 
directions 
 
10.1 Summary of results 
 
Cerebral cavernous malformation is a challenging condition to study because it is not 
particularly common; the annual detection rate of a first-ever CCM was about 0.7 or 
0.8 adults per 100,000 in Scotland in 2010. As a result of their angioarchitecture, 
CCMs are prone to bleed, and therefore an estimation of the risk of intracranial 
haemorrhage is of benefit to patients and clinicians alike. In this thesis, three 
investigations related to haemorrhage in follow-up have been conducted: the first two 
examined two cohorts of adults diagnosed with cerebral cavernous malformation that 
form part of the Scottish Intracranial Vascular Malformation Study (SIVMS), and the 
third is the five-cohort individual patient data meta-analysis.  
In the first analysis, the risk of an intracranial haemorrhage or focal neurological deficit 
during untreated follow-up was investigated in both Scottish cohorts; in the second, 
functional and clinical outcome was compared between treated and conservatively 
managed adults in the earlier cohort (because there was insufficient follow-up in the 
later cohort to enable the analysis to be performed). Finally, the risk of an ICH (or a 
clinical event – either an ICH or FND) in untreated follow-up for adults from five 
international cohorts was investigated, risk factors for ICH (clinical event) were 




10.1.1 Outcome events in Scottish cohorts 
In estimating the risk of an outcome event in the two Scottish cohorts (Chapter 4, (Al-
Shahi Salman et al., 2012)), the risk was separated into two components: (i) the risk of 
a first outcome event (either ICH due to CCM or the composite outcome of ICH or 
FND, due or possibly due to CCM), for adults who presented with a seizure or 
incidentally, and (ii) the risk of a recurrent event, for adults who had already 
experienced a first event, whether at presentation or earlier in the follow-up period. 
In each cohort, whether the outcome was intracranial haemorrhage definitely due to 
CCM or clinical event, due or possibly due to CCM, the risk of a recurrent outcome 
event was substantially greater than the risk of a first event: in the earlier cohort, the 
five-year risk of a recurrent haemorrhage was more than twelve times the five-year 
risk of a first bleed, and similarly the five-year risk of a recurrent clinical event was 
more than four times that of a first.  Evidence from the first cohort suggested that 
women had a substantially greater risk of an outcome event within five years of 
presentation; this appeared biologically plausible, but it was not confirmed when the 
data from the second cohort were analysed two years later.  
The level of dependency for adults from both cohorts who had experienced at least one 
ICH or FND was examined; the subgroups were divided into those who had suffered 
a single event and those who had suffered a recurrence. In each cohort, about 70% of 
adults who had suffered a single outcome event had a favourable outcome (OHS score 
0–1), compared with about 40–55% of those who had experienced at least two events. 
The strength of this investigation is that the study has been very carefully designed. It 
is a prospective population-based observational cohort study, which aimed to recruit 
all adults resident in Scotland, who had been diagnosed with a CCM that had been 
validated by MRI or by pathological examination within two five-year windows: 
between 1999 and 2003 (first cohort) and between 2006 and 2010 (second cohort). In 
addition to meticulous study design, data completeness for this analysis was very high. 
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Although the estimated risks are for the initial five years after presentation, in the first 
cohort follow-up was available for almost all participants for nine years. 
Despite these strengths, however, there are a number of limitations. Cerebral 
cavernous malformation is not a common disease, and therefore the number of people 
diagnosed with the condition was small (n = 141 and 166). Although it was possible 
to obtain an estimate for the risk of a first and a recurrent event, the precision of these 
estimates was poor. This was especially true for the recurrent risk, because the number 
of participants in each cohort who had experienced a first outcome – whether 
intracranial haemorrhage or clinical event – was very small, and consequently the 
number of outcome events (i.e. recurrent events) was even smaller.  
To overcome these limitations, the sample size was increased by collaborating with 
three other research groups and conducting an individual patient data meta-analysis 
(Chapters 6–9, and subsection 10.1.3 below). 
 
10.1.2 Comparison of outcome among treated and 
conservatively managed adults 
In Chapter 5, the effect of treatment on both functional and clinical outcome was 
investigated in the earlier Scottish cohort (Moultrie et al., 2014). Adults in this 
observational study who underwent microsurgical CCM excision had a greater risk of 
sustained poor functional outcome in the first five years of follow-up than those who 
were conservatively managed. In addition, participants whose CCM had been excised 
had over three times the hazard of progression to either a first symptomatic intracranial 
haemorrhage or a new focal neurological deficit compared with individuals who did 
not undergo interventional treatment. 
This analysis shares the same strengths with regard to meticulous study conduct as the 
first analysis; in addition, the fact that the treated group was being compared with a 
concurrent control group (conservative management) ensures that no temporal 
difference exists to influence the result. In this analysis, the limitation of comparatively 
few participants in each group is compounded by the fact that the study is an 
268 
observational design and the two groups were unbalanced at baseline (presentation). 
Statistical techniques – multivariable Cox regression – were used to adjust for baseline 
imbalances (age and mode of clinical presentation) and two other potential predictors 
(sex and brainstem location), but randomization of treatment allocation is the only 
effective method of ensuring that there is no systematic difference between the two 
groups before the treatment is started.  
 
10.1.3 Individual patient data meta-analysis 
In Chapters 6–9, an individual patient data meta-analysis is described, the aim of which 
was to improve the precision of previous estimated risks of ICH or clinical event in 
untreated follow-up and to identify prognostic factors. Almost one thousand adults 
from four different research centres were followed for five years, and two risk factors 
– ICH/FND presentation and brainstem location – were identified that are consistently 
associated with an increased likelihood of experiencing a haemorrhage or focal 
neurological deficit within five years of diagnosis. (In this analysis, date of diagnosis 
was taken as the inception point, whereas in the analysis of the two Scottish cohorts 
date of presentation was taken as inception.) 
The Kaplan-Meier estimated risk of experiencing a first ICH within five years of 
diagnosis was 8.1% (95% CI 6.1% to 10.1%), and a first ICH or FND was 17.0% (95% 
CI 13.6% to 20.3%). Upon identification of the two prognostic factors, the pooled 
cohort was divided into four subgroups: those who possessed neither risk factor (i.e. 
presented with a seizure or incidentally, with a CCM located outside the brainstem) 
formed the lowest-risk, reference group and those with a brainstem CCM who 
presented with an ICH or FND were the highest-risk group. Adults who possessed a 
single risk factor had a similar level of risk, so these two groups were pooled in the 
final model (Model B), which thus consisted of no, one or two risk factors. The hazard 
that an adult with a single risk factor will suffer an ICH (clinical event) within five 
years of diagnosis is four (six) times that of an adult with no risk factors (see Table 
10.1 (Table 8.17 from Chapter 8)). Similarly, the hazard for an adult with both risk 
factors is over fourteen times (eighteen times) that for an individual with none.
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n                % 









ICH only        
Two risk factors 173 18% 36 14.3 7.1 to 28.8 25.7% 18.3 to 33.2 
One risk factor 249 25% 16   4.0 1.8 to 8.7   9.5% 4.9 to 14.1 
No risk factors 566 57% 10   1.0    2.4% 0.9 to 3.8 
ICH or FND        
Two risk factors 113 18% 48 18.0 9.4 to 34.8 50.7% 40.1 to 61.4 
One risk factor 172 27% 29   6.1 3.1 to 12.2 22.3% 14.8 to 29.8 
No risk factors 355 56% 11   1.0  3.7% 1.5 to 5.9 
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To my knowledge, this study is the largest investigation of haemorrhage risk in adults 
diagnosed with cerebral cavernous malformation. Data from five cohorts in four 
countries were cleaned and pooled into a single datafile, to enable the results to be 
synthesized in a meta-analysis. In addition to the number of participants, other 
strengths of this meta-analysis include the harmonization of definitions of outcome 
events, a common inception point, the completeness of baseline characteristics, the 
length of follow-up (five years), the ability to perform the same statistical techniques 
on each dataset, and the consistency in the direction and magnitude of the results, for 
both outcome events. 
Limitations of the meta-analysis include the fact that not all of the eligible study groups 
initially identified and invited to collaborate were able to contribute data, as several 
had disbanded in the intervening years since publication of their results. Another 
weakness was that only three cohorts were able to supply data for focal neurological 
deficit; this was unfortunate because the effects of an FND can be equally as 
devastating to the patient as those of an ICH. However, this latter limitation is a 
consequence of using secondary data that were originally collected for a different 
purpose. 
 
10.2 Future directions 
 
As discussed in the previous section, the untreated clinical course of the disease has 
been explored both in two national cohorts and in a five-cohort meta-analysis. None 
the less, if further progress is to be made in the field, increased collaboration of 
research groups is needed so that a much larger dataset can be created. Following on 
from the current work, various directions that may be followed in the future are 
outlined below.  
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10.2.1 Validation of the prognostic model 
As mentioned in the discussion of the individual patient data meta-analysis (Chapter 
9), the prognostic model has not yet been validated. Although it is a very simple model, 
it has the advantage that both risk factors are available at time of diagnosis, and thus it 
has the potential to be used by clinicians at the appointment when the patient is given 
a CCM diagnosis. However, before it is used in clinical practice, it should be validated 
on an independent dataset (Altman and Royston, 2000).        
 
10.2.2 CCM register 
Although the following areas have not been discussed in this thesis, several pertinent 
clinical questions remain which have been tackled in the past with fairly small samples, 
but which would benefit from being addressed in a much larger population. Examples 
of such areas include whether antithrombotic therapy should be used with adults who 
have been diagnosed with a CCM, and the effect of pregnancy on women who have 
been diagnosed with a CCM. However, each question only affects a small proportion 
of the population diagnosed with a CCM; therefore an international register of people 
with a CCM diagnosis would be beneficial for answering some of these important 
questions that are of relevance to a substantial minority of individuals with CCM. 
 
10.2.3  Comparison of treatment: a future trial?   
In the analysis of treatment methods in Chapter 5, the problem of confounding by 
factors that were imbalanced at presentation and by two putative predictors was 
addressed to some extent by statistical methods. Nevertheless some bias will remain, 
since the allocation of patients to treatment group was determined by local clinicians, 
who were able to take various factors specific to each individual patient into 
consideration in an attempt to select what they considered to be the most appropriate 
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treatment choice, rather than by adults being randomly assigned to a treatment group, 
irrespective of their physical condition.  
Thus long-term follow-up is required for the comparison of the effect of treatment on 
clinical and functional outcome, since it is possible that the risk of a clinical event in 
the conservatively managed group will continue to increase over time, although, based 
on the analysis in Chapter 4, this seems less likely. Additionally, CCM have been 
known to re-grow after surgery, and therefore it is possible that a de novo lesion might 
re-bleed.  
Although there is a second Scottish cohort upon which the analysis of functional 
outcome among different treatment groups can be performed (and the results of this 
analysis can be compared to the earlier cohort), analysis of the later cohort will have 
the same major flaw as the first cohort – namely lack of randomization. In addition, if 
the same follow-up criteria are adhered to – a five-year window after presentation for 
interventional treatment to take place, and then five years for follow-up for those who 
underwent interventional treatment – analysis of the second cohort would not be 
possible until after 2020! 
The investigation in Chapter 5 paves the way for a randomized controlled trial (RCT). 
From a methodological perspective, a randomized controlled trial is required in the 
future to give a definitive answer to the question of the impact of intervention on the 
course of the disease. The random allocation of sufficient numbers of patients to each 
treatment strategy will ensure that potential confounding factors are equally distributed 
in the treatment groups. In addition, eligibility criteria can be pre-specified in the 
protocol so that participants who have, for example, multiple comorbidities, and are 
thus likely to have a poor outcome due to health problems other than CCM, can be 
excluded from recruitment to the trial.  
From a clinical point of view, there is a paucity of well-conducted studies comparing 
patient outcome after different methods of treatment (Recinos et al., 2011, von der 
Brelie and Schramm, 2011, Menon et al., 2011, Berg and Vay, 2011, Poorthuis et al., 
2013, Poorthuis et al., 2014). In particular, several studies report outcomes of treatment 
undertaken over fifteen years ago, which are probably outdated, since neuro-imaging 
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techniques and neuro-navigation have become more sophisticated, and neurosurgical, 
stereotactic radiosurgery methods and electrophysiological monitoring have 
developed in the intervening period.  
However, although a randomized controlled trial is the optimum study design, the 
omens for such a trial are not auspicious: a similar RCT was initiated among eight 
neurovascular research groups in North America, under the leadership of a 
neurological surgery research group at the University of Pittsburgh, several years ago, 
but was abandoned after a year, because no participants had been recruited (see 
Kondziolka and Lunsford’s response to Steiner  (Steiner et al., 2010)). Nevertheless 
recruitment to the abandoned trial was confined to patients with cavernous 
malformations in ‘high-risk’ locations, and to eight research centres in North America 
and Canada, and compared surgical resection with radiosurgery. A future trial would 
need to be more inclusive, both in terms of its patients and the geographical location 
of research centres. 
It is understandable that recruitment of participants to a treatment RCT would be 
challenging: although CCMs are not uncommon, recruitment would be restricted to 
participants where the clinician was in a genuine state of clinical equipoise and the 
patient was willing to be allocated to one of two or three (if stereotactic radiosurgery 
were included) treatments randomly. In practice, recruitment would be restricted to 
adults with at least one risk factor, since individuals with no risk factors would almost 
certainly be unwilling to risk the potentially harmful effects of surgery when their 
estimated risk of a future haemorrhage within five years of CCM diagnosis was 2.4% 
(95% CI 0.9% to 3.8%) (estimated five-year risk of clinical event: 3.7% (95% CI 1.5% 
to 5.9%)). However, widening the inclusion criteria to patients with a cerebral 
cavernous malformation in any location, and extending the invitation to participate to 
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Appendix A: Statistical Analysis Plan for 
Chapter 5 
 




I Baseline Characteristics 
 Total adults with CCM (n = 160) 
o probable/possible (n = 21) – Not_definite_CCM.xls 
o definite (n = 139) –  Definite_CCM_1_patient_row_prim_loc.sav 
 diagnosed at autopsy (n = 5) – include description in ‘Methods’ 
text, but not in tables, as they do not contribute to follow-up 
 surgery (n = 25) 
 conservatively managed (n = 109) 
 Predictors of interest – Baseline_characteristics.sav 
o Age at start of follow-up (or treatment)*† 
o Sex* 
o CCM: single or multiple 
o Location*†  
 symptomatic CCM; or  
 if asymptomatic and multiple including a brainstem 
CCM, then location = brainstem. 
Multivariate analysis will be brainstem vs other 
location. 
 Brainstem = PONS, MEDUL, MIDB (3) 
 Deep = CHOR, THAL, BGANG (2) 
 Cerebellum = CEREBE (1) 
 Lobar = all other (4) 
o Mode of clinical presentation*† 
 epileptic seizure (E) 
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 intracranial haemorrhage (ICH)(Al-Shahi Salman 
et al., 2008) 
 focal neurological deficit (FND)(Al-Shahi Salman 
et al., 2008): 
 non-haemorrhagic FND = NHFTR, NHFPE 
or NHFPR 
 FND not otherwise specified = FNDTR, 
FNDPE or FNDPR 
 incidental (A): 
  if patient was asymptomatic; or 
  if symptoms could not be attributed – 
definitely or possibly -  to the underlying 
CCM. 
Multivariate analysis will be ICH or FND at presentation vs A or E at presentation 
Where an individual who later has interventional treatment presents incidentally or 
with a seizure, but then experiences an ICH or FND due to the CCM or unknown 
cause in the period between presentation and intervention, the mode of clinical 
presentation will be recoded to the last clinical event experienced in untreated 
prospective follow-up and the date of presentation will be changed to the date of first 
clinical event (also, the CCM location may be recoded, if this is appropriate). 
 
*Pre-specified for adjustment of hazard ratios and multivariate analyses 
†May vary according to whether analyses are pre- or post-treatment for the treated group.  
 
 
II Completeness of follow-up 
 Entire cohort: from presentation date, all follow-up, until death of any cause 
or last available follow-up, analysed in February 2011: 
MH_CCM_1stCoh_Presentatn_Untx_Follup_8_outcomes_completeness.xlsx 
MH_CCM_1stCoh_Presentatn_Untx_Follup_8_outcomes_completeness.sav 
 Total = 1,177 person-years actual (of 1,216 potential person-years) 
 Using the Clark et al. method = 97% completeness 
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III Outcome Analyses 
 Included patients: definite CCM and alive at presentation date (n = 134), 
since the five adults who were diagnosed at autopsy do not contribute any 
follow-up (the latter will be described in the ‘Methods’ section, however) 
 
 Period at risk  
o ‘untreated follow-up’:  
 all available follow-up from date of first presentation until 
outcome event or censoring at 5 years for those adults who did not 
have an intervention; or 
 all available follow-up from date of first presentation until date of 
first intervention; and 
o ‘treated follow-up’: all available follow-up from date of first 
intervention until outcome event or censoring at 5 years after 
intervention. 
 
Censoring took place at the earliest occurrence of any of the following: 
death unrelated to CCM; last available follow-up; 5 years after initial 
presentation (conservatively managed group); or 5 years after first CCM 
intervention (treated group). 
 
 Treatment: CCM surgical excision/radiosurgery that was performed and 
treated the CCM. 
 
 Outcome event rates  
o Functional outcome: sustained deterioration, measured from the date 
of the first of two consecutive OHS scores of 2-6, occurring within 5 
years of the start of follow-up (after presentation for the conservatively 
managed group and after first intervention for the treated group) 
(Kaplan-Meier survival analysis and life tables)   
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o Events: first occurrence of ICH/FND/infarction due to CCM, unknown, 
or intervention after the start of follow-up 
 
 Univariate analyses  
o Baseline characteristics  
 Compare baseline characteristics, treated vs conservatively 
managed  
Use:  MH_CCM_1stCoh_134_Untx_Tx.sav (n = 134) 
o Functional outcome – primary outcome 
 Compare hazard ratio for functional outcome, treated (after 
intervention date) vs conservatively managed (after presentation) 
over 5 years 
Use: MH_CCM_1stCoh_134_Untx_Tx.sav (n = 134, OHS 
scores adjusted for treated adults) 
o Clinical events – explanatory secondary outcome measure 
 Describe untreated clinical course in the treated group – i.e. 
number of people who experience ICH or FND, due to CCM or 
unknown cause, before they receive interventional treatment 
(between presentation and intervention dates) 
Use: MH_CCM_1stCoh_post_pres_8_outcomes_25.sav (n = 25) 
 Compare hazard ratio for time to first clinical event (ICH, CI or 
FND, due to CCM, unknown cause or surgical procedure), treated 
group (after first  intervention) vs conservatively managed group 
(after presentation) over 5 years 
Use: 
MH_CCM_1stCoh_134_Untx_Pres_Treated_Post_Tx.sav 
(n = 134) 
 Describe deaths (and their causes) within 30 days of treatment 
Use: MH_CCM_1stCoh_134_Untx_Tx.sav (n = 134) +  
SAIVMS Live database 
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 Adjustment of hazard ratios: for primary and secondary outcomes, 
adjust by factors imbalanced at baseline (age and mode of presentation) and 
known to influence CCM prognosis (CCM primary location and sex) 
 
 Multivariate analyses: outcomes after presentation / intervention date, 
censored at 5 years (Cox proportional hazards, provided assumptions 
fulfilled) 
o We will examine each of the following predictors in the primary and 
secondary analyses, and the number entered will depend on the number 
of outcome events (10 events per variable), but they will be chosen in 
the following order: 
 age at presentation 
 mode of clinical presentation 
 CCM location 
 sex 
Use: MH_CCM_1stCoh_134_Untx_Tx.sav (n = 134) 





AL-SHAHI SALMAN, R., BERG, M.J., MORRISON, L., AWAD, I.A., on behalf of 
the Angioma Alliance Scientific Advisory Board. Haemorrhage from 
cavernous malformations of the brain: definition and reporting standards. 
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Appendix B: Summary Protocol for IPDMA 
 
Untreated Clinical Course of Cerebral Cavernous 
Malformations:   an individual patient data meta-analysis 
 
Margaret Horne1, Ronit Agid2, Kelly D. Flemming3, Robert D. Brown, Jr3,   
Teresa Christianson3, Karel G. terBrugge2,  Robert Willinsky2, I-Chang Su2, 
Christian Stapf5, Gordon Murray1 and Rustam Al-Shahi Salman4 
 
Institutions 
1Centre for Population Health Sciences, University of Edinburgh, UK 
2Division of Neuroradiology, Department of Medical Imaging, Toronto Western 
Hospital, Toronto, Ontario, Canada  
3Department of Neurology, Mayo Clinic, Rochester, MN, USA 
4Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University 
of Edinburgh, UK 
5 Acute Neurovascular Unit, Hôpital Lariboisière, Paris, France 
 
Research problem 
Publications from the Scottish Intracranial Vascular Malformation Study (SIVMS, 
www.saivms.scot.nhs.uk),1 the Mayo Clinic (www.mayoclinic.org/central-nervous-
system-vascular-malformations/),2 the Toronto Brain Vascular Malformations Study 
Group (http://brainavm.oci.utoronto.ca/)3 and others (Figure) constitute the best 
knowledge available about the prospective risks of intracranial haemorrhage and non-
haemorrhagic focal neurological deficits in patients with cerebral cavernous 
malformations (CCM). These papers also identify risk factors for symptomatic events. 
However, as pointed out in accompanying editorials,4, 5 there remain important 
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uncertainties regarding the natural history of people with untreated CCM. All 
published studies to date have been based on relatively small sample sizes, so that even 
when risk factors are identified consistently (e.g. the importance of a prior 
haemorrhage in determining the risk of a future haemorrhage), the magnitude of the 
effect has not been estimated with precision. For other putative risk factors (e.g. patient 
sex or the location of the CCM), the literature is inconsistent. 
We propose an individual patient data meta-analysis of the prognosis of untreated 
CCM to address these outstanding uncertainties. By pooling data from several large 
studies, we shall be able to quantify known risks with much greater precision and 
develop a consensus over putative risk factors. Ultimately we shall develop and 
evaluate/validate a prognostic model based on several covariates. Although not a 
specific aim of the first phase of this collaboration, the exercise of assembling the data 
from several cohorts will also allow us to assess whether it would be feasible to address 
some even more challenging questions, including the impact of pregnancy and 
antithrombotic drugs on the risk of clinical events, and to identify risk factors derived 
from imaging. 
Challenges 
The precise research questions which can be addressed will depend on many factors, 
including the variation in the design of the different constituent studies (for example, 
at what point in their clinical course patients were recruited into the study; whether 
follow-up time can be split as pre-treatment and post-treatment, where applicable; and 
what systems are in place for follow-up), and the types of events  (whether any 
symptomatic neurological events were recorded or only haemorrhagic events, and 
whether these events are confirmed by brain imaging). Equally, the statistical power 
of our analyses will be limited by the number of outcome events that can be included; 
this will also shape the research questions that can be addressed. 
Approach 
We plan, therefore, to adopt a two-step approach to the project. In a first exploratory 
phase, we shall identify collaborators, gather background information on the relevant 
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study designs and databases, and accumulate the data centrally. In the second phase, 
we shall refine the scientific protocol, based around the practical constraints of what 
research questions can be addressed, given the strengths and limitations of the 
assembled data, with the input of our collaborators. To avoid the perception that the 
analysis is ‘data driven’ we set out the primary and secondary objectives below, 
although we recognise that the detailed scientific protocol can only be finalised in the 
light of the results of the first phase of the work. 
The intention is to complete as much as is possible of the first phase in time to inform 
discussions at the first investigator meeting to be held in Edinburgh in September 2012, 





 Descriptive analysis of time-to-event outcomes. Outcomes during untreated 
follow-up will include intracranial haemorrhage (ICH), but also focal 
neurological deficit (FND) or a composite endpoint of ICH or FND, if the data 
have been recorded in such a way as to permit this. In addition, we will 
examine event rates over long periods of follow-up to ascertain whether the 
estimated risk remains constant, or whether it diminishes over several years.  
 Identification of risk factors. In most studies a prior ICH has been identified 
as a risk factor for a future ICH, but the magnitude of this effect is uncertain; 
sex, CCM location, and possibly age are the other putative risk factors, which 
we will examine if there is sufficient power (i.e. enough outcome events). 
 Building and evaluating a multivariate prognostic model. The model will be 
used to predict the probability of a future ICH (± FND, if the data are available) 
for an adult with CCM(s) during untreated follow-up. Pre-specified covariates 
300 
in the model will be chosen for clinical significance and will include prior 
ICH/FND, sex, CCM location and possibly age. 
 
Secondary Objective 
 Exploring potential for future work.  For example, what is the effect of 
pregnancy on the untreated course of the disease; what is the effect of 
antithrombotic therapy on adults with untreated CCM; does CCM size 
influence disease outcome; how does treatment (with neurosurgical excision 
or stereotactic radiosurgery) affect outcome? 
 
Methods 
Eligibility criteria for study cohorts 
 Each study should have a minimum sample size of 60 adults. 
 Period at risk should begin at either (i) first CCM diagnosis (‘date of 
diagnosis’), or (ii) symptoms leading to it (‘date of clinical presentation’), 
thereby enabling calculation of event risk (not retrospective ‘lifetime risk’) at 
standardised time-points in the disease course. 
 ICH should be included as an objective pre-defined clinical outcome.  
 Outcome events should be able to be quantified per patient during the follow-
up period. 
 
Eligibility criteria for patients within study cohorts 
 Adults who have received a first-ever CCM diagnosis.  
 Diagnosis validated either by brain MRI or pathological examination. 
 Patients to have some untreated follow-up time to contribute to the study. 
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Types of outcome measures 
Although ICH is the primary outcome measure in this study, it is important to include 
in our analysis, wherever possible, adults who suffer non-haemorrhagic FNDs – either 
as a separate outcome measure, or as a secondary composite endpoint. Both ICH and 
FND have a similar level of severity for the patient, and in certain circumstances an 
outcome labelled FND may, in reality, be an ICH, but not categorised as such, either 
because the appropriate neuro-imaging was not performed or because the imaging 
failed to detect any blood.6 
 
Analysis 
In this study, our sole interest is the untreated course of the disease: thus adults who 
have received some form of interventional treatment will contribute data to the survival 
analyses only until the date of first treatment, at which point their data will be censored. 
Data will be censored at the earliest occurrence of any of the following: death unrelated 
to CCM; treatment (whether surgery or stereotactic radiotherapy); last available 
follow-up. 
Fundamentally, we will perform analyses within studies and pool the results (e.g. an 
estimated hazard ratio or an estimated adjusted hazard ratio) using forest plots and 
random effects meta-analysis. 
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Figure 1 Risk of symptomatic intracranial haemorrhage during follow-up in studies of the untreated clinical course 
of > 20 participants with cerebral cavernous malformations 
 
 
0 10 20 30 40 50 60 70
Intracranial haemorrhage rate (%/year)
Study Selection criteria Sample size Mean follow-up (yrs)
First/recurrent intracranial haemorrhage not distinguished
First intracranial haemorrhage
Recurrent intracranial haemorrhage
Robinson et al. 1991 None 66 2∙2
Zabramski et al.  1994 Familial 21 2∙2
Porter  et al.  1997 None 110 3∙8
Moriarity et al.  1999 None 68 5∙2
Aiba et al.  1995 None 110 4∙7
Kondziolka et al.  1995 None 122 2∙8
Mathiesen et al.  2003 Brainstem and deep 34 4∙6
Ghannane et al.  2007 None 39 2∙5
Aiba et al.  1995 None 110 4∙7
Kondziolka et al.  1995 None 122 2∙8
Kim et al.  1997 None 62 1∙9
Barker et al.  2001 None 136 3∙8
Fritschi et al.  1994 Brainstem 139 2∙5
Porter et al.  1999 Brainstem 100 2∙0
Hasegawa et al.  2002 Brainstem 83 4∙3
Wang et al.  2003 Brainstem 137 1∙8
Mathiesen et al.  2003 Brainstem and deep 34 4∙6
Flemming et al.  2012 None 108 7∙3
Al-Shahi Salman et al.  2012 None 96 5∙0
Flemming et al.  2012 None 74 7∙3
Al-Shahi Salman et al.  2012 None 18 5∙0
Notes 
1. Areas of point estimates are proportional to the sample size 
of each study. 
2. Error bars represent 95% confidence intervals (if available or 
calculable). 
3. Listed studies are included in the References (1-2, 5-18). 
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Appendix C: Letter of invitation to join the 




DIVISION of CLINICAL NEUROSCIENCES 
University of Edinburgh 
Bramwell Dott Building 
Western General Hospital 
Crewe Rd 
Edinburgh EH4 2XU 
 
Fax                                                                                    
+44 131 332 5150 
Telephone                                                                         
+44 131 537 2915 
Email                                              Rustam.Al-Shahi@ed.ac.uk 
Web                   www.dcn.ed.ac.uk/pages/profiles/rustam.asp 
Skype                                                                   rustamatwork 
 
21 March 2012 
Dear  
Collaborative individual patient data meta-analysis of cerebral cavernous 
malformation prognosis 
I am writing in the hope that you will contribute to an individual patient data meta-
analysis of the prognosis of cerebral cavernous malformations (CCM). At present, this 
collaborative endeavour involves the Scottish Intracranial Vascular Malformation 
Study (SIVMS, a population-based cohort of ~300 adults with CCM),1 the Mayo 
Clinic (a hospital-based cohort of ~300 patients with CCM),2 and the Toronto Brain 
                                                 
1  Al-Shahi Salman R et al. Untreated clinical course of cerebral cavernous malformations: a prospective, 
population-based cohort study. Lancet Neurol 2012; 11: 217-224. 






Vascular Malformation Study Group (a hospital-based cohort of ~800 patients with 
CCM).3 Your work is one of sixteen published series that we have identified by 
systematically reviewing the literature on the untreated outcome for people with 
CCM.4 Although all of these studies have provided valuable information regarding the 
natural history of CCM, there would be several potential benefits of a large 
collaboration: the precision of the estimated risks of first and recurrent intracranial 
haemorrhage (and/or focal neurological deficit) could be improved, some inconsistent 
findings in the literature (for example, the influence of patient sex and CCM location 
on prognosis) could be re-examined, as well as others such as the influences of 
pregnancy and antithrombotic drugs, and a prognostic model with several covariates 
could be developed and validated. 
Looking ahead to publication, you would need to provide your data by the beginning 
of September 2012. We hope to have our first meeting of the CCM collaboration soon 
afterwards at the 1st World AVM Congress in Edinburgh on 18-19 September 2012 
(www.avm2012.org). The paper will include core authors from each group that 
contributes data; other members of the contributing research groups will be listed as 
collaborators (for further details see 
 www.nlm.nih.gov/pubs/techbull/ma08/ma08_collaborators.html). 
Please could you let me know whether you will join us by completing and sending me 
the attached form by Thursday 12 April 2012? 
With best wishes  
       Dr 
Dr Rustam Al-Shahi Salman MA PhD FRCP EdinProfessor Gordon D. Murray  PhD FRCP Edin FRSE 
MRC Senior clinical fellow, University of Edinburgh Professor of Medical Statistics,  
Honorary consultant neurologist, NHS Lothian  University of Edinburgh 
                                                 
3  Porter PJ et al. Cerebral cavernous malformations: natural history and prognosis after clinical deterioration 
with or without hemorrhage. J Neurosurg 1997; 87: 190-7 
4  Collaborator’s work 
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Your name:  
      
Your study:  
      
Please  one answer to each question: 
      
1.  Do you still have the original dataset from your publication about 
CCM? 
Yes  No  
  
      
      
2.  If ‘yes’ to question 1, will you share data with this meta-analysis? Yes  No  
      
3.  If ‘yes’ to question 2, is this dataset stored electronically? Yes  No  
      
4.  Do you have copies of the CCM patients’ brain imaging? Yes  No  
 
5.     Please could you provide the following details about the design of your study? 
      
 a. At what time does follow-up start?  all that apply 
      
  First ever symptom that might have been due to CCM  
      
  Clinical presentation that led to CCM diagnosis  
      
  Time of referral to your service/hospital for consultation  
      
  Time of referral to your service/hospital for CCM treatment  
      
 b. How do you follow-up patients?  all that apply 
      
  Only when they are admitted to hospital attend a clinic appointment  
      
  General (family) practitioners  
      
  Patient telephone calls  
      
  Patient postal questionnaires  
      
  Death records  
      
 c. Which outcome events do you record?  all that apply 
      
  Death  
      
  CCM haemorrhage, confirmed by review of brain imaging  
      
  CCM haemorrhage, based on reports of brain imaging by others  
      
  Focal neurological deficits, where brain imaging has been performed  
      
  Focal neurological deficits, where brain imaging has not been performed  
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Appendix D: Questionnaires for IPDMA 
collaborators 
  
I   Clinical questionnaire for Kelly Flemming (Mayo Clinic) 
      
 
                                                    Please  one answer to each question 
      
1. If your patients have received treatment, can you divide 
follow-up for each patient into: 
 
    before treatment Yes  No  
      
  after treatment Yes  No  
      
2. Does follow-up begin at the same point – the clinical 






       
3. You said in the previous questionnaire that follow-up was 
completed around 2003, apart from those patients who 
presented asymptomatically. Would it be possible to update 
follow-up on all patients? 
    
Yes  No  
    
       
4. Please can you give us more details about how you organize 






  at regular intervals for all patients? Yes   No    
      
  irregularly, depending on each patient’s clinical status? Yes   No    
 
5. 
If follow-up is at regular intervals, please could you specify 
the frequency.     
      
      
      
   
      
Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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II Statistical Questionnaire for the Mayo Clinic study 
Please answer the following questions. 
      
1. How many patients in your CCM cohort are available for  
follow-up analysis? 
   
      
2. In the first questionnaire, you indicated that you record death, 
intracranial haemorrhage (ICH) and non-haemorrhagic focal 
neurological deficit (FND). How many people in your study  
have had, in follow-up: 
    
      
  at least one ICH?     
      
  one or more FND?     
      
  have died?     
 
                                                     Please  one answer to each question 
3. Is a data dictionary available for your dataset? Yes  No  
      
4. What data are you able to send us:    
      
  all clinical events and total duration of follow-up for each  Yes  No  
                                                                  patient?     
  first events only, and the duration of follow-up to that  Yes  No  
  point?     
5.  In what format are you able to share your data?                                                                                
 
      
      
      
   
      
                                                     Please  one answer to each question 
6. What dataset will you share with us:  
      
  a copy of one previously used for a publication analysis? Yes   No  
      
  a recent extract from your database? Yes   No  
       
 Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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III Clinical Questionnaire for the Toronto study 
In questions 1 and 2, please could you clarify when follow-up begins in your study. In the 
previous questionnaire, you indicated that it started at three different time-points – first-ever 
symptom that might have been due to CCM; clinical presentation that led to CCM diagnosis; 
and time of referral to your hospital for CCM treatment.  
                                                    Please  one answer to each question 
    
1. Do you have information about 
 the date and  
 the mode of clinical presentation that led to CCM 
diagnosis 
 for all patients in your study? 
    
Yes  No  
    
Yes  No  
    
      
2. If ‘No’, please can you specify the approximate number / 
percentage of the cohort included at each time-point. 
     
      
  first-ever symptom that might have been due to 
CCM 
   
      
  clinical presentation that led to CCM diagnosis    
       
  time of referral to your hospital for consultation    
       
3. You did not record death as an outcome event in the previous 
questionnaire. Do you know each patient’s vital status at the 
end of follow-up? 
Yes  No  
     
      
4. If your patients have received treatment, can you divide 
follow-up for each patient into: 
    
     
  before treatment Yes   No    
      
  after treatment Yes   No    
      
5. You have said that follow-up occurs when patients are 
admitted to hospital or attend a clinic appointment. Is follow-
up organized at:  
    
 
      
  regular intervals for all patients? Yes   No    
      
  irregularly, depending on each patient’s clinical status? Yes    No    
 
 







Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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IV  Statistical Questionnaire for the Toronto study 
 
 Please answer the following questions. 
      
1. How many patients in your CCM cohort are available for  
follow-up analysis? 
   
      
2. In the first questionnaire, you indicated that you record 
intracranial haemorrhage (ICH) and non-haemorrhagic focal 
neurological deficit (FND). How many people in your study  
have had, in follow-up: 
    
      
  at least one ICH?     
      
  one or more FND?     
      
      
                                                     Please  one answer to each question 
      
3. Is a data dictionary available for your dataset? Yes  No  
      
4. What data are you able to send us:    
      
 
 all clinical events and total duration of follow-up for each 
patient?                                                                 
Yes   No    
    
      
 
 first events only, and the duration of follow-up to that 
point? 
Yes   No    
    
      
5.  In what format are you able to share your data?                                                                                
      
      
      
   
      
                                                     Please  one answer to each question 
6. What dataset will you share with us:  
      
  a copy of one previously used for a publication analysis? Yes   No  
      
  a recent extract from your database? Yes   No  
       
       
 
 Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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V Clinical questionnaire for Christian Stapf (Paris) 
      
In questions 1 and 2, please could you clarify when follow-up begins in your study. In 
the previous questionnaire, you indicated that it started at three different time-points – 
first-ever symptom that might have been due to CCM; clinical presentation that led to 
CCM diagnosis; and time of referral to your hospital for CCM treatment.  
                                                    Please  one answer to each question 
    
1. Do you have information about 
 the date and  
 
 the mode of clinical presentation that led to CCM 
diagnosis 
 for all patients in your study? 
    
Yes  No  
    
Yes  No  
    
      
2. If ‘No’, please can you specify the approximate number / 
percentage of the cohort included at each time-point: 
     
      
  first-ever symptom that might have been due to 
CCM 
   
      
  clinical presentation that led to CCM diagnosis    
       
  time of referral to your hospital for consultation    
       
3. If your patients have received treatment, can you divide 
follow-up for each patient into: 
    
    
 
  before treatment Yes   No    
      
  after treatment Yes   No    
      
4. You have said that patients are contacted at regular intervals  
by telephone. Please can you specify: 
 (i) whether this happens for all patients and  
(ii) the frequency of the follow-up. 






 Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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VI  Statistical questionnaire for the Paris study 
      
 
Please answer the following questions. 
      
1. How many patients in your CCM cohort are available for  
follow-up analysis? 
   
      
2. In the first questionnaire, you indicated that you record death, 
intracranial haemorrhage (ICH) and non-haemorrhagic focal 
neurological deficit (FND). How many people in your study 
have had, in follow-up: 
    
      
  at least one ICH?     
      
  one or more FND?     
      
  or have died?     
 
                                                     Please  one answer to each question 
3. Is a data dictionary available for your dataset? Yes  No  
      
4. What data are you able to send us:    
      
 
 all clinical events and total duration of follow-up for each 
patient?                                                                 
Yes   No    
    
      
 
 first events only, and the duration of follow-up to that 
point? 
Yes   No    
    
      
5.  In what format are you able to share your data?                                                                               
      
      
      
   
      
                                                     Please  one answer to each question 
6. What dataset will you share with us:  
      
 a copy of one previously used for a publication analysis? Yes   No  
 
 
    
 a recent extract from your database? Yes   No  
      
 
Please return by email: rustam.al-shahi@ed.ac.uk or fax: +44 131 332 5150 
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Appendix E: Statistical Analysis Plan for IPDMA 
Clinical course of untreated cerebral cavernous 




A cerebral cavernous malformation (CCM) is a small round cluster of thin-walled, 
dilated blood vessels, packed together with no intervening brain tissue. As a result of 
their angioarchitecture, CCM are prone to bleed. Although the quantity of blood 
leaking out tends to be small because the blood flow is very slow, even a small 
intracranial haemorrhage (ICH) can result in a clinically significant neurological 
deficit, especially when the CCM is located in the brainstem or another eloquent area.  
CCM detection has increased alongside greater use of brain magnetic resonance 
imaging (MRI) (Brown et al., 1996, Al-Shahi et al., 2003). In particular, this can lead 
to many asymptomatic CCM being detected since the prevalence of CCMs is 0.16–
0.39% of the population (Morris et al., 2009, Del Curling et al., 1991). The magnitude 
and predictors of the risk of ICH in the clinical course of untreated CCM are important 
to patients and clinicians because estimates of prognosis inform decisions about 
whether to treat CCM. 
CCMs constitute a challenging condition to study. The diagnosis may be subject to 
detection bias, since it relies on brain imaging of the right type being performed at the 
right time, and clinicians tend to investigate the cause of ICH in young, normotensive 
adults, whereas ICH in older, hypertensive adults is less likely to be further 
investigated. If patients with CCM who are treated conservatively have minor 
symptoms they may be less likely to report them (if they know they will not be treated, 
and their clinicians in turn may be less likely to arrange radiographic investigation) or 
more likely to report them (if they are anxious for the treatment decision to be 
changed). Therefore, because some new focal neurological deficits (FND) may have 
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been undetected ICHs, reporting standards recommend combining proven ICH and 
FND into a composite outcome (Porter et al., 1997, Al-Shahi Salman et al., 2012). 
Risk of intracranial haemorrhage from CCM 
Several studies have described the risk of ICH in the clinical course of untreated CCM 
(Al-Shahi Salman et al., 2012, Flemming et al., 2012, Flemming et al., 2013, Schneble 
et al., 2012). However, the main limitations of these studies have been small sample 
size and short follow-up. Most of these studies were retrospective hospital-based 
series, without clearly-defined diagnostic criteria or outcome events (Al-Shahi Salman 
et al., 2008), and some restrict inclusion to selected participants according to the 
anatomical location of the CCM or whether its cause is genetic/sporadic. 
Comparison of the risks of ICH between these studies is problematic because different 
statistical methods have been used to calculate risk. In many papers, authors have 
calculated the risk of ICH assuming that the CCM is congenital, whereas it is now 
accepted that lesions do occur de novo during lifetime (Zabramski et al., 1994, 
Kattapong et al., 1995, Detwiler et al., 1997). In some studies, the risk per lesion has 
been estimated rather than that per patient. In other studies, the total number of ICHs 
in follow-up rather than the first ICH in follow-up was used to calculate an annual rate, 
and it was also assumed that the annual rate is constant over time, which appears not 
to be the case (Barker II et al., 2001, Al-Shahi Salman et al., 2012). Overall, the annual 
rates of first-ever ICH (0.3% to 1.3%) have been lower than recurrent ICH (6.2% to 
18.3%) from the same CCM, but neither of these rates has been estimated with 
precision (Al-Shahi Salman et al., 2012, Flemming et al., 2012). 
 Predictors of intracranial haemorrhage from CCM 
Most studies have consistently identified the occurrence of a prior ICH as a risk factor 
for an adult developing a subsequent ICH. Studies have varied in whether putative risk 
factors such as patient sex, CCM location or CCM multiplicity have influenced the 
risk of ICH. 
Therefore, the patient’s and clinician’s dilemma about whether, when, and how to treat 
a CCM would be informed by a more precise estimation of the clinical course of 
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untreated CCMs, the identification of prognostic factors, and the derivation and 
validation of a prognostic model. 
 
This collaborative individual patient data meta-analysis 
After conducting a systematic review (Al-Shahi Salman et al., 2012), we identified 
five cohorts of adults with CCM that could provide detailed individual patient data 
regarding clinical outcome (ICH or FND) between diagnosis and either CCM 
treatment or last follow-up. By conducting an individual patient data meta-
analysis(Riley et al., 2010), we will be able to use consistent methods of analysis for 
all patients across studies and investigate two outcomes: ICH alone and a composite 
outcome of ICH and new FND. We aim to improve the precision of previous estimated 
risks of first and recurrent ICH (and also the composite outcome of first or recurrent 
ICH or FND), and identify prognostic factors for ICH/FND. We will also develop and 
evaluate/validate a prognostic model based on several covariates. In exploratory 
subgroup analyses, we will assess whether it would be feasible in the future to examine 
the impact of antithrombotic drugs on the risk of ICH/FNDs and to identify risk factors 
derived from neuro-imaging. 
Study questions 
1. What is the estimated risk of an untreated adult suffering an ICH or FND within 
five years of CCM diagnosis? 
2. Which baseline characteristics modify the risk of ICH or FND occurring within 
five years of CCM diagnosis? 
3. Is it possible to predict, at the time of diagnosis, an individual’s risk of a 




This is a two-stage random-effects individual patient data meta-analysis in which the 
unadjusted and adjusted hazard ratios will be derived for each cohort, and summary 
adjusted hazard ratios will be calculated, if this is appropriate (Riley et al., 2011).  
Study cohorts 
Eligibility criteria 
 Each study should have a minimum sample size of 60 adults. 
 The period at risk should begin at either 
(i) first CCM diagnosis or 
(ii) symptoms leading to it 
thereby enabling calculation of event risk from diagnosis (not retrospective 
‘lifetime risk’). 
 Symptomatic ICH should be included as an objective, pre-defined clinical 
outcome. 
 Outcome events should be able to be quantified per patient during the follow-
up period. 
Data will be used from five cohorts: two cohorts that were recruited at different five-
year time periods in the same prospective, population-based observational study (Al-
Shahi Salman et al., 2012), and three hospital-based cohorts (Porter et al., 1997, 
Flemming et al., 2012b, Schneble et al., 2012a). 
Participant eligibility  
Inclusion criteria 
 Participants with a definite CCM diagnosis. 
 Diagnosis validated either by MRI or pathological examination after surgical 
excision.  
 Participants should be aged 16 years or over at time of diagnosis. 
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 Participants should not have received interventional treatment – surgical 
excision or stereotactic radiotherapy – by the time of diagnosis. 
Exclusion criteria 
 Any adult in a cohort who was diagnosed before the recruitment start date for 
that cohort. The start date for recruitment is calculated as the earliest date after 
which at least six patients have been diagnosed with a CCM within the 
subsequent year. 
Primary objectives 
1. Descriptive analysis of time-to-event outcomes: 
First event 
(i) First ICH in untreated follow-up for those presenting incidentally or 
with a seizure 
(ii) First ICH/FND in untreated follow-up for those presenting 
incidentally or with a seizure 
Recurrent event 
(iii) First ICH in untreated follow-up for those who either presented with 
an ICH or FND initially, or second ICH in untreated follow-up for 
those who presented with a seizure or incidentally and have had a first 
ICH in follow-up   
(iv) First ICH/FND in untreated follow-up for those who either presented 
with an ICH or FND initially, or second ICH/FND for those who 
presented with a seizure or incidentally and have had a first ICH or 
FND in follow-up.   
2. Identification of risk factors for ICH or ICH/FND: 
(i)  a priori specified predictors of interest 
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 core predictors:  
 prior ICH/FND versus other by individual patient 
 CCM location (brainstem versus other) 
 
 potential predictors: 
 sex (female versus male) 
 multiple versus solitary CCM (if sufficient power) 
 age (if sufficient power) 
(ii) exploratory predictors 
 CCM size 
 associated developmental venous anomaly 
3. Building and evaluating a multivariable prognostic model: 
(i) to model the risk of a future ICH (or a composite endpoint of ICH or 
FND, if data are available) for an adult with untreated CCM(s) during 
follow-up 
(ii)  pre-specified covariates as candidates for inclusion in the model were 
chosen for clinical significance and comprise the core, potential and 
exploratory predictors as described above. 
Secondary objective 
Preliminary analyses, of an exploratory nature only since the current study may not be 
adequately powered, will be undertaken in order to determine the potential for future 
work: 
a. potential interactions will be investigated in an exploratory manner:  
i. prior ICH/FND and CCM location 
ii. prior ICH/FND and sex 
iii. age and sex. 
b. effect of antithrombotic therapy 
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Primary outcome events 
(i) Symptomatic ICH 
(ii) A composite endpoint of symptomatic ICH or FND. 
The composite outcome is important, because both ICH and FND have a similar level 
of morbidity for the patient, and in certain circumstances an outcome labelled FND 
may, in reality, be an ICH, but not categorised as such, either because the appropriate 
neuro-imaging was not performed or because the imaging failed to detect any blood 
(Al-Shahi Salman et al., 2008). If appropriate, we may perform a subsidiary analysis 
of the outcomes ‘recurrent ICH’ or ‘recurrent ICH/FND’, which may require 
adjustment of age, CCM location and mode of clinical presentation to be compatible 
with this first outcome event in follow-up. 
Definitions 
 Mode of clinical presentation: In this study when an adult presents with 
several symptoms, the dominant one is taken as the mode of presentation. For 
example, a patient may present with a headache, seizure and ICH, but mode of 
presentation would be recorded as ICH because the headache and seizure are 
symptomatic of the ICH. 
 Intracranial haemorrhage: ICH is defined as ‘acute or subacute onset 
symptoms (any of headache, epileptic seizure, impaired consciousness, 
new/worsened FND referable to the anatomic location of the CCM) and 
radiological, pathological, surgical or rarely only cerebrospinal fluid evidence 
of recent extra- and/or intralesional haemorrhage. The mere existence of a 
haemosiderin halo, or solely an increase in CCM diameter without other 
evidence of recent haemorrhage, are not considered to constitute haemo-
rrhage.’  (Al-Shahi Salman et al., 2008) 
 Non-haemorrhagic focal neurological deficit: A new or worsened FND 
referable to the CCM anatomic location, which may present with other clinical 
features of ICH, but without evidence of recent blood on timely brain imaging 
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and/or pathological examination, or examination of the cerebrospinal fluid (Al-
Shahi Salman et al., 2008).  
 Focal neurological deficit not otherwise specified: This is identical to a 
non-haemorrhagic FND, with the exception that neither pathological 
examination, nor cerebrospinal fluid examination, nor timely imaging have 
been performed at all or at the correct time to establish whether haemorrhage, 
oedema or lesion growth underlie the clinical deterioration (Al-Shahi Salman 
et al., 2008).  
 Seizure: A participant is classified as presenting with an epileptic seizure if 
the seizure was not symptomatic of a concomitant acute ICH or FND, and there 
was no more likely cause for the seizure than the CCM. 
 Incidental: A participant was classified as presenting incidentally if the adult 
had been asymptomatic, or if the symptoms could not be related to the 
underlying CCM. 
 Directly or possibly attributable to the CCM: In some included studies we 
can examine clinical events (ICH or FND) that are either directly attributable 
or possibly attributable to the CCM. In the latter instance, although the 
symptoms are anatomically consistent with the lesion location, it is possible 
that they may be due to another cause, and neuro-imaging has not been able to 
provide a definitive explanation of the cause of symptoms. 
 Inception: This is taken to be the date of first-ever diagnosis of a CCM. 
 Period at risk: All available follow-up from inception until the outcome event 
or censoring.  
 Censoring will take place at the earliest occurrence of any of the following:  
o first interventional treatment (surgical excision or stereotactic radio-
surgery) 
o death,  
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o last available follow-up, or  
o truncation of follow-up 5 years after presentation (or median duration 
of follow-up from all studies) 
unless an outcome event occurs sooner. 
Handling missing data 
During the process of cleaning each dataset, problems of missing data will be 
addressed by contacting the clinician responsible for providing the data and where 
possible will be resolved. In cases where this is not possible, missing values will be 
imputed, if appropriate, using a multiple imputation technique.  
Completeness of follow-up 
We will use one method of reporting completeness of follow-up (Clark et al., 2002), 
which calculates the total actual follow-up accrued as a percentage of the total follow-
up that was potentially available, before death or the end of the five-year period for the 
analyses. 
Heterogeneity 
Heterogeneity is an important consideration, both from the clinical and statistical 
perspectives, and in this study there are three potential sources of heterogeneity.  
(i) Study design 
An example of heterogeneity of study design is that patients in a population-based 
study may be more likely to present incidentally than patients in a hospital-based 
study; to account for this source of heterogeneity, the total dataset will be stratified by 
study design – i.e. population-based cohort vs hospital-based cohort. In addition, 
length of follow-up is an important consideration as outcome events may require 
several years of follow-up. 
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(ii) Baseline characteristics   
Of particular concern are patient age, sex, mode of clinical presentation, CCM location 
and multiplicity, as these may influence outcome: for example, patients in a tertiary 
referral neurosurgery unit may be more likely to harbour brainstem lesions, and 
patients in an institute specialising in genetics may be more likely to have the familial 
form of the disease, with multiple lesions, than patients in general hospitals or the 
community.  
(iii) Hazard ratios 
The final type of heterogeneity is that of hazard ratios (see section ‘Identifying and 
quantifying heterogeneity in hazard ratios’ below); this might make pooling (and the 
derivation of an overall prognostic model) questionable (Borenstein et al., 2009, 
Ioannidis et al., 2008). 
Baseline characteristics 
A table of baseline characteristics, stratified by mode of initial clinical presentation, 
will be presented for each cohort, together with a similar table for the combined 
cohorts.  
 Age at start of follow-up (either CCM diagnosis or other inception point)5 
 Sex 
 CCM multiplicity: single or multiple  
 ‘Primary’ CCM location:* 
o symptomatic CCM; or  
o if asymptomatic and multiple, including a brainstem CCM, then 
location = brainstem.  
Location will be categorised: 
                                                 
5 These variables may vary, according to whether analyses are time to first/second event (for adults 
who present with a seizure or incidentally, and then have an outcome event during follow-up) 
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 Cerebellum 
 Deep (basal ganglia, thalamus or choroid)  
 Brainstem (pons, medulla or midbrain)  
 Lobar (all  other)  
 Mode of clinical presentation:* 
 incidental 
 if patient was asymptomatic 
 if symptoms could not be attributed – definitely or 
possibly – to the underlying CCM 
 epileptic seizure 
 ICH(Al-Shahi Salman et al., 2008) 
 FND(Al-Shahi Salman et al., 2008) 
 
Outcome analyses 
In the main ‘two step’ analysis we will fit univariate and multivariable models to each 
cohort, using forest plots to display the unadjusted and adjusted estimated hazard 
ratios, and we will pool these estimates, where appropriate. As a sensitivity analysis, 
in a ‘one step’ analysis we will fit models to the entire dataset of all patients pooled 
from the individual cohorts, with analyses stratified by a study covariate. 
Individual cohorts 
Descriptive analysis 
We will present tables of the baseline characteristics for each cohort, stratified by mode 
of clinical presentation, so that the similarity of each cohort at inception can be 
assessed.  
Time-to-event analyses 
We will use Kaplan-Meier survival curves (one minus survival plot) to display the 
cumulative proportion of the cohort that experiences the ICH primary outcome event; 
in cohorts where FNDs are recorded, we will separately present Kaplan-Meier survival 
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curves for the incidence of the other primary outcome event (ICH/FND). Each Kaplan-
Meier plot will be stratified by a particular covariate: 
 mode of clinical presentation (ICH or FND vs other)  
 brainstem vs other CCM location  
 sex (female vs male) 
 multiple vs solitary CCM. 
We will use the log-rank test to compare the survival plots for each of these 
stratifications. The length of follow-up period displayed graphically will be up to five 
years, but it will be determined by the numbers at risk at specific time points.  
Univariate analyses 
In both the univariate and multivariable analyses of time to one or other primary 
outcome, we will use the Cox proportional-hazards regression model, provided that 
the proportional-hazards assumption is fulfilled. The following covariates will be 
entered in univariate analyses to determine the unadjusted hazard ratio (and 95% 
confidence interval) for each putative predictor.  
Putative risk factors 
 Covariates of  a priori interest  
o Core covariates 
 Mode of clinical presentation - for survival analyses, mode of 
clinical presentation will be dichotomised:  
ICH or FND at presentation (x = 1) vs incidental or 
seizure at presentation (x = 0) 
 Location - for survival analyses location will be dichotomised:  
brainstem location (x = 1) vs other location (x = 0) 
o Other covariates of  a priori interest 
 Age at start of follow-up (as a continuous variable) 
 CCM multiplicity: multiple (x = 1) vs single (x = 0) 
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 Sex: female (x = 1) vs  male (x = 0) 
 Other potential covariates, depending on whether they have been recorded    
 CCM size 
 antithrombotic therapy: never (x = 0) vs ever (x =1) 
 Design covariate – for multivariable analyses only 
 cohort 
If antithrombotic therapy is included as a potential covariate, then it may need to be 
modelled as a time-varying covariate. 
Multivariable analyses 
The hazard ratios and 95% confidence intervals will be examined for each covariate 
in the univariate analyses. In the multivariable analyses, since there is inconsistency 
about the role of sex as a putative risk factor for ICH or FND, we will force all the 
covariates of a priori interest apart from sex into the model, regardless of their 
statistical significance in the univariate analyses, because they are of clinical 
significance; then, adjusting for these four covariates, sex will be included in the 
model, to ascertain its impact on the outcome.  
The following interactions will also be explored in terms of their potential for future 
research: 
 prior ICH/FND and CCM location  
 prior ICH/FND and sex 
 age and sex 
Sensitivity analysis 
The data from the five cohorts will be pooled and the descriptive analysis, time-to-
event analyses, univariate and multivariable analyses described above will be repeated 




Estimates of the unadjusted and adjusted hazard ratios for the five a priori risk factors 
for 
i. ICH 
ii. ICH or FND  
will be presented in forest plots, together with the 95% confidence interval for each 
covariate. The hazard ratios will be adjusted for factors imbalanced at baseline and/or 
known or suspected to influence CCM prognosis. If appropriate, we will pool all 
studies and calculate unadjusted and adjusted pooled estimates of the hazard ratios. 
Identifying and quantifying heterogeneity in hazard ratios 
To identify any heterogeneity between the cohorts in the hazard ratios, we will  
 compute Q – the weighted sum of squares of deviation of each effect size from 
the mean, on a standardized scale; 
 estimate τ2 – variance of the true effect sizes (estimated by 𝑇2); 
 compute 𝐼2 statistic – proportion of observed dispersion that is real, rather than 
spurious (a measure of inconsistency across the findings of the studies which 
reflects the extent of overlap of confidence intervals). 
 
Prognostic model 
If heterogeneity between the cohorts is sufficiently modest to enable a prognostic 
model to be built, patient data in all cohorts will be pooled to form a single dataset. 
Assuming the proportional-hazards assumption is not violated, the Cox proportional-
hazards regression model will be used to model the risk of a future ICH (and FND, if 
the data are available) for an adult with CCM during untreated follow-up (Harrell et 
al., 1996, Machin et al., 2006). Pre-specified covariates in the model will be selected 
for their clinical significance and will be chosen in order from the five covariates of a 
priori interest listed above, namely, prior ICH/FND, brainstem location, age (as a 
continuous variable), lesion multiplicity, and sex. Other potential covariates include 
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lesion size, and whether the adult has received antithrombotic therapy. If heterogeneity 
between the cohorts is substantial, but the proportional-hazards assumption is not 
violated, then the Cox proportional-hazards regression will be stratified by a ‘study’ 
covariate, with covariates of a priori interest included in the model (Hosmer et al., 
2008, Steyerberg, 2009, Fibrinogen, 2009).   
If appropriate, we will round the regression coefficients, estimate the baseline event 
risk, and then develop a prognostic index by calculating a prognostic score for each 
adult in the dataset. A frequency distribution of the individual scores will be examined, 
and two cut-off points at arithmetically convenient points (e.g. 25% with worst 
prognosis, and 25% with best prognosis) will be used to separate the dataset into high-
, medium- and low-risk categories (Machin et al., 2006, Leonard et al., 1991). A 
Kaplan-Meier plot, stratified by these three risk categories, will then be calculated to 
illustrate the degree of discrimination achieved by the index.  
If the proportional-hazards assumption is seriously violated, then a multivariable 
logistic regression model will be used, with occurrence of ICH (or FND, if data are 
available) within the first five years of follow-up as the dependent variable.  
Model validation 
Internal validation 
It will probably not be possible to validate this model by splitting our current dataset 
in half, as we will have insufficient outcome events in each portion. However, if it is 
not possible to use one or more cohorts in developing the model, then these could 
possibly be used to validate it.  
If the model is built using data from all the cohorts, then the internal–external cross-
evaluation technique will be used to validate the model internally and adjust the model 
for overfitting using a shrinkage factor (Debray et al., 2012, Royston et al., 2004). 
Using this method, the model will be fitted on four of the five cohorts and validated 
on the fifth, for five occurrences (so that each model is omitted from the validation 
process in turn) (Royston et al., 2004, May et al., 2004). We will examine the 
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predictive performance of the model by assessing its calibration and discrimination. 
Calibration compares the level of agreement between, for example, the model 
estimation of the probability of an adult experiencing an ICH within five years and the 
observed frequency of ICH (Moons et al., 2012b). Discrimination describes how well 
the model splits into those who have the outcome of interest and those who do not. 
Harrell’s concordance index (c-index) will be used to quantify the discriminative 
ability of the model and calibration will be assessed using plots and the modified 
Hosmer and Lemeshow test for survival analysis (May and Hosmer, 1998).  
 
Exploratory analyses  
We will explore the potential for future research, depending on the data provided by 
the different studies. 
 Whether an interaction exists between each of the following pairs of covariates: 
o prior ICH / FND and CCM location 
o prior ICH /FND and sex   
o age and sex 
 Effect of antithrombotic therapy on adults with untreated CCM. 
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Table A. 1 Estimated risk of intracranial haemorrhage in five-year follow-up, by sex 






95% confidence interval SE 






  7.3% 
  4.2% 
1.1 to 13.5 
0 to 10.0 
0.032 
0.029 






  3.6% 
  7.1% 
0 to 8.6 
1.0 to 13.2 
0.025 
0.031 







  2.9% 
0 to 26.0 
0 to 8.6 
0.069 
0.029 






  6.1% 
14.2% 
1.7 to 10.6 
7.0 to 21.5 
0.023 
0.037 






  9.5% 
8.2% 
4.6 to 14.4 
3.1 to 13.4 
0.025 
0.026 
       






  7.5% 
  8.8% 
4.9 to 10.1 
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Table A. 2 Estimated risk of intracranial haemorrhage, by CCM multiplicity 






95% confidence interval SE 
Mayo Clinic Multiple 
Solitary 





  7.5% 
7.7 to 33.3 
3.4 to 11.6 
0.065 
0.021 
       
Toronto  Multiple 
Solitary 






0 to 6.3 
6.5 to 15.6 
0.018 
0.023 
       
Paris Multiple 
Solitary 
  27 









       
Scotland, 1999–2003 Multiple 
Solitary 




  9.1% 
  5.4% 
0 to 21.2 
0.8 to 10.0 
0.062 
0.024 
       
Scotland, 2006–2010 Multiple 
Solitary 





  4.4% 
0 to 24.8 
0.6 to 8.3 
0.073 
0.020 
       







  7.4% 
5.8 to 15.1 





Table A. 3 Estimated risk of intracranial haemorrhage, by age-group 






Mayo Clinic ≤ 35 years 
36-53 years 








  7.5% 
  10.6% 
3.4 to 19.5  
1.1 to 13.9  




       
Toronto  ≤ 35 years 
36-43 years 









  3.5% 
5.6 to 19.1 
3.7 to 17.6 




       
Paris ≤ 35 years 
36-53 years 










0 to 31.5 





       
Scotland, 1999–2003 ≤ 35 years 
36-53 years 








  6.1% 
― 
0.6 to 19.4 





       
Scotland, 2006–2010 ≤ 35 years 
36-53 years 







  2.8% 
  8.4% 
  4.8% 
0 to 8.2 
0.5 to 16.4 




       
Pooled cohorts ≤ 35 years 
36-53 years 








  8.2% 
  5.5% 
6.7 to 14.5 
4.8 to 11.5 
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Table A. 4 Estimated risk of clinical event, by mode of presentation: ICH or FND vs other presentation  











  8 
37.6% 
  9.4% 
20.5 to 54.7 
3.2 to 15.6 
0.087 
0.032 
       





  3 
30.8% 
  2.7% 
14.5 to 47.2 
0 to 5.6 
0.084 
0.015 
       





  5 
35.6% 
  4.5% 
27.2 to 43.9 
0.4 to 8.6 
0.042 
0.021 
       







  5.2% 
28.4 to 42.1 





Table A. 5 Estimated risk of clinical event, by CCM location 
Study Risk factor Number of adults Events 5-year estimated risk 95% confidence interval SE 
Scotland, 1999–2003 Brainstem 
Other location 
  17 
118 




23.3 to 70.8 
5.7 to 18.6 
0.121 
0.033 
Scotland, 2006–2010 Brainstem 
Other location 
  25 
135 
10 
  3 
50.3% 
2.4% 
26.7 to 73.9 
0 to 5.1 
0.121 
0.014 








31.7 to 55.0 
6.1 to 15.4 
0.059 
0.024 
       







  8.8% 
35.0 to 54.0 
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Table A. 6 Estimated risk of clinical event, by sex  
 
Study Risk factor 
Number of 
adults 
Events 5-year estimated risk 95% confidence interval SE 





  4 
22.8% 
  8.5% 
12.9 to 32.7 
0.5 to 16.4 
0.050 
0.041 
       




  6 
  7 
  9.8% 
  9.6% 
2.2 to 17.3 
2.7 to 16.4 
0.039 
0.035 
       








12.7 to 25.7 
14.1 to 29.8 
0.033 
0.040 
       








13.4 to 22.6 






Table A. 7 Estimated risk of clinical event, by CCM multiplicity  
Study Risk factor 
Number of 
adults 
Events 5-year estimated risk 95% confidence interval SE 
Scotland, 1999–2003 Multiple 
Solitary 
  24 
111 




5.3 to 42.2 
8.4 to 23.0 
0.094 
0.037 
       
Scotland, 2006–2010 Multiple 
Solitary 
  29 
131 
  2 
11 
10.6% 
  9.5% 
0 to 24.8 
4.1 to 14.9 
0.073 
0.028 
       
Toronto  Multiple 
Solitary 






7.7 to 27.2 
15.6 to 27.5 
0.050 
0.030 
       








9.6 to 24.4 
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Table A. 8 Estimated risk of clinical event, by age-group  
Study Risk factor 
Number of 
adults 
Events 5-year estimated risk 95% confidence interval SE 
Scotland, 1999–2003 ≤ 35 years 
36-53 years 
≥ 54 years 
  50 
  54  
  31 
  9 
  7 




9.0 to 34.1 
4.4 to 23.9 




       
Scotland, 2006–2010 ≤ 35 years 
36-53 years 
≥ 54 years 
  44 
  52 
  64 
  2 
  6 
  5 
  5.2% 
12.4% 
10.4% 
0 to 12.2 
3.1 to 21.7 




       
Toronto  ≤ 35 years 
36-43 years 
≥ 54 years 
116 
141 
  88 
19 
28 




11.2 to 27.1 
19.0 to 38.4 




       
Pooled cohorts ≤ 35 years 
36-53 years 










11.5 to 23.0 
14.9 to 26.6 







Table A. 9 Analysis of time to first intracranial haemorrhage, stratified by sex 
a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for presentation and CCM location.  












95% CI p 
Mayo Clinic 
female 143 7 
3.43 0.064 0.43 0.2 to 1.1 0.072 0.40 0.2 to 1.0 0.050 
male 124 13 
            
Toronto  
female 194 14 
0.08 0.776 1.13 0.5 to 2.5 0.776 0.99 0.4 to 2.2 0.972 
male 151 10 
            
Paris 
female 47 3 
0.387 0.534 2.02 0.2 to 19.5 0.542 0.83 0.1 to 12.8 0.896 
male 34 1 
            
Scotland,  
    1999–2003 
female 80 5 
0.41 0.520 1.70 0.3 to 8.8 0.525 0.89 0.2 to 5.4 0.900 
male 55 2 
            
Scotland,  
    2006–2010 
female 77 2 
1.17 0.280 0.42 0.1 to 2.1 0.295 0.45 0.1 to 2.4 0.349 
male 83 5 
            
Pooled cohorts, 
unstratified 
female 541 31 
0.696 0.404 0.81 0.5 to 1.3 0.405 0.69 0.4 to 1.1 0.148 
male 447 31 




female 541 31 
0.759 0.384 0.80 0.5 to 1.3 0.385 0.69 0.4 to 1.1 0.150 
male 447 31 
 
  345 
Table A. 10 Analysis of time to first intracranial haemorrhage, stratified by CCM multiplicity  
a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for presentation and CCM location.   












95% CI p 
Mayo Clinic multiple CCM 49 8 
7.18 0.007 3.18 1.3 to 7.8 0.011 3.07 1.2 to 7.6 0.015 
solitary CCM 218 12 
            
Toronto  multiple CCM 79 2 
3.43 0.064 0.28 0.1 to 1.2 0.083 0.24 0.1 to 1.03 0.055 
solitary CCM 266 22 
            
Paris multiple CCM 27 4 
– – – – – – – – 
solitary CCM 54 0 
            
Scotland,  
    1999–2003 
multiple CCM 24 2 
0.64 0.425 1.93 0.4 to 9.9 0.433 2.38 0.5 to 12.7 0.310 
solitary CCM 111 5 
            
Scotland,   
    2006–2010 
multiple CCM 29 2 
0.74 0.390 2.03 0.4 to 10.5 0.400 1.08 0.2 to 5.8 0.928 
solitary CCM 131 5 
            
Pooled cohorts, 
unstratified 
multiple CCM 208 18 
2.32 0.128 1.53 0.9 to 2.6 0.131 1.36 0.8 to 2.4 0.267 
solitary CCM 780 44 




multiple CCM 208 18 
2.18 0.140 1.52 0.9 to 2.6 0.142 1.42 0.8 to 2.5 0.219 
solitary CCM 780 44 
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Table A. 11 Analysis of time to first intracranial haemorrhage, stratified by age (3 groups) 
a log rank test for trend, 1 degree of freedom. b Hazard ratio from univariate analysis.     c Hazard ratio is adjusted for presentation and CCM location.   












95% CI p 
Mayo Clinic ≤ 35 years 83 7 
0.04 0.836 
1.13 0.4 to 3.1 0.810 1.08 0.4 to 3.0 0.882 
36-53 years 87 5 0.78 0.3 to 2.4 0.655 0.60 0.2 to 1.9 0.375 
≥ 54 years 97 8 1.00 –  1.00 –  
            
Toronto  ≤ 35 years 116 12 
3.60 0.058 
3.16 0.9 to 11.2 0.074 3.29 0.9 to 11.7 0.065 
36-53 years 141 9 2.13 0.6 to 7.9 0.256 2.44 0.7 to 9.1 0.182 
≥ 54 years 88 3 1.00 –  1.00 –  
            
Paris ≤ 35 years 29 3 
3.04 0.081 
– –  – –  
36-53 years 24 1 – –  – –  
≥ 54 years 28 0 – –  – –  
            
Scotland, 
1999–2003 
≤ 35 years 50 4 
2.48 0.115 
– –  – –  
36-53 years 54 3 – –  – –  
≥ 54 years 31 0 – –  – –  
            
Scotland, 
2006–2010 
≤ 35 years 44 1 
0.00 0.993 
0.77 0.1 to 8.5 0.831 4.64 0.3 to 62.3 0.246 
36-53 years 52 4 2.63 0.5 to 14.3 0.265 20.13 2.2 to 182.7 0.008 
≥ 54 years 64 2 1.00 –  1.00 –  
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Table A. 11 contd  
a log rank test for trend, 1 degree of freedom. b Hazard ratio from univariate analysis.    c Hazard ratio is adjusted for presentation and CCM location.  
 
  
















≤ 35 years 322 27   2.10 1.1 to 4.1 0.028 2.26 1.2 to 4.4 0.016 
36-53 years 358 22 5.05 0.025 1.56 0.8 to 3.1 0.203 1.59 0.8 to 3.2 0.184 
≥ 54 years 308 13   1.00 –  1.00 –  





≤ 35 years 322 27   2.11 1.1 to 4.1 0.028 2.34 1.2 to 4.6 0.013 
36-53 years 358 22 5.01 0.025 1.58 0.8 to 3.1 0.196 1.61 0.8 to 3.2 0.177 
≥ 54 years 
308 13 
  1.00 –  1.00 –  
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Table A. 12 Analysis of time to first intracranial haemorrhage, stratified by age (4 groups) 












95% CI p 
Mayo Clinic ≤ 30 years 62 5 
0.12 0.727 
0.91 0.3 to 2.9 0.874 0.94 0.3 to 3.0 0.921 
31-45 years 64 3 0.51 0.1 to 2.0 0.330 0.46 0.1 to 1.8 0.257 
46-60 years 71 5 0.70 0.2 to 2.2 0.540 0.72 0.2 to 2.3 0.571 
≥ 60 years 70 7 1.00   1.00   
Toronto ≤ 30 years 68 6 
1.75 0.186 
1.36 0.3 to 5.4 0.663 1.39 0.3 to 5.6 0.642 
31-45 years 134 13 1.68 0.5 to 5.9 0.421 1.53 0.4 to 5.4 0.510 
46-60 years 97 2 0.36 0.1 to 2.2 0.262 0.34 0.1 to 2.1 0.244 
≥ 60 years 46 3 1.00    1.00   
Paris ≤ 30 years 23 2 
1.26 0.261 
– – – – – – 
31-45 years 21 1 – – – – – – 
46-60 years 21 1 – – – – – – 
≥ 60 years 16 0 – – – – – – 
Scotland, 
1999–2003 
≤ 30 years 29 1 
0.32 0.570 
– – – – – – 
31-45 years 51 4 – – – – – – 
46-60 years 36 2 – – – – – – 
≥ 60 years 19 0 – – – – – – 
Scotland, 
2006–2010 
≤ 30 years 26 0 
0.67 0.412 
– – – – – – 
31-45 years 52 5 – – – – – – 
46-60 years 43 2 – – – – – – 
≥ 60 years 39 0 – – – – – – 
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Table A. 12 contd  
a log rank test for trend, 1 degree of freedom. b Hazard ratio from univariate analysis.     c Hazard ratio is adjusted for presentation and CCM location.  
 














≤ 30 years 208 14 1.76 0.185 1.32 0.6 to 3.0 0.499 1.52 0.7 to 3.4 0.315 
31-45 years 322 26 1.64 0.8 to 3.4 0.182 1.56 0.8 to 3.2 0.234 
46-60 years 268 12 0.86 0.4 to 2.0 0.724 0.96 0.4 to 2.2 0.925 





≤ 30 years 208 14 1.75 0.186 1.32 0.6 to 3.0 0.502 1.55 0.7 to 3.5 0.298 
31-45 years 322 26 1.71 0.8 to 3.6 0.158 1.65 0.8 to 3.5 0.183 
46-60 years 268 12 0.87 0.4 to 2.0 0.747 0.99 0.4 to 2.3 0.972 
≥ 60 years 190 10 1.00   1.00   
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Table A. 13 Analysis of time to first clinical event, stratified by presentation  
a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for CCM location.  
















ICH or FND 38 12 








ICH or FND 41 10 
22.1 <0.0001 11.52 3.2 to 41.9 <0.0001 4.90 1.2 to 19.4 0.024 Incidental 
or seizure 
119 3 
            
Toronto  
 
ICH or FND 175 50 








ICH or FND 254 72 









ICH or FND 254 72 
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Table A. 14 Analysis of time to first clinical event, stratified by CCM location 
















Brainstem 17 8 








Brainstem 25 10 




            
Toronto  
Brainstem 102 35 








Brainstem 144 53 









Brainstem 144 53 




a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for presentation.   
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Table A. 15 Analysis of time to first clinical event, stratified by sex  
 
a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for presentation and CCM location.   
















female 80 16 
3.91 0.048 2.88 0.96 to 8.6 0.059 1.88 0.6 to 6.0 0.281 




female 77 6 
0.04 0.844 0.90 0.3 to 2.7 0.844 1.02 0.3 to 3.1 0.974 
male 83 7 
Toronto  
female 194 29 
0.15 0.699 0.90 0.5 to 1.5 0.699 0.78 0.5 to 1.3 0.365 




female 351 51 
0.48 0.49 1.16 0.8 to 1.8 0.491 0.94 0.6 to 1.4 0.780 





female 351 51 
0.31 0.579 1.13 0.7 to 1.7 0.580 0.88 0.6 to 1.4 0.558 
male 289 37 
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Table A. 16 Analysis of time to first clinical event, stratified by CCM multiplicity  
a Hazard ratio from univariate analysis.    b Hazard ratio is adjusted for presentation and CCM location.    








95% CI p 
Adjusted 
hazard ratiob 
95% CI p 
Scotland,  
    1999–2003 
 
multiple 24 5 
1.05 0.305 1.69 0.6 to 4.6 0.31 2.08 0.7 to 5.9 0.166 
solitary 111 15 
            
Scotland,  
    2006–2010 
 
multiple 29 2 
0.011 0.916 0.92 0.2 to 4.2 0.916 0.47 0.1 to 2.2 0.328 
solitary 131 11 
            
Toronto  multiple 79 11 
0.70 0.402 0.76 0.4 to 1.5 0.404 0.65 0.3 to 1.3 0.207 solitary 266 44 
            
Pooled cohorts, 
unstratified 
multiple 132 18 
0.008 0.930 0.98 0.58 to 1.64 0.930 0.79 0.5 to 1.3 0.368 
solitary 508 70 




multiple 132 18 
0.085 0.771 0.93 0.55 to 1.56 0.771 0.82 0.5 to 1.4 0.464 
solitary 508 70 
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Table A. 17 Analysis of time to first clinical event, stratified by age (3 groups)  
 
a log rank test for trend, 1 degree of freedom. b Hazard ratio from univariate analysis.     c Hazard ratio is adjusted for presentation and CCM location.   
   












95% CI p 
Scotland,  
    1999–2003 
≤ 35 years 50   9 
0.40 0.530 
1.34 0.4 to 4.4 0.625 2.05 0.6 to 6.9 0.245 
36-53 years 54   7 0.88 0.3 to 3.0 0.843 1.09 0.3 to 3.8 0.891 
≥ 54 years 31   4 1.00   1.00   
            
Scotland,  
   2006–2010 
≤ 35 years 44   2 
0.16 0.694 
0.61 0.1 to 3.1 0.551 1.90 0.3 to 10.4 0.462 
36-53 years 52   6 1.59 0.5 to 5.2 0.445 4.98 1.3 to 18.6 0.017 
≥ 54 years 64   5 1.00   1.00   
            
Toronto  ≤ 35 years 116 19 
1.40 0.237 
1.87 0.8 to 4.3 0.138 1.96 0.9 to 4.5 0.109 
36-53 years 141 28 2.59 1.2 to 5.7 0.018 2.99 1.4 to 6.6 0.007 
≥ 54 years 88   8 1.00   1.00   
            
Pooled cohorts, 
unstratified 
≤ 35 years 210 30 
1.81 0.178 
1.58 0.9 to 2.9 0.130 1.84 1.0 to 3.3 0.046 
36-53 years 247 41 1.94 1.1 to 3.4 0.022 2.43 1.4 to 4.3 0.002 
≥ 54 years 183 17 1.00   1.00   




≤ 35 years 210 30 
1.14 0.285 
1.47 0.8 to 2.7 0.205 1.86 1.0 to 3.4 0.044 
36-53 years 247 41 1.83 1.0 to 3.2 0.038 2.41 1.4 to 4.3 0.003 
≥ 54 years 183 17 1.00   1.00   
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Table A. 18 Analysis of time to first clinical event, stratified by age (4 groups) 
 
a log rank test for trend, 1 degree of freedom.  b Hazard ratio from univariate analysis.     c Hazard ratio is adjusted for presentation and CCM location.  












95% CI p 
Toronto ≤ 30 years  68   9 
0.90 0.343 
1.23 0.4 to 3.7 0.711 1.28 0.4 to 3.8 0.657 
31-45 years 134 30 2.37 0.9 to 6.1 0.074 2.21 0.9 to 5.7 .0102 
46-60 years   97 11 1.23 0.4 to 3.5 0.700 1.18 0.4 to 3.4 0.757 
≥ 60 years   46   5 1.00   1.00   
Scotland, 
1999–2003 
≤ 30 years   29   6 
0.13 0.720 
0.86 0.2 to 3.1 0.818 1.42 0.4 to 5.2 0.594 
31-45 years   51   7 0.59 0.2 to 2.0 0.405 0.78 0.2 to 2.7 0.691 
46-60 years   36   3 0.32 0.1 to 1.4 0.133 0.51 0.1 to 2.4 0.393 
≥ 60 years   19   4       
Scotland, 
2006–2010 
≤ 30 years   26   0 
0.10 0.748 
– – – – – – 
31-45 years   52   7 1.88 0.5 to 7.3 0.361 3.76 0.9 to 15.2 0.062 
46-60 years   43   3 0.81 0.2 to 4.0 0.798 0.94 0.2 to 4.7 0.944 




≤ 30 years 123 15 
1.12 0.290 
1.02 0.5 to 2.2 0.959 1.22 0.6 to 2.6 0.613 
31-45 years 237 44 1.73 0.9 to 3.3 0.091 1.77 0.9 to 3.4 0.078 
46-60 years 176 17 0.85 0.4 to 1.8 0.659 0.93 0.4 to 1.9 0.841 





≤ 30 years 123 15 
0.62 0.433 
0.93 0.4 to 2.0 0.861 1.22 0.6 to 2.6 0.617 
31-45 years 237 44 1.59 0.8 to 3.0 0.156 1.76 0.9 to 3.4 0.088 
46-60 years 176 17 0.80 0.4 to 1.7 0.564 0.94 0.4 to 2.0 0.864 
≥ 60 years 104 12 1.00   1.00   
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Table A. 19 Model A: comparison of analyses, unstratified and stratified by 'study' 
 Unstratified  Stratified by ‘study’ 
Predictor b SE(b) 
Hazard ratio 
Estimate              95% CI 
 b SE(b) 
Hazard ratio 
Estimate                 95% CI 
        
ICH only          
          
ICH/FND presentation 1.580 0.351 4.854 2.438–9.665  1.559 0.355 4.950 2.467–9.932 
Brainstem location 1.1420 0.285 3.064 1.753–5.357  1.124 0.288 3.077 1.751–5.408 
          
Clinical event          
          
ICH/FND presentation 1.627 0.299 5.088 2.834–9.134  1.648 0.303 5.195 2.867–9.416 
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Table A. 20 Model B: comparison of analyses, unstratified and stratified by 'study' 
  Unstratified   Stratified by ‘study’ 
Predictor b SE(b) 
Hazard ratio 
Estimate              95% CI 
 b SE(b) 
Hazard ratio 
Estimate                 95% CI 
        
ICH only          
          
1 risk factor 1.375 0.403 3.955 1.795–8.716  1.397 0.405 4.042 1.826–8.948 
2 risk factors 2.659 0.358 14.283 7.086–28.789  2.683 0.365 14.627 7.153–29.909 
          
Clinical event          
          
1 risk factor 1.809 0.354 6.105 3.050–12.223  1.842 0.357 6.309 3.134–12.702 
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Figure A. 1 Kaplan-Meier plots comparing estimated risk of first ICH, stratified by 
presentation: ICH or FND presentation (continuous line) vs other presentation (dotted 
line)  
 




Figure A. 2 Kaplan-Meier plots comparing estimated risk of first ICH or FND, stratified 
by presentation: ICH or FND presentation (continuous line) vs other presentation 
(dotted line) 








Figure A. 3 Kaplan-Meier plots comparing estimated risk of first ICH, stratified by CCM 
location: brainstem (continuous line) vs other location (dotted line)  
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Figure A. 4 Kaplan-Meier plots comparing estimated risk of first ICH or FND, stratified 






Figure A. 5 Kaplan-Meier plots comparing estimated risk of first ICH, stratified by sex: 
female (continuous line) vs male (dotted line)   
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Figure A. 6 Kaplan-Meier plots comparing estimated risk of first ICH or FND, stratified 
by sex: female (continuous line) vs male (dotted line) 
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 Number of adults at risk (number of ICH in preceding year)  
Female: 541 454(12) 381(9) 328(4) 271(5) 230(1)  
Male: 447 366(14) 312(8) 257(6) 206(2) 167(1)  
   




 Number of adults at risk (number of ICH in preceding year)  
Female: 351 301(19) 255(15) 212(8) 165(6) 140(3)  
Male: 289 254(16) 215(8) 175(7) 137(3) 108(3)  
 
Figure A. 7 Kaplan-Meier plot comparing estimated risk of (a) first ICH or (b) first 




y = 0 
Female 
Male 
y = 0 
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Figure A. 8 Kaplan-Meier plots comparing risk of first ICH, stratified by CCM 







Figure A. 9 Kaplan-Meier plots comparing estimated risk of first ICH or FND, stratified 
by CCM multiplicity: multiple CCM (continuous line) vs solitary CCM (dotted line) 
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 Number of adults at risk (number of ICH in preceding year)  
        Multiple 208 173(8) 151(5) 122(3)   99(2)   83(0)  
        Single 780 647(18) 542(12) 463(7) 378(5) 314(2)  
   




  Number of adults at risk (number of ICH or FND in preceding year)  
        Multiple 132 115(7) 102(2)   79(6)   61(2)   52(1)   
        Single 508 440(28) 368(21) 308(9) 241(7) 196(5)   
   
Figure A. 10 Kaplan-Meier plots comparing estimated risk of (a) first ICH or (b) first 















Figure A. 11 Kaplan-Meier plots comparing estimated risk of first ICH, stratified by 
age-group: 35 years or younger (continuous line) vs 36-53 years (dotted line) vs 54 
years or older (broken line)   
 
  371 
  
 
Figure A. 12 Kaplan-Meier plots comparing estimated risk of first ICH, stratified by 
age-group: 35 years or younger (continuous line) vs 36-53 years (dotted line) vs 54 
years or older (broken line)  
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     Number of adults at risk (number of ICH in preceding year)  
    35 years or younger at 
diagnosis 
322 254(13) 226(6) 196(6) 161(0) 134(2)  
    36–53 years at diagnosis 358 297(7) 238(9) 196(3) 168(3) 141(0)  
    54 years or older at diagnosis 308 269(6) 229(2) 193(1) 148(4) 122(0)  
   




 Number of adults at risk (number of ICH in preceding year)  
 35 years or younger at diagnosis 210 176(12) 159(7) 136(7) 108(1) 89(3)  




132(6) 109(4) 91(2)  
 54 years or older at diagnosis 183 165(8) 145(2) 119(2)    85(4) 68(1)  
 
Figure A. 13 Kaplan-Meier plots comparing estimated risk of (a) first ICH or (b) first 









y = 0  
 
A  35 years or younger at time of diagnosis 
B  36–53 years at time of diagnosis 
C  54 years or older at time of diagnosis  
 
 










Figure A. 14 Forest plots displaying random-effects meta-analyses for sex,  
(a) unadjusted and  (b) adjusted for the two core predictors, for ICH only 
   
NOTE: Weights are from random effects analysis
























  1.07 .25 .5 10 25
(a) Female vs male sex (unadjusted) for first ICH
NOTE: Weights are from random effects analysis
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Figure A. 15 Forest plots displaying random-effects meta-analyses for sex,  
(a) unadjusted and  (b) adjusted for the two core predictors, for ICH or FND 
  
NOTE: Weights are from random effects analysis


















  1.25 .5 10
(a) Female vs male sex (unadjusted) for first ICH or FND
NOTE: Weights are from random effects analysis


















  1.25 .5 10
(b) Female vs male sex (adjusted for presentation and CCM location) for first ICH or FND
 








Note  The Parisian cohort was not included in these meta-analyses because only adults with 
multiple CCMs suffered an intracranial haemorrhage, and therefore hazard ratios could not 




Figure A. 16 Forest plots displaying random-effects meta-analyses for CCM 
multiplicity, (a) unadjusted and (b) adjusted for two core predictors, for ICH only  
  
NOTE: Weights are from random effects analysis





















  1.06 .25 10 20
(a) CCM multiplicity (unadjusted) for first ICH
NOTE: Weights are from random effects analysis
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Figure A. 17 Forest plots displaying random-effects meta-analyses for CCM 
multiplicity, (a) unadjusted and (b) adjusted for two core predictors, for ICH or FND 
   
NOTE: Weights are from random effects analysis


















  1.1 .5 5
(a) CCM multiplicity (unadjusted) for first ICH or FND
NOTE: Weights are from random effects analysis


















  1.1 .5 5 10
(b) CCM multiplicity (adjusted for presentation and CCM location) for first ICH or FND
 










Figure A. 18 Forest plots displaying random-effects meta-analyses for age,  
(a) unadjusted and (b) adjusted for two core predictors, for ICH only 
   
NOTE: Weights are from random effects analysis
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(a) Age per decade (unadjusted) for first ICH 
NOTE: Weights are from random effects analysis
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Figure A. 19 Forest plots displaying random-effects meta-analyses for age,  







NOTE: Weights are from random effects analysis


















  1.7 2
(c) Age per decade (unadjusted) for first ICH or FND
NOTE: Weights are from random effects analysis


















  1.5 2
(d) Age per decade (adjusted for presentation and CCM location) for first ICH or FND
